<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>Real Life Evaluation of Ferring's Zomacton® With the Zomajet® Vision X Device</title>
	<pubDate>2013-12-24T12:48:54+01:00</pubDate>
	<wp:post_id>4594</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ferring is to collect long-term data on the treatment adherence and patient's acceptability when Zomacton&reg;10 mg is administered with the Zomajet&reg; Vision X device in patients with a growth hormone deficiency or Turner's syndrome.<wbr> PE will measure rate of overall treatment adherence.<wbr> the investigation location site is localized at the H&ocirc;pital des Enfants, CHU de Toulouse (France).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">n=90 </div><div style="margin-bottom: 10px;">Start date: May 2014 - Completion date: Sept 2017 /<wbr> October 2017 </div><div>Source:  <a href="http://www.clinicaltrials.gov/ct2/show/NCT02018172?recr=Open&no_unk=Y&fund=2&rcv_s=11%2F24%2F2013&rank=190" class="defaultlink">NCT02018172</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7554">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-24T12:48:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-24T12:48:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Magnetic Device for Migraine with Aura Approved in the US</title>
	<pubDate>2013-12-24T12:19:41+01:00</pubDate>
	<wp:post_id>4595</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: eNeura Therapeutics secured the first FDA approval for its magnetic migraine treatment, the Cerena Transcranial Magnetic Stimulator (TMS).<wbr> The device is aimed at relieving pain in patients &gt;18 years of age that suffer from migraine headaches accompanied by an aura.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Device Description</STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.eneura.com/tms.html">http:/<wbr>/<wbr>www.<wbr>eneura.<wbr>com/<wbr>tms.<wbr>html</A> </div><div style="margin-bottom: 10px;">The portable handheld device is designed so that patients hold it with both hands against the back of their head and a button is pressed to administer magnetic pulses.<wbr> The device utilizes a single-pulse Transcranial Magnetic Stimulation technology that delivers a non-invasive pulse of magnetic energy for less than one minute.<wbr> In turn, this stimulates the occipital cortex in the brain, disrupts cortical spreading depression, the abnormal electrical activity underlying the aura phase of the migraine, and alleviates pain.<wbr> </div><div><STRONG>Trial Details </STRONG>- NCT00449540 <A href="http://www.clinicaltrials.gov/ct2/show/NCT00449540?term=NCT00449540&amp;rank=1">http:/<wbr>/<wbr>www.<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT00449540?term=NCT00449540&amp;rank=1</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7323">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-24T12:19:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-24T12:19:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sagent Pharm. Launches Octreotide Acetate Injection in the US</title>
	<pubDate>2013-12-24T12:06:15+01:00</pubDate>
	<wp:post_id>4596</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The product is available in 5 vial presentations (3 in signle-dose vials and 2 in multi-dose vials).<wbr> The 'product use' section of the Material Safety Data Sheet (MSDS) features 2 indications: carcinoid tumours and VIPoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Presentations</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="font-size: 8pt;"><SPAN style="text-decoration: underline;">For single-dose vials</SPAN>, each mL contains 50 mcg, 100 mcg or 500 mcg octreotide (as acetate) and the following inactive ingredients: 7 mg sodium chloride, 2 mg glacial acetic acid USP, 2 mg sodium acetate trihydrate USP and water for injection USP, q.<wbr>s.<wbr> to 1 mL.<wbr><BR></SPAN>
</LI>
<LI><SPAN style="font-size: 8pt;"><SPAN style="text-decoration: underline;">For multi-dose vials</SPAN>, each mL contains 200 mcg or 1000 mcg octreotide (as acetate) and the following ingredients: 7 mg sodium chloride, 2 mg glacial acetic acid USP, 2 mg sodium acetate trihydrate USP, 5 mg phenol USP and water for injection USP, q.<wbr>s.<wbr></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 8pt;">Please see full information at : <A href="http://www.sagentpharma.com/octreotide-acetate-injection.html">http:/<wbr>/<wbr>www.<wbr>sagentpharma.<wbr>com/<wbr>octreotide-acetate-injection.<wbr>html</A><BR></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="font-size: 8pt;">About Sagent Pharmaceuticals</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 8pt;">Sagent is an injectable pharmaceutical company, which develops and sources products, which it sells in the US.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><SPAN style="font-size: 8pt;">Presence in China: </SPAN></SPAN><SPAN style="font-size: 8pt;">300,000 square foot FDA- and cGMP-compliant, sterile manufacturing facility located in Chengdu, China, that utilizes state-of-the-art isolation technology for aseptic filling.<wbr> The facility is fully operational, was inspected by the FDA in 2012.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 8pt;">The Company offers a range of products across anti-infective, oncolytic and critical care indications in a range of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it focuses to develop injectable products.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 8pt;">As of December 31, 2010, it marketed 22 products, all of which were generic injectable products, and had a pipeline, which included 46 new products represented by 77 Abbreviated New Drug Applications (ANDAs), which either are under review by the US </SPAN><SPAN style="font-size: 8pt;">FDA or were approved and their associated products are pending commercial launch.<wbr></SPAN> </div><div><EM><SPAN style="font-size: 8pt;"><SPAN style="font-size: 8pt;">Source: Sagent Pharm</SPAN></SPAN></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7553">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-24T12:06:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-24T12:06:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive Results from the Interim Analysis of Antisense's ATL1103 for Acromegaly</title>
	<pubDate>2013-12-24T11:17:15+01:00</pubDate>
	<wp:post_id>4597</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The interim analysis from the POC trial was undertaken on the 8 patients who have completed the full 3 months of dosing at both dosing levels employed in the study.<wbr> Enrolment into the 24 patient trial is expected to be completed early in the new year.<wbr> The company looks forward to the reporting of the statistical analysis of the sIGF-I data from all patients (expected in the second quarter of 2014) and to the potential verification of results achieved in this interim analysis.<wbr> Based on these interim results, the company will be following up interest from pharmaceutical companies in partnering the development of ATL1103 for Ph3 trials.<wbr> Findings are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Findings</STRONG> </div><div style="margin-bottom: 10px;">In the 4 patients who received the 400 mg per week dose, ATL1103 reduced sIGF-I levels consistently and by an average (mean) of 30% (range 4% to 48%) at week 14 (one week past the last dose) which is the primary efficacy time point for the trial.<wbr> sIGF-I levels were reduced by a mean of 38% (28 &ndash; 48%) in the 3 patients who had lower body weights (58 - 83 kg at screening) and thereby received a relatively higher dose per kg bodyweight.<wbr> The one patient showing the lowest sIGF-1 reduction at week 14 had the highest body weight (132 kg at screening).<wbr> <BR><BR>At the 200 mg per week dose, no consistent reduction in mean sIGF-I levels was observed at week 14, although some sIGF-I reduction was noted in individual patients.<wbr> <BR><BR>The time course data at the 400 mg per week dose generally shows a progressive rate of reduction in sIGF-I over the dosing period.<wbr> This is further support for the therapeutic action of ATL1103 observed in this trial and suggests that continued dosing of ATL1103 at the 400 mg per week dose for longer than 3 months could result in additional reductions in sIGF-I.<wbr> <BR><BR>While sIGF-I levels were substantially suppressed in 3 patients receiving the 400 mg per week dose of ATL1103, their sIGF-I levels did not reduce all the way to normal levels, however this is not surprising considering the study design was not optimised for this endpoint, the small number of patients analysed thus far and that their starting sIGF-I levels (2.<wbr>4 to 5 times above normal) appear higher when compared to average starting levels of acromegaly patients in larger published clinical studies (e.<wbr>g.<wbr> 1.<wbr>8 times above normal).<wbr> <BR><BR>To date no patients dosed with ATL1103 have withdrawn from the study nor have any serious adverse events, believed to be treatment-related, been reported.<wbr> So far, both doses appear to be well tolerated.<wbr> The positive safety profile to date suggests the drug may be tolerated at higher levels than 400 mg per week and so the Company is considering the prospect of conducting a small add-on study to support the use of a higher dose in Phase III trials for dose escalation in patients with more active disease.<wbr> <BR><BR>Other important parameters of drug activity being measured in all patients that will also be assessed at the end of the study include Growth Hormone and Growth Hormone Binding Protein levels along with a more comprehensive assessment of the safety data.<wbr> Such additional data is expected to give further valuable insight into the safety, activity and mechanism of action of ATL1103 at both dose levels in this patient population.<wbr> <BR><BR><STRONG>Ph2 Design</STRONG> </div><div style="margin-bottom: 10px;">- <SPAN style="text-decoration: underline;">Design</SPAN>: randomised, open-label, parallel group study </div><div style="margin-bottom: 10px;">- <SPAN style="text-decoration: underline;">Objective</SPAN>: safety, tolerability, pharmacokinetics and efficacy of two subcutaneous dosing regimens of ATL1103 in 24 adult patients with acromegaly dosed with ATL1103 for 13 weeks (3 months) with two months of follow up.<wbr> </div><div style="margin-bottom: 10px;">- <SPAN style="text-decoration: underline;">Protocol:</SPAN> Two ATL1103 dosing regimens are being tested (a) 200 mg 3 times in the first week then once weekly thereafter (200 mg/<wbr>week) or (b) 200 mg 3 times in the first week then twice weekly thereafter (400 mg/<wbr>week).<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Endpoints</SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>The primary endpoints are (i) to evaluate the safety and tolerability of ATL1103 in patients with acromegaly, and (ii) to evaluate the single dose and multiple dose pharmacokinetic profiles of ATL1103 via the subcutaneous route in patients with acromegaly.<wbr>
</LI>
<LI>A secondary endpoint is the evaluation of ATL1103's effect on serum insulin like growth factor I (IGF-I) levels in patients.<wbr> The secondary endpoint is the average percentage reduction in serum IGF-I levels at the end of treatment compared to baseline levels for each of the two dosing regimens used in the Ph2 study.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Drug Patent</STRONG> </div><div style="margin-bottom: 10px;">ATL1103 commercialisation is covered by patents to at least 2024, with the potential for extensions up to 2029 in some countries and 2030 in the US.<wbr> </div><div><EM>Source: Antisente Therapeutics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7552">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-24T11:17:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-24T11:17:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Three New Patents for Restasis (Allergan's #2 Drug)</title>
	<pubDate>2013-12-23T14:28:00+01:00</pubDate>
	<wp:post_id>4598</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has obtained new patents for its eye drops.<wbr> Earlier composition patent on the product is due to expire in May 2014.<wbr> In June 2013, the FDA published guidelines indicating that a generic competitor could be approved without human testing, meaning the agency is conceptually open to the idea of granting approval to a generic without running a study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The FDA said in its proposed guidance that conducting a study in humans to test whether the drugs are essentially equivalent would not be feasible or reliable due to the "modest efficacy" of Restasis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Allergan estimates that 2013 sales of Restasis will come in at $900M to $920M (roughly 15% of total sales).<wbr> </div><div><EM>Source: FirstWord; Reuters</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7322">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-23T14:28:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-23T14:28:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Clinical Trial Data Capture Moves To A New Level With The Use Of Formula-1 Technology</title>
	<pubDate>2013-12-23T13:09:28+01:00</pubDate>
	<wp:post_id>4599</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment In September 2011 GSK announced a partnership with the Formula-1 
McLaren Group to share knowledge and expertise with the aim of improving 
business performance.<wbr> This weekend the fruits of their efforts were aired on 
British Television with Sky News highlighting how use of McLaren's monitoring 
technology is to be deployed in research trials in stroke and arthritis to 
monitor patient's reactions to new medications.<wbr> </div><div style="margin-bottom: 10px;">Smart sensors used by McLaren to track the performance of their cars on the 
track are being used in this context for the first time GSK hopes that by 
precisely tracking the movements of patients they will get earlier feedback on 
whether a drug helps to get them back on their feet.<wbr> </div><div style="margin-bottom: 10px;">Currently doctors try to estimate a patient's response to a drug by asking 
them to diarize how far and how often they walk.<wbr> </div><div style="margin-bottom: 10px;">Dr Caroline Hargrove, technical director at McLaren Applied Technologies, is 
adapting the sensors and the software used to analyse the data for human 
use.<wbr> </div><div style="margin-bottom: 10px;">"Rather than how fast you have gone round a lap, it's how many minutes of 
walking you have done," she said.<wbr> </div><div style="margin-bottom: 10px;">But sensors that are taped to the neck can monitor patients day and night, 
providing a far more objective - and accurate - measure of activity.<wbr> </div><div style="margin-bottom: 10px;">Dr Ravi Rao, a consultant rheumatologist and medicines development leader at 
the company, said the data can be analysed to determine the duration of an 
arthritis patient's stiffness in the morning.<wbr> </div><div style="margin-bottom: 10px;">"These quality of life measures, in terms of how a patient is functioning 
with a disease, are incredibly important - more important sometimes than a blood 
test or a physical examination.<wbr>" </div><div style="margin-bottom: 10px;">GSK hopes the technology will speed up drug development.<wbr> </div><div><A href="http://news.sky.com/story/1185621/formula-one-technology-used-in-drug-trials">http:/<wbr>/<wbr>news.<wbr>sky.<wbr>com/<wbr>story/<wbr>1185621/<wbr>formula-one-technology-used-in-drug-trials</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10717">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-23T13:09:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-23T13:09:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Upholds Fampridine (FAMPYRA®) Patent</title>
	<pubDate>2013-12-23T12:13:11+01:00</pubDate>
	<wp:post_id>4600</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The EU patent (EP-1 732 548 B) is set to expire in 2025, absent any additional exclusivity granted based on regulatory review timelines.<wbr> In addition, FAMPYRA® received 10-year market exclusivity upon approval by the <ORG>EU Commission</ORG> that is set to expire in 2021.<wbr> FAMPYRA®<SUP> </SUP>is indicated in the <ORG>EU for the improvement of walking in adult patients with MS with walking disability (EDSS 4-7).<wbr> </ORG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">FAMPYRA® is exclusively developed and commercialized outside <LOCATION value="LC/us;LB/nam">the US by <ORG>Biogen Idec</ORG> under a collaboration and licensing agreement with Acorda.<wbr> (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=4398" class="defaultlink">Neurology4398: Biogen Idec Gains Rights to Acorda's Fampridine-SR</a>).<wbr></LOCATION> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">AMPYRA® is covered by multiple patents providing coverage through 2027.<wbr> </div><div style="margin-bottom: 10px;">AMPYRA®<SUP> </SUP>has Orphan drug status providing market exclusivity through <CHRON>January 22, 2017</CHRON>.<wbr> </div><div><EM>Source: Acorda</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7320">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-23T12:13:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-23T12:13:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly and PeptiDream Sign Therapeutic Peptides Deal</title>
	<pubDate>2013-12-23T10:58:01+01:00</pubDate>
	<wp:post_id>4601</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PeptiDream will identify macrocyclic peptides as potential drug candidates, and Lilly will be responsible for any development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">PeptiDream's proprietary PD Platform is a highly versatile peptide generation and selection platform based on three core technologies; 1) Flexizyme, 2) translation, cyclization, and peptide modifying technologies, and 3) PD display.<wbr> </div><div style="margin-bottom: 10px;">The combination of these 3 technologies into the PD Platform allows PeptiDream to produce libraries of trillions of unique cyclic and helical nonstandard peptides with unparalleled diversity.<wbr> </div><div style="margin-bottom: 10px;">The PD Platform allows PeptiDream to identify hundreds of novel nonstandard macrocylic peptides against a target in weeks, covering a wide variety of peptide classes and structures.<wbr> </div><div style="margin-bottom: 10px;">Researchers can then screen hundreds of hits a week for the desired target binding, selectivity, and biochemical activity by independently expressing each peptide using PeptiDream's PDTS translation system, without the bottleneck of expensive and time consuming chemical synthesis.<wbr> Leads can then be chemically synthesized and purified for further development.<wbr> </div><div><EM>Source: PeptiDream</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10716">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-23T10:58:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-23T10:58:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer and Pekin U. Ink GP Training and Development Project</title>
	<pubDate>2013-12-23T10:18:14+01:00</pubDate>
	<wp:post_id>4602</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: General practice plays a vital role in China's medical system.<wbr> Per the agreement, Pekin University Health Science Center will host activities subsidized by Pfizer.<wbr> Details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Peking University Executive Headmaster Ke Yang indicated that the center fully recognizes the importance of nurturing health professionals.<wbr> It will therefore explore innovative training objectives, teaching concepts, curriculum settings, evaluation standards and faculty improvement.<wbr> </div><div style="margin-bottom: 10px;">The training and development project aimed at improving capabilities and quality at 20,000 community medical institutions in China.<wbr> </div><div style="margin-bottom: 10px;">Pfizer will also partially fund scholarship for 210 GPs to attend the University of Birmingham over the next 3 years.<wbr> </div><div><EM>Source: GBI Pharma</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10715">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-23T10:18:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-23T10:18:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CHMP Postpones Final Decision On Teva/Active Biotech's Laquinimod</title>
	<pubDate>2013-12-23T10:00:22+01:00</pubDate>
	<wp:post_id>4603</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Active Biotech noted on Friday that the CHMP has yet to reach a final decision on approval of Laquinimod for the treatment of relapsing-remitting multiple sclerosis with a verdict is now anticipated in January 2014.<wbr> </div><div style="margin-bottom: 10px;">No explanation has been given for the delay with the overall review process having been initiated in July 2012.<wbr> </div><div style="margin-bottom: 10px;">Prospects for Laquinimod are viewed by analysts as uncertain as the European submission was based on results from two phIII trial ALLEGRO and BRAVO and BRAVO did not meet its primary endpoint of reduction in annualised relpase rates versus placebo.<wbr> </div><div style="margin-bottom: 10px;">Moreover, the US FDA has requested that a third phIII trial be undertaken under a special protocol assessment.<wbr> </div><div><STRONG>Teva still hopes that it will be able to launch the drug in 2014</STRONG> having demonstrated that a significant difference was observed in annualised relapse rates in the BRAVO study when an inbalance between study arms was corrected.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7318">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-23T10:00:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-23T10:00:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva Has Stopped the Promotion of Zoladex in Germany</title>
	<pubDate>2013-12-20T14:47:25+01:00</pubDate>
	<wp:post_id>4604</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Stefan Pfeifer (Business Unit Director Urology), we have learnt that Teva has stopped promotion of Zoladex, and that invitations to EAU and AUA have been cancelled.<wbr> The agreement between the two companies is set to end on March 31, 2014.<wbr> The question now is whether AZ will look at another partner or not.<wbr> Another scenario recently emerged which indicates that Teva may be interested in acquiring Acino's goserelin.<wbr> </div><div>The news comes from multiple sources that have independent direct contacts with TEVA reps.<wbr> There have been rumours about difficult discussions between Astra and TEVA for some time, so this news was not a big surprise at all.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9387">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-20T14:47:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-20T14:47:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Milestone Reached for Exelixis' Cometriq for MTC</title>
	<pubDate>2013-12-20T11:44:14+01:00</pubDate>
	<wp:post_id>4605</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="color: #000000;">Comment: </SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="color: #000000;"></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="color: #000000;"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="color: #000000;"></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="color: #000000;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="color: #000000;"></SPAN> </div><div><EM><SPAN style="color: #000000;"></SPAN></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7551">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-20T11:44:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-20T11:44:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Data From PREVAIL to be Presented at International Congress</title>
	<pubDate>2013-12-20T11:22:39+01:00</pubDate>
	<wp:post_id>4606</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medivation and Astellas have announced that additional data from the Phase 3 PREVAIL trial evaluating enzalutamide in patients with chemotherapy-na&iuml;ve metastatic prostate cancer will be highlighted in a late-breaking oral presentation at the upcoming ASCO GU Cancers Symposium in San Francisco.<wbr> Of note, B.<wbr> Tombal will present the Ph2 results of enzalutamide monotherapy in hormone-na&iuml;ve PCa patients.<wbr> </div><div>- Enzalutamide in men with chemotherapy-na&iuml;ve metastatic prostate cancer (mCRPC): Results of Phase 3 PREVAIL Study - Presenter: Tomasz M.<wbr> Beer, OHSU Knight Cancer Institute, Oregon Health &amp; Science University <BR><BR>&bull; Session Detail: Welcome and General Session 1: Integrating Androgen Axis Therapy across the Disease Spectrum <BR>(January 30, 2014 from 7:45 a.<wbr>m - 9:45 a.<wbr>m).<wbr> <BR><BR>- Abstracts to be presented during General Poster Sessions <BR><BR>&bull; (Abstract #62) Enzalutamide monotherapy: Phase 2 study results in hormone-na&iuml;ve prostate cancer patients.<wbr> Presenter: Bertrand Tombal, Universit&eacute; Catholique de Louvain, Cliniques Universitaires Saint-Luc (11:30 a.<wbr>m.<wbr> - 1:00 p.<wbr>m.<wbr>, Thursday, January 30, 2014).<wbr><BR>&bull; (Abstract #247) Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone.<wbr> Presenter: Mark Creamer Scholz, Prostate Oncology Specialists (12:00 - 1:30 p.<wbr>m.<wbr>, Friday, January 31, 2014).<wbr><BR><BR><EM>Source: GlobalData</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9386">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-20T11:22:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-20T11:22:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Collaborations Pave The Way Forward For Merck's Development Of Its PD-1 Immunotherapy</title>
	<pubDate>2013-12-19T14:41:48+01:00</pubDate>
	<wp:post_id>4607</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Merck &amp; Co has enterered into a collaborative agreement with GSK 
to study its experimental PD-1 immunotherapy MK-3457 in combination with GSK's 
approved oral kinase inhibitor Votrient (pazopanib) in advanced renal 
cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature Of The Collaboration</STRONG> </div><div style="margin-bottom: 10px;">Full details of the collaboration have not been disclosed but in 
brief the companies will conduct a phI/<wbr>II trial to assess the efficacy and 
safety of MK-3475 in combination with Votrient in treatment-naive patients with 
advanced disease.<wbr> The companies will also undertake studies of MK-3457 in 
combination with other products in GSK's portfolio in future.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Striking Results In Melanoma</STRONG> </div><div style="margin-bottom: 10px;">Last month, Merck announced that MK-3475 significantly prolonged survival in 
a phI study in patients with advanced melanoma with the 12-month survival rate 
tracking around 81%, a figure that compares favourable with BMS's competing 
nivolumab (62%) and the (82%) seen for nivolumab in combination with 
BMS's Yervoy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Areas Of Investigation</STRONG> </div><div>MK-3457 is being studied in 10 clinical trials for several malignancies 
including bladder, colorectal, gastic and renal cancer.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9385">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-19T14:41:48+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-19T14:41:48+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galderma Looses Key US Patent Case</title>
	<pubDate>2013-12-19T14:14:20+01:00</pubDate>
	<wp:post_id>4608</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : On Wednesday Galderma's monopoly on its brand-name acne treatment 
Differin Gel 0.<wbr>3% in the US expired, when the generic drug company 
Tolmar Inc.<wbr> and its lawyers at McDermott Will persuaded the Federal Circuit to 
invalidate Galderma's patents.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Significance Of This Patent Expiry<BR><BR></STRONG>US sales of the 
product, which is the number 2 product worldwide in the topical anti-acne 
market were $125m in 2012 according to IMS.<wbr> </div><div style="margin-bottom: 10px;">Acne product sales represent the group's top selling 
therapy area in the year to December 2012, accounting for sales 
of Euro 356m versus group sales of Euro 1.<wbr>59bn.<wbr> Its overall sales 
profile is shown below.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10714_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld10714attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10714_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10714">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-19T14:14:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-19T14:14:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Secures Algeta Purchase With Raised Offer</title>
	<pubDate>2013-12-19T10:24:22+01:00</pubDate>
	<wp:post_id>4609</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After raising its offer price from 336 crowns to 362 crowns, Algeta's board unanimously backed Bayer's sweetened offer.<wbr> With the deal now secured, Bayer effectively gains full control of the prostate cancer drug Radium -223 (Xofigo).<wbr> </div><div style="margin-bottom: 10px;">Bayer's offer represents a 37% premium to Algeta's closing price on November 25th the day before the offer became public.<wbr> </div><div><STRONG>Background</STRONG> - see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9340" class="defaultlink">Oncology9340: Bayer in Early Stage Talks to Acquire Algeta</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9383">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-19T10:24:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-19T10:24:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Retrophin Unveils ACTH Analog</title>
	<pubDate>2013-12-19T10:04:47+01:00</pubDate>
	<wp:post_id>4610</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: IND filing and Ph1 PK trial for RE-034, an ACTH analog (1-24), are expected in H1:2014.<wbr> The company intends to initiate trials for infantile spasms (West syndrome), nephrotic syndrome and 2 other undisclosed indications.<wbr> Additional details from the company's conference call are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7315_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7315_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7315_3_ScreenCapture3.jpg"> </div><div><EM>Source: Retrophin RE-034 conference call</EM> </div><!-- Comment details --><a name="neurology7315attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7315_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7315_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(106,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7315_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(137,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7315">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-19T10:04:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-19T10:04:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Versartis' Once-Monthly Dosing rhGH Granted ODD in the US</title>
	<pubDate>2013-12-18T17:56:03+01:00</pubDate>
	<wp:post_id>4611</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The US ODD comes 3 months after a similar designation by the EU Commission.<wbr> The drug (VRS-317) is currently being advanced through the ongoing Ph2 in paediatric GHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">An international Ph3 in PGHD is planned to start in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7549_1_ScreenCapture1.jpg"> </div><div><EM>Source: Versartis</EM> </div><!-- Comment details --><a name="endocrinology7549attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7549_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7549">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-18T17:56:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-18T17:56:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Reinforces its Commercial Platform in Growth Markets</title>
	<pubDate>2013-12-18T13:06:47+01:00</pubDate>
	<wp:post_id>4612</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda has established its wholly-owned subsidiary in Israel, the sixthiest entity after Algeria, Ecuador, Peru, Singapore, and Vietnam.<wbr> According to Business Monitor International, pharma sales in Israel totaled $1.<wbr>5bln in 2012 and are expected to grow at a CAR of 6% (between 2013 and 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Population growth
</LI>
<LI>Increase need for specialty treatments
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">HQ: Tel Aviv Area </div><div style="margin-bottom: 10px;">Country manager: Arie Kramer (joined from AbbVie where he headed Finance and Strategic Commercial Planning.<wbr> Previously he has served as GM, CFO at Novartis Consumer Health in Israel).<wbr> </div><div style="margin-bottom: 10px;">Mission: sales and marketing of selected products, with an initial focus on <STRONG>oncology</STRONG> </div><div style="margin-bottom: 10px;">Business Development: local partners with complementary portfolios are sought </div><div style="margin-bottom: 10px;">Major Products Sold in Israel: Actos, Atacand, Contoloc, <STRONG>Lucrin</STRONG>, Xefo, Mepact.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9381">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-18T13:06:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-18T13:06:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</title>
	<pubDate>2013-12-18T10:38:44+01:00</pubDate>
	<wp:post_id>4613</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Belgium based, private company presented at ENDO2013 preclinical PK and efficacy data of its oral small-molecule NK3 receptor antagonist program.<wbr> ESN364, the lead candidate issued from this program, is scheduled for FIM in 4Q:13 (endometriosis and polycystic ovary syndrome).<wbr> Of note, the company is actively seeking partner for ESN282 (inflammatory diseases such as ulcerative colitis).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9023">...</a><br></div><div style="margin-bottom: 10px;">Euroscreen has announced initiation of the Phase I clinical trial for ESN364.<wbr> The main study objective is the assessment of the safety, tolerability and pharmacokinetics of ESN364 in healthy male and female volunteers.<wbr> </div><div style="margin-bottom: 10px;">In addition, hormone levels will also be monitored as biomarkers of on-target activity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: Approximately 64 healthy subjects will participate in the study.<wbr> </div><div><STRONG>Timelines and Next Steps</STRONG>: Successful completion of this European Phase I clinical trial will enable the initiation of Proof-Of-Concept Phase II studies of ESN364 in patients suffering from sex-hormone related disorders such as Endometriosis, Poly-Cystic Ovarian Syndrome (PCOS), Uterine Fibroids, and possibly other related diseases.<wbr> Phase II studies are projected to start in Q4, 2014.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9380">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9023">View thread  Oncology9023: Euroscreen's ESN364 to Enter Clinical for Endometriosis and PCOS</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-18T10:38:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-18T10:38:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PMS Study of BOTOX® for NDO in Korea</title>
	<pubDate>2013-12-17T19:23:11+01:00</pubDate>
	<wp:post_id>4614</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Poised to start soon and last 3 years, this trial will evaluate the safety and efficacy of BOTOX&reg; to treat urinary incontinence in patients with neurogenic detrusor overactivity (NDO) not adequately controlled by anticholinergic drugs.<wbr> PE will measure the number of participants with AEs and ADRs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Completion date: Dec 2016 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">Approx 600 participants (both genders) with urinary incontinence due to NDO treated with BOTOX&reg; as per local standard of care in clinical practice.<wbr> </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02010788?recr=Open&no_unk=Y&fund=2&rcv_s=11%2F17%2F2013&rank=234" class="defaultlink">NCT02010788</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7314">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-17T19:23:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-17T19:23:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Reprimanded By The ABPI For Continual Breach Of The Code Of Practice</title>
	<pubDate>2013-12-17T15:54:34+01:00</pubDate>
	<wp:post_id>4615</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has been publicly reprimanded by the ABPI's Code of 
Practice Appeal Board, for a run of breaches relating to its failure to comply 
with an undertaking, by continuing to claim that its Vistabel/<wbr>Botox 
(onabotulinumtoxin A) was clinically more potent than Merz' product 
Bocouture/<wbr>Xeomin (incobotulinumtoxin A).<wbr> </div><div style="margin-bottom: 10px;">Merz claimed that at a meeting, and through one of its representatives, 
Allergan continued to misrepresent data relating to the relative potencies of 
the two rival medicines, despite rulings in previous cases that it should not do 
so.<wbr> </div><div>Source: Pharmatimes December 17th </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7313">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-17T15:54:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-17T15:54:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Almirall Buys US Aqua Group For Dermatology Commercialisation Purposes</title>
	<pubDate>2013-12-17T13:13:04+01:00</pubDate>
	<wp:post_id>4616</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Almirall is to buy US Aqua Pharmaceuticals for up to $400m paving 
the way for commercialisation of its dermatology products in the US, a key 
growth platform for the group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Almirall's Dermatology Presence</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Almirall's Dermatology R&amp;D Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>The Aqua Pharmaceutical Acquisition</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_5_ScreenCapture5.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_6_ScreenCapture6.jpg"> </div><!-- Comment details --><a name="pharmaworld10713attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(138 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(125,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(131,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(123,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(131,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(75,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(30,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10713_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(76,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10713">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-17T13:13:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-17T13:13:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant Adds Solta Medical in its Aesthetic Portolio</title>
	<pubDate>2013-12-17T11:33:22+01:00</pubDate>
	<wp:post_id>4617</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: With the $250M acquisition of Solta Medical, Valeant will access to products used in procedures such as skin rejuvenation, skin tightening and body contouring.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Solta's leading aesthetic devices are a natural fit with Valeant's facial injectables, professional skin care products and physician dispensed products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Financial</STRONG>: Valeant will acquire all of the outstanding common stock of <ORG value="NASDAQ-NMS:SLTM">Solta Medical, Inc.<wbr> for <MONEY>$2.<wbr>92</MONEY> per share in cash, which represents a 40% premium to Solta's closing share price on <CHRON>December 13, 2013</CHRON>, the last trading day prior to announcement, or a transaction value of approximately <MONEY>$250 million</MONEY>.<wbr></ORG> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG>: the transaction is expected to close Q1:14 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Business</STRONG>: Solta designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Products</STRONG>: </div><div style="margin-bottom: 10px;"><UL><LI>Thermage CPT system that provides non-invasive treatment options using radiofrequency energy for skin tightening</LI>
<LI>Fraxel repair system for use in dermatological procedures requiring ablation, coagulation, and resurfacing of soft tissue; </LI>
<LI>Clear + Brilliant system to improve skin texture and help prevent the signs of aging skin; </LI>
<LI>Liposonix system that destroys unwanted fat cells resulting in waist circumference reduction.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>2012 Total Sales</STRONG>: approx.<wbr> <MONEY>$145M.<wbr></MONEY> </div><div><EM>Source: Valeant</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7311">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-17T11:33:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-17T11:33:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CAM2029 To Be Developed For Both Acromegaly & Carcinoid Syndrome</title>
	<pubDate>2013-12-17T11:30:53+01:00</pubDate>
	<wp:post_id>4618</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During a recent French gastroenterology congress M Pavel (NET KOL) spoke about two new galenic forms of octreotide, refering to Camurus CAM2029, in-licensed by Novartis and oral octreotide in-licensed by Roche from Chiasma.<wbr> </div><div style="margin-bottom: 10px;">Thanks to Caroline Sert (Franchise Medical Advisor) &amp; Jean-Francois Mocho (Franchise Marketing) we have accees to some of the slides that were presented.<wbr> </div><div style="margin-bottom: 10px;">M Pavel explained that few data are available as yet in the public domain.<wbr> She spoke about phI/<wbr>II data and about CAM2029 having 5-7 times the bioavailability of Sandostatin LAR.<wbr> Pavel acknowledged that development will be for both acromegaly and NET (carcinoid syndrome) and that development will start in 2014 (no precise date defined).<wbr> </div><div style="margin-bottom: 10px;">Slides presented on Octreolin were similar to what have been presented at other congresses.<wbr> </div><div style="margin-bottom: 10px;">Nothing was mentioned about non-functioning NET or pasireotide.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="endocrinology7546attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(98,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7546_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(104 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7546">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-17T11:30:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-17T11:30:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK Increases Stake in its Indian Business and Announces Measures on its Marketing Practices</title>
	<pubDate>2013-12-17T10:55:33+01:00</pubDate>
	<wp:post_id>4619</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK has offered to acquire an additional 24.<wbr>2% stake in its Indian business for around $1bln.<wbr> Management sees India as a strategic opportunity for the future, "particularly the volume opportunity".<wbr> In parallel, the company has announced several measures regarding sales practices, which are part of a "broad effort to improve transparency" and not "related to its Chinese problems".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">GSK said it will: </div><div style="margin-bottom: 10px;">- stop paying doctors to promote its products at events </div><div style="margin-bottom: 10px;">- still pay fees to doctors carrying out company-sponsored clinical research, advisory activities and market research </div><div style="margin-bottom: 10px;">- stop payments to healthcare professionals for attending medical conferences (by the start of 2016) </div><div style="margin-bottom: 10px;">- remove individual sales targets for its marketing staff (a new compensation system will be implemented by early 2015) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Markets pharmaceuticals and vaccines in respiratory, cardiovascular, oncology anti-infectives and dermatology.<wbr> </div><div style="margin-bottom: 10px;">2012 turnover: $421M </div><div><EM>Source: FirstWord; ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10711">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-17T10:55:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-17T10:55:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Theratechnologies To Pursue US Commercialisation Of Its Product</title>
	<pubDate>2013-12-16T15:55:08+01:00</pubDate>
	<wp:post_id>4620</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Theratechnologies Inc.<wbr>, a biopharmaceutical company has agreed to 
terminate its collaboration and licensing agreement with EMD Serono in order to 
regain US commercialisation rights for tesamorelin a synthetic form of 
growth-hormone-releasing hormone which is used in the treatment of 
HIV-associated lipodystrophy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of proposed agreement, EMD Serono agreed to terminate its 
collaboration and licensing agreement with Theratechonologies in consideration 
of an early termination fee of US$20m payable over a five-year period starting 
on the first anniversary of the closing date.<wbr> Starting in 2016, 
Theratechnologies will also pay an undisclosed, increasing royalty based on 
annual net sales.<wbr> Royalties will be paid until a cumulative aggregate amount is 
reached or until January 1, 2024, the first of these events to occur.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Consequences Of The Deal</STRONG> </div><div style="margin-bottom: 10px;">As a result of the termination of licensing agreement, Theratechnologies will 
regain all commercialization rights for Egrifta in the US and will be 
responsible for all operations in the US relating to Egrifta, including the 
conduct of the post-approval </div><div style="margin-bottom: 10px;">The transaction represents a cornerstone of the Company’s business plan 
to maximize the commercial potential for Egrifta in the United States and 
elsewhere.<wbr> By regaining rights to Egrifta it will have full control over a 
product it knows intimately.<wbr>” </div><div>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7545">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-16T15:55:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-16T15:55:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Auxilium Doses First Patient In Ph2b Frozen Shoulder Symdrome</title>
	<pubDate>2013-12-16T15:38:07+01:00</pubDate>
	<wp:post_id>4621</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As flagged last week, Auxillium has now initiated a 300 patients phIIb frozen-shoulder study with its collagenase clostridium histolyticum (CCH) Xiaflex, an interesting development programme to monitor in light of Ipsen's development of Toxin E for rotator cuff injuries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Is Frozen-Shoulder Study (FSS) </STRONG> </div><div style="margin-bottom: 10px;">FSS can be a prolonged, painful condition of the shoulder in which increased capsular collagen thickening and subsequent capsular contraction in the shoulder joint is thought to cause a loss of range of motion in the shoulder and pain.<wbr> The condition is believed to affect approximately two to five percent of the general adult population and the full duration of the disease can last from approximately one year to up to 3.<wbr>5 years.<wbr> Some cases never completely resolve.<wbr> The majority of cases are currently managed conservatively with prolonged physical therapy and occasionally with steroid injections.<wbr> It is estimated that approximately 300,000 cases of FSS are diagnosed annually and approximately 10 percent are treated with an invasive intervention such as surgery or manipulation under anesthesia on an annual basis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Study Design</STRONG> </div><div style="margin-bottom: 10px;">The Phase 2b study is a double-blind, placebo-controlled study of the safety and efficacy of CCH for the treatment of Stage 2 (frozen stage) unilateral idiopathic FSS.<wbr> The study will enroll approximately 300 adult men and women at approximately 35 sites in the U.<wbr>S.<wbr> and Australia.<wbr> Subjects will be randomized 3:1 to receive CCH or placebo and will receive up to three ultrasound-guided injections of study drug.<wbr> Each injection will be separated by a minimum of 21 days.<wbr> All subjects will also perform home shoulder exercises after the first injection.<wbr> </div><div style="margin-bottom: 10px;">In a prior Auxilium Phase 2a FSS study, both the 0.<wbr>58mg (1mL) and 0.<wbr>58mg (2mL) dosing arms showed statistically significant improvements.<wbr> </div><div style="margin-bottom: 10px;">The Phase 2b study's primary endpoint is the change (degrees) from baseline to the Day 95 follow-up visit in active forward flexion in the affected shoulder compared to placebo.<wbr> Patients will also be assessed using the American Shoulder and Elbow Surgeons (ASES) Scale for function and pain as well as additional patient reported outcome measures.<wbr> Safety assessments will be made during all study visits and immunogenicity testing will be performed at screening and at the end of the study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Perception</STRONG> </div><div>FSS is viewed by Auxillium as a condition with no approved therapies and limited treatment options.<wbr> Innovative treatment approaches such as CCH, if approved by the FDA, may allow patients quicker relief from limits in range of motion and associated pain.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7308">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-16T15:38:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-16T15:38:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Richter to Establish Strategic Position in Brazil for its Female HC Business</title>
	<pubDate>2013-12-16T12:06:55+01:00</pubDate>
	<wp:post_id>4622</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Richter as acquired 51% stake in Brazil's NextPharma to register and distribute its female HC products in the South American countries.<wbr> Richter also said it had secured an option to buy the remaining 49% of the company.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Milestones</STRONG> </div><div style="margin-bottom: 10px;">Next Pharma, a private company founded in 2010, would register and establish a sales network for Richter's female healthcare products, such as its Esmya medicine for the treatment of uterine myoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>NextPharma Network</STRONG> </div><div>Large private and public hospitals, retail chains as well as government agencies in Brazil.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9379">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-16T12:06:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-16T12:06:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan to Test BOTOX® for Bilateral Masseter Muscle Hypertrophy (MMH)</title>
	<pubDate>2013-12-13T18:08:54+01:00</pubDate>
	<wp:post_id>4623</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 5-arm Ph2 which is poised to start in January 2014 will assess the safety and efficacy of a range of doses of BOTOX&reg;.<wbr> PE will measure lower facial volume calculated by digital imaging.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">Recruitment: n=200 </div><div style="margin-bottom: 10px;">Completion date: Nov 2015 /<wbr> Sept 2016 </div><div style="margin-bottom: 10px;">Doses: 24U; 48U; 72U; 96U </div><div style="margin-bottom: 10px;">Administration /<wbr> Duration: im injection to the bilateral masseter muscle on D1 and retreatment at D180 if applicable.<wbr> </div><div style="margin-bottom: 10px;">Location: Canada </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02010775?recr=Open&fund=2&rcv_s=11%2F12%2F2013&rank=236" class="defaultlink">NCT02010775</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7307">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-13T18:08:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-13T18:08:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Ph2 Trial With Teva's Huntexil for Huntington</title>
	<pubDate>2013-12-13T16:20:13+01:00</pubDate>
	<wp:post_id>4624</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pridopidine 45mg, 67.<wbr>5mg, 90mg, and 112.<wbr>5mg will be assessed twice-daily vs placebo for the symptomatic treatment of Huntington's Disease.<wbr> PE will determine change from baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at week 26.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Teva is engaged in the development of pridopidine (Huntexil, ASP2314, ACR 16).<wbr> </div><div style="margin-bottom: 10px;">The drug candidate is in Ph3 for the treatment of motor disorders including Huntington's disease.<wbr> </div><div style="margin-bottom: 10px;">In September 2012, Teva announced that it has concluded an Asset Transfer Agreement with NeuroSearch A/<wbr>S to purchase all rights, assets and obligations relating to Huntexil.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">Recruitment: n=400 </div><div style="margin-bottom: 10px;">Start date: Jan 2014 - Jan 2015 /<wbr> Feb 2015 </div><div style="margin-bottom: 10px;">Location: EU /<wbr>US </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02006472?term=NCT02006472&rank=1" class="defaultlink">NCT02006472</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7523c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">On April 24h Teva announced the enrollment of the first patient in the Pride-HD study.<wbr> To be noted, the completion date has been delayed to March 2015, and locations expanded to global from EU/<wbr>US.<wbr> </div><div style="margin-bottom: 10px;">Professor G.<wbr> Bernhard Landwehrmeyer, M.<wbr>D.<wbr>, Ph.<wbr>D, FRCP, and professor of neurology, Ulm University Hospital, Germany will be the lead study investigator.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Drug</STRONG> </div><div style="margin-bottom: 10px;">Pridopidine is an investigational, oral, small molecule being developed for the symptomatic treatment of Huntington&rsquo;s disease (HD).<wbr> Teva intends to design and complete new clinical studies of pridopidine to assess its potential for symptomatic relief of HD.<wbr> Earlier clinical studies of pridopidine conducted in the U.<wbr>S.<wbr>, EU and Canada in patients with HD indicate a significant treatment effect on an important secondary endpoint, Total Motor Score (TMS).<wbr> </div><div>In previous studies, where doses up to 45 mg bid were tested, pridopidine was well tolerated with an adverse event profile similar to placebo, and treatment with pridopidine was not associated with worsening of disease signs and symptoms.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7306">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-13T16:20:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-13T16:20:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GTx Plans Regulatory Meeting With The FDA To Define Pathway For nmCRPC Approval For GTx-756</title>
	<pubDate>2013-12-12T16:05:25+01:00</pubDate>
	<wp:post_id>4625</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GTx has announced a poster presentation on its SARM Enobosarm as a 
potential treatment for Androgen Recptor-Positive Breast Cancer at the upcoming 
SABC congress.<wbr> The drug is currently being evaluated in phII study for the 
treatment of metastatic breast cancer.<wbr> Meanwhile, a phII study 
with GTx-758 in patients with mCRPC is ongoing with the goal 
being to develop the drug as the first secondary hormonal therapy in men, who have non-metastatic castration resistant 
prostate cancer 
nmCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Capesaris Program</STRONG> </div><div style="margin-bottom: 10px;">The GTx-758 phase 2 study was originally designed to evaluate the safety and effectiveness of three doses of the drug; 125 milligrams, 250 milligrams, and 500 milligrams, oral daily dose.<wbr> The primary endpoint of the study is the proportion of patients with a greater than 50% reduction from baseline in serum PSA by day 90.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Other key endpoints include, free testosterone levels, sex hormone binding globulin levels, and total testosterone levels in the study subjects.<wbr> Prostate cancer progression is also being monitored.<wbr> In addition, the clinical studies evaluating the ability of GTx-758 to treat certain estrogen deficiency side effects associated with androgen deprivation therapy such as hot flashes, bone loss and insulin resistance.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">After reviewing data collected to date from the 125 milligram dosing arm, showing the ability of the drug to substantially increase 
sex hormone binding globulin and lower free testosterone, the clinical protocol was recently amended to eliminate the third dosing arm of 500 milligrams originally designed for the study and to increase the number of subjects to be involved in the 125 milligram and 250 milligram dosing arms to 38 subjects per arm.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The number of subjects per arm was increased to provide greater confidence in the safety of GTx-758 and to date  no evidence of venous thromboembolic events or SAEs has been seen.<wbr> 
Enrollment in the 125 milligram cohort is ongoing and assuming there continues to be no unacceptable incidents of venous thromboembolic 
events observed 
in patients 
in this cohort, GTx will then make the decision whether to proceed with dosing of the 250 milligram cohort.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">GTx noted that when primary 
androgen deprivation therapy 
fails, the majority of patients 
develop non-metastatic castration resistant 
prostate cancer 
nmCRPC for which 
there are no approved secondary hormonal 
therapies.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>GTx-758 Unique MOA Compared To Androgen 
Antagonists</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">GTx believes GTx can offer a unique secondary hormonal 
treatment option 
for men with nmCRPC.<wbr> Other agents under development 
basically have 
the same mechanism of action as androgen receptor antagonist, and only have activity against the androgen receptor signaling 
pathway in prostate cancer cells, as it means to prevent metastatic progression.<wbr> As an oral estrogen receptor agonist, GTX-758 is viewed 
as  a new chemical entity with a unique drug mechanism.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">GTx is positoining GTx-758 as a drug that not only affects the androgen receptor signaling 
pathway in prostate cancer cells by maximally suppressing 
circulating free 
testosterone, but also through its estrogenic 
effects provides 
the potential 
to improve bone quality by decreasing bone turnover.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Objective Positioning - Preferred Secondary Hormonal 
Therapy For nmCRPC</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">GTx is stating that bone-only 
agents such 
as bisphosphonates and 
denosomab have 
been shown to prevent bone metastatic disease, and treat skeletal related events in patients – excuse me, in prostate and other cancers.<wbr> With a dual mechanism to prevent metastatic 
disease that 
is directly 
by reducing 
available free 
testosterone to 
prostate cancer 
cells, and indirectly by improving bone quality, to make the bone environment more resistant metastases, GTx-758 could thererfore, it claims, become a preferred secondary 
hormonal therapy 
for men with non-metastatic 
castration resistant prostate 
cancer.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Moreover, by replacing estrogen, the drug may also provide the pro-estrogenic benefits 
to improve other estrogen deficiency side effects commonly associate with primary, androgen 
deprivation therapy, 
such as hot flashes, bone loss in fractures, and metabolic syndrome in insulin resistance.<wbr> 
</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Next Steps</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">GTx plans to meet with FDA to discuss data from its 
ongoing Phase 
2 clinical study, and a 
proposal to develop 
GTx-758 as the first secondary hormonal 
therapy in men, who have nmCRPC.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Its short-term objective is to complete the current Phase 2 safety and dose finding clinical study in metastatic castration 
resistant prostate 
cancer patients.<wbr> Its regulatory objective 
is to find a way forward with the regulatory 
agency that 
will allow the grou to use an earlier endpoint like progression free survival (PFS) rather than OS 
as the clinical benefit endpoint required 
for approval 
in men with nmCRPC.<wbr></P> </div><div><P class="pwrapper">source: <A href="http://phx.corporate-ir.net/phoenix.zhtml?c=148196&amp;p=irol-calendarPast">http:/<wbr>/<wbr>phx.<wbr>corporate-ir.<wbr>net/<wbr>phoenix.<wbr>zhtml?c=148196&amp;p=irol-calendarPast</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9375">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-12T16:05:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-12T16:05:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ScinoPharm Completes API Plant in China</title>
	<pubDate>2013-12-12T15:56:44+01:00</pubDate>
	<wp:post_id>4626</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the beginning of the year ScinoPharm formed a JV with Foresee Pharmaceuticals, a US drug devlivery company, to focus on developing controlled-release formulations of leuprolide for PCa.<wbr> Combination of ScinoPharm's API and Foresee's stabilized injectable formulation holds all the card to start playing the FOPs game.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The completion of the Changshu plant is an important milestone for ScinoPharm as it is the first API production plant to be built in accordance with the latest GMP requirements announced by the China Food and Drug Administration (CFDA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10710_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10710_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="pharmaworld10710attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10710_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10710_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(48,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10710">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-12T15:56:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-12T15:56:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Auxilium Moves Forward With LSE Programme For Xiaflex In Frozen Shoulder</title>
	<pubDate>2013-12-12T15:33:38+01:00</pubDate>
	<wp:post_id>4627</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Auxilium's presentation at this week's Oppenheimer H/<wbr>C conference focused on the recent approval of Xiaflex in the US for the treatment of Peyronie's disease but also noted was the group plans to initiate a phIIb study with the drug in frozen should syndrome before the year-end.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Auxilium concluded a phase II a study in frozen shoulder(adhesive capsulitis) earlier this year demonstrating a statisitcally significant dose response in terms of pain and function over baseline scores.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="neurology7304attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(310 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(201,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(271,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(235,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7304_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(222 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7304">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-12T15:33:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-12T15:33:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NPS Pharmaceuticals's Investor Day - Key Takeaways On New Endocrinology Drug NATPARA</title>
	<pubDate>2013-12-12T15:12:33+01:00</pubDate>
	<wp:post_id>4628</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During last week's investor event, the majority of the focus was on group's new endocrinology drug NATPARA (recombinant human parathyroid hormone) for the treatment of hypoparathyroidsim, the last classic endocrine deficiency disorder without an approved replacement therapy.<wbr> </div><div style="margin-bottom: 10px;">NPS filed a BLA with the FDA in October this year which should lead to a late 2014 approval.<wbr> EU commercialisation plans have yet to be disclosed.<wbr> </div><div style="margin-bottom: 10px;">Analysts at Morgan Stanley are projecting that worldwide sales of Natpara will reach $835m by 2021 with EU commercialisation taking place in 2016 and contributing $284m to worldwide sales by 2021.<wbr> </div><div style="margin-bottom: 10px;">Some of the key slides from the investor event last week are highlighted below: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Results With Natpara</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_14_ScreenCapture14.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_15_ScreenCapture15.jpg"> </div><!-- Comment details --><a name="endocrinology7542attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(112,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(84,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(100,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(152,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(103,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(61,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(103 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(172,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(192,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(161,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(100,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(81,9 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(109,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(125,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7542_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(89,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7542">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-12T15:12:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-12T15:12:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>France's TC Grants Reimbursement to Xtandi</title>
	<pubDate>2013-12-11T17:32:35+01:00</pubDate>
	<wp:post_id>4629</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Transparency Commission (TC) of the Higher Authority on Healthcare (HAS) in France has provided a favourable opinion for the reimbursement of Astellas 's Xtandi (enzalutamide).<wbr> In particular, the drug is approved for the treatment of adult men with mCRPC in patients previously treated with a docetaxel-containing drug.<wbr> The TC has proposed a reimbursement rate of 100%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The decision was taken on the basis of the assessment of the clinical value of the drug (Service Médical Rendu, SMR) which was rated "important".<wbr> </div><div style="margin-bottom: 10px;">In addition, the TC has also assessed that Xtandi brings a moderate improvement to medical benefit (ASMR III rating).<wbr> </div><div style="margin-bottom: 10px;">The full reimbursement decision is attached (in French).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Full reimbursement is generally granted under the French system to innovative and expensive drugs that obtain an important SMR rating.<wbr> The effectiveness of the drug has been assessed through data of the Phase III AFFIRM trial which evaluated efficacy and tolerability of Xtandi against a placebo arm.<wbr> The reimbursement decision has considered Johnson &amp; Johnson (US)'s Zytiga (abiraterone acetate) a valid comparator and has assigned Xtandi the same ASMR rating.<wbr> </div><div style="margin-bottom: 10px;">In addition, the TC decision to grant Xtandi an ASMR rating of III will ensure Astellas the opportunity to maintain over the next five years a price level higher than the lowest price applied in the four main European markets – the European-level price guarantee.<wbr> However, odds for success for Astellas to secure sales growth for Xtandi in the French market will also be influenced by the competition of other treatment approved for the same indications such as Zytiga.<wbr> The drug has been approved by the European Commission in June 2013.<wbr> </div><div>Source: IHS Global Insight </div><!-- Comment details --><a name="oncology9373attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9373_1_XTANDI%255fPIC%255fINS%255fAvis2%255fCT13108.pdf">XTANDI_PIC_INS_Avis2_CT13108.pdf</a>&nbsp;&nbsp;(128,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9373">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-11T17:32:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-11T17:32:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Rhenovia's RHEDAR for Huntington Available for Out-Licensing</title>
	<pubDate>2013-12-11T10:55:57+01:00</pubDate>
	<wp:post_id>4630</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: RHEDAR already went through Ph2 in other therapeutic indications, represents a de-risked drug and is a good candidate for fast-track development and relatively straightforward POC in HD patients for improvement of their QoL with disease-modifying potential.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">RHEDAR is available for out-licensing, and/<wbr>or co-development, and a back-up strategy with an already patented chemical series has been identified.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7302_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7302_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Source: <EM>Discovery of a new mode of action of RHEDAR through modeling and simulation, and its repositioning for Huntington's Disease Treatment</EM> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- founded in May 2007 by an international team highly committed to find new solutions to treat Alzheimer's disease (AD) and other diseases of the central nervous system (CNS).<wbr> </div><div style="margin-bottom: 10px;">- Rhenovia has the legal form of an SAS.<wbr> At present, it is mainly funded by the founders and the team.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7302_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="neurology7302attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7302_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7302_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(129,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7302_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(132,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7302_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(11,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7302">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-11T10:55:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-11T10:55:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Reckitt Benckiser Investor Event - Key Takeaways About Its Consumer Health Strategy</title>
	<pubDate>2013-12-10T16:44:44+01:00</pubDate>
	<wp:post_id>4631</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At a recent investor event Reckitt highlighted some interesting 
dynamics about the consumer OTC and vitamin supplement markets in addition to 
focusing on its own strategy and the scientific manner in which it is addressing 
the OTC gastrointestinal market.<wbr> </div><div style="margin-bottom: 10px;">Below is a selection of slides presented during the 2-day event </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_14_ScreenCapture14.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_15_ScreenCapture15.jpg"> </div><!-- Comment details --><a name="gastroenterology1932attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(94,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(107,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(106,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(93,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(104,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(121,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(108,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(115,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(122 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(68,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1932_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(140,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1932">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-10T16:44:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-10T16:44:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche "On the heels of cancer: biomarkers and combination therapies"</title>
	<pubDate>2013-12-09T17:51:21+01:00</pubDate>
	<wp:post_id>4632</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a press release issued today, Roche has highlighted its activities in the cancer biomarker area and how these are likely to result in greater use of combination therapies than is the case today.<wbr> Behind this is the significant advances being made in next generation sequencing, something Dr Attard (Royal Marsden Uk) alluded to in a recent interview regarding developments in the prostate cancer market.<wbr> He suggested such developments will ultimately change the treatment paradigm within 5-8 years.<wbr> </div><div style="margin-bottom: 10px;"><P class="leadtext"><STRONG>On the heels of cancer: biomarkers and combination therapies</STRONG></P> </div><div style="margin-bottom: 10px;">To adapt anti-cancer treatments as much as possible to an individual patient and his or her disease, guiding biomarkers are needed.<wbr> What are we doing now at Roche in that area? What will new diagnostic and therapeutic approaches look like? </div><div style="margin-bottom: 10px;">Answers were given at the first Oncology Biomarker Symposium in Basel in October and can be found in an interview with its organizer Astrid Kiermaier, Associate Director Oncology Biomarker development: </div><div style="margin-bottom: 10px;"><STRONG>Nearly all pharmaceutical companies are doing biomarker research now.<wbr> Are we at Roche /<wbr>Genentech really a leader in the field?</STRONG> </div><div style="margin-bottom: 10px;">Yes! We start with biomarker discovery very early in research and continue through development of a potential drug and it&rsquo;s registration.<wbr> Currently about 70 % of our anti-cancer drug candidates in clinical development are being developed with a companion diagnostic &ndash; a tool, telling doctors which patient are highly likely to benefit from a drug.<wbr> That&rsquo;s far above average of the pharmaceutical industry.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How are cancer patients being diagnosed today?</STRONG> </div><div style="margin-bottom: 10px;">Tumour tissue is used for most cancer classification and the therapy decisions that follow.<wbr> Several methods are used to detect the presence and levels of proteins in that tissue that correlate with disease subtypes and that are predictive for drug benefit.<wbr> In addition, we collect blood plasma to extract genetic material from tumours, that means, DNA that is released into the blood stream from tumour cells.<wbr> Analysis of this circulating DNA allows characterisation of mutations associated with response or resistance further informing patient care.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What will the cancer diagnostics of tomorrow look like?</STRONG> </div><div style="margin-bottom: 10px;">Technology platforms that can assess many biomarkers at the same time for example next generation sequencing, are starting to enter the field and are expected to supersede single marker analysis via classical methods over the next few years.<wbr> This is a real leap forward both in terms of the information we get, but also in light of the limited tissue available from cancer patients.<wbr> Future developments in both therapeutic and diagnostics will be driven primarily by an increased understanding of the signalling or immune pathways that are inappropriately regulated in cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Will pathway-based therapies instead of organ-specific therapies be the consequence?</STRONG> </div><div style="margin-bottom: 10px;">While pathway specific therapies would be ideal, biology teaches us differently.<wbr> First, it is important to understand whether a certain pathway really drives the cancer.<wbr> Even though we once believed that treating a cancer based on genotype would be the future of cancer medicine, we have since learned that anatomic origin really matters.<wbr> For example: One of our drugs is highly effective as a monotherapy in malignant melanoma carrying a V600 mutation in the BRAF oncogene.<wbr> But there is little or no activity in the context of this mutation in colorectal cancer.<wbr> Research is needed to decipher why.<wbr> Is the V600 mutation a driver in colorectal cancer, a &ldquo;passenger&rdquo; or do we need to hit two targets at the same time? Our exploratory analyses are aimed at addressing these important questions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Will there be more combination treatments in future?</STRONG> </div><div style="margin-bottom: 10px;">Yes, if treatments only intervene at one node of a signalling cascade, other signalling pathways can still be activated, bypass the first blockade enabling uncontrolled cell growth, and making the treatment ineffective.<wbr> Again, it is important to understand the biology of the diseases we aim to treat, the pathways that are driving tumours, the cross-talk between pathways and how this may impact treatment outcome.<wbr> These questions are integral to our biomarker programmes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What are immunotherapies in oncology?</STRONG> </div><div style="margin-bottom: 10px;">They aim to enhance or re-vitalize the body&rsquo;s natural immune response so that it can destroy tumour cells.<wbr> Tumours often develop mechanisms to evade the body&rsquo;s own immune system that would otherwise destroy cancerous cells.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How does biomarker research help in developing these therapies?</STRONG> </div><div style="margin-bottom: 10px;">Biomarker teams try to understand the immune cell repertoire found in the patient&rsquo;s body and tumour.<wbr> Furthermore, we would like to identify mechanisms to restore or to generate an anti-tumour immune response.<wbr> Biomarkers are needed to fully appreciate the complexity of human cancer immune biology and to identify patients most likely to benefit from immunotherapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Why aren&rsquo;t all potential anti-cancer drugs being co-developed with a companion diagnostic?</STRONG> </div><div style="margin-bottom: 10px;">Our overall objective is to co-develop all our drug candidates with a companion diagnostic.<wbr> However, the biology of the diseases may be too complex to enable us to identify a biomarker that qualifies for a companion diagnostic at the start of phase III.<wbr> In those cases biomarker research is continued throughout phase III and post registration.<wbr> In addition, some examples of our drugs are very active in specific diseases - reducing the need for a companion diagnostic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How are biomarkers used beyond the development of companion diagnostics?</STRONG> </div><div style="margin-bottom: 10px;">Biomarker studies can help to understand disease biology and to identify patient subgroups with the highest unmet medical need.<wbr> Furthermore, biomarkers can help to understand the outcome of combination therapies and how to rationally design drug combination therapies.<wbr> Understanding the development of resistance against cancer therapies is another goal of biomarker research.<wbr> Last but not least, a good new biomarker tells us much earlier than traditional clinical assessments like x-ray imaging whether a drugs work.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key success factors for an ideal companion diagnostic?</STRONG> </div><div><DIV class="text-highlite clearfix">
<P>A companion diagnostic should be easy to use, accurate, standardized, broadly available, cost effective and, importantly, validated in clinical trials.<wbr> Ideally, the companion diagnostic is co-developed with the drug and clinically validated prospectively enabling regulatory approvals and reimbursement decisions.<wbr></P>
<P>Source: <a href="http://www.roche.com" class="defaultlink" title="http://www.roche.com">roche.com</a></P>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9370">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-09T17:51:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-09T17:51:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dose-Response Study of Xeomin® for Spasticity due to CP</title>
	<pubDate>2013-12-06T16:58:49+01:00</pubDate>
	<wp:post_id>4633</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: XARA is a Ph3 prospective, multicenter, randomized, double-blind, paralell-group, dose-response study to determine whether injections of Xeomin® into muscles of one or both arms alone or in combination with injections into one or both legs are effective and safe in treating children/<wbr>adolescents (age 2-17 years) with spasticity due to CP.<wbr> PE will evaluate change from baseline in Ashworth Scale in the primary clinical target pattern, i.<wbr>e.<wbr> elbow flexors or wrist flexors.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: n=344 </div><div style="margin-bottom: 10px;">Start date: Jan 2014 Completion date: March 2016 /<wbr> April 2017 </div><div style="margin-bottom: 10px;"><U>Dosage</U> </div><div style="margin-bottom: 10px;">IncobotulinumtoxinA (8 Units per kg body weight)IncobotulinumtoxinA (6 Units per kg body weight)IncobotulinumtoxinA (2 Units per kg body weight) </div><div style="margin-bottom: 10px;">Location: USA; Argentina; Canada; Mexico </div><div><A href="http://clinicaltrials.gov/ct2/show/NCT02002884?recr=Open&amp;fund=2&amp;rcv_s=11%2F06%2F2013&amp;rank=241">Source: NCT02002884</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7301">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-06T16:58:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-06T16:58:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novartis to Assess Pasireotide LAR and Everolimus in Progressive Metastatic GEP-NETs</title>
	<pubDate>2013-12-06T16:31:59+01:00</pubDate>
	<wp:post_id>4634</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis to Assess Pasireotide LAR and Everolimus in Progressive Metastatic GEP-NETs</span>&nbsp;<br><span style="font-size: 12px;">Comment: The COOPERATE-1 study will enroll approx.<wbr> 60 participants with confirmed diagnosis of grade 1/<wbr>2 advanced NET of the gastroenteropancreatic system, and progressive disease within last 12 months.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=6092">...</a><br></div><div style="margin-bottom: 10px;">Status of the study just changed from "Recruiting" to "Active, not recruiting".<wbr> Other parameters changes such as end date and recruitment are provided below.<wbr> </div><div style="margin-bottom: 10px;">End Date is now March 2014 </div><div style="margin-bottom: 10px;">Enrollment: changed from 60 (anticipated) to 36 (actual) </div><div style="margin-bottom: 10px;">2 German sites were withdrawn: Bingen and Heidelberg </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7541">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6092">View thread  Endocrinology6092: Novartis to Assess Pasireotide LAR and Everolimus in Progressive Metastatic GEP-NETs</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-06T16:31:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-06T16:31:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Lexicon R&D Day</title>
	<pubDate>2013-12-06T15:59:50+01:00</pubDate>
	<wp:post_id>4635</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.01i">
<DIV class="ii" id="endocrinology7533.01ii">Comment: On December 5th, management gave a presentation of the company's R&amp;D programs.<wbr><WBR> First part of the agenda was dedicated to LX4211 for type 2DM and type 1DM.<wbr></WBR><WBR> The second part covered Telotristat etiprate for carcinoid syndrome and UC, followed by a review of recent results of LX1033 for IBS-d.<wbr></WBR><WBR> Recent findings from a primary research with 45 US oncologists undertaken by the company and NET Claims data from IMS are highlighted below as well as a selection of key slides.<wbr></WBR></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.02i">
<DIV class="ii" id="endocrinology7533.02ii"><STRONG></STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.03i">

<DIV class="ii"><STRONG>TELESTAR Ph3 Study Design</STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.04i">
<DIV class="ii" id="endocrinology7533.04ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_2_ScreenCapture2.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_1_ScreenCapture2.jpg"></A></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.05i">
<DIV class="ii" id="endocrinology7533.05ii">Location: Currently &gt;50 sites active in North America, EU and Australia</DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.06i">
<DIV class="ii" id="endocrinology7533.06ii">Recruitment: n=30 patients randomized</DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.07i">

<DIV class="ii"><STRONG></STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.08i">
<DIV class="ii" id="endocrinology7533.08ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_3_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_2_ScreenCapture3.jpg"></A></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.09i">

<DIV class="ii"><STRONG></STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.010i">
<DIV class="ii" id="endocrinology7533.010ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_4_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_3_ScreenCapture4.jpg"></A></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.011i">

<DIV class="ii"><STRONG></STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.012i">
<DIV class="ii"><STRONG>Assessment of US Carcinoid Market</STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.013i">
<DIV class="ii" id="endocrinology7533.013ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_5_ScreenCapture5.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_4_ScreenCapture5.jpg"></A></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.014i">

<DIV class="ii"><STRONG></STRONG></DIV>

<DIV class="ii">Source: primary research with 45 oncologists Aug 2013</DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.015i">
<DIV class="ii" id="endocrinology7533.015ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_6_ScreenCapture6.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_5_ScreenCapture6.jpg"></A></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.016i">


<DIV class="ii"><STRONG></STRONG></DIV>

<DIV class="ii">
<DIV class="ii">Source: primary research with 45 oncologists Aug 2013</DIV></DIV>

<DIV class="ii"><STRONG></STRONG></DIV>


<DIV class="ii"><STRONG></STRONG></DIV>

<DIV class="ii">
<DIV class="ii">Source: primary research with 45 oncologists Aug 2013</DIV></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.017i">
<DIV class="ii" id="endocrinology7533.017ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_7_ScreenCapture7.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_6_ScreenCapture7.jpg"></A></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.018i">

<DIV class="ii"><STRONG></STRONG></DIV>

<DIV class="ii">
<DIV class="ii">Source: primary research with 45 oncologists Aug 2013</DIV></DIV>

<DIV class="ii"><STRONG></STRONG></DIV>

<DIV class="ii"><STRONG></STRONG></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.019i">
<DIV class="ii" id="endocrinology7533.019ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_8_ScreenCapture8.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_7_ScreenCapture8.jpg"></A></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="endocrinology7533.020i">

<DIV class="ii"><STRONG></STRONG></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="i hovered" id="endocrinology7533.021i">
<DIV class="ii" id="endocrinology7533.021ii"><a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7533_9_ScreenCapture9.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_8_ScreenCapture9.jpg"></A></DIV></DIV> </div><div><DIV class="i" id="endocrinology7533.022i">

<DIV class="ii"><EM>Source: Lexicon</EM></DIV></DIV> </div><!-- Comment details --><a name="endocrinology7535attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_9_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(101,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7535_10_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(181,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7535">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-06T15:59:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-06T15:59:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong's Botulinum Toxin NABOTA Gains Ground in Latin America</title>
	<pubDate>2013-12-06T14:26:56+01:00</pubDate>
	<wp:post_id>4636</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Daewoong inked a contract worth approx KRW 100 bln (US$94 million) with global aesthetic company PharmaVital.<wbr> Clinical trials are unnecessary in Latin America and Daewoong will enter the approval process (1.<wbr>5-2 years) immediately.<wbr> NABOTA will be released gradually from 2014 to 2016 in Latin America.<wbr> Of note, PharmaVital markets Siax (Medy-tox botulinum toxin A).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">15 LatAm countries, including the largest markets: Mexico, Colombia, Venezuela and Brazil.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Marketing timelines: from 2014 to 2016 </div><div style="margin-bottom: 10px;">Supply contract: PharmaVital will supply NABOTA for 5 years after its roll-out in each country.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.pharmavital.net/web/">http:/<wbr>/<wbr>www.<wbr>pharmavital.<wbr>net/<wbr>web/<wbr></A> </div><div style="margin-bottom: 10px;">HQ: Panama </div><div style="margin-bottom: 10px;"><U>Products</U>: Siax; Bioage; Perfectha; </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7296_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7296_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7296_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- export contract (KRW 300 bln) with Evolus - (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7191" class="defaultlink">Neurology7191: Evolus to Sell Daewoong's Botulinum Toxin (Nabota) in the US and EU Markets</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Daewoong secured domestic marketing approval of NABOTA on November 29.<wbr> The drug is scheduled to be released in early- 2014 after preparation for marketing and production.<wbr> </div><div><EM>Source: Daewoong; Korea Investment</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7296">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-06T14:26:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-06T14:26:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Reorganisation of Almirall Operations in EU Affects 250 Jobs in Spain</title>
	<pubDate>2013-12-06T13:48:35+01:00</pubDate>
	<wp:post_id>4637</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Although Spain is one of the top five pharmaceutical markets in Europe, the impact of a number of cost-containment measures and in particular the implementation of the reference-pricing system, with its most updated version in March 2011 has been increasingly affecting profit growth.<wbr> Amirall has reported that economic decisions made by health authorities in EU have hit the introduction and uptake of new medicines.<wbr> In Spain where the pharma market has been contracting for the past 4 years, the company's restructuring will affect 250 positions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Spain</U>: YTD June 2013 sales decreased by 17.<wbr>3% to €134.<wbr>1M (vs €162.<wbr>0M).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recently Actavis mandated Rotschild to advise on the sale of its EU units (Itally, Spain, France, Germany, and the NL).<wbr> </div><div><EM>Sources: FirstWord; IHS;</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10706">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-06T13:48:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-06T13:48:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Avanir Provides Pipeline Update</title>
	<pubDate>2013-12-05T17:55:56+01:00</pubDate>
	<wp:post_id>4638</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Comment: 
Yesterday at the Piper Jaffray H/<wbr>C conference, Avanir gave an update on its 
strong revenue growth +100% and its pipeline, which will 
now focus on its 2nd generation, patent-protected deuterated 
dextromethorpan.<wbr> The indication focus will be behavioural &amp; mood disorders 
plus multiple sclerosis and diabetic neuropathic pain.<wbr> PhII MS pain data is due 
before the year-end.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><B><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Current 
Financial Progress</SPAN></B> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Commenting 
on the group's revenue development over the last year Keith Katkin 
President &amp; CEO noted:-</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">"If 
you look at our last reported quarter with the quarter ending September 30, 
which happens to be our fiscal year end as well and look at what we've 
accomplished in fiscal 2013, it was really a tremendous year for the company.<wbr> 
Over 100% growth in NUEDEXTA gross revenue in the year with $92.<wbr>1 million in 
gross revenue.<wbr> And if you just look at the business metrics or unit growth over 
the last quarter, quarter and a half, it's still strong.<wbr> So you look at the 
quarter ended September 30, the sequential quarter-over-quarter growth in unit 
demand was 12%.<wbr> You look at this quarter, the first seven weeks of this quarter 
over the first seven weeks of last quarter and we're up just shy of 
10%.<wbr>"</SPAN> </div><div style="margin-bottom: 10px;"><B><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Development 
Perspective </SPAN></B> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Keith 
Katkin elaborated on how dextromethorpan has a very interesting 
profile, modulating both sigma-1 and through NMDA two receptors it 
has talked a lot about.<wbr> But how looking further, NUEDEXTA activates 
serotonin and norepinephrine, two receptors which play a significant role in a 
number of CNS products, many of which are approved for very large indications.<wbr> 
</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">He 
stated, "we think about the therapeutic potential of dextromethorphan and 
we think about the pharmacology, we see tremendous amounts of potential use for 
dextromethorphan.<wbr> So obviously, we're FDA-approved for pseudobulbar affect.<wbr> But 
we really think given the pharmacology, we can be effective in mood and behavior 
disorders, in various types of pain, and also in movement disorders.<wbr>" 
</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">"So 
we've thought about our clinical development program, we've really focused in 
those three different areas, in the mood and behavior disorders.<wbr> We've got 
pseudobulbar affect, plus we have an ongoing Phase II study in agitation, 
secondary to Alzheimer's disease.<wbr> And we announced just a couple of weeks ago 
that we're going to start a Phase II study in treatment-resistant depression in 
the second half of 2014.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">In 
the pain space, we have done a number of studies, both in diabetic peripheral 
neuropathic pain and in pain secondary to multiple sclerosis.<wbr> We'll have data 
from our most recent trial in pain and multiple sclerosis by the end of this 
year.<wbr> And then in movement disorders, we've got a levodopa-induced dyskinesias 
in Parkinson's patients study that's ongoing funded by the Michael J.<wbr> Fox 
Foundation.<wbr>" </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">"We've 
designed our development program for NUEDEXTA with all of those potential 
applications in mind, and we look forward to getting started and get data over 
the few weeks and throughout 2014 as well.<wbr>" </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">"If 
you think about the evolution of a clinical program, we started in diabetic 
peripheral neuropathic pain.<wbr> And then when we first got NUEDEXTA approved for 
pseudobulbar affect, we really – we thought that focusing the pain program on 
pain secondary to multiple sclerosis would be a good idea.<wbr> We thought that would 
be a good idea for two reasons.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-GB"><SPAN style="mso-list: Ignore">·         
</SPAN></SPAN><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">One, 
because our intellectual property in pain was not as long as our intellectual 
property for PBA.<wbr> But in pain secondary to multiple sclerosis, there's a 
possibility to get orphan drug status.<wbr> And so, we've made a decision to move 
down that path.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-GB"><SPAN style="mso-list: Ignore">·         
</SPAN></SPAN><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">In 
addition, there were no approved therapies for treatment of central neuropathic 
pain secondary to multiple sclerosis.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">"For 
all of those reasons, MS pain made a lot of sense for the company.<wbr> Since 
initiating that program, we've in-licensed deuterated dextromethorphan.<wbr> And 
deuterated dextromethorphan has really changed how we can think about the 
overall development program.<wbr> It's got a very long intellectual property life 
through 2030.<wbr> Also – the way the deuterated works is it actually allows us 
to significantly reduce the amount of quinidine in the second generation 
compound.<wbr> So, what we've decided is that, going forward, we will definitely 
pursue diabetic peripheral neuropathic pain assuming we see a signal in the 
Phase II MS pain study.<wbr>" </SPAN> </div><div><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">Source: 
</SPAN><A href="http://www.avanir.com/"><SPAN style="FONT-FAMILY: 'Verdana','sans-serif'; COLOR: blue; FONT-SIZE: 10pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-GB">www.<wbr>avanir.<wbr>com</SPAN></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7295">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-05T17:55:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-05T17:55:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Astellas Press Conference</title>
	<pubDate>2013-12-05T11:42:23+01:00</pubDate>
	<wp:post_id>4639</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has highlighted new therapeutic areas,  current and future product strategy, outlined its multi-track R&amp;D system, and presented recent figures on the pharma market, vision and changes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company is focused on maximazing value of new products and overcoming the upcoming of patent cliffs (generic versions of the Micardis family of hypertensives in 2017 H2, and the expiry of the US patent on Vesicare in 2018).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>maximizing its OAB franchise (Vesicare; Mirabegron)</LI>
<LI>strengthening the oncology field (with additional XTANDI indications)</LI>
<LI>building on partnerships and marketing alliances (Amgen, MSD, Astellas BioPharma)</LI>
</UL> </div><div style="margin-bottom: 10px;">Life cycle management and continuous product rollout have been outlined as part as the strategy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Field of skeletal muscle activation (in collboration with Cytokinetics)</LI>
<LI>Mitochondria related diseases (in collaboration with Mitokyne)</LI>
<LI>Regenerative drugs (external resources such as academia, biotech .<wbr>.<wbr>.<wbr>)</LI>
<LI>Vaccines (partnering)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- by utilizing more external capabilities and resources </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9369attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(134,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(84,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(65,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(67,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9369_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(71 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9369">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-05T11:42:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-05T11:42:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Poll Results Report US-based Oncologists and Urologists Anticipate Early Usage of Xofigo</title>
	<pubDate>2013-12-05T10:49:33+01:00</pubDate>
	<wp:post_id>4640</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Data from the FirstWord poll reveals that physicians appear to be positive towards utilising Xofigo across the entire treatment paradigm (36% prominently in pre-chemo and 38% in the post-chemo settings).<wbr> Selected data are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Where are you using/<wbr>where do you plan to initially use Xofigo in the treatment algorithm ? </div><div style="margin-bottom: 10px;"><U>Oncologists</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9368_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Urologists</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9368_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">- On a scale of 1 (very difficult) to 7 (very easy) can you assess how convinient from a logistical perspective (i;e reimbursement, coordination with administrating physician) it typically has been to secure treatment for a patient with Xofigo ? </div><div style="margin-bottom: 10px;"><U>All</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9368_3_ScreenCapture3.jpg"> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><a name="oncology9368attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9368_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9368_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9368_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(16,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9368">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-05T10:49:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-05T10:49:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation/Astellas' Enzalutamide to Enter Registration Trial for Non-Metastatic CRPC</title>
	<pubDate>2013-12-04T09:51:03+01:00</pubDate>
	<wp:post_id>4641</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000; FONT-SIZE: 8pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000; FONT-SIZE: 8pt"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000; FONT-SIZE: 8pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000"><SPAN style="FONT-SIZE: 8pt"></SPAN><SPAN style="FONT-SIZE: 8pt"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000"><U>PE</U>: same for both studies</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000"><U>Protocol</U>: PROSPER may allow patients to continue on ADT while the SPARTAN trial is only including patients who have progressed on first-generation anti-androgens.<wbr></SPAN> </div><div><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; COLOR: #000000"><EM>Source: Medivation; Astellas; </EM><A href="https://www.clinicaltrialsregister.eu/ctr-search/search?query=enzalutamide"><SPAN style="COLOR: #000000"><EM>https:/<wbr>/<wbr>www.<wbr>clinicaltrialsregister.<wbr>eu/<wbr>ctr-search/<wbr>search?query=enzalutamide</EM></SPAN></A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9362">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-04T09:51:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-04T09:51:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>IBS-D Ph2 of Lexicon's LX1033 Fails to Show Improvement Vs Placebo</title>
	<pubDate>2013-12-03T16:31:36+01:00</pubDate>
	<wp:post_id>4642</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The primary endpoint of this study was the change in stool consistency averaged from baseline to day 28.<wbr> All treatment groups, including placebo, showed significant improvements over time, yet differences between placebo and LX1033 in stool consistency were not statistically significant.<wbr> The company noted there were positive trends on a separate, abdominal pain responder analysis at the highest dose.<wbr> More information to come during the company R&amp;D Day on Dec.<wbr> 5th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In this Phase 2 study of IBS-d, 373 patients were randomized to be treated for 28 days with either placebo or one of three different dose levels of LX1033 for 28 days, 1000 mg twice daily, 500 mg twice daily, and 500 mg three times daily.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint was the change from baseline in stool consistency as evaluated by the Bristol Stool Form Scale.<wbr> </div><div style="margin-bottom: 10px;">A key secondary endpoint was the change from baseline in abdominal pain, and other endpoints included the change in plasma 5-HIAA.<wbr> </div><div><EM>Source: Lexicon</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1931">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-03T16:31:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-03T16:31:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways From the 2nd EU Congress on Endometriosis (Nov 28-30 in Berlin)</title>
	<pubDate>2013-12-03T14:58:47+01:00</pubDate>
	<wp:post_id>4643</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: More than 670 gynaecologists (vs 622 in 2012) from 51 countries (vs 43 last year) attended the congress.<wbr> This year selected theme was deep-infiltrating endometriosis (DIE), a particular form of endometriosis that penetrates under the peritoneal surface.<wbr> The congress mainly focused on live surgeries, a crosssection of current research areas and discussions of case studies, but did not provide new data/<wbr>results on drugs.<wbr> Thank to Patrick Cabri (Medical Director Uro-Onco Franchise), we have got feedback from the two only pharma representatives.<wbr> Bayer opened the event with a three-module session focused on the challenges in the management of endometriosis, clinicial experience and evidence-based treatment with Visanne, and current controversies in the medical management of the condition.<wbr> On the second day, Takeda's lunch symposium titled 'start of the art in endometriosis therapy' dealt with the role of GnRH agonists in the treatment of the condition.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Current classification</STRONG> (K.<wbr> Biberoglu, Turkey) - Most widely used staging system for endometriosis is the revised American Society for reproductive Medicine (rASRM) classification system.<wbr> Additional staging tools have been published but can only be seen as added classification.<wbr> The fertility index (EFI) is one of those but is very subjective.<wbr> Can only be used if goal of treatment is fertility.<wbr> Brazil is preparing the AAGL classification which is only based on the surgical findings.<wbr> Ideal tool does not exist yet.<wbr> No clear conclusion from the author, still use the rASRM! </div><div style="margin-bottom: 10px;"><STRONG>Mechanisms of pain in endometriosis</STRONG> (K.<wbr> Vincent, GB) - Mechanism of pain is very complex.<wbr> Chronic pain may alter the volume of some parts of the brains (thalamus for example).<wbr> Body adaptation to chronic pain (this may explain the “low” score at VAS).<wbr> It is important that pain management in endometriosis is initiated early.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>A stepwise approach to management</STRONG> (N.<wbr> Leyland, Canada) - Full explanation of the Canadian guidelines.<wbr> Those guidelines recommend a stepwise approach to early medical treatment with the aim of delaying the need for surgery and primarly focusing on alleviating pain.<wbr> Similar findings at the ESHRE guidelines 2013 and WES consensus 2011.<wbr> Still open for discussion: what is the role of medical therapy in treatment of DIE? </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Pathophysiology of endometriosis and rationale for progestin therapy</STRONG> (F.<wbr> Petraglia, It) - Three theories on the appearance of endometriosis: one as retrograde migration of endometrial cells during menstruation, the second is the migration of those cells through the vascular bed in the uterus and the last and new is the migration of stem cells to the adjacent tissues.<wbr> Visanne has pleiotropic effects (multiple targets) = stop proliferation as well as inflammation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Visanne data</STRONG> (T.<wbr> Faustmann, Bayer) - Presentation of main clinical and safety data by the head of Medical affairs Bayer.<wbr> Additional clinical data from Japan has also been shown with the clear statement that a partner is performing those activities, with no direct involvement of Bayer.<wbr> From Japan a publication is expected on the recurrence rate between Visanne and a GnRHa.<wbr> No publication date yet.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Anti-inflammatory effects of Visanne</STRONG>: new data (M.<wbr> Mueller, CH) - Presentation of interim data on some cytokines (from peritoneal fluid taken during surgery): Macrophage chemotactic factor-1 (MCP-1), Midkine and Glycodelin-A.<wbr> All are potent inflammatory cytokines.<wbr> Study compared placebo with Visanne and a GnRHa, both prescribed for 3 months before surgery.<wbr> Significant reduction on cytokines levels for both products when compared to placebo, no difference between Visanne and GnRHa.<wbr> In conclusion: Visanne has a potent anti-inflammatory effect, similar to GnRHa.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Real-world experience with Visanne</STRONG> (N.<wbr> Leyland, Canada) - In Canada there is a long waiting list for operating rooms.<wbr> Therefore drugs have been used during this period.<wbr> The objective is to improve symptoms, not to improve the surgery! Bleeding under Visanne can be present but mostly during the first 3 months.<wbr> Thereafter improvement.<wbr> If the bleeding is still problematic 1 (or 2) dose(s) of GnRHa followed by Visanne thereafter is recommended.<wbr> For DIE his experience is that Visanne reduce the lesion size by 30% if given 6 months pre-operatively.<wbr> Visanne is a less expensive treatment as second-line treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Specific comments from audience</STRONG> </div><div style="margin-bottom: 10px;">1/<wbr> Has Visanne an effect on fibroma’s? - No data available.<wbr> In Japan there might be some observations showing some volume reduction.<wbr> No more info.<wbr> </div><div style="margin-bottom: 10px;">2/<wbr> Has Dienogest a contraceptive effect? - No studies as such.<wbr> It could be used as off-label use but the intake has to be well planned.<wbr> Due to compliance issues (forgetting an intake) it is recommended to use in addition a barrier method during the first 6 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Controversies in medical management of endometriosis</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>In Europe: +/<wbr>- 14 Mio women suffer from endometriosis.<wbr> Proportion of DIE (deep infiltrating endometriosis): 10% to 20%</LI>
<LI>DIE: only 30% of patients will have a recurrence after surgical intervention, often in the urinary tract (from 4.<wbr>4% to 12% according to the literature).<wbr></LI>
<LI>Incomplete excisional surgery is the main cause of recurrence.<wbr></LI>
<LI>Surgery need specialized centers &amp; trained gynecologists.<wbr> It is also technically challenging.<wbr></LI>
<LI>Center of excellence in Europe: 600 centers only.<wbr> Therefore waiting lists for surgery, leading to medical treatment necessity.<wbr> Fact: Sometimes women feel good under medication that they postpone the surgery!</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Pf.<wbr> Chapron</U> concluded this session highlighting the following: </div><div style="margin-bottom: 10px;"><UL><LI>Medical treatment is efficient to treat DIE</LI>
<LI>Progesterone receptors in smooth muscles surrounding the endometriotic cells have been shown</LI>
<LI>Surgery and medical treatment are required and to be initiated as earlier as possible.<wbr></LI>
<LI>Not all patients are well surgically treated therefore the need for medical treatment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Causes of subfertility: Dyspareunia; Phagocytosis increase; Change in peritoneal fluid; Gametes transportation; Disturbed ovum pick-up.<wbr> </div><div style="margin-bottom: 10px;">Maturation of oocyte in endometriotic milieu lead to less implantation rate/<wbr>pregnancy (shown through endometriotic donor to no endometriosis receptor study) </div><div style="margin-bottom: 10px;"><STRONG>Role of GnRHa</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>If surgery only: 80% improvement in pain but recurrence of 20% in 5 years</LI>
<LI>Reduction of recurrence rates (Hemming, reprod med 1998)</LI>
<LI>Recurrence rate: 50% after 12 months for DIE, less for SUP or OMA</LI>
<LI>If surgery done just before menses higher recurrence rate</LI>
<LI>Intermittent GnRHa treatment: can lead to 10 months off treatment.<wbr> Ideal for long term treatment.<wbr></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Will be published in the <EM>Journal of Endometriosis and Pelvic Pain Disorders</EM> within 3 months.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9358">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-03T14:58:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-03T14:58:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Findings from Two Ph3 with Fampridine-SR for Spasticity in SCI</title>
	<pubDate>2013-12-03T12:48:11+01:00</pubDate>
	<wp:post_id>4644</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The results which have been recently published in <EM>Spinal Cord</EM> show that Fampridine-SR was well tolerated.<wbr> No significant differences were observed between treatment groups for the primary end points of Ashworth score and SGI.<wbr> The overall results of previous studies and those reported here suggest that further evaluation of fampridine-SR may be warranted in patients with SCI.<wbr> </div><div style="margin-bottom: 10px;"><P-H4><STRONG>Study Details</STRONG></P-H4> </div><div style="margin-bottom: 10px;"><P-H4>- design </P-H4> </div><div style="margin-bottom: 10px;"><P-H4>2 randomized, double-blind, placebo-controlled trials.<wbr> </P-H4><P-H4><A href="http://ci.beaufour-ipsen.com/“,”http://clinicaltrials.gov/ct2/show/study/NCT00041717?term=fampridine&amp;phase=2&amp;rank=8&amp;show_locs=Y#locn“,”">NCT00041717</A> </P-H4><P-H4><A href="http://ci.beaufour-ipsen.com/“,”http://clinicaltrials.gov/ct2/show/NCT01683838?term=fampridine&amp;phase=2&amp;rank=9“,”">NCT01683838</A></P-H4> </div><div style="margin-bottom: 10px;"><P-H4>- recruitment </P-H4><P-H4>the populations were 212 and 203 patients in the 2 studies.<wbr></P-H4> </div><div style="margin-bottom: 10px;">- locations </div><div style="margin-bottom: 10px;"><P-H4>US &amp; Canada </P-H4><P-H4>- methods </P-H4><P-H4>Patients with incomplete chronic SCI were randomized to twice daily fampridine-SR 25 mg or placebo, with a 2-week single-blind placebo run-in, a 2-week titration, 12 weeks of stable dosing, 2 weeks of downward titration and 2 weeks of untreated follow-up.<wbr> </P-H4> </div><div><P-H4>Source: <I>Spinal Cord</I> advance online publication 12 November 2013; doi: 10.<wbr>1038/<wbr>sc.<wbr>2013.<wbr>137</P-H4> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7290">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-03T12:48:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-03T12:48:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Closes the Sale of its Obesity Intervention Business for Up to $110M</title>
	<pubDate>2013-12-03T11:57:01+01:00</pubDate>
	<wp:post_id>4645</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Apollo Endosurgery, Inc.<wbr>, a developer of medical devices for endoscopic surgical procedures, has acquired the obesity intervention division of Allergan (the LAP-BAND® adjustable gastric banding system, and the ORBERA™ intra-gastric balloon system).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The purchase price of up to $110 million includes an upfront cash payment of $75 million, a minority equity interest in Apollo by Allergan of $15 million, and up to $20 million in additional contingent consideration to be paid upon achievement of certain regulatory and sales milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Allergan announced the transaction during its Q3 earnings on Oct 29.<wbr> </div><div><EM>Source: Allergan; Apollo Endosurgery</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7289">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-03T11:57:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-03T11:57:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>IQWiG Reports Xtandi Has Additional Benefit for Post-Chemo Prostate Cancer</title>
	<pubDate>2013-12-03T08:39:55+01:00</pubDate>
	<wp:post_id>4646</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Medivation/<wbr>Astellas' Xtandi has 'major' additional benefit over BSC in patient without visceral metastases and 'significant' additiona benefit over BSC in patients with visceral metastases.<wbr> </div><div style="margin-bottom: 10px;">IQWiG also reported that Xtandi improved OS in patients without visceral metastases and delayed onset of complications and improve dpain in patients with and without visceral metastases.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Comments are due Dec.<wbr>23, with a final benefit assessment from G-BA expected in February.<wbr> </div><div><EM>Source: Biocentury</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9356">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-03T08:39:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-03T08:39:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Gastrin Antagonist Demonstrates Preliminary Proof Of Efficacy In Type I Gastric Carcinoid</title>
	<pubDate>2013-12-02T21:04:50+01:00</pubDate>
	<wp:post_id>4647</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Gastrin Antagonist Demonstrates Preliminary Proof Of Efficacy In Type I Gastric Carcinoid</span>&nbsp;<br><span style="font-size: 12px;">Comment: At this week's UKI NETs meeting, Andrew Moore from the University of Liverpool presented early clinical trial data on the gastrin CCK2 receptor antagonist netazepide in type-1 gastric NET.<wbr> The small study in 8 patients demonstrated tumour regression and a good tolerability profile.<wbr> The first clinical presentation on this product was made at ENETS 2012.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7523">...</a><br></div><div>CCK2 could be a potential target for peptide approach as well.<wbr> One of the clinical investigator involved in this study would be Timothy Wang of Columbia University whom I met recently.<wbr> He is interested in working with us as well.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7532">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7523">View thread  Endocrinology7523: New Gastrin Antagonist Demonstrates Preliminary Proof Of Efficacy In Type I Gastric Carcinoid</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-02T21:04:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-02T21:04:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results Of New Allergan Sponsored US Spasticity Survey</title>
	<pubDate>2013-12-02T13:11:38+01:00</pubDate>
	<wp:post_id>4648</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The National Stroke Association and Allergan recently conducted a US 
survey to understand the true impact of this condition on stroke survivors and 
their caregivers.<wbr> According to the findings, 70 percent (n=300) of stroke 
survivors living with spasticity and their caregivers rank spasticity as one of 
the top three symptoms impacting their life post-stroke, ranking second only to 
paralysis.<wbr> Yet, close to 50 percent of stroke survivors and their caregivers are 
unaware of the available treatment options.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the results of the survey Dr.<wbr> Elliot J.<wbr> Roth, Medical Director 
of the Patient Recovery Unit and Attending Physician, Rehabilitation Institute 
of Chicago; Professor &amp; Chairman, PM&amp;R, Northwestern University Feinberg 
School of Medicine states in the press realease "Spasticity is a disabling 
condition, but, oftentimes, patients are either uncomfortable or too overwhelmed 
to discuss it with their physician.<wbr> The focus after someone has experienced a 
stroke is so commonly on preventing a second stroke that rehabilitation goals 
are covered in broad terms.<wbr> This can leave patients and their caregivers feeling 
unprepared for a larger discussion about the post-stroke symptoms they may be 
experiencing, including spasticity.<wbr> It’s critical that patients and caregivers 
understand that even if a person has been experiencing spasticity for years, in 
many cases, there are ways to help manage the condition,” </div><div style="margin-bottom: 10px;">Although 95 percent (n=780) of physicians surveyed believe spasticity has a 
moderate to severe impact on their patients’ lives, approximately 31 percent of 
neurologists and 27 percent of primary care physicians who treat stroke 
survivors focus their efforts on preventing a secondary stroke versus discussing 
physical complications like spasticity.<wbr> </div><div style="margin-bottom: 10px;">For more information about spasticity, including an interactive discussion 
guide patients are referred to a website which potentially may be sponsored by 
Allergan <A href="http://www.SpasticityAfterStroke.com">www.<wbr>SpasticityAfterStroke.<wbr>com</A>.<wbr> </div><div>Source: Yuma Arizona News </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7288">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-02T13:11:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-02T13:11:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New COO at Takeda to Become Next CEO</title>
	<pubDate>2013-12-02T11:37:33+01:00</pubDate>
	<wp:post_id>4649</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Christophe Weber, head of vaccines at GSK, will take over as COO in April 2014, and is expected to become joint CEO and COO (with Hasega as chairman) in June 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- the next 2-3 years will see a succession of global launches, and the new CEO will face challenges to maximize the drug's global potential in EU, US and EM.<wbr> </div><div style="margin-bottom: 10px;">- As Weber was responsible for vaccines at GSK he will help Takeda build in this new area (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1864" class="defaultlink">GastroEnterology1864: Takeda's New Strategy Targets the Vaccine Market</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>PhD in pharmceutics</LI>
<LI>Broad experience at GSK, where he heads vaccines.<wbr> He also was responsible for the US and Asia.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10701">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-12-02T11:37:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-12-02T11:37:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progenics To Relaunch Azedra Registrational Trial</title>
	<pubDate>2013-11-29T18:31:17+01:00</pubDate>
	<wp:post_id>4650</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Progenics has announced it is resuming a phase 2b clinical study of 
safety and efficacy of a novel targeted radiotherapy, Azedra<SUP>™</SUP>, in 
patients suffering from pheochromocytomas.<wbr> Existing options for these rare 
endocrine tumors that form in the adrenal glands can fail to result in effective 
disease treatment.<wbr> </div><div style="margin-bottom: 10px;">Commenting on Azedra the trials lead investigator Daniel Pryma, 
M.<wbr>D.<wbr>, Assistant Professor of Radiology and Nuclear Medicine/<wbr>Molecular Imaging 
Modality Chief of the <ORG>Department of Radiology</ORG> at the <ORG>University 
of Pennsylvania Perelman School of Medicine</ORG>,  said, "I have seen in 
my own research evidence that Azedra is a promising agent for the treatment of 
metastatic pheochromocytoma and paraganglioma — two orphan oncology indications 
with tragically unmet needs.<wbr> There currently are no medications approved 
specifically to treat pheochromocytomas and paragangliomas.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Azedra originally was developed by <ORG>Progenics' Molecular Insight 
Pharmaceuticals</ORG> (MIP) subsidiary, which commenced the phase 2b study under 
a 2009 Special Protocol Assessment (SPA) with the US FDA.<wbr> </div><div style="margin-bottom: 10px;"><ORG>The compound also has Orphan Drug and Fast Track designations.<wbr> In late 
2010 MIP suspended the trial, with enrollment two-thirds complete, to seek 
additional funding.<wbr> Progenics, which acquired MIP in early 2013, plans for 
patient recruitment to continue after making drug supply manufacturing 
arrangements for the trial.<wbr> </ORG> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Following a successful completion of this phase 2b study, Progenics intends 
to submit a New Drug Application (NDA) and request priority review to receive 
<ORG>FDA</ORG> action on the application within six months instead of the 
standard ten.<wbr> </div><div style="margin-bottom: 10px;">Azedra may also have utility in treating neuroblastomas and other 
neuroendocrine diseases.<wbr> </div><div style="margin-bottom: 10px;">Hagop Youssoufian, M.<wbr>Sc.<wbr>, M.<wbr>D.<wbr>, Executive Vice President of Research 
and Development for Progenics, said, "Azedra has the potential to be the first 
approved treatment for pheochromocytomas.<wbr> Our team is energized by this 
opportunity to potentially bring a treatment option with improved dosing, safety 
and efficacy to patients suffering with these devastating conditions.<wbr>" </div><div>Source: <A href="http://www.progenics.com">www.<wbr>progenics.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7531">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-29T18:31:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-29T18:31:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TASQ Therapy Area Landscape</title>
	<pubDate>2013-11-29T15:54:54+01:00</pubDate>
	<wp:post_id>4651</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached a newly created competitive landscape for 
TASQ.<wbr> This slide kit has been created in close collaboration with Scientific 
Intelligence and the Uro-Oncology Franchise.<wbr> </div><div style="margin-bottom: 10px;">We encourage you to contribute to our internal knowledge by evaluating and 
responding to some of the "Key Intelligence Questions" included in this 
document.<wbr> However, no matter what competitive information/<wbr>soft intelligence you 
have that relates to this area, please do keep us informed of any key 
developments in your countries.<wbr> </div><div>We hope that you will find it a useful tool.<wbr> </div><!-- Comment details --><a name="oncology9355attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9355_1_Final%20TASQ%255fTAL%255f29th%255fNov2013.ppt">Final TASQ_TAL_29th_Nov2013.ppt</a>&nbsp;&nbsp;(3,6 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9355">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-29T15:54:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-29T15:54:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nanomedicine Platform Takes A Leap Forward</title>
	<pubDate>2013-11-28T17:25:05+01:00</pubDate>
	<wp:post_id>4652</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:BIND Therapeutics, a clinical nanomedicine platform company has announced that the company's co-founders have successfully engineered targeted nanoparticles to cross biological barriers, potentially broadening future therapeutic applications for its platform.<wbr> Its previously announced Accurins, have to date has been partnered with a number of companies and its proprietary nanoengineered docetaxel BIND-014 is in phII for the treatment of mCRPC (data from a recent presentation highlighting its activity is shown below).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Published Paper</STRONG> </div><div style="margin-bottom: 10px;">The data has been published in a paper entitled, <EM>"Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery,"</EM> published in the November 27, 2013 online issue of <EM>Science Translational Medicine</EM>, </div><div style="margin-bottom: 10px;"><STRONG>The Key Discovery</STRONG> </div><div style="margin-bottom: 10px;">BIND's co-founders Robert Langer Sc.<wbr>D.<wbr>, and Omid Farokhzad, M.<wbr>D.<wbr>, have demonstrated the ability to enhance the surface properties of the nanoparticle to target the neonatal Fc receptor (FcRn), a transport receptor present on the plasma membrane of cells that form many of the biological barriers in the body including: intestinal epithelial barrier, pulmonary epithelial barrier, blood-brain barrier, fetal-placental barrier, and blood-ocular barrier.<wbr> </div><div style="margin-bottom: 10px;">The FcRn function is to shuttle Immunoglobulin G (IgG) molecules across biological barriers that are otherwise impermeable to IgG.<wbr> Taking advantage of the biological properties of the FcRn as a model transcellular trafficking receptor, the investigators demonstrated for the first time, proof of concept in a preclinical model that targeted therapeutic nanoparticles can exploit biological transport pathways and gain access to biological compartments that are otherwise impermeable to nanoparticles and other macromolecules.<wbr> </div><div style="margin-bottom: 10px;">The FcRn-targeted nanoparticles were shown in an animal model to cross the intestinal epithelial barrier after oral administration and enter the systemic circulation, displaying an absorption efficiency that enabled uptake of therapeutic dose levels.<wbr> As expected, the FcRn-mediated nanoparticle absorption was lost in animals deficient in FcRn expression.<wbr> Using insulin as a model large molecular weight drug with minimal oral bioavailability, the FcRn-targeted nanoparticles were able to significantly increase insulin bioavailability resulting in plasma glucose modulation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Credit Suisse H/<wbr>C Conference Presentation</STRONG> </div><div style="margin-bottom: 10px;">" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_1_ScreenCapture1.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_10_ScreenCapture10.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_11_ScreenCapture11.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_12_ScreenCapture12.jpg"> </div><!-- Comment details --><a name="oncology9353attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(96,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(89,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(90 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(108,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(110 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(84,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(75 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(637 B)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(118,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9353_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(73,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9353">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-28T17:25:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-28T17:25:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sativex® Approved in Switzerland</title>
	<pubDate>2013-11-28T11:47:16+01:00</pubDate>
	<wp:post_id>4653</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A full MA has been granted by the Swissmedic authorities for the treatment of moderate to severe spasticity in MS patients who have not responded adequately to other anti-spasticity medications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Depending on completion of P&amp;R procedures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">23 countries, including 17 in EU (on prescription in UK, Spain, Germany; Canada; Denmark, Norway, Israel, Austria, Poland, Sweden, Italy and Finland).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Launch currently in preparation for further 8 EU countries, as well as Australia, New Zealand and Kuwait.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7287">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-28T11:47:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-28T11:47:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lead Investigator Reports on Xofigo</title>
	<pubDate>2013-11-28T11:35:35+01:00</pubDate>
	<wp:post_id>4654</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chris Parker, the PI of ALSYMPCA trial and consultant clinical oncologist at the Royal Marsden hospital in London, provides his views on the radioactive nature of Xofigo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Xofigo is an alpha-emitter, while current radiation therapies use beta-emitters such as barium and strontium.<wbr> </div><div style="margin-bottom: 10px;">Parker suggests that the limited usage of older radioactive therapies stems primarily from their lack of efficacy.<wbr> </div><div style="margin-bottom: 10px;">Xofigo provides an OS benefit, a QoL benefit, and benefit in terms of time to first skeletal-related event, and a much more favourable profile.<wbr> " .<wbr>.<wbr>.<wbr> so to me, there's no comparison".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">EU experience with radioactive therapies is broadly thought to be greater than in the US, due to less familiarity with radiotherapies among physicians in the country.<wbr> Also, in the US a nuclear license is required to administer the drug.<wbr> </div><div style="margin-bottom: 10px;"><U>UK perpsectives:</U> Parker suggests that there will be little issue with how Xofigo is used in the UK.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
20 centers in the UK have already been involved in the ALSYMPCA study, and it would perharps require just 10 centers to cater for expected demand in the country.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Parker reports that "in the ALSYMPCA trial Xofigo was used in combination with a whole range of different hormone therapies, corticosteroids, oestrogens, anti-androgens, ketoconazole, and given the mechanism of actions, it is completely different to hormonal agents.<wbr>" He adds "I don't anticipate any problems, any difficulties in combining Xofigo with either abiraterone or enzalutamide".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Parket oulines it is " .<wbr>.<wbr>.<wbr> a particulalrly viable route given the safety profile of the drug" .<wbr>.<wbr>.<wbr> "toxicity of six cycles of Xofigo is remarkably low".<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9350">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-28T11:35:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-28T11:35:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Expanded Treatment Protocol of Pasireotide LAR for Acromegaly</title>
	<pubDate>2013-11-27T18:34:14+01:00</pubDate>
	<wp:post_id>4655</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new study planned as an expanded treatment protocol to provide acromegalic patients access to pasireotide LAR while regulatory approval for pasireotide is sought.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> </div><div style="margin-bottom: 10px;">The ACCESS Ph4 trial is an open-label, multi-center, safety monitoring program for treating patients with SOM230 who have need to receive medical therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Intervention</STRONG> </div><div style="margin-bottom: 10px;">Pasireotide LAR will be administered intramuscularly (i.<wbr>m.<wbr>) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">approx.<wbr> 26 sites in the US </div><div>Source: Please see @ <A href="http://clinicaltrials.gov/ct2/show/NCT01995734?term=PROSTATE+OR+BOTULINUM+OR+ACROMEGALY+OR+NEUROENDOCRINE+OR+CUSHING&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=10%2F27%2F2013&amp;rank=1&amp;submit_fld_opt=">NCT01995734<BR></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7530">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-27T18:34:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-27T18:34:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Gastrin Antagonist Demonstrates Preliminary Proof Of Efficacy In Type I Gastric Carcinoid</title>
	<pubDate>2013-11-27T14:48:14+01:00</pubDate>
	<wp:post_id>4656</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At this week's UKI NETs meeting, Andrew Moore from the University of Liverpool presented early clinical trial data on the gastrin CCK2 receptor antagonist netazepide in type-1 gastric NET.<wbr> The small study in 8 patients demonstrated tumour regression and a good tolerability profile.<wbr> The first clinical presentation on this product was made at ENETS 2012.<wbr> </div><div style="margin-bottom: 10px;">Netrazepide is being developed by a company called Trio Pharmaceuticals based in Sussex UK.<wbr> It in-licensed the product from Ferring which had been previously developing the drug for gastroeoesophageal reflux disease.<wbr> Ferring stopped development in 2005.<wbr> In June 2007, orphan designation was granted by the EMEA to Trio Medicines for YF-476 for the treatment of gastric carcinoid, following a positive opinion by the COMP in April 2007 </div><div style="margin-bottom: 10px;">A copy of the trial protocol (attached) details the previous clinical development of this drug and shows that the drug is also being evaluated for  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI>In 7/<wbr>8 patients the number and or size of the NETs decreased (mean reduction in the size of the largest tumouir was 33%, mean reduction in tumour number 30%) but none showed a complete tumour response.<wbr>
</LI>
<LI>Serum chromagrainin A concentrations decreased in all patients during treatment, but fasting gastrin concentrations were unchanged.<wbr>
</LI>
<LI>Netazepide was well tolerated, caused no serious AEs and no cases of haematological, renal or hepatic toxicity
</LI>
</UL> </div><div style="margin-bottom: 10px;">For previous data presented at ENETS by Helge Waldrum in 2012 please follow the link attached (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=6889" class="defaultlink">Endocrinology6889: ENETS Intelligence Part 3- Key Developments With Imaging, Translational Science & Notable Posters</a>) </div><div>Source: UKI NETS Abstract Programme </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7532c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>CCK2 could be a potential target for peptide approach as well.<wbr> One of the clinical investigator involved in this study would be Timothy Wang of Columbia University whom I met recently.<wbr> He is interested in working with us as well.<wbr> </div></div><a name="endocrinology7523attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7523_1_journal.pone.0076462.s002%5b1%5d.pdf">journal.pone.0076462.s002[1].pdf</a>&nbsp;&nbsp;(1,4 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7523">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-27T14:48:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-27T14:48:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck Serono's US Ambition</title>
	<pubDate>2013-11-27T14:11:43+01:00</pubDate>
	<wp:post_id>4657</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During a recent visit to Merck Serono's bio-incubator in Israel Stefan Oschmann stated to reporters that the group was actively looking for deals to lift its US drug sales, which currently only account for 20% of group sales.<wbr> </div><div style="margin-bottom: 10px;">He stated: "Its not that we're not present but we need new products for the US market.<wbr> If you want to be successful in the US market you have to introduce new products and that is what we are working on".<wbr> </div><div style="margin-bottom: 10px;">In the past few years the company has faced a number of late stage setbacks and it is now looking to rebuild its late-stage pipeline through acquisiiton or in-licensing.<wbr> </div><div style="margin-bottom: 10px;">He continued " Will that be enough to be a major player in the US.<wbr> We shall see.<wbr>" </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10699">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-27T14:11:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-27T14:11:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' FGFR Inhibitor Dovitinib + Abiraterone to Enter Ph2 for mCRPC</title>
	<pubDate>2013-11-26T17:19:53+01:00</pubDate>
	<wp:post_id>4658</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this POC study is to learn if adding dovitinib to the combination of abiraterone acetate and prednisone may help to control mCRPC.<wbr> PE will measure change in gene expression.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=60 </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: April 2014 - Completion date: April 2021 </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;">Dovitinib + Abiraterone Acetate + Prednisone </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="MARGIN-TOP: 0.5ex">
<UL><LI>Participants receive a single daily oral dose of Dovitinib for 5 consecutive days, on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.<wbr> Starting dose will be 400 mg daily.<wbr></LI>
<LI>Participant to take 4 tablets (250 mg each) orally (PO) daily of Abiraterone acetate.<wbr></LI>
<LI>Participant to take 5 mg oral prednisone, twice daily.<wbr></LI>
</UL></DIV> </div><div>Source <A href="http://clinicaltrials.gov/ct2/show/study/NCT01994590?term=PROSTATE+OR+BOTULINUM+OR+ACROMEGALY+OR+CUSHNG+OR+NEUROENDOCRINE&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=10%2F26%2F2013&amp;rank=8&amp;show_desc=Y#desc">NCT01994590</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9346">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-26T17:19:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-26T17:19:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>POC Study to Evaluate Cabozantinib with Abiraterone in Pre-Chemo Patients with Bone-Metastatic CRPC</title>
	<pubDate>2013-11-26T17:01:17+01:00</pubDate>
	<wp:post_id>4659</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This Ph2 study is designed to evaluate the safety and efficacy of the combination.<wbr> PE will measure radiographic PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=280 </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Dec 2013 </div><div style="margin-bottom: 10px;">Completion date: June 2016 /<wbr> Dec 2016 </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;">4-arm study: </div><div style="margin-bottom: 10px;"><UL><LI>
cabozantinb 40 mg daily with abiratarone and prednisone</LI>
<LI>
cabozantinib 20 mg daily with abiraterone and prednisone</LI>
<LI>
cabozantinb 20 mg every other day with abiraterone and prednisone</LI>
<LI>
abiraterone with prednisone only</LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="MARGIN-TOP: 0.5ex"><STRONG>Location: </STRONG>USA</DIV> </div><div><DIV class="indent2" style="MARGIN-TOP: 0.5ex">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT01995058?term=PROSTATE+OR+BOTULINUM+OR+ACROMEGALY+OR+CUSHNG+OR+NEUROENDOCRINE&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=10%2F26%2F2013&amp;rank=3&amp;submit_fld_opt=">NCT01995058</A></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9345">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-26T17:01:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-26T17:01:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve mCRPC</title>
	<pubDate>2013-11-26T16:51:51+01:00</pubDate>
	<wp:post_id>4660</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of the PLATO Ph4 trial is to evaluate the efficacy and safety of continued treatment with enzalutamide plus abiraterone and prednisone, as compared to treatment with abiraterone and prednisone alone in patients with chemotherapy-naive metastatic prostate cancer, whose disease has progressed following enzalutamide therapy.<wbr> PE will measure PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=500 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Men with metastatic castration-resistant prostate cancer</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Progressive disease on androgen deprivation therapy</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients must agree to continue androgen deprivation therapy with a GnRH agonist/<wbr>antagonist throughout the study or have had a prior bilateral orchiectomy</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">ECOG performance score ≤ 1</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Estimated life expectancy of ≥ 12 months</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Nov 2013 </div><div style="margin-bottom: 10px;">Completion date: June 2016 /<wbr> Sept 2016 </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;">2 arms trial </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="MARGIN-TOP: 0.5ex">- Enzalutamide (160 mg) administered as four 40-mg capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="MARGIN-TOP: 0.5ex">
<DIV class="indent2" style="MARGIN-TOP: 0.5ex">- Enzalutamide placebo (placebo) capsules (identical in appearance to enzalutamide) administered as 4 capsules by mouth once daily in combination with abiraterone (1000 mg) administered as four 250-mg tablets by mouth once daily and prednisone (10 mg) administered as one 5-mg tablet by mouth twice daily.<wbr></DIV>
<DIV class="indent2" style="MARGIN-TOP: 0.5ex"><STRONG>Location</STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;">USA </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT01995513?term=PROSTATE+OR+BOTULINUM+OR+ACROMEGALY+OR+CUSHNG+OR+NEUROENDOCRINE&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=10%2F26%2F2013&amp;rank=2&amp;submit_fld_opt=">NCT01995513</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9343">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-26T16:51:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-26T16:51:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Germany's Pharma Market Value Grows 5.3% y/y in January–September to €25.2 billion</title>
	<pubDate>2013-11-26T15:09:18+01:00</pubDate>
	<wp:post_id>4661</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The growth has been driven by strong sales of cancer and immunosuppressant drugs, among others, with a particular focus on sales of high-cost innovative products.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Overall market value up 5.<wbr>3% y/<wbr>y in January–September</B></P> </div><div style="margin-bottom: 10px;">The overall value of the German pharmaceutical market – including both the retail pharmacy and the hospital markets – grew in the first three quarters by 5.<wbr>3% year on year (y/<wbr>y), according to data from IMS Health, to EUR25.<wbr>2 billion (USD34.<wbr>1 billion).<wbr> The figure is calculated based on hospital prices and ex-manufacturer prices, without consideration of mandatory discounts or savings from discount contracts.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>GKV funds' spending up 5.<wbr>2% y/<wbr>y</B></P> </div><div style="margin-bottom: 10px;">Spending by Germany's statutory health insurance (GKV) funds on pharmaceuticals in the first three quarters is reported to have increased by 5.<wbr>2% y/<wbr>y to EUR22.<wbr>9 billion.<wbr> This amount does not include savings from discount contracts or patient co-payments<I>.<wbr></I> Looking at the overall value of the retail pharmaceutical market, measured in terms of ex-manufacturer prices – including both prescription and non-prescription drugs – this is reported to have increased by 4.<wbr>6% y/<wbr>y to EUR19.<wbr>8 billion.<wbr> In terms of volume, the retail pharmaceutical market is reported have grown 5.<wbr>2% y/<wbr>y to 1.<wbr>1 billion packages.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Hospital drug market value up 10% y/<wbr>y</B></P> </div><div style="margin-bottom: 10px;">The value of the hospital-drug market grew by 10% y/<wbr>y in January–September.<wbr> IMS Health has reported that there was an especially large increase in spending on medicines dispensed by outpatient departments, which reportedly increased by 15% y/<wbr>y in the first three quarters, thanks to an increase in the use of innovative therapies that allow for the treatment of serious conditions outside of hospitals.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Strong growth in sales of cancer drugs in hospital and retail segments</B></P> </div><div style="margin-bottom: 10px;"><U>In the hospital sector</U>, the largest group by sales value, other neoplastic agents (L0X1 in the anatomical therapeutic chemical – ATC – grouping system), increased in sales by 17.<wbr>4% y/<wbr>y to EUR684.<wbr>2 million in January–September.<wbr> Also recording a significant growth in sales in the hospital sector during this period was other immunosuppressants (L04X), which posted an increase in sales of 22.<wbr>9% y/<wbr>y to EUR113.<wbr>9 million.<wbr> </div><div style="margin-bottom: 10px;"><U>In the retail pharmacy market</U>, the largest increase was also observed in sales of drugs in the "other neoplastic agents" group, which recorded an increase of 18.<wbr>5% y/<wbr>y in sales by value to EUR1.<wbr>143 billion and was also the bestselling group in this market segment.<wbr> Another ATC group, including a good number of innovative, high-cost medicines, the anti-tumour necrosis factor (TNF) group, used in the treatment of a number of serious conditions including rheumatoid arthritis, saw an increase in sales in the retail pharmacy sector of 19.<wbr>3% y/<wbr>y in January-September, to EUR875.<wbr>9 million.<wbr> Anti-TNF products were the second largest selling group in this market segment in the period under review.<wbr> </div><div style="margin-bottom: 10px;">The value of mandatory discounts provided by pharmaceutical producers in the first nine months of the year is reported to have increased by around 5% y/<wbr>y to around EUR2 billion.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>September sees 8% y/<wbr>y surge</B></P> </div><div style="margin-bottom: 10px;">Looking at the individual months and quarters, there was a strong surge in the value of the retail pharmaceutical market in September, with growth of around 8% y/<wbr>y, to EUR2.<wbr>2 billion, although the market's volume is reported to have declined during the month by around 5% y/<wbr>y.<wbr> The expenditure of the GKV funds in September, meanwhile, is reported to have increased by 9.<wbr>1% y/<wbr>y to EUR2.<wbr>58 billion </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Physicians favour innovative treatments</B></P> </div><div style="margin-bottom: 10px;">According to IMS Health, as reported by German medical newspaper <I>Ärzte Zeitung</I>, an important factor in the growth of the market over the course of 2013 is the "structural component", which refers to changes in the prescribing habits of physicians, who are reported to be prescribing increasing numbers of innovative products.<wbr> As the source reports, this factor has steadily grown in importance over the course of the year.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Outlook and implications</B></P> </div><div style="margin-bottom: 10px;">The figures for the first three quarters of 2013 follow on in the same vein as those from the first half, which also saw growth in the German market driven by increased sales of high-cost innovative drugs, and in particular cancer and immunosuppressant drugs.<wbr> </div><div style="margin-bottom: 10px;">Considering the fact that in 2012 the spending of the GKV funds on drug reimbursement increased by just 1.<wbr>5% y/<wbr>y, the fact that over the course of 2013 the funds' spending has grown to such an extent indicates a strong underlying demand in the German market, with emphasis on the strong growth of the hospital-drug sector, which has been driven by growth in the dispensing of high-cost innovative medicines in inpatient departments.<wbr> </div><div style="margin-bottom: 10px;">For the innovative pharmaceutical industry, the figures are positive and show that in spite of the ongoing austerity measures, which are set to be extended beyond 2013, the German market continues to be favourable towards innovation and their opportunities in the German market remain strong.<wbr> There remains a risk, however, that the new grand coalition government, set to be inaugurated finally in the near future, which includes a new coalition partner for the "Union" in the German Social Democratic Party (SPD) which is likely to be more keen to rein in pharmaceutical spending, may look at the current trend in pharma spending and push for more cost-containment measures.<wbr> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10697">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-26T15:09:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-26T15:09:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer in Early Stage Talks to Acquire Algeta</title>
	<pubDate>2013-11-26T10:23:25+01:00</pubDate>
	<wp:post_id>4662</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Algeta received “a preliminary acquisition proposal” for $2.<wbr>4 bln (336 kroner ($55.<wbr>03) a share).<wbr>The offer values Algeta 27% higher than yesterday’s closing price of 264.<wbr>6 kroner.<wbr> Algeta Management reported that ".<wbr>.<wbr>.<wbr> There’s no guarantee Bayer’s proposal will result in a deal".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The deal would give Bayer full rights to Xofigo (radium 223 dichloride), which the drugmakers are developing under a 2009 agreement.<wbr> </div><div style="margin-bottom: 10px;"><U>Xofigo Status</U> </div><div style="margin-bottom: 10px;"><UL><LI>EU: Xofigo was granted MA in Europe on Nov 15 2013 for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.<wbr> (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9320" class="defaultlink">Oncology9320: Xofigo® Approved in the EU</a>)</LI>
<LI>US: FDA approved the drug in May.<wbr> Q3:13 net sales for Xofigo amounted to EUR 12m (USD 17m).<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Analysts predict that the product could generate annual global sales of $940 million by 2018.<wbr> </div><div><EM>Source: Bayer; FirstWord; ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9340">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-26T10:23:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-26T10:23:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Heat Biologics to Start Ph1/2 to Prevent Recurrence of Bladder Cancer</title>
	<pubDate>2013-11-26T09:42:40+01:00</pubDate>
	<wp:post_id>4663</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company's HS-410 is a biologic product candidate which consists of a bladder cancer cell line that has been genetically modified using Heat's ImPACT technology platform to secrete a wide range of bladder cancer antigens bound to a gp96 adjuvant, and is designed to activate a T-cell mediated pan-antigen immune response against the patient's bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Company expects to begin enrolling patients in this study by the end of December 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Objectives</U>: The Phase 1/<wbr>2 trial is designed to examine safety, tolerability, immune response and preliminary clinical activity of HS-410 in patients with high risk, superficial bladder cancer who have completed surgical resection and 6 weekly intravesical bacillus Calmet-Guerin (BCG) immunotherapy installations.<wbr> </div><div style="margin-bottom: 10px;"><U>Location</U>: The Company anticipates including approximately 8-10 clinical sites.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.heatbio.com/?page_id=30">http:/<wbr>/<wbr>www.<wbr>heatbio.<wbr>com/<wbr>?page_id=30</A> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9339_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9339attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9339_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(134,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9339">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-26T09:42:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-26T09:42:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi to Spend Up to €2bn Per Year on Acquisitions</title>
	<pubDate>2013-11-26T09:31:18+01:00</pubDate>
	<wp:post_id>4664</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: CEO C.<wbr> Viehbacher said the company will keep reinforcing growth platforms such as diabetes, vaccines, self-medictions, emerging markets, rare diseases and animal health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">CEO reported that 2/<wbr>3 of the company's research budget is now allocated to biological treatments that are 'difficult to copy'.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10696">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-26T09:31:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-26T09:31:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Final Registration Trial with MYOBLOC® to Treat Sialorrhea</title>
	<pubDate>2013-11-25T17:23:40+01:00</pubDate>
	<wp:post_id>4665</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Final Registration Trial with MYOBLOC® to Treat Sialorrhea</span>&nbsp;<br><span style="font-size: 12px;">Comment: This MYOBLOC® trial is a nationwide, multicenter, double-blinded, placebo-controlled study that will enroll patients who have been diagnosed with sialorrhea due to multiple causes.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7269">...</a><br></div><div style="margin-bottom: 10px;">The Ph3 trial ("MYSTICOL") has just been listed in the <EM>clinicaltrials.<wbr>gov</EM> database, and brings additional information (please see below).<wbr> PE is to evaluate Unstimulated Salivary Flow Rate.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Official title</SPAN>: Efficacy and Safety Study of MYOBLOC&reg; Followed by Open-Label Multiple-Treatment With MYOBLOC&reg; in the Treatment of Troublesome Sialorrhea in Adult Subjects (MYSTICOL) </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Objective</SPAN>: This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions.<wbr> MYOBLOC will be injected directly into the salivary glands.<wbr> MYOBLOC has been shown in previous trials to safely decrease saliva production, thereby demonstrating its potential as a safe and effective treatment for troublesome sialorrhea </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment:</SPAN> n= 180 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Timelines</SPAN>: completion date July 2015 </div><div>Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01994109?term=PROSTATE+OR+BOTULINUM+OR+ACROMEGALY+OR+NEUROENDOCRINE+OR+SPASTICITY&recr=Open&no_unk=Y&fund=2&rcv_s=10%2F25%2F2013&rank=6&submit_fld_opt=" class="defaultlink">NCT01994109</a> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7286">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7269">View thread  Neurology7269: Final Registration Trial with MYOBLOC® to Treat Sialorrhea</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-25T17:23:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-25T17:23:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Alongside Its R&D Day Novartis Sweetens The Market With A $500m Share Buyback</title>
	<pubDate>2013-11-24T16:25:29+01:00</pubDate>
	<wp:post_id>4666</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Alongside Its R&D Day Novartis Sweetens The Market With A $500m Share Buyback</span>&nbsp;<br><span style="font-size: 12px;">Comment: During its annual R&amp;D day, Novartis highlighted its continual 
focus on innovation as a means of delivering superior shareholder returns within 
the pharma market.<wbr> It also illustrated how its pharma business is poised to 
enter a new growth phase based on the ongoing strength of its oncology business 
plus new business opportunities in dermatology, heart failure, respiratory 
medicine and cell therapy.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9330">...</a><br></div><div style="margin-bottom: 10px;">The detailed commentary from the meeting included several interesting comments on Sandostatin, Camurus, Signifor and Afinitor all of which are highlighted below.<wbr> Herve Hoppenot,  President of Novartis Oncology, noted that the deal with Camurus was "a way to continue the life cycle management of the molecules that could be <STRONG>potentially replacing the LAR formulation</STRONG>" </div><div style="margin-bottom: 10px;">When questioned about forecasts for Sandostatin and seemingly any lack of expectation of generics, Hoppenot stated "we have not seen good quality substitutable generics of Sandostatin LAR where the patent is already expired and it has been going on.<wbr> It&rsquo;s a very difficult product to mimic to have the same PK of hormones.<wbr> So it&rsquo;s not easy to do.<wbr> And what we have observed is that it was not happening where it was possible from the patent standpoint.<wbr> So in some way, you have a mix of all of these elements that says Exjade/<wbr>Sandostatin (a new category) will be growing over the next five year.<wbr> And I think, in some way, we could do better than that.<wbr>" </div><div style="margin-bottom: 10px;">Commenting on Afinitor's potential it was interesting to note the reference to NET but perhaps more importantly the reference to the earlier than expected data on the carcinoid indication.<wbr> </div><div style="margin-bottom: 10px;">"So when we think about Afinitor for the next few years, we are very much aligned with what we said last time is that we see a franchise of indication.<wbr> So it&rsquo;s the number of indications, where the big one will be the metastatic breast cancer indication and will continue to grow significantly over the next year and will be complemented by growth in neuroendocrine tumor and TSC and potentially with other new indications in the future.<wbr>" </div><div style="margin-bottom: 10px;">"When you compare to what I was showing last year, in fact, we are very much aligned on most of the indications.<wbr> Hepatocellular carcinoma indication will not take place.<wbr> As you know, we have published that the putative study we had in that indication was negative, but at the same time, the carcinoid studies that we were speaking about last year has been advanced earlier.<wbr> So the net-net of the two is that the potential for Afinitor is certainly as large as what we were speaking about a year ago and we see it as a multibillion potential for our portfolio by 2017 and 2018.<wbr>" </div><div style="margin-bottom: 10px;">Finally, there was confirmation that a filing for Signifor in acromegaly will be made in the fourth quarter:- </div><div>"You see a number of very important filings, serelaxin, RLX030 for acute heart failure in both Europe and the U.<wbr>S.<wbr>, Xolair in new indication for chronic spontaneous urticaria, <STRONG>Signifor for acromegaly</STRONG>, and AIN457 for psoriasis, all during the fourth quarter.<wbr> So, we&rsquo;ve delivered on the promise.<wbr> Some have come a bit earlier, some a bit later, but overall it&rsquo;s been a quite productive year from a development perspective.<wbr>" </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9337">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9330">View thread  Oncology9330: Alongside Its R&D Day Novartis Sweetens The Market With A $500m Share Buyback</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-24T16:25:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-24T16:25:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Effect of Needle Size on Pain Perception With Injection of Botox® for Wrinkles</title>
	<pubDate>2013-11-22T19:16:20+01:00</pubDate>
	<wp:post_id>4667</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The small pilot study will compare the levels of pain resulting from injections of Botox&reg; for wrinkles on the forehead and between the eyes using two different sized needles (32 gauge and 30 gauge needles).<wbr> PE is to assess Visual analog score (VAS) pain rating after each side is injected.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<P style="margin-top: 1ex; margin-bottom: 1ex;">Subjects will be screened, assessed, and randomized to be injected with the toxin using a 30-gauge needle on one side of the face and injected using a 32-gauge needle on the other side during their first clinic visit.<wbr></P>
<P style="margin-top: 1ex; margin-bottom: 1ex;">This study is a pilot study designed to determine feasibility of these procedures.<wbr></P>
</DIV> </div><div style="margin-bottom: 10px;"><STRONG>Participants </STRONG>n=30 (female; 25-70 years old) with moderate dynamic forehead/<wbr>glabellar wrinkles </div><div style="margin-bottom: 10px;"><STRONG>PI</STRONG>: Murad Alam, MD (Northwestern University): </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Nov 2013 - Completion date: Jan 2014 </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01981174?term=BOTULINUM+OR+PROSTATE+OR+ACROMEGALY+OR+NEUROENDOCRINE&recr=Open&no_unk=Y&rcv_s=10%2F01%2F2013&rank=29" class="defaultlink">NCT01981174</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7285">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-22T19:16:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-22T19:16:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Role of Radiopharmaceutical Therapy in mCRPC</title>
	<pubDate>2013-11-22T18:20:42+01:00</pubDate>
	<wp:post_id>4668</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif;">Comment: Bors&ograve; <EM>et al</EM>.<wbr> from <SPAN style="text-align: left; line-height: 12px; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; white-space: normal; float: none; letter-spacing: normal; color: #000000; font-weight: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Santa Maria della Misericordia' Hospital in Italy published the results from the small pilot study to to investigate the outcome when docetaxel based regimen was given to patients following treatment with radiopharmceutical agents (in this study, samarium-153 labelled lexidronam, &beta;-particle emitter that is approved exclusively for the bone pain palliation).<wbr> In ESMO 2013, redium-223 was reported to demonstrate survival benefit as well as pain palliation.<wbr> These initial findings from Bors&ograve; group justify intense investigation should be warrented prior to or in combination with docetaxel in mCRPC.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN style="text-align: left; line-height: 12px; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; white-space: normal; float: none; letter-spacing: normal; color: #000000; font-weight: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The challgene of radiopharmceutical agents has always been associated with concerns of toxicities, and especially in combination with chemotherapy.<wbr> Bors&ograve; <EM>et al.<wbr> </EM><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">investigated whether docetaxel administered to mCRPC patients after treatment with samarium-153-labeled ethylene-diamine-tetra-methylene-phosphonic acid (Sm-EDTMP) has increased toxicity and/<wbr>or reduced antitumor efficacy.<wbr></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN style="text-align: left; line-height: 12px; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; white-space: normal; float: none; letter-spacing: normal; color: #000000; font-weight: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><SPAN style="text-decoration: underline;">Study Design</SPAN>: 30 mCRPC patients with skeletal metastases were enrolled.<wbr> Patients received standard therapy with docetaxel (75 mg/<wbr>m intravenously every 21 days for at least six cycles) on average 6 weeks after Sm-EDTMP (37 MBq/<wbr>kg).<wbr> Patients were monitored for the presence of toxicities, and antitumor efficacy was assessed by changes in serum prostate-specific antigen levels.<wbr> </SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><SPAN style="text-align: left; line-height: 12px; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; white-space: normal; float: none; letter-spacing: normal; color: #000000; font-weight: normal; word-spacing: 0px; text-decoration: underline; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; text-decoration: underline; -webkit-text-stroke-width: 0px;"><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; text-decoration: underline; -webkit-text-stroke-width: 0px;">Results: </SPAN></SPAN></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><TABLE border="0" class="normaltable" style="width: 624px; height: 212px;"><TBODY><TR><TD>Parameter</TD>
<TD>Median</TD>
<TD>Mean</TD>
</TR>
<TR><TD>Biochemical Response (PSA )</TD>
<TD colspan="2">&gt; 80% with favourable biochemical response</TD>
</TR>
<TR><TD>Time to clinical progression (months)</TD>
<TD>9.<wbr>1</TD>
<TD>9.<wbr>8</TD>
</TR>
<TR><TD>OS (months)</TD>
<TD>19.<wbr>9</TD>
<TD>24.<wbr>5</TD>
</TR>
<TR><TD>&nbsp;</TD>
<TD colspan="2">5 /<wbr> 24 patients (21%) were alived more than 5 years after enrollment</TD>
</TR>
<TR><TD>Toxicities</TD>
<TD colspan="2">No additional haematological toxicities observed (other than those common to docetaxel based regimen)</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The author concludes "Prior administration of Sm-EDTMP does not cause additional toxicities for subsequent treatment with docetaxel and does not reduce the antitumor efficacy of the latter" and therefore </SPAN>suggested further investigation should be warrented <SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">on the possible synergistic effects of combined strategies with the two agents.<wbr> Currently radium-223's broad label allows its utilisation within mCRPC patients with no known visceral metastases, however, similar to other radiopharmaceutical agents, safety and tolerability concern is a big challenge.<wbr> There is currently an ongoing multicentre Phase 3 study (Canada, US, Europe, Mexico, and Israel- n=1500; See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=8345" class="defaultlink">Oncology8345: New Trial with Bayer's Alpharadin for CRPC</a></SPAN><SPAN style="text-align: left; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px/17px arial, helvetica, clean, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-stroke-width: 0px;">) to address lack of long term safety data in a single arm with radium-223 injection once every 4 weeks.<wbr> This small Italian pilot study provides a good rationale for chemo naive mCRPC patients with bone metastases and possibility of combination strategy with docetaxel.<wbr> </SPAN>There is currently a small Phase 1/<wbr>2 trial (n=60-See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=6543" class="defaultlink">Oncology6543: Combination Alpharadin/<wbr>Docetaxel Trial in Patients with Bone Metastases from CRPC</a>) in US to explore safety of combination of radium-223 and docetaxel and results are expected 2014 Q4.<wbr> This should help the urology and oncology communities to further define the role of radium-223 in mCRPC setting.<wbr> </div><div>Note: The journal article is an epublication ahead of print in Nuclear Medicine Communication Jan 2014 (Volume 35 Issue 1 p88-94).<wbr> The details and abstract of the article is available in Pearl.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9333">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-22T18:20:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-22T18:20:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alongside Its R&D Day Novartis Sweetens The Market With A $500m Share Buyback</title>
	<pubDate>2013-11-22T15:02:07+01:00</pubDate>
	<wp:post_id>4669</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During its annual R&amp;D day, Novartis highlighted its continual 
focus on innovation as a means of delivering superior shareholder returns within 
the pharma market.<wbr> It also illustrated how its pharma business is poised to 
enter a new growth phase based on the ongoing strength of its oncology business 
plus new business opportunities in dermatology, heart failure, respiratory 
medicine and cell therapy.<wbr> </div><div style="margin-bottom: 10px;">Some of the critical steps it has taken to sustain innovation were 
highlighted by CEO Joe Jiminez in his introductory presentation.<wbr> </div><div style="margin-bottom: 10px;">.<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">Alongside this emphasis on innovation, Novartis maintains a sharp focus 
on productivity and the financial criteria it applies to investments </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Pharmaceuticals Poised For A New Growth Phase</STRONG> </div><div style="margin-bottom: 10px;">This is going to be based on its strong regulatory track record as 
highlighted below.<wbr> Note the reference to a Q413 filing for Signifor in 
acromegaly </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Ongoing Success Of The Oncology Business Unit With Sandostatin &amp; 
Signifor Cited Amongst The Key Strategic Brands</STRONG> </div><div style="margin-bottom: 10px;">Afinitor is mentioned as having blockbuster potential largely based on its 
application in breast cancer but supported by sales in other indications such as 
NET.<wbr> Pivotal <STRONG>data from its non-functioning carcinoid trial is 
expected in 2014.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_19_ScreenCapture19.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_20_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_21_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_22_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_23_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_24_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_25_ScreenCapture25.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_26_ScreenCapture26.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9337c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The detailed commentary from the meeting included several interesting comments on Sandostatin, Camurus, Signifor and Afinitor all of which are highlighted below.<wbr> Herve Hoppenot,  President of Novartis Oncology, noted that the deal with Camurus was "a way to continue the life cycle management of the molecules that could be <STRONG>potentially replacing the LAR formulation</STRONG>" </div><div style="margin-bottom: 10px;">When questioned about forecasts for Sandostatin and seemingly any lack of expectation of generics, Hoppenot stated "we have not seen good quality substitutable generics of Sandostatin LAR where the patent is already expired and it has been going on.<wbr> It&rsquo;s a very difficult product to mimic to have the same PK of hormones.<wbr> So it&rsquo;s not easy to do.<wbr> And what we have observed is that it was not happening where it was possible from the patent standpoint.<wbr> So in some way, you have a mix of all of these elements that says Exjade/<wbr>Sandostatin (a new category) will be growing over the next five year.<wbr> And I think, in some way, we could do better than that.<wbr>" </div><div style="margin-bottom: 10px;">Commenting on Afinitor's potential it was interesting to note the reference to NET but perhaps more importantly the reference to the earlier than expected data on the carcinoid indication.<wbr> </div><div style="margin-bottom: 10px;">"So when we think about Afinitor for the next few years, we are very much aligned with what we said last time is that we see a franchise of indication.<wbr> So it&rsquo;s the number of indications, where the big one will be the metastatic breast cancer indication and will continue to grow significantly over the next year and will be complemented by growth in neuroendocrine tumor and TSC and potentially with other new indications in the future.<wbr>" </div><div style="margin-bottom: 10px;">"When you compare to what I was showing last year, in fact, we are very much aligned on most of the indications.<wbr> Hepatocellular carcinoma indication will not take place.<wbr> As you know, we have published that the putative study we had in that indication was negative, but at the same time, the carcinoid studies that we were speaking about last year has been advanced earlier.<wbr> So the net-net of the two is that the potential for Afinitor is certainly as large as what we were speaking about a year ago and we see it as a multibillion potential for our portfolio by 2017 and 2018.<wbr>" </div><div style="margin-bottom: 10px;">Finally, there was confirmation that a filing for Signifor in acromegaly will be made in the fourth quarter:- </div><div>"You see a number of very important filings, serelaxin, RLX030 for acute heart failure in both Europe and the U.<wbr>S.<wbr>, Xolair in new indication for chronic spontaneous urticaria, <STRONG>Signifor for acromegaly</STRONG>, and AIN457 for psoriasis, all during the fourth quarter.<wbr> So, we&rsquo;ve delivered on the promise.<wbr> Some have come a bit earlier, some a bit later, but overall it&rsquo;s been a quite productive year from a development perspective.<wbr>" </div></div><a name="oncology9330attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(160,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(90,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(110 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(112,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(119,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(108,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(134,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(92,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(97,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(100 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(103 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(132,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(103,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(100,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(103,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(152,4 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(77,9 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(99,1 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(155,4 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_21_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(141,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_22_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(148,3 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_23_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(147,4 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_24_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(140,7 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_25_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(102,3 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9330_26_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(74,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9330">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-22T15:02:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-22T15:02:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>China to Become World's Second Largest Pharma Market Within 5 Years</title>
	<pubDate>2013-11-22T07:59:14+01:00</pubDate>
	<wp:post_id>4670</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The IMS Institute for Healthcare Informatics has estimated in its annual report that China's drug market will grow at 14-17% over the next five years, due to expanded medical insurance coverage guided by the government.<wbr> As such, China is predicted to become the world's second largest pharmaceutical market within that time.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><BR><BR><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The report also indicates that global prescription drug spending will soon exceed USD 1 trillion (RMB 6.<wbr>1 trillion), largely due to the imminent launches of several innovative drugs, and increasing healthcare spending in emerging markets, especially China.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Furthermore, global drug consumption began to rebound in 2013 after several patent expiries, budget restraint in many countries, and downward pressures on economic growth.<wbr> </SPAN> </div><div><SPAN style="text-align: justify; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px Arial, Helvetica, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">By 2017, generics are pegged to increase their average global market share from 27% to 36%, reaching 63% in emerging economic superpowers.<wbr></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10694">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-22T07:59:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-22T07:59:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas to Start WW Ph3 with Mirabegron +/- Solifenacin for OAB</title>
	<pubDate>2013-11-21T18:05:39+01:00</pubDate>
	<wp:post_id>4671</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of the SYNERGY study is to examine how well combination of solifenacin (Vesicare) and mirabegron (Betmiga, Betanis, Myrbetriq) works compared to each medicine alone in the treatment of bladder problems.<wbr> PE will assess change from baseline in mean number of incontinence episodes per 24 hours at end of treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Enrollment</STRONG> </div><div style="margin-bottom: 10px;">n=3393 </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Nov 2013 - Completion: March 2015 /<wbr> June 2015 </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01972841?recr=Open&no_unk=Y&fund=2&rcv_s=10%2F21%2F2013&rank=148" class="defaultlink">NCT01972841</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9328">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-21T18:05:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-21T18:05:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Æterna Zentaris Inc</title>
	<pubDate>2013-11-21T12:40:25+01:00</pubDate>
	<wp:post_id>4672</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment Aeterna Zentaris has raised $15.<wbr>1m through the sales of 13.<wbr>1m shares 
to continue to fund the ongoing drug development of its LHRH-conjugate for the 
treatment of endometrial cancer and preparations for the commercial launch of 
its growth hormone deficiency diagnostic Solorel.<wbr> </div><div>Zoptarelin doxorubicin (AEZS-108) program is in phIII development for 
endometrial cancer, whilst earlier this month Aeterna submitted an NDA to the 
FDA for Solorel macimorelin to diagnose adult growth hormone 
deficiency.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9327">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-21T12:40:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-21T12:40:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</title>
	<pubDate>2013-11-21T09:24:02+01:00</pubDate>
	<wp:post_id>4673</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</span>&nbsp;<br><span style="font-size: 12px;">Comment: Park Avenue Plastic Surgeon Dr Ramtin Kassir has released results of the study which findings demonstrate that Dysport lasts longer and works faster than Botox when used at a dose ratio of 2.<wbr>5:1 in the frown region and 3:1 in the crow's feet region.<wbr> Safety profile was similar for both products.<wbr> Key results are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7271">...</a><br></div><div>I have received the article from the PR agency.<wbr> Please find attached.<wbr> </div><!-- Comment details --><br><a name="neurology7284attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7284_1_Dysport%20botox%20paper%202013.pdf">Dysport botox paper 2013.pdf</a>&nbsp;&nbsp;(661,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7284">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7271">View thread  Neurology7271: Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-21T09:24:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-21T09:24:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</title>
	<pubDate>2013-11-20T10:10:37+01:00</pubDate>
	<wp:post_id>4674</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</span>&nbsp;<br><span style="font-size: 12px;">Comment: Park Avenue Plastic Surgeon Dr Ramtin Kassir has released results of the study which findings demonstrate that Dysport lasts longer and works faster than Botox when used at a dose ratio of 2.<wbr>5:1 in the frown region and 3:1 in the crow's feet region.<wbr> Safety profile was similar for both products.<wbr> Key results are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7271">...</a><br></div><div>These data will reinforce Dysport key messages (fast onset of action, longer duration, physician and patient satisfaction) and confirm the results of Dr Mark Nestor's publications in 2011.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7283">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7271">View thread  Neurology7271: Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-20T10:10:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-20T10:10:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update On The Phase 3 SYNERGY CRPC Trial</title>
	<pubDate>2013-11-20T10:03:20+01:00</pubDate>
	<wp:post_id>4675</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OncoGenex Pharmaceuticals has announced that the SYNERGY trial with custirsen in combination with 1st-line docetaxel is continuing as planned per the recommendation of IDMC following an interim analysis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The primary registration Phase 3 SYNERGY trial is designed to evaluate a survival benefit for custirsen in combination with first-line docetaxel chemotherapy in men with metastatic castrate-resistant prostate cancer (CRPC).<wbr> </div><div style="margin-bottom: 10px;">Approximately 1,023 men have been enrolled to SYNERGY at 140 sites primarily in <LOCATION value="LB/nam">North America</LOCATION> and <LOCATION value="LR/eur">Europe</LOCATION>.<wbr> SYNERGY completed enrollment in 2012 and final survival results are expected to be announced by mid-2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">"The recommendation for SYNERGY to continue to final analysis is not surprising as the criteria to achieve statistical significance on the interim are considerably more stringent than the criteria required for the final analysis," stated <PERSON value="APIN:3784621101">Scott Cormack</PERSON>, President and CEO of OncoGenex.<wbr> "We do not believe these results can be interpreted to predict the final outcome of SYNERGY and we eagerly anticipate the reporting of final survival results next year.<wbr>" </div><div style="margin-bottom: 10px;">OncoGenex and custirsen co-development and commercialization partner, <ORG value="NYSE:TEVA">Teva Pharmaceutical Industries, Ltd.<wbr></ORG>, continue to remain blinded to all SYNERGY data and analyses, including details regarding survival and statistical evaluations.<wbr> </div><div>Source: <A href="http://www.oncogenex.com/">www.<wbr>oncogenex.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9326">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-20T10:03:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-20T10:03:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</title>
	<pubDate>2013-11-20T09:16:29+01:00</pubDate>
	<wp:post_id>4676</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</span>&nbsp;<br><span style="font-size: 12px;">Comment: Park Avenue Plastic Surgeon Dr Ramtin Kassir has released results of the study which findings demonstrate that Dysport lasts longer and works faster than Botox when used at a dose ratio of 2.<wbr>5:1 in the frown region and 3:1 in the crow's feet region.<wbr> Safety profile was similar for both products.<wbr> Key results are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7271">...</a><br></div><div>Apparently the paper has not been published yet.<wbr> We will track its publication.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7282">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7271">View thread  Neurology7271: Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-20T09:16:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-20T09:16:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GWPharma - Full Year 2013 Results Key Takeaways</title>
	<pubDate>2013-11-19T13:19:31+01:00</pubDate>
	<wp:post_id>4677</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GW Pharma has today reported full-year 2013 figures with 
revenues down £4.<wbr>8m to £27.<wbr>3m.<wbr> Lower milestone revenue was a key factor 
impacting the comparison, which also translated into a net loss of £4.<wbr>5m vs 
profit after tax of £2.<wbr>5m in 2012.<wbr> Despite adverse financial comparisons, 
the group has had a successful year making its IPO debut in May this year 
and with in-market sales of Savitex increasing by 25%.<wbr> 
Savitex is now approved in 22 countries (ex US) as a treatment for MS 
spasticity with a number of on-going commercial launches planned over the next 
12 months.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_2_ScreenCapture3.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">In terms of the company overall, 2013 has been a productive year in terms of 
development acitivity, with the company particularly enthusiastic about its 
clinical programme in pediatric epilepsy, where the following achievements were 
noted:- </div><div style="margin-bottom: 10px;"><UL><LI>Expansion of epilepsy research program through commencement of a new 
  orphan pediatric epilepsy program for:-</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Epidiolex® (purified extract of Cannabidiol, or CBD)</LI>
<LI>FDA orphan drug designation granted by FDA for Epidiolex in Dravet 
    syndrome</LI>
<LI>Seven physician-led INDs granted by FDA to treat 125 pediatric epilepsy 
    patients in the U.<wbr>S.<wbr> with Epidiolex</LI>
<LI>Epidiolex pediatric epilepsy clinical trials in planning for 2014</LI>
<LI>Additional epilepsy pipeline candidate, GWP42006 (Cannabidivarin or 
    CBDV), commenced Phase 1 trial in September 2013</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_3_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_4_ScreenCapture5.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_5_ScreenCapture6.jpg"> </div><!-- Comment details --><a name="neurology7278attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(88,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_2_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(141,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(149,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(141,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7278_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(108,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7278">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-19T13:19:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-19T13:19:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights of MedyTox' Q3:13 Results</title>
	<pubDate>2013-11-19T10:41:19+01:00</pubDate>
	<wp:post_id>4678</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Overall sales for the quarter grew 10.<wbr>2% y-y to W10.<wbr>1bn (+21% y-y in domestic market, +0.<wbr>3% y-y in export market), operating profit declined 9.<wbr>5% y-y to W4.<wbr>1bn.<wbr> Sales of new filler products (Neuramis) already contributing 10% of total sales revenue after its launch in July.<wbr> The company expects better top-lines growth in Q4:13 on upfront payment for licensing agreement with Allergan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7273_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><U>Domestic sales</U>: reached W5.<wbr>3bn (up 20.<wbr>7% y-y).<wbr> </div><div style="margin-bottom: 10px;"><U>Asia and Eastern Europe</U>: sales rose 0.<wbr>8% y-y to W3.<wbr>2bn and 49.<wbr>7% y-y to W0.<wbr>4bn, respectively, lifting Medytox’s exports 5.<wbr>8% y-y to W5.<wbr>4bn.<wbr> </div><div style="margin-bottom: 10px;"><U>Latin America and other overseas markets</U>: sales slid 49.<wbr>7% y-y to W1.<wbr>2bn.<wbr> </div><div><EM>Source: Woori Report (Nov.<wbr> 18, 2013); Nomura Report (Nov.<wbr> 15, 2013); Shinhan Investment Corp Report (Nov.<wbr>18, 2013).<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7273">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-19T10:41:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-19T10:41:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Triple-Blind Study Comparing Botox Vs Dysport for Wrinkles</title>
	<pubDate>2013-11-19T09:41:54+01:00</pubDate>
	<wp:post_id>4679</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Park Avenue Plastic Surgeon Dr Ramtin Kassir has released results of the study which findings demonstrate that Dysport lasts longer and works faster than Botox when used at a dose ratio of 2.<wbr>5:1 in the frown region and 3:1 in the crow's feet region.<wbr> Safety profile was similar for both products.<wbr> Key results are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Differences were observed in the duration before improvement of wrinkles: A larger number of patients had a quicker onset of action with Dysport than with Botox.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>After 3 months, Dysport was active for a larger percentage in the frown and crow's feet regions; although there was an increase in the number of patients who reported no difference between the two treatments at this time.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Response rates for both Dysport and Botox were equivalent in both frown and crow's feet regions up to approximately 3 months; however, the response rates were higher at 4 and 5 months with Dysport.<wbr> Patient satisfaction findings were generally consistent at each time point</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Dr.<wbr> Kassir's experience with Dysport demonstrated a longer duration of activity and faster results in a larger number of patients in comparison with Botox when used at a dose ratio of 2.<wbr>5:1 in the frown region (between the nose and eyes) and 3:1 in the crow's feet region.<wbr></LI>
<LI>The safety profile was similar for both products.<wbr> </LI>
<LI>These findings from Dr.<wbr> Kassir's triple blind study suggest that Dysport is a safe effective alternative to Botox when injected for treatment of wrinkles in the frown and crow's feet areas.<wbr></LI>
<LI>For the frown area, Dr.<wbr> Ramtin Kassir recommends more concentrated forms, more injection areas, and more superficial injections to decrease the incidence of brow or eyelidptosis (loss of elasticity and resulting droopiness) and to decrease the migration of treatment.<wbr></LI>
</UL> </div><div>Many thanks to the Ipsen Aesthetic people for their feedback.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7282c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Apparently the paper has not been published yet.<wbr> We will track its publication.<wbr> </div></div><a name="Neurology7283c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>These data will reinforce Dysport key messages (fast onset of action, longer duration, physician and patient satisfaction) and confirm the results of Dr Mark Nestor's publications in 2011.<wbr> </div></div><a name="Neurology7284c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>I have received the article from the PR agency.<wbr> Please find attached.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7271">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-19T09:41:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-19T09:41:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Final Registration Trial with MYOBLOC® to Treat Sialorrhea</title>
	<pubDate>2013-11-18T17:37:34+01:00</pubDate>
	<wp:post_id>4680</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This MYOBLOC® trial is a nationwide, multicenter, double-blinded, placebo-controlled study that will enroll patients who have been diagnosed with sialorrhea due to multiple causes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">MYOBLOC® will be injected directly into the salivary glands, and the efficacy and safety will be analyzed over the course of 1 year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">When MYOBLOC® is injected directly into the salivary glands, it inhibits the release of the neurotransmitter acetylcholine, resulting in decreased saliva production, thereby decreasing drooling.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Albany, NY; Aurora, CO; Baltimore, MD; Bedford, TX; Boca Raton, FL; Cleveland, OH; Escondido, CA; Houston, TX; Kirkland, WA; Los Angeles, CA; New York, NY; Port Charlotte, FL; Port Royal, SC; Salt Lake City, UT; San Antonio, TX; Southfield, MI; St.<wbr> Louis, MO; Tacoma, WA; Tulsa, OK; and Washington, DC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On Aug 13 2010 US WorldMeds acquired Solstice Neurosciences for $35.<wbr>7 million.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
Rationale: The acquisition expands US WorldMeds’ operations, adds to the company’s growing portfolio of products and enhances the company’s ability to create and deliver high-quality specialty pharmaceutical products to its targeted global markets.<wbr></LI>
</UL> </div><div><EM>Source: US WorldMeds</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7286c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The Ph3 trial ("MYSTICOL") has just been listed in the <EM>clinicaltrials.<wbr>gov</EM> database, and brings additional information (please see below).<wbr> PE is to evaluate Unstimulated Salivary Flow Rate.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Official title</SPAN>: Efficacy and Safety Study of MYOBLOC&reg; Followed by Open-Label Multiple-Treatment With MYOBLOC&reg; in the Treatment of Troublesome Sialorrhea in Adult Subjects (MYSTICOL) </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Objective</SPAN>: This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions.<wbr> MYOBLOC will be injected directly into the salivary glands.<wbr> MYOBLOC has been shown in previous trials to safely decrease saliva production, thereby demonstrating its potential as a safe and effective treatment for troublesome sialorrhea </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment:</SPAN> n= 180 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Timelines</SPAN>: completion date July 2015 </div><div>Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01994109?term=PROSTATE+OR+BOTULINUM+OR+ACROMEGALY+OR+NEUROENDOCRINE+OR+SPASTICITY&recr=Open&no_unk=Y&fund=2&rcv_s=10%2F25%2F2013&rank=6&submit_fld_opt=" class="defaultlink">NCT01994109</a> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7269">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-18T17:37:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-18T17:37:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi Dealt A Blow With Late Stage Pipeline Failure</title>
	<pubDate>2013-11-18T17:09:25+01:00</pubDate>
	<wp:post_id>4681</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment Sanofi announced today the decision to halt all clinical trials and 
cancel plans for regulatory filings with its investigational JAK2 inhibitor, 
fedratinib (SAR302503).<wbr> The drug was due to be filed for approval in the EU 
&amp; US in Q4 this year.<wbr> </div><div style="margin-bottom: 10px;">Following a thorough risk benefit assessment including consultation with the 
US FDA, study investigators, independent expert neurologists and 
neuro-radiologists, Sanofi has determined that the risk to patient safety 
outweighs the benefit that fedratinib could bring to patients with 3 different 
types of myleoprofliferative disease.<wbr> </div><div style="margin-bottom: 10px;">The decision follows recent reports of cases of Wernicke's encephalopathy in 
patients participating in clinical trials with the drug.<wbr> </div><div>Source: <A href="http://www.sanofi.com">www.<wbr>sanofi.<wbr>com</A><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"> </SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9323">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-18T17:09:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-18T17:09:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's Largest Manufacturing Plant to be Built in China</title>
	<pubDate>2013-11-18T16:25:28+01:00</pubDate>
	<wp:post_id>4682</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J&amp;J has announced that it has signed an agreement with Chinese firm Xi'an Hi-Tech Industry Development Zone on 14 November to establish a new J&amp;J manufacturing plant in Xi'an capital of the Shaanxi province, reports <I>China Daily</I>.<wbr> J&amp;J's Corporate Vice President Clifford Holland, who was cited by the source, announced that this will be the company's largest investment in a single project in China, although the amount was not disclosed by Holland.<wbr> </div><div style="margin-bottom: 10px;">According to the source, the plant is expected to be one of the largest biopharmaceutical factories in China, with a total floor area of 267,000 square metres.<wbr> In addition, according to the source, the construction of the first phase of the project is expected to start in April 2014, with the plant expected to launch its operations in 2016.<wbr> The new facilities are expected to have an annual production capacity of 5 billion tablets, with annual sales revenues of CNY10 billion (USD1.<wbr>6 billion).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The new J&amp;J-Xi'an plant is a highly ambitious project of the US company wishing to build what is expected to be the largest biopharmaceutical plant in China, with a high production turnover and strong sales revenues.<wbr> The plant is expected to replace the existing Janssen Pharmaceutical Ltd plant and should become one of the top research and development hubs in Asia, aimed at producing drugs that meet the requirements of the Chinese and other emerging markets within and outside Asia </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10688">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-18T16:25:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-18T16:25:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sophiris Reports The Intiation of PhIII Development With Its New BPH Therapy</title>
	<pubDate>2013-11-18T12:54:16+01:00</pubDate>
	<wp:post_id>4683</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sophiris recently reported that the company has commenced enrolment of a phIII study called PLUS-1 evaluating PRX302 (topsalysin), an injectable intraprostatic therapy as a treatement for lower urinary tract symptomms of BPH.<wbr> The treatment is designed to be administered by a urologist.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The Phase 3 international, multi-center trial, will enroll approximately 440 patients.<wbr> The randomized, double-blind trial will assess the safety and efficacy of a single intraprostatic injection of PRX302 (0.<wbr>6 &micro;g/<wbr>g prostate) for the treatment of BPH.<wbr> The primary endpoint is the International Prostate Symptom Score (IPSS) total score change from baseline over 52 weeks.<wbr> Secondary endpoints include Qmax (maximum urine flow) change from baseline over 52 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Financing</STRONG> </div><div style="margin-bottom: 10px;">During the third quarter Sophiris successfully completed an initial U.<wbr>S.<wbr> public offering raising $65m including the capital necessary to advance PRX302 into its first Phase 3 clinical trial.<wbr> The Sophiris team has quickly mobilized since completing the offering and already enrolled the first patients into the first Phase 3 trial of PRX302.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Competing Status of NX-1207</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">Interestingly, Nymox reoprted last week that a safety monitoring committee found no significant safety concerns in the open-label, U.<wbr>S.<wbr> Phase III NX02-0022 trial with its lyophilized version of 2.<wbr>5 mg intraprostatic NX-1207.<wbr> Nymox said that over 50% of a planned 200 BPH patients previously treated with NX-1207 have been enrolled.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Recordati has exclusive rights to this product from Nymox to NX-1207 in over 80 countries, including those in Europe and the Commonwealth of Independent States.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">By way of comparison the clinical development pathway for NX-1207 has been as follows:-</P> </div><div style="margin-bottom: 10px;"><UL><LI>
 June 2009, the Corporation began conducting the first of two pivotal double blind placebo controlled Phase 3 trials for NX-1207 that incorporated specific protocol design recommendations provided by the FDA.<wbr>

</LI>
<LI>
The two pivotal Phase 3 studies for NX-1207 are being conducted at well-known investigational sites across the U.<wbr>S.<wbr> with planned enrolment of 1,000 patients.<wbr>

</LI>
<LI>
In July 2012, Nymox announced the completion of enrollment for the Phase 3 repeat injection Study NX02-0020.<wbr> The NX02-0020 study started in July 2011 and involved men who had previously participated in one of the earlier Nymox NX-1207 studies for BPH.<wbr>

</LI>
<LI>
On January 22, 2013, Nymox announced the completion of the six month primary endpoint evaluating safety for the NX02-0020 study and reported that the safety assessment was positive with no reported significant adverse events related to the drug and none of the reported sexual, cardiovascular, or other side effects that are associated with approved BPH medications.<wbr>

</LI>
<LI>
On November 28, 2012, Nymox announced completion of patient enrollment in the Corporation&rsquo;s pivotal U.<wbr>S.<wbr> Phase 3 NX02-0017 Study of NX-1207 for BPH.<wbr>

</LI>
</UL> </div><div><P align="left">Source: <a href="http://www.sophiris.com" class="defaultlink" title="http://www.sophiris.com">sophiris.com</a></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9321">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-18T12:54:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-18T12:54:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck KGaA's China Plant to be its Second Largest WW</title>
	<pubDate>2013-11-18T09:24:08+01:00</pubDate>
	<wp:post_id>4684</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company will invest €80M ($108M) to create a new 40,000 m² plant in the Greater Shanghai region to produce drugs for daibetes (Glucophage), cardiovascular disease (Concor) and thyroid disorder (Euthyrox).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Construction is scheduled to be completed by 2016, with commercial production starting in 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10686">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-18T09:24:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-18T09:24:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Merz 2012/2013 Results</title>
	<pubDate>2013-11-15T17:34:35+01:00</pubDate>
	<wp:post_id>4685</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Group revenues increases by 7.<wbr>4% to €980.<wbr>2M (vs 17% for 2011/<wbr>2012).<wbr> Major growth drivers were foreign operations and the aesthetic business.<wbr> In Russia, Brazil, Mexico and its Asian locations, the company reported it wants to achieve a leading position with both its OTC/<wbr>OTX products and its products for aesthetics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the therapeutic market, business grew above the trend line in all the major markets of Europe.<wbr> </div><div style="margin-bottom: 10px;">In the market serving German clinics and pharmacies Merz also recorded double-digit growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the fall of 2013, Merz obtained CE certification for its internally developed MHA100 hyaluronic acid filler.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Internationally, Merz generated revenue of €837.<wbr>4M (85.<wbr>4% of total revenue).<wbr> </div><div style="margin-bottom: 10px;">Revenue of €142.<wbr>8M was generated on the German market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company is working intensively on reinforcing its positions on the North America and the emerging markets (such as Russia, Brazil, and Mexico).<wbr> </div><div style="margin-bottom: 10px;">In China, Merz is preparing to set up its own organization.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Royalties for Memantine rose by more than 8 % on the prior year thanks to the marketing successes of Merz's partners, Forest Laboratories in the US and Daiichi Sankyo in Japan.<wbr> </div><div style="margin-bottom: 10px;">With support from Merz, Forest launched a once-daily dosage of the medication for dementia on the market in June 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Merz Pharma Group employs 2,443 people worldwide (prior year: 2,396).<wbr> </div><div style="margin-bottom: 10px;">The Company generated 2011/<wbr>2010 revenue of EUR 913.<wbr>1 million See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=6667" class="defaultlink">Neurology6667: Merz Reports 2011/<wbr>12 Financial Results</a>.<wbr> </div><div><EM>Source: Merz</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7266">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-15T17:34:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-15T17:34:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xofigo® Approved in the EU</title>
	<pubDate>2013-11-15T17:20:47+01:00</pubDate>
	<wp:post_id>4686</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Xofigo® 1000 kBq/<wbr>ml, solution for injection has been granted MA less than 2 months after it gained a positive opinion from the EMA CHMP.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The approval of Xofigo is based on data from the pivotal Phase III ALSYMPCA (<B>AL</B>pharadin in <B>SYM</B>ptomatic <B>P</B>rostate <B>CA</B>ncer) trial.<wbr> </div><div style="margin-bottom: 10px;">- Christopher Parker, M.<wbr>D.<wbr>, Principal Investigator of the ALSYMPCA trial and Consultant Clinical Oncologist at The Royal Marsden NHS Foundation Trust, and Honorary Reader in Prostate Oncology at The Institute of Cancer Research, London.<wbr> </div><div><EM>Source: Bayer</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9417c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Following EMA approval, Bayer HealthCare annouced UK launch of Xofigo® (radium-223 dichloride) solution for injection on 13th January 2014.<wbr> Joe Hemphill (BU Head Speciality medicine, Bayer) stated " The launch and availability of Xofigo in the UK should be welcomed news for physicians and patients, who have been looking for new treatment options".<wbr> </div><div style="margin-bottom: 10px;">The technology appraisal has been sumbitted to NICE and first committee took place on 25 Sept 2013, however, outcome of the commitee could not be released as the marketing authorisation had not been granted at the time.<wbr> </div><div style="margin-bottom: 10px;">The expected date of issue is Feburary 2014.<wbr> </div><div><EM>Source: nice.<wbr>org.<wbr>uk, FirstWorld, PBR</EM> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9320">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-15T17:20:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-15T17:20:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph1 Study of PM01183 in Combination With Doxorubicin for Gastroenteropancreatic NETs</title>
	<pubDate>2013-11-14T17:57:14+01:00</pubDate>
	<wp:post_id>4687</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph1 study has currently met its primary end point, and is now recruiting patients to be treated at the recommended dose expansion cohort of selected tumor types (endometrial adenocarcinomas, neuroendocrine tumors, and SCLC).<wbr> PharmaMar's PM01183 is a new compound that has been described as an interfacial inhibitor of transactivated transcription which also acts in the tumour's microenvironment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Ph1b completed in May 2013.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>Complete and partial radiological remissions were observed in patients with small-cell lung, bladder, breast, endometrial and ovarian cancers, neuroendocrine tumours, and synovial sarcoma.<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">Completion date: June 2014 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=73 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Spain; UK </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT01970540?recr=Open&amp;no_unk=Y&amp;cond=neuroendocrine&amp;fund=2&amp;rcv_s=10%2F14%2F2013&amp;rank=1">NCT1970540</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7521">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-14T17:57:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-14T17:57:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo's Once-Weekly GH to Enter FIM Comparative Trial for PGHD</title>
	<pubDate>2013-11-14T17:34:13+01:00</pubDate>
	<wp:post_id>4688</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The pediatric Ph1 study will be starting next month in approx.<wbr> 32 children aged 6 to 13 years.<wbr> PE will assess incidence of AEs.<wbr> In October last year the company started a similar designed Ph1 in AGHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Dec 2013 - Completion date: Nov 2014 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=32 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Confirmed diagnosis of GHD (growth hormone deficiency) as defined by two different GH (growth hormone) stimulation tests, peak GH level below or equal to 7.<wbr>0 ng/<wbr>ml.<wbr> For children with three or more pituitary hormone deficiencies only one GH stimulation test will be needed.<wbr> If in accordance with country specific practice, growth hormone deficiency can be defined by only one GH stimulation test, peak GH level below or equal to 7.<wbr>0 ng/<wbr>ml.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Pre-pubertal children at screening.<wbr> Boys: Tanner stage 1 and age above or equal to 6 years and below 13 years.<wbr> Girls: Tanner stage 1 and age above or equal to 6 years and below 12 years</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Body weight above or equal to 16.<wbr>0 kg and below or equal to 50.<wbr>0 kg</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Stable GH replacement treatment for at least 3 months</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">Austria; Belgium; France; Israel; Macedonia; Norway; Slovenia; Spain; Sweden; Switzerland.<wbr> </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT01973244?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=10%2F14%2F2013&amp;rank=155">NCT01973244</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7520">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-14T17:34:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-14T17:34:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Focus on Merck Serono Q3 & 9M 2013 Results</title>
	<pubDate>2013-11-14T16:32:00+01:00</pubDate>
	<wp:post_id>4689</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cost efficiencies and resource allocation in marketing and selling have fueled Merck Serono improvement.<wbr> The unit registered solid organic sales of 5% driven by emerging markets and Japan.<wbr> Saizen Q3 organic sales increased by 1% to €61M, and 9M organic sales decreased by 3% (to €175M).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7518_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7518_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7518_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> Moderate organic sales growth  EBITDA pre ~ €1.<wbr>9 - 2.<wbr>0 bn </div><div><EM>Source: Merck</EM> </div><!-- Comment details --><a name="endocrinology7518attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7518_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7518_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(101,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7518_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(75,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7518">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-14T16:32:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-14T16:32:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Synergy Moves Into PhIII Development With New GI Drug</title>
	<pubDate>2013-11-14T12:03:35+01:00</pubDate>
	<wp:post_id>4690</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Synergy Pharmaceuticals Inc.<wbr> today announced the start of the first 
of two planned phase 3 clinical trials to confirm the safety and efficacy of 
plecanatide, its lead GC-C agonist and once-daily oral treatment, in adult 
patients with chronic idiopathic constipation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is plecanatide?</STRONG> </div><div style="margin-bottom: 10px;">Plecanatide is a synthetic analog of uroguanylin, a naturally occurring human 
GI hormone and physiological agonist of the GC-C receptor.<wbr> Orally administered 
plecanatide mimics uroguanylin’s natural activity, binding to and activating the 
GC-C receptor expressed in the GI tract, resulting in fluid secretion and 
normalization of bowel movement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pivotal Study Design<BR></STRONG><BR>The pivotal phase 3 trial is a 
randomized, double-blind, clinical trial to compare a 12-week, dose-ranging 
regimen of plecanatide (3.<wbr>0 and 6.<wbr>0mg) against placebo in adult patients with 
CIC.<wbr> The study will be conducted at approximately 180 sites in the United States 
and Canada and will enroll approximately 1350 patients with CIC.<wbr> The primary 
endpoint of the study is the proportion of patients who are overall responders 
for the 12-week treatment period.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Progress To Date<BR></STRONG><BR>“Plecanatide has already 
demonstrated a favorable safety and efficacy profile in a recently completed 
large, multi-center study in 951 patients with CIC,” said Dr.<wbr> Gary S.<wbr> Jacob, 
Chief Executive Officer of Synergy Pharmaceuticals Inc.<wbr> “We look forward to 
further evaluating the effect of plecanatide in CIC patients and believe it is 
well positioned to be the best-in-class GC-C agonist with superior pharmacologic 
properties that support a very unique tolerability profile.<wbr>” </div><div style="margin-bottom: 10px;">In early 
2013, Synergy announced positive results from a large multicenter trial of 
plecanatide in patients with CIC and completed an end-of-phase 2 meeting with 
the U.<wbr>S.<wbr> Food and Drug Administration (FDA) in July covering the registration 
program for plecanatide to treat CIC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Development Plans</STRONG> </div><div>Synergy plans to announce topline data results from its ongoing phase 2b 
study of plecanatide in IBS-C patients in 1Q2014.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1930">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-14T12:03:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-14T12:03:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon's Sipuleucel-T With Enzalutamide in Men With mCRPC</title>
	<pubDate>2013-11-13T17:16:26+01:00</pubDate>
	<wp:post_id>4691</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph2 has been designed to assess the effects of PROVENGE (sipuleucel-T) when administered concurrently or sequentially with XTANDI (enzalutamide).<wbr> PE will assess peripheral PA2024-specific T cell immune response to sipuleucel-T over time via a T cell stimulation index from a proliferation assay.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=100 </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Sept 2013 - Completion date: Sept 2015 </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">This study consists of 3 phases.<wbr> The screening phase will begin at the completion of the informed consent process and continue through registration.<wbr> The active phase will begin at registration and continue through the post-treatment visit (30 to 37 days following the last study treatment).<wbr> The long term follow-up (LTFU) phase will begin after the post-treatment visit and will continue until the subject's death or until Dendreon terminates the study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">US: 5 sites recruiting </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01981122?recr=Open&no_unk=Y&fund=2&rcv_s=10%2F13%2F2013&rank=87" class="defaultlink">NCT01981122</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9319">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-13T17:16:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-13T17:16:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon Updates on Significant Progress in Q3:13</title>
	<pubDate>2013-11-13T17:00:08+01:00</pubDate>
	<wp:post_id>4692</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Q3 call contained incremental updates.<wbr> The most important event was the results obtained from the renal impairment proof of concept study in T2DM.<wbr> With respect to telotristat etiprate program, the company indicated it has expanded the number of activated sites in the Ph3 carcinoid trial.<wbr> Top-line data of LX1033 for IBS-d are expected second half of this month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Q3 Financial Results</STRONG> </div><div style="margin-bottom: 10px;">Revenues decreased to $0.<wbr>2 million from $0.<wbr>4 million in the prior-year period.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nine-Month Revenues</STRONG> </div><div style="margin-bottom: 10px;">Revenues decreased to $0.<wbr>8 million from $0.<wbr>9 million in the prior year period.<wbr><BR><BR><STRONG>Key Messages from Q&amp;A Session</STRONG> </div><div style="margin-bottom: 10px;">Questions mostly focused on <SPAN style="text-decoration: underline;">LX4211 partnership</SPAN>.<wbr> The company still expects to enter Ph3 by YE13/<wbr>1H14 with a partner.<wbr> Management reported that " .<wbr>.<wbr>.<wbr> We're continuing to make progress in our partnership discussions and our objective remains to move into Phase 3 with a partner in the near-term.<wbr> We do want to have a partner in place in particularly type 2 diabetes before launching that Phase 3 program.<wbr> And that timing is going to depend upon getting that finalized.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>WedBush Estimates </STRONG><EM>(source: Nov 12 report)</EM> </div><div><UL><LI>LX1032 for Carcinoid Syndrome may be launched in 2015, with gross sales reaching over $400 million in 2019.<wbr>
</LI>
<LI>
LX1033 for IBS-d could be launched in 2016 with gross sales reaching over $1 billion in 2021.<wbr>

</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10685">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-13T17:00:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-13T17:00:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>immatics and Roche Sign Therapeutic Cancer Vaccine Deal</title>
	<pubDate>2013-11-13T15:52:00+01:00</pubDate>
	<wp:post_id>4693</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agreement will focus on the research, clinical development and commercialisation of a number of new tumour-associated peptide (TUMAP)-based cancer vaccine candidates and other immunotherapies in oncology, targeting  prostate and non-small cell lung cancer.<wbr> The most advanced cancer vaccine candidate covered by the agreement is IMA942, in Ph1 for gastric cancer </div><div style="margin-bottom: 10px;"><STRONG>Financial</STRONG> </div><div style="margin-bottom: 10px;"><EM>immatics </EM>will receive an upfront payment of $17 million and committed research funding + potential milestone payments that could reach values in excess of $1 billion and royalties across three cancer indications, based on sales of the cancer vaccines and immunotherapies resulting from this agreement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Collaboration</STRONG> </div><div style="margin-bottom: 10px;">In parallel with the clinical development of IMA942 by Roche, <EM>immatics</EM> will conduct research on behalf of Roche using its unique <a href="http://www.immatics.com/index.php?page=87" class="defaultlink">XPRESIDENT®</a> technology platform to identify novel and relevant TUMAP candidates for the development of cancer vaccines and other compounds targeting cancer peptide antigens, primarily in gastric, prostate and non-small cell lung cancer.<wbr> </div><div style="margin-bottom: 10px;">The XPRESIDENT&reg; discovery platform is to date the only known high-throughput research technology to directly identify, quantify, and prioritize cancer antigens recognized by T lymphocytes (type of white blood cell) based on the ability of the immune system to detect them.<wbr> </div><div><EM>Source: immatics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9318">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-13T15:52:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-13T15:52:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BOTOX® Injection Could Treat Prostate Cancer</title>
	<pubDate>2013-11-13T15:02:42+01:00</pubDate>
	<wp:post_id>4694</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Dailymail has issued two articles regarding the use of experimental BOTOX&reg; in snapping hip syndrome, BPH and prostate cancer.<wbr> By blocking the effect of nerves BOTOX&reg; could be used to target the nerves supplying tumours.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Prostate Cancer and BPH</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Prostate Cancer</SPAN> </div><div style="margin-bottom: 10px;">The article issued on Nov 12th highlights that BOTOX&reg; injection could treat the condition by freezing tumours.<wbr> </div><div style="margin-bottom: 10px;">In a trial at Texas University, BOTOX&reg; is being assessed on 15 men with localised cancer.<wbr> Half f the gland will be injected with the toxin and the other with saline (<a href="http://www.clinicaltrials.gov/ct2/show/NCT01520441?term=texas+university+AND+BOTOX&rank=1" class="defaultlink">NCT01520441</a>).<wbr> Early results from 3 patients on the trial show the side of the tumour injected with BOTOX&reg; has shrivelled significantly; the other side had not.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Enlarged Prostate (BPH)</SPAN> </div><div style="margin-bottom: 10px;">Researchers at the U.<wbr> of Pittsburgh found that 75% of men injected with BOTOX&reg; had some easing of their symptoms </div><div style="margin-bottom: 10px;">See full article <A href="http://www.dailymail.co.uk/health/article-2501316/The-Botox-injection-freeze-prostate-cancer.html">http:/<wbr>/<wbr>www.<wbr>dailymail.<wbr>co.<wbr>uk/<wbr>health/<wbr>article-2501316/<wbr>The-Botox-injection-freeze-prostate-cancer.<wbr>html</A> </div><div style="margin-bottom: 10px;"><STRONG>Snapping Hip Syndrome</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Etiology:</SPAN> rare syndrome caused by the movement of a muscle or tendon over a bony part of the hip, and causes pain and weakness during movement.<wbr> </div><div style="margin-bottom: 10px;">The article reports that the sybdrome ceased after four injections in the hip and buttock area.<wbr> The treatment is thought to strengthen the muscles causing the snapping in the hip.<wbr> </div><div style="margin-bottom: 10px;">See full article <A href="http://www.dailymail.co.uk/health/article-2502842/Groom-walks-time-wedding-having-BOTOX-injections-legs.html">http:/<wbr>/<wbr>www.<wbr>dailymail.<wbr>co.<wbr>uk/<wbr>health/<wbr>article-2502842/<wbr>Groom-walks-time-wedding-having-BOTOX-injections-legs.<wbr>html</A> </div><div>Source: the Dailymail Online </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9315">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-13T15:02:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-13T15:02:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Acquires Partner Anteis</title>
	<pubDate>2013-11-13T12:18:51+01:00</pubDate>
	<wp:post_id>4695</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: While the recent acquisition of Neocutis S.<wbr>A.<wbr>, which specializes in the development of dermocosmetic pre- and post-treatments for aesthetic procedures, strengthens Merz&rsquo;s position in the U.<wbr>S.<wbr> market, the acquisition of Anteis enhances the company&rsquo;s footprint in a whole range of markets around the world.<wbr> Financials terms of the acquisition have not been disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">As the exclusive distributor of Belotero Balance&reg; since its approval in the U.<wbr>S.<wbr> in 2011, Merz has already collaborated successfully with Anteis for several years.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">The acquisition strengthens Merz Aesthetics&rsquo; portfolio and reinforces its market position in the field of aesthetic medicine while merging Anteis&rsquo; operations into one of the leading providers worldwide.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Anteis SnapShot</STRONG> </div><div style="margin-bottom: 10px;">Swiss company - Global player in the area of injectable medical devices based on biopolymer transformation.<wbr> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="text-decoration: underline;">Focus</SPAN>: development of several highly innovative and highly differentiated products in the field of aesthetics, e.<wbr>g.<wbr> wrinkle-filling gels, resorbable implants and cutaneous rehydration gels.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="text-decoration: underline;">Products Lines</SPAN>: Esth&eacute;lis, Fort&eacute;lis, Mesolis and Mod&eacute;lis as well as the Jolidermis range and the Anteis Injection System are available in over 90 countries in five continents.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Besides aesthetic dermatology, Anteis is also active in the fields of ophthalmology and orthopedics.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Background - Neocutis Acquisition</STRONG></P> </div><div><P align="left">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7090" class="defaultlink">Neurology7090: Merz Acquires Swiss Dermatology Company</a></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7262">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-13T12:18:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-13T12:18:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Q3 Earnings - Key New Trials Planned</title>
	<pubDate>2013-11-13T12:17:34+01:00</pubDate>
	<wp:post_id>4696</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medivation has raised its guidance for XTANDI sales in 2013 from $345m to $365m based on robust uptake seen during the quarter.<wbr> It also provided an update on its development plans, hinting at a new MO trial and announcing the initiation of the PLATO study, a trial evaluating combination therapy in patients whose disease has progressed on enzalutamide.<wbr> </div><div style="margin-bottom: 10px;">Medivation did confirm that it is seeing strong underlying demand for XTANDI, reflected by prescriptions for more than 45,000 bottles written by approximately 4,500 individual prescribers since our launch in September of 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PLATO Trial</STRONG> </div><div style="margin-bottom: 10px;">This study will evaluate the efficacy and safety of continued treatment with enzalutamide plus abiraterone and prednisone, as compared to treatment with abiraterone and prednisone alone in patients with chemotherapy-naive metastatic prostate cancer, whose disease has progressed following enzalutamide therapy.<wbr> The purpose of this trial is to help determine the potential clinical benefits of extending time on enzalutamide treatment by adding an additional therapy in patients with progressive chemotherapy-naive metastatic prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">The global randomized double-blind placebo-controlled trial is designed to enroll approximately 500 chemotherapy-naive patients with metastatic CRPC.<wbr> The primary endpoint of the trial is progression-free survival.<wbr> </div><div style="margin-bottom: 10px;">We have two ongoing clinical trials, TERRAIN and STRIVE that are comparing the effect of enzalutamide head-to-head versus bicalutamide, the most commonly used antiandrogen.<wbr> </div><div style="margin-bottom: 10px;">In July, Astellas completed targeted patient enrollment in the TERRAIN trial, which enrolled approximately 370 men with metastatic disease primarily in Europe.<wbr> Astellas is currently following these patients.<wbr> Enrollment is continuing in the STRIVE trial, which is targeting approximately 400 men with either metastatic or non-metastatic disease primarily in the U.<wbr>S.<wbr>  Medivation is also continuing to enroll patients in our study evaluating enzalutamide in a phase 2 trial in an area where there is a significant unmet medical need, androgen receptor-positive triple negative breast cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New PhIII MO CRPC Trial</STRONG> </div><div style="margin-bottom: 10px;">Regarding its planned MO trial, managment noted that it is expecting the first patient to enter the trial any day.<wbr> It stated that it is going to be a large global trial with both U.<wbr>S.<wbr> and x-U.<wbr>S.<wbr> participation.<wbr> When questioned further about high the design might be different to that being undertaken with the Aragon drug, the only comment was that we&rsquo;re very much looking forward to talking about the trial, but we&rsquo;re going to wait &lsquo;til the first patient is enrolled.<wbr> I think the good news for us is that with XTANDI, we have two positive overall survival trials already completed, as well as an excellent safety profile.<wbr> So I think that puts us in a very strong position to recruit this trial.<wbr> </div><div>Source: <A href="http://www.medivation.com/">www.<wbr>medivation.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9313">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-13T12:17:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-13T12:17:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Scottish Medicines Consortium Approves Enzalutamide and Axitinib</title>
	<pubDate>2013-11-13T12:07:51+01:00</pubDate>
	<wp:post_id>4697</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Scotland has become the first part of the UK to approve enzalutamide for routine use on the NHS for men with advanced PCa, and axitinib for second line kidney cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Figures</STRONG> </div><div style="margin-bottom: 10px;">Prostate cancer affects more than 2500 people in Scotland each year, with the disease becoming more advanced in 10% to 20% of sufferers, but drugs firm Astellas Pharma Limited said a trial shows that the new medicine meant patients lived an average of 4.<wbr>8 months longer.<wbr> </div><div>On average there are more than 800 cases of kidney cancer a year in Scotland, with around 340 deaths a year from the disease.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9312">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-13T12:07:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-13T12:07:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biogen Continues To Make Very Strong Progress With Its Newly Launched Multiple Sclerosis Therapy</title>
	<pubDate>2013-11-12T18:05:17+01:00</pubDate>
	<wp:post_id>4698</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Biogen-Idec's presentation today at the Credit Suisse H/<wbr>C Conference 
elaborated on the market segementation that exists in the multiple sclerosis 
market and highlighted some new statistics on the uptake of Tecfidera.<wbr> There was 
no new information forthcoming on European approval.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Tom Kingsley Executive VP Commercial Operations noted that one of the reasons 
for talking about the Tecfidera numbers was that the company wants to start 
talking to physicians and patients about this.<wbr> This is a marketing campaign that 
will be launched.<wbr> By telling physicians and patients that approx 35,000 patients 
are on therapy and that 5000 physicians are writing that kind of script that 
will reinforce the momentum of the product.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">In the Q/<wbr>A that followed one topic that emerged was pricing and reimbursement 
in the MS market.<wbr> Tony Kingsley Executive VP Commercial Operations made the 
following comments:- </div><div>If you look at the MS market today, relative to the US there are two 
important differences which you can see broadly in Europe.<wbr> The first is there is 
a big difference in the pricing in Europe between products that are first line 
labeled and second line labeled.<wbr> So Tysabri, for example is priced at a 
signficantly higher price than Avonex, Copaxone and some of the interferons and 
that's because they have more restrictive labels.<wbr> If you look at the platform 
therapies today, European net prices are typically half or left of what US 
prices are.<wbr> </div><!-- Comment details --><a name="neurology7261attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(176,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(138,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(186,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(163,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(183,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(187,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(173,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7261_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(153,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7261">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-12T18:05:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-12T18:05:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon Q3 Figures - Declining Sales But Uptake In Enrollments Points To Stronger Year-end</title>
	<pubDate>2013-11-12T16:51:28+01:00</pubDate>
	<wp:post_id>4699</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Net product revenue was down 12.<wbr>8% in the quarter, whilst 
profitability has improved with the quarterly net loss now $67.<wbr>2m vs $154.<wbr>9m a 
year ago.<wbr> Despite the shortfall in revenues Dendreon has observed a 
strengthening of its business during the past two months with more patient 
enrollments seen in October than in any other month this year.<wbr> It has also 
stepped up its clinical development activity with a XTANDI sequencing study now 
initiated and 23 investigator studies underway, including 3 evaluating 
combination usage with a PD1-inhibitors and one with Xofigo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Company Goals</STRONG> </div><div style="margin-bottom: 10px;">Accelerating the path towards profitability has been a key 
business priority and to this end the company  is continuing 
to restructure its business and implementing further cost reduction 
processes in order to become a leaner more nimble biotechnology company focused 
on immuno-oncology.<wbr> Headcount as a results will have fallen from more than 2000 
at its peak to approx.<wbr> 820 once the restructuring is complete and more than 
$125m will be removed from operating expenses.<wbr> Realisation of these targets 
should be achieved as early as Q12014.<wbr> Meanwhile, the group's cash position 
remains strong with $233m available as of Sept 30th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Quarterly Revenue Influences</STRONG> </div><div style="margin-bottom: 10px;">Third quarter results were impacted by increased competition and sales force 
vacancies.<wbr> 27 net new accounts were accrued with community clinics now 
accounting for 71% of total sales (an area perceived as offering long-term 
growth potential).<wbr> Within this community setting oncology accounted for 37% of 
business, urology 34% and academic centres 19%.<wbr> Urology sales were down 5% 
oncology down 10% and academic centres down 3%.<wbr> </div><div style="margin-bottom: 10px;">With regard to competitive influences, the greatest impact was seen in small 
low volume accounts across all market segments although some top urology 
accounts did slow down in the quarter.<wbr> </div><div style="margin-bottom: 10px;">Sale vacancies also had an impact forcing some re-alignment of sales efforts 
on large accounts.<wbr> In fact the number of large accounts (run rate &gt;$1m) is 
now at an all time high with 94 accounts up from 85 in Q2 and 54 in Q1.<wbr> This 
coupled with more patient enrollments points towards a stronger Q413/<wbr>Q114 
picture than seen over the last quarter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PROVENGE Outlook</STRONG> </div><div style="margin-bottom: 10px;">Managment believes that with an increasing amount of data surrounding 
PROVENGE coming into the marketplace with regard to MOA and usage in combination 
with other agents KOL suport for the drug is strengthening.<wbr> Education and 
increasing patient awareness is a top priority and to this end Dendreon has 
recently initiated a DTC advertising campaign in the US.<wbr> </div><div style="margin-bottom: 10px;">Noted as one of the key milestones of the quarter was the European approval 
of PROVENGE and the commercially favourable label which includes PSA quartile 
analysis and the correlation between immune parameters and overall survival.<wbr> 
This label will allow for a unique commercial messaging in Europe compared to 
the US a factor that should assist with reimbursement discussions.<wbr> </div><div style="margin-bottom: 10px;">Dendreon has in place a European CMO for production and is in discussions 
with potential European partners prioritising its plans for launch.<wbr> </div><div style="margin-bottom: 10px;">Dendreon had anticipated that the PREVAIL survival benefit may be so large 
that it might create an imperative for its use as a front-line therapy in mCRPC.<wbr> 
In the event the 2.<wbr>2 month improvement in median OS suggests there will be less 
urgency to use XTANDI that previously anticipated.<wbr> It therefore, contineus to 
see physicians sequencing PROVENGE as an initial therapy or in combination with 
other therapies approved for mCRPC.<wbr> Dendreon was also keen to point out the 
sobering data that is starting to emerge on cross-resistance between hormonal 
agents and for that matter chemotherapy, which heightens the need for 
alternative agents.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dendreon's Sequencing Studies</STRONG> </div><div style="margin-bottom: 10px;">In order to evaluate potential synergies of combination therapy, Dendreon is 
continuing to pursue a clinical programme to support this concept.<wbr> Its two phII 
studies i) combination with abiraterone; and 2) combination with ADT are fully 
enrolled.<wbr> Data presented at ECCO indicates that PROVENGE and Zytiga can be given 
concurrently without affecting PROVENGE potentcy and or immunological prime 
boost responses.<wbr> </div><div style="margin-bottom: 10px;">Finally, Dendreon announced that its seqencing study with XTANDI is now 
active and enrolling patients with the 1st patient having been treated.<wbr> To 
increase its engagement with clinical researchers, Dendreon is supporting 23 
novel investigator initiated studies at 19 sites.<wbr> One particular focus has 
been getting access to checkpoint inhibitors, where Dendreon is now 
supporting three investigator initiated trials What Dendreon witnessed in its 
neoadjuvant trial of PROVENGE was up-regulation of PD-1 on tumour infiltrating 
lymphocytes.<wbr> So there is an evolving though that combining PROVENGE with a 
PD1-inhibitor could create some synergistic response.<wbr> </div><div>Source: <A href="http://www.dendreon.com">www.<wbr>dendreon.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9310">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-12T16:51:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-12T16:51:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Daewoong Still Awaits Toxin Approval In Korea But Analysts Are Impressed With The Export Deal It Has Negotiated</title>
	<pubDate>2013-11-12T10:32:57+01:00</pubDate>
	<wp:post_id>4700</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Daewoong Still Awaits Toxin Approval In Korea But Analysts Are Impressed With The Export Deal It Has Negotiated</span>&nbsp;<br><span style="font-size: 12px;">Comment: The latest report on Daewoong from Korea Investment &amp; Securities Co (November 6th) notes that the company is still waiting for MFDS approval of its Botox biosimilar Nabota.<wbr> Approval had been expected by end-September following a regulatory filing for glabellar lines in May.<wbr> The assumption is it will now be approved this month with market launch occuring in January 2014.<wbr> More detail on Nabota's route to commercialisation in the US has come from the CPhI meeting where the link with the US <STRONG>ALPHAEON Corporation</STRONG> (a lifestyle healthcare company) was established.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7257">...</a><br></div><div>Very interesting article.<wbr> We apparently will have an additional global toxin-filler couple with Evosyal and Teosyal.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7260">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7257">View thread  Neurology7257: Daewoong Still Awaits Toxin Approval In Korea But Analysts Are Impressed With The Export Deal It Has Negotiated</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-12T10:32:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-12T10:32:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Manufacturing Plant For Zoladex</title>
	<pubDate>2013-11-11T10:50:04+01:00</pubDate>
	<wp:post_id>4701</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca has announced it will invest &pound;120 in a new facility to continue the production of its prostate cancer drug Zoladex.<wbr> </div><div style="margin-bottom: 10px;">Zoladex is AZ's 5th largest selling brand with annual sales of around $1bn.<wbr> Sales for the 9 months 2013 were $749m -1% </div><div style="margin-bottom: 10px;">The new facility will be built at the group's manufacturing site in Macclesfield and will sevure 300 existing Zoladex jobs and will create more than 200 temporary positions in the area between now and early 2017.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For Investment</STRONG> </div><div style="margin-bottom: 10px;">The continued global demand for Zoladex, particularly in Japan and emerging markets including China and Russia, is what has resulted in the decision to invest in replacing some of the existing facilities where the medicine is currently produced at the Macclesfield site.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timeline For Completion</STRONG> </div><div>The building of the new facility will begin in 2013 and is due to be completed by 2016.<wbr> Products manufactured in the new facility will begin to be supplied to markets in 2017.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9306">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-11T10:50:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-11T10:50:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Clinical Hold On Proellex Development To Be Lifted</title>
	<pubDate>2013-11-11T10:18:09+01:00</pubDate>
	<wp:post_id>4702</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Repros has been given guidance by the FDA on acceptable endpoints for a new phIIb uterine fibrodis study with oral Proellex and been advised to submit a request for lifting its clinical hold.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">Proellex is an oral selective progesterone receptor modulator (SPRM).<wbr> Earlier studies have shown highly statistically significant results in achieving clinically relevant improvements in menstrual bleeding as well as symptoms associated with tumor bulk via a previously validated quality of life instrument (UFSQOL).<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Background</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Repros development was put on holdy by the FDA in 2009 after clinically significant increases in liver enzymes were observed at the 25 and 50 mg Proellex doses in Phase III trials.<wbr> In 2010, the agency replaced a full clinical hold on oral Proellex with a partial hold so that the company could conduct a Phase II trial evaluating lower doses of the compound</P> </div><div style="margin-bottom: 10px;"><P align="left">In October 2012, Repros said FDA converted a full clinical hold on additional trials of oral Proellex to a partial hold to allow the company to conduct a placebo-controlled Phase II trial evaluating low-dose Proellex in endometriosis</P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;">The Company currently has three open INDs for Proellex: </div><div style="margin-bottom: 10px;"><UL><LI>70,535 - oral treatment of fibroids STATUS: Full Clinical Hold
</LI>
<LI>76,631 &mdash; oral treatment for endometriosis STATUS: Partial Clinical Hold and in Phase 2
</LI>
<LI>112,576 &mdash; vaginal treatment for fibroids STATUS: Initiating Phase 2b
</LI>
</UL> </div><div><P align="left"></P> </div><!-- Comment details --><a name="oncology9304attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9304_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9304">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-11T10:18:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-11T10:18:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>More Safety Concerns About Another MS Drug</title>
	<pubDate>2013-11-08T15:52:33+01:00</pubDate>
	<wp:post_id>4703</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: US regulatory officials have raised concerns about Sanofi's new 
multiple sclerosis drug Lemtrada ahead of a November 13 advisory panel focusing 
on multiple serious and potentially fatal safety issues.<wbr> </div><div style="margin-bottom: 10px;">Their report suggests that the risks might be too great to justify approval 
unless the drug shows "substantial clinical benefit".<wbr> </div><div style="margin-bottom: 10px;">Lemtrada, also known as alemtuzumab, is given via an intravenous drip for 5 
days and for 3 days one year later.<wbr> It is designed to reprogramme the immune 
system.<wbr> </div><div style="margin-bottom: 10px;">Sanofi acquired it when it bought Genzyme in 2011 for $20.<wbr>1bn.<wbr> Its prospects 
were centre-stage in that takeover battle, with contingent value rights linked 
to its future success.<wbr> </div><div>Source: FDA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7259">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T15:52:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T15:52:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Incidence of Seizures in mCRPC Patients Treated with Enzalutamide</title>
	<pubDate>2013-11-08T14:57:46+01:00</pubDate>
	<wp:post_id>4704</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas and Medivation have started recruiting approx.<wbr> 400 participants in the US.<wbr> PE will assess the proportion of evaluable subjects with at least one confirmed seizure as adjudicated by the Independent Adjudication Committee (IAC).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Startd date: Sept 2013 - Completion: June 2018.<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG>Selected Inclusion Criteria</STRONG></P> </div><div><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject has histologically confirmed metastatic adenocarcinoma of the prostate.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject has ongoing androgen deprivation therapy with a Gonadotropin-releasing hormone (GnRH) analogue (agonist or antagonist) or bilateral orchiectomy (i.<wbr>e.<wbr>, surgical or medical castration).<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Subject has disease progression by at least one of the following:
<OL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Prostate-Specific Antigen (PSA) progression defined by a minimum of 2 rising PSA levels with an interval of at least 1 week between each draw;</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Bone disease progression as defined by Prostate Cancer Working Group 2 guidelines (at least 2 new lesions) on bone scan; or</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Soft tissue disease progression as defined by RECIST 1.<wbr>1</LI>
</OL></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">For subjects who have not had an orchiectomy, there must be a plan to maintain effective GnRH-analogue therapy for the duration of the study.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject must have failed at least one course of androgen deprivation therapy (ADT), i.<wbr>e.<wbr>, treatment with GnRH analogues.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Subject has been evaluated by a local neurologist prior to study entry who has determined the subject has at least one risk factor for seizure including:
<OL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">past history of seizure due to any cause except a single febrile seizure in childhood.<wbr> Patients with a history of seizures should not have had a seizure within 12 months of Screening and must have had no anticonvulsants for 12 months prior to Screening,</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">history of cerebrovascular accident (CVA) or transient ischemic attack (TIA),</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">history of traumatic brain or head injury with loss of consciousness</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">unexplained loss of consciousness within the last 12 months,</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">presence of a space occupying lesion in the brain including previously treated brain metastasis(es) or primary central nervous system (CNS) tumor,</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">history of arteriovenous malformations of the brain,</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">history of brain infection (i.<wbr>e.<wbr>, abscess, meningitis, or encephalitis),</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">current use of medication that may lower seizure threshold</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">presence of Alzheimer's disease, meningioma, leptomeningeal disease from prostate cancer.<wbr></LI>
</OL></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9302">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T14:57:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T14:57:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong Still Awaits Toxin Approval In Korea But Analysts Are Impressed With The Export Deal It Has Negotiated</title>
	<pubDate>2013-11-08T14:32:31+01:00</pubDate>
	<wp:post_id>4705</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The latest report on Daewoong from Korea Investment &amp; Securities Co (November 6th) notes that the company is still waiting for MFDS approval of its Botox biosimilar Nabota.<wbr> Approval had been expected by end-September following a regulatory filing for glabellar lines in May.<wbr> The assumption is it will now be approved this month with market launch occuring in January 2014.<wbr> More detail on Nabota's route to commercialisation in the US has come from the CPhI meeting where the link with the US <STRONG>ALPHAEON Corporation</STRONG> (a lifestyle healthcare company) was established.<wbr> </div><div style="margin-bottom: 10px;">The Korean invetment report highlights the latest domestic market share trend data, seemingly supplied by Daewoong.<wbr> citing Botox's share of the market in 2012 as 30% Medytoxin 37%, Hugel 31% and others 2%.<wbr> Reference is we believe to the cosmetic market.<wbr> </div><div style="margin-bottom: 10px;">The analysts view the agreement with Evolus in the US as very positive news, especially given the drug's recognition in an overseas market prior to release in Korea.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Evolus's Ownership Structure &amp; Route To Commercialisation Of Its New Toxin</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Evolus was is in fact acquired by the US lifestyle marketing company ALPHAEON Corporation in October this year.<wbr></STRONG> It is a company that has been grabbing US headlines since its inception.<wbr> Apparently, the most memorable launch of this year's American Society of Plastic Surgeons (ASPS) meeting was the introduction of <STRONG>ALPHAEON</STRONG>.<wbr> With a megawatt exhibit that dominated the floor, and a plethora of execs and ladies in chic red cocktail dresses at the launch party at San Diego's luxe W Hotel, </div><div style="margin-bottom: 10px;"><STRONG>ALPHAEON was founded earlier 2013 by private equity investor Strathspey Crown Holdings LLC, where former president of Allergan Medical Robert E.<wbr> Grant serves as CEO.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>ALPHAEON's</STRONG> recent moves include the acquisition of an exclusive US license from Visiometrics SL to market the HD Analyzer&trade; for early cataract detection; the exclusive US license to market the Swiss Teoxane Laboratories' portfolio of dermal fillers and cosmeceuticals, including the TEOSYAL line; the acquisition of Evolus Inc; the exclusive license to market EVOSYAL, a Botulinum toxin Type A and the exclusive worldwide licensing rights to the TouchMD&trade; an interactive software platform.<wbr> According to Grant, it is also in negotiations with a slew of other players in aesthetics, ophthalmology, cosmetic dentistry, orthopedics, and other sectors as ALPHAEON works to expand its reach.<wbr> </div><div style="margin-bottom: 10px;">Its business model is to partner with board-certified physician specialists and help them be more successful with the private-pay segment of their practices.<wbr> It offers services and systems to help them run their practices more efficiently and profitably.<wbr> It is also building a portfolio of products&mdash;determined by its founding physician investors&mdash;that ALPHAEON physician practices can purchase.<wbr> </div><div style="margin-bottom: 10px;">The plan is that EVOSYAL and TEOSYAL will be marketed side-by-side both in the US and internationally.<wbr> Presently, TEOSYAL is a leading dermal filler in Europe and widely recognized for its smooth and long-lasting results </div><div style="margin-bottom: 10px;"><P align="left">Evolus Inc.<wbr>, founded in 2012, is headquartered in Santa Barbara, California.<wbr> The company it is claimed has a robust and experienced R&amp;D team with international neurotoxin manufacturing, clinical and regulatory experience.<wbr> Key management includes<STRONG> Chief Executive Officer J.<wbr> Christopher Marmo Ph.<wbr>D.<wbr>, who previously led Allergan's Medical Device R&amp;D organization and was responsible for managing three FDA facial aesthetics clinical trials and obtaining two PMA approvals</STRONG>; and Chief Medical Officer John Gross, MD, who chairs the Injectable Safety Coalition.<wbr></P> </div><div><P align="left">Source: <A href="http://alphaeon.com/press">http:/<wbr>/<wbr>alphaeon.<wbr>com/<wbr>press</A></P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7260c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Very interesting article.<wbr> We apparently will have an additional global toxin-filler couple with Evosyal and Teosyal.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7257">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T14:32:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T14:32:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Corcept Reports Q3 Results and Mifepristone Update</title>
	<pubDate>2013-11-08T14:29:42+01:00</pubDate>
	<wp:post_id>4706</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Net revenue were $2.<wbr>6M, compared to $1.<wbr>9M in the previous quarter, an increase of 39%.<wbr> The company expects initial feedback and questions from the EMA in Q1:14 for Corluxin (Cushing's syndrome).<wbr> In the US, the drug (called Korlym) was launched in April 2012, and was the first FDA-approved oral therapy for the syndrome.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Joseph K.<wbr> Belanoff, CEO, reported " .<wbr>.<wbr>.<wbr> Our Cushing's syndrome business added new prescribers in every part of the country.<wbr> Many physicians with one patient taking Korlym found that the drug worked and wrote prescriptions for second and third patients.<wbr> With greater visibility into the business, we can now provide revenue guidance for the balance of 2013 and will provide revenue guidance for fiscal 2014 at our year-end conference call".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company outlined that Ph3 enrollment of Korlym for psychotic depression has accelerated.<wbr> </div><div style="margin-bottom: 10px;">Findings from the 1st study of mifepristone + chemo for metastatic triple-negative breast cancer will be presented at the Breast Cancer Sympo in San Antonio (Dec 2014).<wbr> </div><div>Source: Corcept </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7517">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T14:29:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T14:29:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>More Jobs to be Cut at Novartis</title>
	<pubDate>2013-11-08T13:13:23+01:00</pubDate>
	<wp:post_id>4707</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/19px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10683">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T13:13:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T13:13:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Salix Acquires Gastro and Diabetes Drugs with $2.6 Bln Santarus Buy</title>
	<pubDate>2013-11-08T11:58:03+01:00</pubDate>
	<wp:post_id>4708</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Financial Acquisition Details</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Transaction Rationale</STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">
 </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1928_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Santarus, Inc.<wbr> is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists.<wbr> </div><div style="margin-bottom: 10px;">The company's current commercial efforts are focused on 5 products.<wbr> UCERIS<SUP>®</SUP> (budesonide) ER tablets for the induction of remission in patients with active, mild to moderate UC, and ZEGERID<SUP>®</SUP> (omeprazole/<wbr>sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists.<wbr> GLUMETZA<SUP>®</SUP> (metformin hydrochloride extended release tablets) and CYCLOSET<SUP>®</SUP> (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and FENOGLIDE (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol, are promoted to endocrinologists and other physicians who treat patients with type 2 diabetes.<wbr> </div><div><EM>Source: Salix; Santarus; ThomsonOne</EM> </div><!-- Comment details --><a name="gastroenterology1928attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1928_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1928">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T11:58:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T11:58:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Shire & BMS Restructure Research & Development Focus</title>
	<pubDate>2013-11-08T11:21:21+01:00</pubDate>
	<wp:post_id>4709</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Both Shire &amp; BMS announced changes in their R&amp;D strategy yesterday, the former taking the decision to focus primarily on rare diseases and BMS discontinuing its discovery work in HCV, diabetes and neuroscience.<wbr> BMS in particular intends to increase its investment in cancer immunotherapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Shire's Re-orientation</STRONG> </div><div style="margin-bottom: 10px;">Shire will discontinue early undisclosed programs outside of rare diseases.<wbr> By early it typically means preclinical or phI.<wbr> Shire's early development is conducted at its Basingstoke site where it plans to terminate up to 180 of the 500 positions located there.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BMS' s New Research Focus</STRONG> </div><div>In addition to oncology, BMS will continue to focus on HIV, HBV, heart failure and fibrotic disease.<wbr> The cuts elsewhere will result in 70-75 positions being terminated.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10682">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T11:21:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T11:21:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Results from Allergan's Survey in Women with OAB</title>
	<pubDate>2013-11-08T11:00:26+01:00</pubDate>
	<wp:post_id>4710</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The survey conducted by Allergan, and endorsed by the Women’s Health Foundation, reports that almost two-thirds of women in the US have never even had a discussion about their bladder health with a physician.<wbr> Allergan's official website dedicated to Botox for OAB is coming soon online.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Bladder health issues are estimated to affect approximately 45% of the world’s population ages twenty years or older - (Irwin DE, Kopp ZS, Agatep B, et al.<wbr> Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.<wbr> BJU Int.<wbr> 2011 doi: 10.<wbr>1111/<wbr>j.<wbr>1464-410X.<wbr>2010.<wbr>09993.<wbr>x).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to urologist Elizabeth Mueller, M.<wbr>D.<wbr>, MSME, Associate Professor and Division Director of Female Pelvic Medicine and Reconstructive Surgery in the Departments of Urology and Obstetrics &amp; Gynecology at Loyola University " .<wbr>.<wbr>.<wbr> For many of my patients, one treatment can last up to six months before the effects wear off".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Kelton OAB Quarterly Index Survey, Allergan, 2013, The Overactive Bladder Survey was conducted between April 12th and April 23rd, 2013 among 1,045 nationally representative American women ages 45 and older, using an email invitation and an online survey.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><A href="http://www.botoxforoab.com/">http:/<wbr>/<wbr>www.<wbr>botoxforoab.<wbr>com/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7253">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-08T11:00:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-08T11:00:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Pharmaceutical Price Regulation Scheme (PPRS) in the UK</title>
	<pubDate>2013-11-07T17:49:03+01:00</pubDate>
	<wp:post_id>4711</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Association of the British Pharmaceutical Industry (ABPI) and the Department of Health (DoH) announced yesterday (6 November) that they had agreed on new Pharmaceutical Price Regulation Scheme (PPRS).<wbr> The new PPRS, known as PPRS 2014, will commence on 1 January 2014 and is set to be in place for five years.<wbr> Two of the key objectives of PPRS 2014 are to ensure that the bill to the National Health Service (NHS) for branded medicines will stay within "affordable limits" and to improve access to innovative drugs by making sure that the drugs that receive positive guidance from National Institute for Health and Care Excellence (NICE) are made available within the NHS.<wbr> </div><div style="margin-bottom: 10px;">The details of the scheme, which will apply to all branded, licensed products, as defined by the 2009 scheme (excluding over-the-counter (OTC) drugs), are as follows: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>In order to ensure that the level of NHS expenditure on branded drugs supplied by companies under the scheme is maintained, the allowed growth rate of the sales of the NHS-branded drugs supplied by the companies under the scheme is to remain flat for the first two years, and then grow at 1.<wbr>8%, 1.<wbr>8%, and 1.<wbr>9% in the following three years.<wbr>
</LI>
<LI>The industry will make payments to the DoH if the spending is exceeded.<wbr>
</LI>
<LI>The scheme includes a "pre-agreed profile of payments" for the five-year scheme.<wbr> These payments are set at a level to ensure that the Growth Rate of Measured Spend (sales of NHS-branded medicines supplied by companies in the voluntary scheme) is at the Allowed Growth Rate".<wbr> The initial annual payment is set at 3.<wbr>74% of the company's sales to the NHS-branded medicines in 2014, net of all discounts, excluding sale s pertaining to brand-equalisation deals.<wbr>
</LI>
<LI>Companies that had sales of below GBP5 million in the previous year will be exempt from making payments,
</LI>
<LI>According to the deal, the pricing of new products are to remain unchanged, with companies being able to price new active substances at their discretion.<wbr> The document further specifies that "the assumption is that prices at launch will be set at a level that is close to their expected value as assessed by NICE".<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG>Value-based pricing</STRONG></P> </div><div style="margin-bottom: 10px;">According to the DoH, "NICE will continue its work to introduce broader value assessment for new medicines covered by value-based pricing, which will now be introduced in autumn 2014 following public consultation".<wbr> With reference to NICE appraisals, the document also states that the cost-effectiveness threshold currently applied by NICE will be "retained at a level consistent with the current range" and will not be changed for the five-year period covered by PPRS 2014.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG>Statutory Pharmaceutical Pricing Scheme</STRONG></P> </div><div style="margin-bottom: 10px;">The government has also published the revised Statutory Pharmaceutical Pricing Scheme.<wbr> It covers prescription-only and branded drugs that are not covered by the PPRS agreement, and applies to around 10% of branded drugs The scheme includes: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>A price cut of 15%.<wbr>
</LI>
<LI>An exemption for firms with NHS sales of less than GBP5 million from the price cut.<wbr>
</LI>
<LI>The scheme will not be introducing price cuts to average selling prices or specific provisions for line extensions.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG>Outlook and implications</STRONG></P> </div><div style="margin-bottom: 10px;">The current PPRS is to succeed the 2009 scheme, but, unlike the previous scheme which involved a price cut on pharmaceuticals, the new one involves companies making payments to the government in case spending on branded drugs is exceeded.<wbr> The deal is thus reflective of the government's cost-containment policies with UK health secretary Jeremy Hunt noting that the agreement ensured that patients had access to most advanced medicines while maintaining NHS costs.<wbr> The expenditure on branded drugs amounted to GBP12 billion.<wbr> </div><div style="margin-bottom: 10px;">On the other hand, while the deal maintains certain aspects of the current system in place, such as free pricing for branded drugs, the government's intention to contain expenditure on branded drugs has led the president of ABPI to note that the negotiations for the deal were based on "a myth that medicines are expensive in the UK".<wbr> The president further noted that prices in the UK were among the lowest in Europe.<wbr> </div><div style="margin-bottom: 10px;">Overall, the new PPRS deal agreed by the government and the ABPI comes after discussions in the past two years over the expected overhaul of the scheme with the introduction of VBP.<wbr> However, the DoH has said that the VBP will be introduced later next year &ndash; the details of the VBP system are yet to be confirmed.<wbr> </div><div style="margin-bottom: 10px;">However, IHS Global Insight's view is that the industry's attempt to tone down some of the more controversial aspects of the pending VBP introduction has led pharma companies to accept a payback agreement.<wbr> A payback is not a favoured approach for the pharmaceutical industry, and in this case companies must have agreed to it to avoid a bigger-than-before cut in the list price of drugs and a subsequent adverse effect on prices of these drugs in countries using the UK as a reference market in their international reference pricing calculation.<wbr> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10681">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-07T17:49:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-07T17:49:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>International Trial with Pasireotide +/- Cabergoline for Cushing's Disease</title>
	<pubDate>2013-11-06T14:32:14+01:00</pubDate>
	<wp:post_id>4712</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis's POC sponsored trial is to assess whether pasireotide s.<wbr>c alone and combined with cabergoline will give reliefs on patients with recurrent, persistent and newly diagnosed condition.<wbr> Safety, the changes in QoL and on clinical signs and symptoms of Cushing's disease will be evaluate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/study/NCT01915303?term=novartis+AND+cushing&amp;fund=2&amp;rank=4&amp;show_locs=Y#locn"><STRONG></STRONG></A> (MACS2125) </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">The Ph2 trial is poised to start this month and complete in October 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=128 </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG>Protocol</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">The study will enroll 2 groups of patients.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Pasireotide naive patients at the time of screening (Group 1) </P> </div><div style="margin-bottom: 10px;"><UL><LI>patients will begin study treatment of pasireotide at 0.<wbr>6mg twice a day for 8 weeks.<wbr> After 8 weeks, if cortisol level is not controlled and the dose is tolerated well, pasireotide will be increased to 0.<wbr>9mg for another 8 weeks.<wbr> If during or at the end of the 8 week period, cortisol level is still not controlled cabergoline will be added at 0.<wbr>5mg once a day.<wbr> Cabergoline can be increased up to 1.<wbr>0mg once a day in combination with pasireotide.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Patients receiving maximal tolerated dose of pasireotide at the time of screening (Group 2).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
<DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">patients will immediately begin combination treatment by adding cabergoline at 0.<wbr>5mg once a day to the current pasireotide treatment.<wbr> Cabergoline dose can be increased up to 1.<wbr>0mg once a day if cortisol is not controlled at a lower dose.<wbr></P></DIV></DIV></DIV></DIV></LI>
</UL> </div><div><DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG>Location</STRONG></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">40 study sites (US; Argentina; belgium; Brazil; Bulgaria; Colombia; France; Germany; Greece; Italy; Malaysia; Spain; Turkey; Venezuela)</P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Source: </P></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7514">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-06T14:32:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-06T14:32:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Fined for Promotion of Unapproved Drugs</title>
	<pubDate>2013-11-06T10:55:29+01:00</pubDate>
	<wp:post_id>4713</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J&amp;J has agreed to pay &gt; $2.<wbr>2 billion for the off-label uses of three psychiatric drugs.<wbr> This agreement is the third-largest settlement with a drugmaker in U.<wbr>S.<wbr> history.<wbr> </div><div style="margin-bottom: 10px;">J&amp;J is fined for illegal marketing tactics and kickbacks to persuade physicians and pharmacies to prescribe Risperdal, Invega and Natrecor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Later year <STRONG>GSK</STRONG> paid $3 billion in fines to settel criminal and civil violations involving 10 of its drugs.<wbr> </div><div>Prior to that, <STRONG>Pfizer</STRONG> paid $2.<wbr>3 billion in criminal and civil fines.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10678">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-06T10:55:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-06T10:55:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis to Close Research Site in UK</title>
	<pubDate>2013-11-06T09:37:13+01:00</pubDate>
	<wp:post_id>4714</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has started consultations on the closure of the Horham site, with the possible loss of up to 371 positions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to proactively adapt to external challenges </div><div style="margin-bottom: 10px;">- to align resources with other global R&amp;D sites </div><div style="margin-bottom: 10px;"><EM>Source: FirstWord</EM> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>3,000 people across 9 sites, including Novartis UK HQs in Frimley, Surrey.<wbr> </LI>
<LI>These sites are responsible for research, development, sales, marketing and manufacturing of products used in the UK and worldwide.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10676_1_ScreenCapture1.jpg"> </div><div><EM>Source: Novartis UK</EM> </div><!-- Comment details --><a name="pharmaworld10676attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10676_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10676">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-06T09:37:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-06T09:37:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aeterna Zentaris Seeks US Approval For AGHD Diagnostic Solorel</title>
	<pubDate>2013-11-06T08:41:41+01:00</pubDate>
	<wp:post_id>4715</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Commment: Having completed a succesful phIII programme, Aeterna Zentaris 
has submitted an NDA to the FDA for its oral ghrelin mimetic growth hormone 
secretagogue for the diagnosis of adult growth hormone deficiency.<wbr> </div><div style="margin-bottom: 10px;">Macimorelin if approved will be the first oral diagnostic product for AGHD 
evaluation.<wbr> </div><div style="margin-bottom: 10px;">As part of its lifecycle expansion plans, Aeterna is also looking at the 
possibility of gaining a lable for pediatric GHD diagnosis and diagnosis of GH 
deficiency in traumatic brain injury patients.<wbr> The drug is also being evaluated 
in  a phII trial in cancer cachexia.<wbr> </div><div>Source: <A href="http://www.aezsinc.com">www.<wbr>aezsinc.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7513">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-06T08:41:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-06T08:41:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's Successful Trademark Challenge Against Botulex Cream</title>
	<pubDate>2013-11-06T08:17:38+01:00</pubDate>
	<wp:post_id>4716</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Trademark Trial &amp; Appeals Board has found that Allergan's "Botox" name is a famous trademark and that another company couldn't register the world "Botulex" for marketing a non-injectable alternative to the cosmetic treatment.<wbr> Botulex is made by Kessen-Klein in Germany and advertised on-line as a product with similar properties to Botox.<wbr> </div><div style="margin-bottom: 10px;">The TTAB claimed that Allergan has spent more than $10bn in advertising the name over the past 14 years and that within the target demographic - high income women between ages 30-60, 95% know what Botox is.<wbr> </div><div style="margin-bottom: 10px;">The company challenged was KRL Group Inc, a merchandiser based in Florida </div><div style="margin-bottom: 10px;"><STRONG>What is Botulex &amp; Who Makes It?</STRONG> </div><div style="margin-bottom: 10px;">Botulex is produced by a German cosmetic company Kessep-Klein.<wbr> It is a cream-based formula that claims to work just as effectively as Botox without injections or toxic side effects.<wbr> </div><div style="margin-bottom: 10px;">Product claims are that it works by quickly penetrating the skin cells with its potent formula, revitalizing weak skin cells and making skin appear younger looking again.<wbr> </div><div style="margin-bottom: 10px;">Like Botox, it also claims to block neurotransmitters signals which cause muscle contraction in the face.<wbr> </div><div style="margin-bottom: 10px;">Botulex is not available in retail stores, but there are plenty of retailers online selling this Botox knock-off, usually priced at around $50.<wbr>00 per bottle.<wbr> Free samples and a lifetime money-back guarantee are also offered.<wbr> </div><div style="margin-bottom: 10px;">Botulex, according to its website, contains these ingredients: Purified Water, Acetyl Hexapaptide-3, Palmitoyl Oligopeptide, Palmitoyl Tetrapeptide-3, Sodium Hyaluronate, Dimethylaminoethanol (DMAE), Coenzyme Q-10, Hydrolyzed Marine Collagen (and) Silanetriol (and) Glutamylamidoethyl Imidazole (and) Fructose Oligossacarides (and) Porphyridium Cuentum Extract, Acrylamide Sodium Acrylate Copolymer (and) Paraffinium Liquidium Myristate, Silk Aminoacids, Avocado Oil, Methylparaben, Imida Zolidinyl Urea, EDTA, Propylparaben, Tocopheral Acetate, Thyme Extract, Citric Acid.<wbr> </div><div style="margin-bottom: 10px;">Botulex&rsquo;s formula is mainly comprised of amino acids.<wbr> Its main ingredient, Acetyl Hexapaptide-3, is an amino acid that is said to relax facial muscles, therefore preventing the formation of wrinkles.<wbr> Not much evidence supports this theory, however, except for one obscure study conducted by an unknown group.<wbr> That study stated continual, high dosage use of Acetyl Hexapaptide-3 reduced the appearance of wrinkles by up to 30% after one month of use.<wbr> .<wbr> </div><div>Source: Law 360 and The Performance Leader (Beauty Product Review Website) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7251">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-06T08:17:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-06T08:17:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Report on Endo Q3 Earnings and Acquisition of Paladin Labs</title>
	<pubDate>2013-11-05T15:21:42+01:00</pubDate>
	<wp:post_id>4717</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comments: Management reported that the $1.<wbr>6 billion acquisition will expand Endo presence in Canada and emerging markets, and complement its U.<wbr>S strengths.<wbr> Of note, Paladin's Travelan which is the first OTC product for the prevention of travellers' diarrhea, and Urodicin in Ph3 for bladder cancer.<wbr> Endo's pipeline lists an androgen receptor antagonist in Ph1 for CRPC, and among its products Valstar (for CIS bladder cancer) and Vantas (histrelin sc implant for prostate cancer).<wbr> More details on the transaction and Endo's Q3 financial results are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Third quarter 2013 branded pharmaceutical revenues were <MONEY>$366 million</MONEY>, a 12 percent decrease compared to third quarter 2012 branded pharmaceutical revenues </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10671_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10671_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10671_3_ScreenCapture3.jpg"></U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10671_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><U>Terms</U> </div><div style="margin-bottom: 10px;">The deal, which will also create a separate company called Knight Therapeutics Inc that will own Impavido, is expected to immediately add to Endo's 2014 adjusted earnings per share.<wbr> </div><div style="margin-bottom: 10px;"><U>Financial Terms</U> </div><div style="margin-bottom: 10px;">At $77 per Paladin share, the transaction represents a 20% premium to the Paladin closing share price on November 4, 2013 of $63.<wbr>91 and a 25% premium to Paladin's 3 month volume weighted average share price of $61.<wbr>67.<wbr> </div><div style="margin-bottom: 10px;"><U>Timelines</U> </div><div style="margin-bottom: 10px;">The transaction is expected to close in the first half of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10671_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Specialty pharmaceutical company.<wbr> </div><div style="margin-bottom: 10px;"><U>- Focus</U>: acquisition or in-licensing of innovative pharmaceutical products for the Canadian and world markets.<wbr> </div><div style="margin-bottom: 10px;"><U>- Key products</U> serve growing drug markets including ADHD, pain, urology and allergy, with a strong pipeline of new product launches over the next 12 months.<wbr> </div><div style="margin-bottom: 10px;"><ORG value="Toronto:PLB">Paladin Labs</ORG> owns a controlling stake in <ORG>Laboratorios Paladin, S.<wbr>A.<wbr> de C.<wbr>V.<wbr></ORG> in <LOCATION value="LC/mx;LB/cam">Mexico</LOCATION> and a 61.<wbr>5% ownership stake in publicly traded <ORG>Litha Healthcare Group Limited</ORG> in <LOCATION value="LC/za;LB/safr">South Africa.<wbr></LOCATION> </div><div style="margin-bottom: 10px;"><U>Growth Drivers</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10671_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Selected Pipeline</U> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10671_2_ScreenCapture2.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10671">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-05T15:21:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-05T15:21:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Shire Reports Good Growth in Q3:13</title>
	<pubDate>2013-11-05T11:14:49+01:00</pubDate>
	<wp:post_id>4718</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management announced the 'One Shire' reorganization being well underway.<wbr> Product sales increased by 13% to $1,195 million (Q3 2012: $1,055 million) and represented 97% of total revenues (Q3 2012: 96%).<wbr> Lialda/<wbr>Mezavant (for UC) increased by 17% to $142M (vs $104M for Q3:12).<wbr> Looking for diversification away from Vyvanse seems to be key to the Shire future.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="pharmaworld10670attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(44 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10670_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(23,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10670">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-05T11:14:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-05T11:14:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sutent Reimbursement for pNET in Australia</title>
	<pubDate>2013-11-05T09:45:19+01:00</pubDate>
	<wp:post_id>4719</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Monica de Abadal (Medical Director, Australia), we have learnt that the Pharmaceutical Benefits Scheme (PBS) recommended listing Sutent<SUP></SUP> (sunitinib malate) as a Section 85* for unresectable, well-differentiated pancreatic neuroendocrine tumour (pNET) in patients who meet certain criteria.<wbr> The drug was on the PBS for RCC (2009), but this is the first time it is listed for pNET, after it was denied about 18 months ago.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">*Section 85 means that authority is required for prescription.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7509_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Cost</STRONG> </div><div>See @ <A href="http://www.pbs.gov.au/medicine/item/9417P-9418Q-9419R-9420T-9421W-9422X-9488J-9489K-9490L">http:/<wbr>/<wbr>www.<wbr>pbs.<wbr>gov.<wbr>au/<wbr>medicine/<wbr>item/<wbr>9417P-9418Q-9419R-9420T-9421W-9422X-9488J-9489K-9490L</A> </div><!-- Comment details --><a name="endocrinology7509attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7509_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(93,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7509">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-05T09:45:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-05T09:45:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merz Post Marketing Trial to Assess Efficacy and Safety of Xeomin® for LLS in MS Patients</title>
	<pubDate>2013-11-05T09:35:35+01:00</pubDate>
	<wp:post_id>4720</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merz Post Marketing Trial to Assess Efficacy and Safety of Xeomin® for LLS in MS Patients</span>&nbsp;<br><span style="font-size: 12px;">Comment: Poised to start next month, the Ph4 trial will determine if Xeomin® (IM injection 200 to 400U) will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.<wbr> PE will assess mean change from injection visit to week 6 in the Modified Ashworth score between Xeomin® vs placebo group.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7242">...</a><br></div><div>This is an ISS in 30 patients so it might be considered as a pilot study to complement Merz's current clinical adult spasticity package but probably not a pivotal study to gain registration in this patient population with a dose ranging from 200 to 400U xeomin.<wbr> Nevertheless, this is a very interesting study and design.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7250">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7242">View thread  Neurology7242: Merz Post Marketing Trial to Assess Efficacy and Safety of Xeomin® for LLS in MS Patients</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-05T09:35:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-05T09:35:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merz Post Marketing Trial to Assess Efficacy and Safety of Xeomin® for LLS in MS Patients</title>
	<pubDate>2013-11-04T16:41:31+01:00</pubDate>
	<wp:post_id>4721</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merz Post Marketing Trial to Assess Efficacy and Safety of Xeomin® for LLS in MS Patients</span>&nbsp;<br><span style="font-size: 12px;">Comment: Poised to start next month, the Ph4 trial will determine if Xeomin® (IM injection 200 to 400U) will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.<wbr> PE will assess mean change from injection visit to week 6 in the Modified Ashworth score between Xeomin® vs placebo group.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7242">...</a><br></div><div>As outlined by Katie Ruffle (Neurology Regulatory Management) this is not a 'post-marketing' study.<wbr> Merz does not have approval of adult LLS in the US (or any spasticity indication).<wbr> The trial is categorised on the basis that the product used is an approved product, and therefore considered by cinicaltrials.<wbr>gov as a Ph4.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7247">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7242">View thread  Neurology7242: Merz Post Marketing Trial to Assess Efficacy and Safety of Xeomin® for LLS in MS Patients</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-04T16:41:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-04T16:41:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Reports Increase in Sales but Decline in Profits</title>
	<pubDate>2013-11-04T14:30:31+01:00</pubDate>
	<wp:post_id>4722</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_11_ScreenCapture11.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_1_ScreenCapture1.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_6_ScreenCapture6.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_3_ScreenCapture3.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_9_ScreenCapture9.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_4_ScreenCapture4.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_5_ScreenCapture5.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_12_ScreenCapture12.jpg"></SPAN> </div><!-- Comment details --><a name="oncology9297attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(3,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(30,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9297_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(161,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9297">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-04T14:30:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-04T14:30:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck & AstraZeneca Report on China Headcount</title>
	<pubDate>2013-11-04T13:43:16+01:00</pubDate>
	<wp:post_id>4723</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AZ reported an expansion of operation sales teams targeting oncology and gastrointestinal product growth, and in contrast to Merck reduction in middle and senior-level staff.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In response to media reports of impending global layoffs at its parent company, Merz reported that China team, particularly middle and senior management, is unchanged.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">AZ insiders have disclosed that the previously announced globall staff cut have begun to impact China, where middle and senior-level reductions will be significant, except operations that are expanding.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10667">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-04T13:43:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-04T13:43:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring Appoints New Senior Vice President Asia Pacific</title>
	<pubDate>2013-11-04T13:25:17+01:00</pubDate>
	<wp:post_id>4724</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alex Chang will head Ferring's Asia Pacific area, which includes China, Japan, South Korea, South East Asia, India, Australia, New Zealand and South Africa.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">As Head of the Asia Cluster at Novartis since 2011, he led 9 country operations and 2,700 employees.<wbr> </div><div style="margin-bottom: 10px;">Prior to Novartis, he held several senior management positions for Janssen in China and Taiwan, and for BMS in China and the US.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10666">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-04T13:25:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-04T13:25:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intelligence From The EANM Congress (Lyon October 2013) - Part 1 Neuroendocrine Tumour Treatment</title>
	<pubDate>2013-11-01T18:09:20+01:00</pubDate>
	<wp:post_id>4725</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_39_ScreenCapture40.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="endocrinology7504attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(219 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(210,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(140,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(212,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(174,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(186,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(191,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(243,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(217,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(198,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(198,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(186 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(147,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(150,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(143,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(211,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(239,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(151,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_19_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(202,1 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_20_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(101,7 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_21_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(142,7 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_22_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(141,5 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_23_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(125,8 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_24_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(103 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_25_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(100,7 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_26_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(153,3 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_27_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(184,1 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_28_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(88,5 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_29_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(129,9 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_30_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(152,4 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_31_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(124,1 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_32_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(56,5 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_33_ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(99,2 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_34_ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_35_ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(97,9 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_36_ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(233,8 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_37_ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(184,3 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_38_ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(98,8 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_39_ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_40_ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(73,1 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_41_ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(107 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_42_ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(91,1 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_43_ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(78,2 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_44_ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(117,6 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_45_ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(120,1 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_46_ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(118,8 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_47_ScreenCapture48.jpg">ScreenCapture48.jpg</a>&nbsp;&nbsp;(115,1 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_48_ScreenCapture49.jpg">ScreenCapture49.jpg</a>&nbsp;&nbsp;(131,7 KB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_49_ScreenCapture50.jpg">ScreenCapture50.jpg</a>&nbsp;&nbsp;(64,3 KB)<br>&nbsp;&nbsp;50.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_50_ScreenCapture52.jpg">ScreenCapture52.jpg</a>&nbsp;&nbsp;(152,3 KB)<br>&nbsp;&nbsp;51.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_51_ScreenCapture53.jpg">ScreenCapture53.jpg</a>&nbsp;&nbsp;(150,2 KB)<br>&nbsp;&nbsp;52.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_52_ScreenCapture54.jpg">ScreenCapture54.jpg</a>&nbsp;&nbsp;(107,4 KB)<br>&nbsp;&nbsp;53.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_53_ScreenCapture55.jpg">ScreenCapture55.jpg</a>&nbsp;&nbsp;(144,9 KB)<br>&nbsp;&nbsp;54.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_54_ScreenCapture56.jpg">ScreenCapture56.jpg</a>&nbsp;&nbsp;(147,5 KB)<br>&nbsp;&nbsp;55.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_55_ScreenCapture57.jpg">ScreenCapture57.jpg</a>&nbsp;&nbsp;(132,2 KB)<br>&nbsp;&nbsp;56.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_56_ScreenCapture58.jpg">ScreenCapture58.jpg</a>&nbsp;&nbsp;(127,7 KB)<br>&nbsp;&nbsp;57.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_57_ScreenCapture59.jpg">ScreenCapture59.jpg</a>&nbsp;&nbsp;(146,6 KB)<br>&nbsp;&nbsp;58.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_58_ScreenCapture60.jpg">ScreenCapture60.jpg</a>&nbsp;&nbsp;(129,4 KB)<br>&nbsp;&nbsp;59.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_59_ScreenCapture61.jpg">ScreenCapture61.jpg</a>&nbsp;&nbsp;(95,9 KB)<br>&nbsp;&nbsp;60.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_60_ScreenCapture62.jpg">ScreenCapture62.jpg</a>&nbsp;&nbsp;(139,2 KB)<br>&nbsp;&nbsp;61.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_61_ScreenCapture63.jpg">ScreenCapture63.jpg</a>&nbsp;&nbsp;(115,7 KB)<br>&nbsp;&nbsp;62.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7504_62_ScreenCapture64.jpg">ScreenCapture64.jpg</a>&nbsp;&nbsp;(148,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7504">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-11-01T18:09:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-11-01T18:09:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Post Marketing Trial to Assess Efficacy and Safety of Xeomin® for LLS in MS Patients</title>
	<pubDate>2013-10-31T17:05:33+01:00</pubDate>
	<wp:post_id>4726</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Poised to start next month, the Ph4 trial will determine if Xeomin® (IM injection 200 to 400U) will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.<wbr> PE will assess mean change from injection visit to week 6 in the Modified Ashworth score between Xeomin® vs placebo group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Principal Investigator</STRONG> </div><div style="margin-bottom: 10px;">Keith R Edwards, MD </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Nov 2013 - Completion date: May 2014 /<wbr> Sept 2014 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=30 </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Male or female patients with clinically definite MS, either RRMS or a progressive form (SPMS, PPSM, PRMS)</P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Ages 18-65 years.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients must be in a stable state, with no clinical relapses or methylprednisolone treatments in the last 30 days, or have slowly progressive MS, with an EDSS score of 2.<wbr>0-6.<wbr>5.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients must have functionally significant spasticity in predominantly one lower extremity as determined by a score of &gt;2 on the Modified Ashworth Scale at screen.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><STRONG>Location</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Multiple Sclerosis Center of Northeastern New York</P> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT01968902?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=09%2F30%2F2013&amp;rank=292">NCT01968902</A></P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7247c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>As outlined by Katie Ruffle (Neurology Regulatory Management) this is not a 'post-marketing' study.<wbr> Merz does not have approval of adult LLS in the US (or any spasticity indication).<wbr> The trial is categorised on the basis that the product used is an approved product, and therefore considered by cinicaltrials.<wbr>gov as a Ph4.<wbr> </div></div><a name="Neurology7250c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>This is an ISS in 30 patients so it might be considered as a pilot study to complement Merz's current clinical adult spasticity package but probably not a pivotal study to gain registration in this patient population with a dose ranging from 200 to 400U xeomin.<wbr> Nevertheless, this is a very interesting study and design.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7242">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T17:05:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T17:05:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novo's Once-Weekly GH to Enter Clinical Trial in AGHD</title>
	<pubDate>2013-10-31T16:53:10+01:00</pubDate>
	<wp:post_id>4727</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novo's Once-Weekly GH to Enter Clinical Trial in AGHD</span>&nbsp;<br><span style="font-size: 12px;">Comment: The newly listed Ph1 trial in clinicaltrials.<wbr>gov will assess safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (NNC0195-0092) compared to once daily Norditropin NordiFlex®.<wbr> Primary endpoint will measure incidence of AEs.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7115">...</a><br></div><div style="margin-bottom: 10px;">A second Ph1 is planned to start in Dec 2013 in EU and Asia in PGHD.<wbr> PE will assess incidence of AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Completion dates: Nov 2014 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=32 </div><div style="margin-bottom: 10px;"><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Confirmed diagnosis of GHD (growth hormone deficiency) as defined by two different GH (growth hormone) stimulation tests, peak GH level below or equal to 7.<wbr>0 ng/<wbr>ml.<wbr> For children with three or more pituitary hormone deficiencies only one GH stimulation test will be needed.<wbr> If in accordance with country specific practice, growth hormone deficiency can be defined by only one GH stimulation test, peak GH level below or equal to 7.<wbr>0 ng/<wbr>ml.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Pre-pubertal children at screening.<wbr> Boys: Tanner stage 1 and age above or equal to 6 years and below 13 years.<wbr> Girls: Tanner stage 1 and age above or equal to 6 years and below 12 years
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Body weight above or equal to 16.<wbr>0 kg and below or equal to 50.<wbr>0 kg
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Stable GH replacement treatment for at least 3 months
</LI>
</UL> </div><div><P class="color-bullet" style="margin-top: 0.7ex;">Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01973244?recr=Open&no_unk=Y&fund=2&rcv_s=09%2F30%2F2013&rank=142" class="defaultlink">NCT01973244</a></P> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7503">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7115">View thread  Endocrinology7115: Novo's Once-Weekly GH to Enter Clinical Trial in AGHD</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T16:53:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T16:53:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca's Q3:13 Sales Declined Due to Loss of Exclusivity on Brands</title>
	<pubDate>2013-10-31T14:34:46+01:00</pubDate>
	<wp:post_id>4728</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Q3 revenue were down 4% (CER): approx $350M decline from loss of exclusivity.<wbr> Sales of Zoladex slighlty decreased in the third quarter to $246M (vs $274M in Q3 2012), and to 749M for the nine months (vs $822M).<wbr> Management provided its success stories in China and Russia, and highlighted Japan as a key growth platform.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><U>AstraZeneca in China</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><U>AstraZeneca in Russia</U></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="oncology9296attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(62,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(58,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(59,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(47,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(107,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(22,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(66,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9296_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(82,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9296">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T14:34:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T14:34:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Highlights from Takeda's 6-Month Period</title>
	<pubDate>2013-10-31T12:21:24+01:00</pubDate>
	<wp:post_id>4729</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Results show resilience of base business and growth of new products.<wbr> H1 sales of leuprorelin increased by 11.<wbr>8% (+5.<wbr>2% LFL).<wbr> All regions delivered positive underlying growth, with strong momentum in emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_6_ScreenCapture6.jpg"> </div><!-- Comment details --><a name="oncology9295attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(35,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(27,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(61,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(32,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9295_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(30,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9295">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T12:21:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T12:21:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Delivered Solid Q3:13 Results</title>
	<pubDate>2013-10-31T11:20:13+01:00</pubDate>
	<wp:post_id>4730</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer has reported good performance across all divisions.<wbr> Xarelto, Eylea, Stivarga and Xofigo posted combined sales of €407M (Q3 2012: €82M).<wbr> Kogenate remains n°1 pharma product with strong sales of €321M (Q3 2012: €300M).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9293_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">€12 million in Q3 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9293_2_ScreenCapture2.jpg"> </div><div><EM>Source: Bayer</EM> </div><!-- Comment details --><a name="oncology9293attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9293_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(18,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9293_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(56,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9293">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T11:20:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T11:20:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FirstWord Survey Highlights Strong Level Of Support For XTANDI In Pre-Chemo CRPC</title>
	<pubDate>2013-10-31T10:16:50+01:00</pubDate>
	<wp:post_id>4731</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A recent survey undertaken by FirstWord indicates that data from the PREVAIL study looks poised to translate into clear commercial advantage for XTANDI in the pre-chemotherapy setting.<wbr> Moreover, a moderate to high level of comfort was also expressed by up to 70% of respondents with usage in the hormone ablation setting post surgery.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white"><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
<LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
<LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
<LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
<LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
<LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="BACKGROUND: white; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="FONT-FAMILY: 'Arial','sans-serif'; COLOR: black; FONT-SIZE: 11pt"></SPAN></LI>
</UL> </div><div><EM>Source: FirstWord Survey October 2013</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9289">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T10:16:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T10:16:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis Reported Q3:13 Results and Updated the Five Ongoing Trials of Cabozantinib</title>
	<pubDate>2013-10-31T10:11:40+01:00</pubDate>
	<wp:post_id>4732</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management confirmed it expects top-line data from both COMETs in 2014 (cabozantinib for CRPC).<wbr> In earlier lines of the disease, cabozantinib with abiraterone trial is expected to start 4Q:13.<wbr> COMETRIQ®, currently approved in the US for metastatic medullary thyroid cancer, is in the last phase of review process before CHMP opinion.<wbr> Additional details on RCC and HCC trials are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Revenues for the quarter included net product revenues of <MONEY>$4.<wbr>8 million</MONEY> (20% quarter-on-quarter increase).<wbr> </div><div style="margin-bottom: 10px;">COMETRIQ® became commercially available in late <CHRON>January 2013.<wbr></CHRON> </div><div style="margin-bottom: 10px;">Price for COMETRIQ® is $10,395 for a 28-day supply.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management indicated that " .<wbr>.<wbr>.<wbr> COMET-1 investigators have been interested in continuing to participate in cabozantinib studies to make the drug available to their patient population.<wbr> So, they are starting now to participate in COMET-2 and the accrual is ongoing.<wbr> So, that's quite gratifying".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology9288attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(45,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9288_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(45,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9288">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T10:11:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T10:11:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche's New Dual-Action Molecule Shows Promise in Diabetes and Obesity</title>
	<pubDate>2013-10-31T09:57:51+01:00</pubDate>
	<wp:post_id>4733</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new molecule targets receptor for GLP-1 and GIP, and was assessed in a short clinical study involving 53 obese patients with TDM as well as on mice, rats and monkeys.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Roche acquired rights to the new product after buying Marcadia Biotech in 2011, and currently has the drug in Ph1 development.<wbr> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=6098" class="defaultlink">Endocrinology6098: Roche Acquires New GLP-1/<wbr>GIP Agonist</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Munich team, working with scientists from Indiana U.<wbr>, detailed the advantages of the new GLP-1/<wbr>GIP drug in a paper in the journal Science Translational Medicine.<wbr> </div><div style="margin-bottom: 10px;">The experimental molecule proved considerably more effective than existing medications in controlling blood glucose levels and reducing weight.<wbr> In some of the tests, the impact of the dual-action treatment was equivalent to that seen with a 10-fold higher dose of approved GLP-1 drugs.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7502">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-31T09:57:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-31T09:57:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>POC Study of AstraZeneca's Olaparib With Abiraterone for mCRPC</title>
	<pubDate>2013-10-30T16:56:30+01:00</pubDate>
	<wp:post_id>4734</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The RCT will compare the efficacy, safety and tolerability of Olaparib (PARP inhibitor) given in addition to abiraterone in patients with mCRPC who have received prior chemotherapy containing docetaxel.<wbr> PE will assess safety, tolerability of daily olaparib when given in addition to abiraterone and prednisolone, and radiologic PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">2-part study: </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline">Part A</SPAN> is an open-label safety run-in study to assess the safety, tolerability and pharmacokinetics (PK) of olaparib when given in addition to abiraterone 1000 mg once daily.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline">Part B</SPAN> is a randomised, double-blind, placebo controlled comparison of the efficacy, safety and tolerability of the dose of olaparib selected from Part A when given in addition to abiraterone, versus placebo given in addition to abiraterone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Dec 2013 - Completion date: June 2016 /<wbr> July 2018 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">N=170 </div><div style="margin-bottom: 10px;"><STRONG>Locations</STRONG> </div><div style="margin-bottom: 10px;">EU sites (UK; Belgium; Netherlands) </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT01972217?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=09%2F30%2F2013&amp;rank=77" class="defaultlink">NCT01972217</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9286">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-30T16:56:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-30T16:56:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Allergan Q3 Figures - Key Takeaways</title>
	<pubDate>2013-10-30T16:23:35+01:00</pubDate>
	<wp:post_id>4735</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Q3 Figures - Key Takeaways</span>&nbsp;<br><span style="font-size: 12px;">Comment: Allergan has reported its highest level of sales growth since 2008 
with revenues in Q3 up by 14% in l.<wbr>c.<wbr> and 12% in US dollars and all operating 
regions achieving at least double-digit growth.<wbr> Botox is growing in line with 
the market +14% with new indications underpinning growth.<wbr> The attraction of the 
Medy-Tox agreement appears to be predominantly focused on aesthetic use of the 
liquid toxin but other indications are also under review.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7236">...</a><br></div><div>As David Pyott noted, the full approval is important in terms of the injector programme, do we have any information about Allergan's clinical development in Frontalis? </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7241">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7236">View thread  Neurology7236: Allergan Q3 Figures - Key Takeaways</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-30T16:23:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-30T16:23:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi Q3 Sales Impacted by Lower Growth in the Chinese Pharma Market</title>
	<pubDate>2013-10-30T10:10:05+01:00</pubDate>
	<wp:post_id>4736</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: For the first time in five quarters, total sales for Q3  increased by 0.<wbr>6% to &euro;8,432M.<wbr> Sales for the Pharmaceuticals business were &euro;6,674 million in the third quarter, an increase of 2.<wbr>7%.<wbr> Sanofi reported mixed Q3 results for Jevtana&reg; (cabazitaxel) in the US, Western Europe and Emerging markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sales in China</STRONG> </div><div style="margin-bottom: 10px;">Sales in China grew 5.<wbr>0% to &euro;351 million given the slowdown in the pharmaceutical market as a result of the industry probe in the quarter.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>JevtanaSales</STRONG> </div><div style="margin-bottom: 10px;">Jevtana </div><div style="margin-bottom: 10px;"> </div><div><EM></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9283">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-30T10:10:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-30T10:10:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Neurocrine Reported Q3 Financial Results and Incremental Updates on Elagolix</title>
	<pubDate>2013-10-30T09:02:03+01:00</pubDate>
	<wp:post_id>4737</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Highlighting pipeline, the company outlined that in 2014, it intends to initiate another clinical study of NBI-98854 in tardive dyskinesia patients.<wbr> This study is currently in the design phase, and the results of the Kinect and Kinect 2 studies will serve to inform the ultimate design of this clinical trial.<wbr> Management confirmed elagolix timing previously provided on AbbVie's Q3 call, and updated on EU/<wbr>US approval.<wbr> Neurocrine reported a net loss of $11.<wbr>1 million compared to a net loss of $3.<wbr>1 million for the same period in 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Messages on Elagolix from the Q&amp;A Session</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Analyst's question</SPAN> " .<wbr>.<wbr>.<wbr> Regarding the second trial, it looks like on clin trials that that trial is listed as having a 12-month extension like the first trial.<wbr> Do you have a sense as to whether the extension in the second trial is going to be needed for approval? And then secondly, there was initial talk about the possibility that the MEA might want an active controlled trial.<wbr> Do you have any sense as to whether the two Phase III elagolix trials satisfied both the US and the EU?" </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Chris O'Brien (SVP, Chief Medical Officer"</SPAN> responded that ".<wbr>.<wbr>.<wbr> My understanding of the second endometriosis trial is that 12-month follow-up period is the potential for follow-up.<wbr> That the bulk of the off drug safety follow-up will come from the first pivotal trial which is primarily the US trial.<wbr> The second trial is multinational, smaller in size.<wbr> And not meant to be rate limiting.<wbr> So I think the option there is that if it's needed, based on data from the first trial, then obviously it's available .<wbr>.<wbr>.<wbr> Obviously most endometriosis -- most European trials for which there is a comparator, an active comparator trial is generally sought by EMA.<wbr> In this case, AbbVie has not been specific as to their plans.<wbr> These efforts, these two pivotal trials that are going on are meant to support the most important market opportunity which is here in the US".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Analyst Forecast</STRONG> </div><div style="margin-bottom: 10px;">Analysts with Morgan Stanley plan an NDA filing for endometriosis in 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reminder of the Elagolix Programs</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Endometriosis </SPAN>AbbVie is currently conducting the Violet Petal Study, a Phase III study of elagolix for endometriosis.<wbr> The study is a 24-week, multinational, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of elagolix in 875 women, age 18 to 49, with moderate to severe endometriosis-associated pain.<wbr> Approximately 160 sites in the United States, Puerto Rico and Canada are conducting this study.<wbr> </div><div style="margin-bottom: 10px;">AbbVie recently initiated the second Phase III study of elagolix for endometriosis.<wbr> This study is similar in design to the Violet Petal Study and will assess 788 women, age 18 to 49, with moderate to severe endometriosis-associated pain at more than 200 sites globally<STRONG>.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Uterine Fibroids </SPAN>AbbVie is also currently conducting a Phase IIb study.<wbr> This study is assessing uterine blood loss in 280 women with heavy uterine bleeding due to uterine fibroids.<wbr> </div><div><EM>Source: Neurocrine</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9282">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-30T09:02:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-30T09:02:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Q3 Figures - Key Takeaways</title>
	<pubDate>2013-10-29T18:28:45+01:00</pubDate>
	<wp:post_id>4738</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has reported its highest level of sales growth since 2008 
with revenues in Q3 up by 14% in l.<wbr>c.<wbr> and 12% in US dollars and all operating 
regions achieving at least double-digit growth.<wbr> Botox is growing in line with 
the market +14% with new indications underpinning growth.<wbr> The attraction of the 
Medy-Tox agreement appears to be predominantly focused on aesthetic use of the 
liquid toxin but other indications are also under review.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Sales</STRONG> </div><div style="margin-bottom: 10px;">Q3 sales increased by 13.<wbr>9% in l.<wbr>c.<wbr> in line with expectations and with 
double-digit growth being recorded in both aesthetic and therapeutic franchises.<wbr> 
Allergan claims to have gained some share in therapeutics gowing on the back of 
new categories such chronic migraine and urology offset by minor share loss in 
aesthetics as new products enter the world market.<wbr> In the US strong growth has 
similarly been underpinned by new indications but also by increased growth in 
rehabilitation bemefotomg from a sales force expansion executed at the back-end 
of 2012 and it claims "Ipsen's downsizing".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Therapeutic Developments</STRONG> </div><div style="margin-bottom: 10px;">Regarding migraine the emphasis is on TV advertising and sheperding patients 
through their first year of treatments helping to ensure loyalty and repeat yes.<wbr> 
Meanwhile, in the urology TA Allergan claims that over 3000 urologists are now 
regular injectors out of a potential univers of 10,000 many of whom do not 
address incontinence.<wbr> Euro gynaecologists apparently are a particular group 
focusing on this type of treatment option.<wbr> Preparing for further growth, the 
group is adding a modest number of field representatives in the US.<wbr> </div><div style="margin-bottom: 10px;">In Europe where reimbursement has been secured, Allergan claims to be 
satisfied with initial demand for Botox for chronic migraine and for 
bladder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Aesthetic Developments</STRONG> </div><div style="margin-bottom: 10px;">Allergan enjoyed strong growth in Q3 with the exception of markets where new 
products are being introduced e.<wbr>g.<wbr> Canada, Australia, Korea and Mexico.<wbr> Strong 
growth markets include Russia, Japan, China, Asia &amp; Brazil.<wbr> In the US growth 
has accelerated to a low double-digit rate and Allergan believes it is holding 
share.<wbr> Similarly, in Europe where the market is growing mid-high single digits 
it claims to be holding share.<wbr> In relation to the recent US approval of canthal 
lines, Pyott did note that there is some existing off-label usage but states the 
full approval is important in terms of the injector programme that the group can 
now initiate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Comments In Relation To The Medy-Tox Acquisition</STRONG> </div><div style="margin-bottom: 10px;">David Pyott's comments on this topic were fairly limited but he did state 
"Our global partnership with Medy-Tox excluding Korea is a reflection of our 
long-term efforts to continue to build the facial aesthetics business and should 
result in us offering an expanded suite of products including a potential liquid 
presentation.<wbr> The Medy-Tox transaction is contingent upon receiving certain 
government approvals (in Korea we presume)" Later in the call during the Q/<wbr>A he 
further commented:- "Clearly the liquid would have predominantly greatest 
interest for us in aesthetics but we're also looking at other things with 
Medy-Tox as well.<wbr> It is a very interesting company with good science" </div><div style="margin-bottom: 10px;"><STRONG>Financial 
Guidance</STRONG> </div><div style="margin-bottom: 10px;">Regarding full year expectation, Allergan estimates product net sales in the 
region of $6.<wbr>125bn to $6.<wbr>2bn and diluted earnings per share in the range of 
$4.<wbr>74 and $4,76.<wbr> Interestingly it noted that the divestiture of the obesity 
intervention business was agreed yesterday for a cash payment of $75m to an as 
yet undisclosed purchaser.<wbr> </div><div>source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7241c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>As David Pyott noted, the full approval is important in terms of the injector programme, do we have any information about Allergan's clinical development in Frontalis? </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7236">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-29T18:28:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-29T18:28:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan has Started Comparative Trial for Perioral Lines</title>
	<pubDate>2013-10-29T17:23:11+01:00</pubDate>
	<wp:post_id>4739</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The prospective, randomized, controlled, multi-center study will assess the safety and effectiveness of JUVEDERM® Ultra XC injectable gel vs Merz' Belotero Balance® for perioral lines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01970397?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=09%2F29%2F2013&amp;rank=256"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: n=130 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Have moderate to severe perioral lines as assessed by the Investigator using the 4-point POLSS (none, mild, moderate, and severe)</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Accept the obligation not to receive any other facial procedures or treatments at any time during the study that are not study related</LI>
</UL> </div><div style="margin-bottom: 10px;">Completion date: May 2014 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7235">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-29T17:23:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-29T17:23:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biogen-Idec Results - Tecfidera (BG-12) Becomes Leading US MS Oral Therapy 6-Months Post Launch</title>
	<pubDate>2013-10-29T16:58:27+01:00</pubDate>
	<wp:post_id>4740</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Biogen-Idec posted a strong set of quarterly figures yesterday with sales of the new oral multiple sclerosis therapy Tecfidera exceeding analyst expectations at $286m W/<wbr>W (estimates were $205-235m).<wbr> Analysts are now forecasting peak annual sales for the product of $3bn.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Commenting on the performance of its MS drugs, George Scangos CEO, noted that progress with Tecfidera had been achieved importantly by increasing the group's overall market share without disproportionately diluting the rest of the group's MS franchise.<wbr> With regard to the situation in the EU he referred to the press release from the EMA on Friday that announced it was evaluating Tecfidera and expects to make a decision on regulatory/<wbr>data protection at its November meeting.<wbr> Scampos stated " we believe that we're entitled to regulatory/<wbr>data protection and we're working diligently to achieve that outcome.<wbr>Our goal is to launch the product with both IP protection and regulatory data protection".<wbr> </div><div style="margin-bottom: 10px;">It was noted that Tecfidera has taken share from the injectable segment of the market but that within that segment Avonex continues to hold up well.<wbr> In the coming year, the group looks forward to the potential launch of Plegridy a pegylated interferon which has the potential to provide patients with another efficacious treatment option with less frequent dosing.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_5_ScreenCapture5.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="neurology7232attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(147,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(129,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(183,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(171,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(136 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(114 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7232_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(190,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7232">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-29T16:58:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-29T16:58:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's Q3 Performance Driven by Costs Cuts and Growing Sales of Oncology Drugs</title>
	<pubDate>2013-10-29T13:49:51+01:00</pubDate>
	<wp:post_id>4741</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncology business increased 26% operationally due to the continued strong performance of Inlyta® (axininib) and Xalkori® (crizotinib) in several major markets.<wbr> Genotropin sales decreased both in the US and ROW.<wbr> Somavert sales increased in all markets.<wbr> The company remains on track to begin operations in the new commercial structure at the start of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10532" class="defaultlink">PharmaWorld10532: Pfizer to Separate Operations into Three Business Segments</a>.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>Genotropin</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><U>WW</U> sales decreased 4% operationally to $570M</LI>
<LI><U>US</U> sales decreased 3% operationally to $145M</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Somavert</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI><U>WW</U> sales increased 11% operationally to $159M</LI>
<LI><U>US</U> sales increased 15% operationally to $38M</LI>
<LI><U>EU</U> (Western Europe, Finland and the Scandinavian countries) sales increased 7% operationally to $98M</LI>
<LI><U>ROW</U> (Australia, Canada, Japan, New Zealand and South Korea) sales increased 12% operationally to $12M</LI>
<LI><U>Emerging markets</U> (Asia (excluding Japan and South Korea), Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe) sales increased 33% operationally to $11M</LI>
</UL> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9278_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9278attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9278_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9278">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-29T13:49:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-29T13:49:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon May Confirm With Its Q3 Figures That The Company Is Up For Sale</title>
	<pubDate>2013-10-28T09:20:03+01:00</pubDate>
	<wp:post_id>4742</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A report on Bloomberg is indicating that Dendreon is up for sale, after weaker than expected sales of its lead immunotherapy cancer vaccine PROVENGE.<wbr> </div><div style="margin-bottom: 10px;">Bloomberg is citing people familiar with the matter suggesting it is working with JP Morgan to find a buyer.<wbr> </div><div style="margin-bottom: 10px;">Dendreon's 2nd quarter sales came in slightly below market expectations at $73.<wbr>4m vs consensus estimates of $74.<wbr>8m but the company did note that 2013 sales would not match those of 2012.<wbr> We should hear more tomorrow when the company reports its 3rd quarter figures.<wbr> </div><div style="margin-bottom: 10px;">The introduction of J&amp;J's Zytiga into the chemotherapy naive segment of the market has clearly impacted Provenge's sales uptake.<wbr> It recently reported a 50% increase in US sales with 50% of its US revenues being generated in the chemotherapy naive segment of the market.<wbr>.<wbr> </div><div>Source: Bloomberg, Reuters, FirstWord.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9275">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-28T09:20:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-28T09:20:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie's Q3:13 Sales Growth Driven by Humira</title>
	<pubDate>2013-10-25T14:43:33+02:00</pubDate>
	<wp:post_id>4743</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="BACKGROUND-COLOR: #ffffff">Humira delivered </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">more than 19% global operational growth in Q:3 (vs 16% in Q:2).<wbr> S</SPAN>ales performance was also driven by solid growth from other products such as Synthroid, Creon, Zemplar and Duodopa.<wbr> Management reported that the second Ph3 trial of elagolix for endometriosis is similar in design to the initial Ph3 trial, which is scheduled to provide top-line data in the second half of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Sales Breakdown</U> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> in the US RA is now in the high 30% range; it is a little below 40% of our total US sales.<wbr> Gastro is about a quarter of our sales.<wbr> Psoriasis right now is about 15% or so of sales.<wbr> And the remainder is in the spondo area, the psoriatic arthritis, ankylosing spondylitis, those types of indications.<wbr> </div><div style="margin-bottom: 10px;">It is similar ex-US.<wbr> I would say RA is probably in the mid-30% of the ex-US franchise.<wbr> Psoriasis again is down in that 14%, 15% range.<wbr> SPA ex-US is approaching 30%, and again gastro is probably about a quarter of our sales.<wbr> So hopefully that gives you a pretty good feel of how the sales mix up today" </div><div style="margin-bottom: 10px;"><U>Intellectual Property</U>: U.<wbr>S Patent protection till end of 2016 </div><div style="margin-bottom: 10px;"><U><STRONG>New Indication - Hidradenitis Suppurativa </STRONG></U> </div><div style="margin-bottom: 10px;"> </div><div>S<EM>ource: AbbVie</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9270">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-25T14:43:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-25T14:43:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance Has Raised $10M</title>
	<pubDate>2013-10-25T13:47:48+02:00</pubDate>
	<wp:post_id>4744</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the beginning of April, the company already raised $33M.<wbr> Proceeds of the financing will be used to support the registration trials of RT-001 (its topical delivery of the botulinum toxin type A), and additionaly of RT002 (its injectable toxin).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7231_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Estimated Approval Timelines</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7231_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7231_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=6922" class="defaultlink">Neurology6922: Revance Therapeutics Secures Financing For PhIII BoNT-A Trials</a>.<wbr> </div><div><EM>Source: TAL_Traction CI; DowJones</EM> </div><!-- Comment details --><a name="neurology7231attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7231_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7231_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(14,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7231_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(8,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7231">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-25T13:47:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-25T13:47:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UCB Highlights Revenue for the First Nine Months of 2013</title>
	<pubDate>2013-10-25T13:20:46+02:00</pubDate>
	<wp:post_id>4745</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the reporting of sales for the first nine months of 2013, the company highlighted its strategy to deliver growth.<wbr> Core medicines such as Cimzia®, Vimpat® and Neupro® have been driving UCB performance during the period of reference.<wbr> The company also outlined its competitive late-stage pipeline in CNS and Immunology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_4_ScreenCapture4.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_5_ScreenCapture5.jpg"> </div><div><EM>Source: UCB</EM> </div><!-- Comment details --><a name="pharmaworld10662attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(85,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(85,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(51,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10662_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(68,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10662">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-25T13:20:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-25T13:20:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FluidCrystal® Awarded Best Innovation in Formulation at CPhI 2013</title>
	<pubDate>2013-10-25T11:05:11+02:00</pubDate>
	<wp:post_id>4746</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After individual presentations by nine award finalists at the Speaker's Corners, Camurus’ was announced as winner of the Award for 'Best Innovation in Formulation'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">2013 location: Frankfurt </div><div style="margin-bottom: 10px;">World's leading pharmaceutical networking event, hosting over 30,000 attendees from 140 countries and 2,200 exhibitors.<wbr> </div><div><EM>Source: Camurus</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7500">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-25T11:05:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-25T11:05:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NPS Builds On Gattex Position With BLA Submission For Natpara</title>
	<pubDate>2013-10-25T09:57:53+02:00</pubDate>
	<wp:post_id>4747</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NPS has submitted a sBLA to the FDA for the approval of Natpara recombinant human parathyroid hormone 1-84, rhPTH(1-84)) a bioengineered replacement for endogenous PTH to treat hypoparathyroidism a rare endocrine disorder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Is Hypoparathyroidism?</STRONG> </div><div><DIV id="pageContent">
<DIV id="layout5-container1">
<DIV class="page-container-body">
<DIV class="contentModule">
<DIV id="pageContent">
<DIV id="layout5-container1">
<DIV class="page-container-body">
<DIV class="contentModule">
<DIV id="pageContent">
<DIV id="layout5-container1">
<DIV class="page-container-body">
<DIV class="contentModule">
<P>Hypoparathyroidism is a disorder in which the body produces insufficient levels of parathyroid hormone, a principal regulator of the body&rsquo;s mineral homeostasis.<wbr> When the body has too little parathyroid hormone, blood calcium levels drop and phosphorus levels increase.<wbr> Hypoparathyroidism is associated with a number of symptoms, including fatigue, muscle spasms and cramps, tingling, tetany, seizures, brain fog/<wbr>mental lethargy, anxiety, and depression.<wbr> Patients with hypoparathyroidism also experience a number of comorbid conditions such as heart arrhythmias, kidney stones, and bone abnormalities.<wbr></P>
<P>There is currently no FDA-approved replacement therapy for hypoparathyroidism, which is currently managed with large doses of calcium supplementation and active vitamin D therapy to raise the calcium levels in the blood and reduce the severity of symptoms.<wbr> Over time, calcium may build up in the body and result in serious health risks, including calcifications in the kidneys, arteries or brain.<wbr></P>
<P><STRONG>Basis For Submission</STRONG></P>
<TABLE border="0" cellpadding="0" cellspacing="0" style="width: 100%;"><TBODY><TR><TD class="cont-mod-none-body" colspan="2" valign="top">
<DIV class="text">
<P>The company&rsquo;s clinical development program for Natpara has included 12 pharmacology studies, five efficacy and safety studies in hypoparathyroidism, and a supporting development program consisting of seven studies in osteoporosis.<wbr> The pivotal Phase 3 study known as REPLACE, was a randomized, double-blind, placebo controlled study of 134 patients with hypoparathyroidism.<wbr></P>
<P>The results from the REPLACE study were recently published in <EM>The Lancet Diabetes &amp; Endocrinology</EM>.<wbr> Key findings from the study are summarized below.<wbr></P>
<UL><LI class="bwlistitemmargb">Fifty-three percent of Natpara-treated patients achieved the primary endpoint by decreasing doses of oral calcium and active vitamin D by 50 percent or more, while maintaining serum calcium levels by the end of the treatment phase.<wbr> In contrast, only 2 percent of the placebo group (P&lt;0.<wbr>001) met the primary endpoint.<wbr>
</LI>
<LI class="bwlistitemmargb">Among secondary endpoints, by Week 24, 43 percent (36/<wbr>84) of patients treated with Natpara were able to achieve independence from active vitamin D therapy and required only 500 mg/<wbr>day or less of oral calcium, as compared to five percent (2/<wbr>37) of patients treated with placebo (p&lt;0.<wbr>0001).<wbr>
</LI>
<LI class="bwlistitemmargb">From baseline, patients treated with Natpara reduced their oral calcium dose by an average of 52 percent (P&lt;0.<wbr>001), whereas those treated with placebo increased their average dose by 6 percent.<wbr>
</LI>
<LI class="bwlistitemmargb">The between-group differences in the average decrease from baseline for prescribed doses of both calcium and active vitamin D were apparent from week three until week 24 (p&lt;0.<wbr>002).<wbr> Despite the large reductions in oral calcium and active vitamin D doses, serum calcium remained at or above baseline levels for the Natpara-treated patients without increasing mean urinary calcium excretion.<wbr>
</LI>
<LI class="bwlistitemmargb">Mean serum phosphate concentrations were similar (at the upper limit of normal) for both Natpara and placebo at baseline, but fell within normal in the Natpara group upon treatment and remained lower than in the placebo group throughout treatment (P&lt;0.<wbr>003 at all time points).<wbr>
</LI>
<LI class="bwlistitemmargb">At week 24, mean serum phosphate levels (&plusmn;SD) had decreased by 0.<wbr>46 (0.<wbr>80) mg/<wbr>dL and 0.<wbr>09 (0.<wbr>66) mg/<wbr>dL for the Natpara and placebo groups, respectively (P&lt;0.<wbr>001).<wbr>
</LI>
<LI class="bwlistitemmargb">Natpara also showed a reduced calcium-phosphate product and replicated another effect of endogenous PTH by maintaining the serum level of 1,25-dihydroxyvitamin D despite a statistically significant mean reduction in active vitamin D doses.<wbr>
</LI>
<LI class="bwlistitemmargb">The overall incidence of adverse events (AE) and percentage of patients with an AE was similar between placebo (100 percent) and Natpara (93 percent) groups.<wbr> By study end, 93 percent (84/<wbr>90) of patients in the Natpara group and 100 percent (44/<wbr>44) in the placebo group had at least one adverse event.<wbr> The most common AEs were nervous system, metabolism and nutrition, musculoskeletal and connective tissue, and gastrointestinal disorders.<wbr> During the maintenance phase of the study (weeks 16&ndash;24), a smaller proportion of Natpara-treated patients reported clinical symptoms associated with hypocalcaemia than those in the placebo-treated group; however, the difference was not statistically significant.<wbr> Serious adverse event (SAE) rates were also similar between the placebo-treated (9 percent) and Natpara-treated (11 percent) groups.<wbr> Only one serious AE of hypercalcemia in the Natpara group was considered treatment-related, and did not lead to study discontinuation.<wbr> Three of 90 (3 percent) patients in the Natpara group discontinued treatment due to an AE, but only one of these patients&rsquo; events were thought to be related to treatment.<wbr>
</LI>
</UL>
<P>The FDA has granted orphan drug status for Natpara for the treatment of hypoparathyroidism</P>
</DIV>
</TD>
</TR>
</TBODY>
</TABLE>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7499">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-25T09:57:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-25T09:57:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Prospective Ph4 Comparing Gait Before and After Xeomin® in Multiple Sclerosis Patients</title>
	<pubDate>2013-10-24T18:47:43+02:00</pubDate>
	<wp:post_id>4748</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Multiple Sclerosis Center of Northeastern New York in collaboration with Merz will determine if Xeomin&reg; will prove effective for significantly improving lower extremity spasticity and will be well tolerated by the majority of MS patients.<wbr> PE will assess mean change from injection visit to week 6 in the Modified Ashworth score between Xeomin&reg; and placebo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details <a href="http://clinicaltrials.gov/ct2/show/study/NCT01968902?recr=Open&no_unk=Y&fund=2&rcv_s=09%2F24%2F2013&rank=254&show_desc=Y#desc" class="defaultlink">NCT01968902</a> - SPASTICITY-001</STRONG> </div><div style="margin-bottom: 10px;">PI: Keith R Edwards, MD </div><div style="margin-bottom: 10px;">Timelines: start date: Nov 2013 - Completion date: May 2014 /<wbr> Sept 2014 </div><div style="margin-bottom: 10px;">Recruitment: n= 30 (patients included are to have functionally significant equinovarus spasticity in primarily one lower extremity; functionally significant spasticity is defined as spasticity impairing gait during observation of during a 25 foot walk, causing falls, or leading to secondary orthopedic complications such as genu recurvatum or pain in the low back or hip.<wbr> The patients are to be ambulatory, with stable disease).<wbr> </div><div>Dosage: 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7229">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-24T18:47:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-24T18:47:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aptalis Hires Banks for an IPO</title>
	<pubDate>2013-10-24T16:27:56+02:00</pubDate>
	<wp:post_id>4749</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aptalis Pharma has appointed underwriters for an initial public offering after efforts to sell the company failed.<wbr> However it is still possible that a sale of Aptalis occurs, even as the company heads towards a stock market flotation.<wbr> Goldman Sachs Group and JPMorgan Chase will lead the offering.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1906" class="defaultlink">GastroEnterology1906: TPG Is Exploring The Sale of Specialty Drugmaker Aptalis</a>.<wbr> </div><div>TPG bought the drugmaker, known as Axcan Pharma, for $1.<wbr>3 billion in 2008 and merged it with Eurand Pharmaceuticals in 2011.<wbr> The combined company was renamed Aptalis.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1926">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-24T16:27:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-24T16:27:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OXiGENE Presents PC Data Demonstrating Antitumor Activity of ZYBRESTAT(R) in pNET</title>
	<pubDate>2013-10-23T17:50:52+02:00</pubDate>
	<wp:post_id>4750</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OXiGENE, Inc a clinical-stage biopharmaceutical 
company has presented data at the AACR meeting from a preclinical study of 
ZYBRESTAT®  demonstrating statistically significant treatment differences 
with the drug in a model of pNET.<wbr> It has an interesting development pipeline 
surrounding this product, with the lead indication being anaplastic thyroid 
cancer, where it is aiming for an EU submission in 2015.<wbr> </div><div style="margin-bottom: 10px;">The poster, titled "Combretastatin A-4 Phosphate (CA4P) is effective for the 
treatment of functional pancreatic neuroendocrine tumors (PNETs) in a transgenic 
mouse model," was presented by <PERSON>ZiQiang Yuan</PERSON>, MD, Research 
Assistant Professor, <ORG>Department of Surgery</ORG>, <ORG value="ACORN:4068800954">Albert Einstein College of 
Medicine</ORG>.<wbr> <PERSON>Steven K.<wbr> Libutti</PERSON>, MD, FACS, Professor of 
Surgery and Genetics, <ORG value="ACORN:4068800954">Albert 
Einstein College of Medicine</ORG>, and <ORG value="ACORN:0645376148">Montefiore Medical Center</ORG>, is the senior author.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Aim &amp; Study Methodology</STRONG> </div><div style="margin-bottom: 10px;">This study was designed to evaluate the efficacy of systemic administration 
of ZYBRESTAT or CA4P for the treatment of functional insulinomas in a transgenic 
mouse model of PNETs.<wbr> </div><div style="margin-bottom: 10px;">The treatment group received ZYBRESTAT three times per week for four weeks, 
and the control group received a placebo.<wbr> After four weeks, tumor size, serum 
insulin levels and other efficacy parameters, including apoptosis (cell death), 
cell proliferation and effects on tumor vasculature, were assessed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What does the data show?</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Treatment with ZYBRESTAT resulted in a significant and sustained decrease 
  in circulating insulin, with maximum effect seen by day 17 (p &lt; 
  0.<wbr>0001).<wbr></LI>
<LI>The reduction in insulin was accompanied by a significantly reduced tumor 
  size in the treated group compared to the placebo group (p=0.<wbr>0128).<wbr></LI>
<LI>Treatment with ZYBRESTAT was shown to disrupt tumor vasculature, induce 
  apoptosis (cell death) and inhibit tumor cell proliferation.<wbr></LI>
<LI>ZYBRESTAT was shown to be well tolerated, with no obvious 
toxicity.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Commenting on the data Dai Chaplin, PhD, former Chief Scientific 
Officer of <ORG value="NASDAQ-SMALL:OXGN">OXiGENE</ORG> and 
currently a scientific advisor and member of the Company's Board of Directors.<wbr> 
stated "The results of this preclinical study are very encouraging, showing a 
high degree of efficacy at well-tolerated doses.<wbr> This study identifies vascular 
disruption induced by CA4P as a key mechanism in reducing both circulating 
hormone levels and tumor size," </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Based on this data Oxigene is considering the potential of ZYBRESTAT either 
as a mono or combination therapy.<wbr> It hopes to be able to undertake 
clinical trials in PNETs in the future, either independently or in collaboration 
with a development partner.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Oxigene's Investment in VDA technology/<wbr>Pipeline Status</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_5_ScreenCapture5.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_6_ScreenCapture6.jpg"> </div><!-- Comment details --><a name="endocrinology7498attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(177,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(141,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(186,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(190 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(94 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7498_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(154,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7498">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-23T17:50:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-23T17:50:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves First Filler for Volume Loss in the Cheek Area</title>
	<pubDate>2013-10-23T16:01:15+02:00</pubDate>
	<wp:post_id>4751</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan's JUVÉDERM VOLUMA™ XC is the first and only filler approved in the US specifically formulated to temporarily correct age-related volume loss in the cheeck area in adults &gt;21 years old.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Helps create a more youthful appearance to the face and provides natural-looking and long-lasting results up to two years with optimal treatment (JUVÉDERM VOLUMA™ Patient Labeling, 2013).<wbr> </div><div style="margin-bottom: 10px;">- Made with Allergan's proprietary VYCROSS™ technology, an advanced manufacturing process that results in a smooth gel that flows easily and consistently.<wbr> This unique formulation contributes to the lift capacity to correct volume loss in the cheek area and to the duration of the product (JUVÉDERM VOLUMA™ Directions for Use 2013, pg 11- Carruthers J, Carruthers A, Tezel A, Kraemer J, <PERSON>Craik L</PERSON>.<wbr> Volumizing with a 20-mg/<wbr>mL smooth, highly cohesive, viscous hyaluronic acid filler and its role in facial rejuvenation therapy.<wbr> <I>Dermatol Surg</I>.<wbr> 2010; 36(suppl3): 1886-1892.<wbr> p1887A,B).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Juvederm Voluma differs from Juvederm Ultra in that the product is much thicker (more viscous).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7227_2_ScreenCapture2.jpg"> </div><div><EM>Source: Allergan</EM> </div><!-- Comment details --><a name="neurology7227attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7227_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(64,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7227">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-23T16:01:15+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-23T16:01:15+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tokai Pharma Has Reported Positive Results With Galeterone In Enzalutamide Cell Lines</title>
	<pubDate>2013-10-23T15:30:00+02:00</pubDate>
	<wp:post_id>4752</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tokai has presented new preclinical data at the AACR supporting that its lead candidate, galeterone (TOK-001) may represent the next-generation of therapy for patients with castration-resistant prostate cancer (CRPC) and disease that has progressed despite treatment with enzalutamide (Xtandi).<wbr> </div><div style="margin-bottom: 10px;">Growth <EM></EM>Conference on Molecular Targets and Cancer Therapeutics in Boston.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">&ldquo;These data demonstrate preclinical proof-of-principle that galeterone is a potent androgen receptor antagonist and may overcome the anti-androgen resistance mechanisms that are commonly observed in CRPC following treatment with other currently available agents,&rdquo;commented Amina Zoubeidi, Ph.<wbr>D.<wbr>, assistant professor, Department of Urologic Sciences, University of British Columbia and research scientist, Vancouver Prostate Centre, and coauthor of the study.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">A copy of the poster presentation is attached but a few of the key results are highlighted below.<wbr></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9261_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9261_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Galeterone is currently being investigated in <STRONG>ARMOR2</STRONG>, a Phase 2 clinical trial evaluating the efficacy and safety of a new oral formulation of galeterone in four distinct populations of CRPC patients: 1) metastatic treatment-na&iuml;ve patients; 2) non-metastatic treatment-na&iuml;ve patients; 3) patients who have progressed while taking Zytiga&reg; (abiraterone acetate) and 4) patients who have progressed while taking Xtandi&reg; (enzalutamide).<wbr> The primary endpoints of the study are reduction in prostate-specific antigen (PSA) levels and safety.<wbr> The secondary endpoints include tumor responses by RECIST, levels of circulating tumor cells and markers of CYP17 lyase inhibition and AR modulation.<wbr> Patients who respond to therapy will have the opportunity to continue treatment in an extension arm of the trial.<wbr> ARMOR2 is being conducted globally at leading prostate cancer treatment centers.<wbr> </div><div style="margin-bottom: 10px;">Galeterone was reformulated prior to the initiation of the ARMOR2 clinical trial in order to increase the drug exposure and mitigate the effect of food on oral bioavailability.<wbr> The new formulation has been shown to be unaffected by diet, and therefore can be <A href="http://www.tokaipharma.com/news.php">taken with or without food</A>.<wbr> </div><div>The study is scheduled to complete in terms of primary endpoint in June 2014 based on the inclusion of 144 patients.<wbr> </div><!-- Comment details --><a name="oncology9261attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9261_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(139,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9261_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(147,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9261_3_Nakouzi%2dAACR%2dEORTC%2d2013%2dPoster%2dMDV%2dresistance%2dedits%5b1%5d.pdf">Nakouzi-AACR-EORTC-2013-Poster-MDV-resistance-edits[1].pdf</a>&nbsp;&nbsp;(3,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9261">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-23T15:30:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-23T15:30:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GSK's Chinese Sales Slump</title>
	<pubDate>2013-10-23T15:12:10+02:00</pubDate>
	<wp:post_id>4753</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GSK has reported today that its Chinese sales have slumped by 61% in 
the third quarter, a fall that was far steeper than many analysts had 
predicted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Importance To GSK</STRONG> </div><div style="margin-bottom: 10px;">Although the market accounts for less than 4% of group sales, it sees it as a 
vital market for the future and has some 7000 staff in the country.<wbr> </div><div style="margin-bottom: 10px;">Worldwide GSK reported flat sales at $6.<wbr>51bn </div><div style="margin-bottom: 10px;"><STRONG>Scandal is not impacting all companies to the same 
degree</STRONG> </div><div style="margin-bottom: 10px;">GSK appears to have suffered the most damage from the bribery scandal, with 
Swiss drug companies Roche and Novartis reporting little impact on their third 
quarter sales.<wbr> The company has suffered most where other drug options are 
available such as in the respiratory market with Advair.<wbr> Astra Zeneca's 
Symbicort is the alternative.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10661">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-23T15:12:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-23T15:12:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS' Q3 Fueled by Strong Sales of Cancer and Diabetes Drugs</title>
	<pubDate>2013-10-23T15:10:43+02:00</pubDate>
	<wp:post_id>4754</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Net sales increased by 9% to $4.<wbr>1 billion.<wbr> Growth was driven by strong performance of Yervoy (melanoma), Sprycel (leukemia), and Onrencia (rheumatoid arthritis).<wbr> Management outlined its <SPAN style="BACKGROUND-COLOR: #ffffff">significant </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">commitment to advancing the field of immuno oncology in </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff">exploring its use in </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">pancreatic, gastric, and triple breast cancer as well as malignancies</SPAN>.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9259_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported that: </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> <SPAN style="BACKGROUND-COLOR: #ffffff">one of the most valuable aspects of the immuno therapy </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">is the durable response".<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="BACKGROUND-COLOR: #ffffff"><SPAN style="BACKGROUND-COLOR: #ffffff"> " .<wbr>.<wbr>.<wbr> we are thinking in the US </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">and outside of the US of creating </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">an infrastructure and a structure that </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">doesn't need to be changed at every indication, and </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">also we need to start very early with this new prescribers </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">the education of the new prescribers, remember the </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">work we are to do with the melanoma prescribers at </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">the beginning to familiarize them with immune oncology, </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">the same needs to be done with a much broader base </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">in the US and internationally to, you know, to familiarize </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">them with the immune oncology and the other line especially </SPAN><SPAN style="BACKGROUND-COLOR: #ffffff">for long cancer prescribers".<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9259_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9259_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">PD-1 is BMS' key immuno-oncology pipeline candidate.<wbr> </div><div><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- in late ’13, BMS will receive PD-1/<wbr>Yervoy combo data in-house and decide on dosing for Ph.<wbr> 3 combo trial starts.<wbr></P></BLOCKQUOTE> </div><!-- Comment details --><a name="oncology9259attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9259_4_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9259_5_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(50,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9259_6_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(81,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9259">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-23T15:10:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-23T15:10:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Positive Opinion for Allergan's VISTABEL® (Moderate-to-Severe Lateral Canthal Lines)</title>
	<pubDate>2013-10-23T11:52:18+02:00</pubDate>
	<wp:post_id>4755</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This positive opinion follows the recent authorisation for a similar indication by the FDA.<wbr> In Japan, estimated approval timeline is H1:16.<wbr> </div><div style="margin-bottom: 10px;"><P class="c2"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">For VISTABEL®, France serves as the Reference Member State in the Mutual Recognition Procedure.<wbr> </div><div style="margin-bottom: 10px;">Following the Positive Opinion from Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), the healthcare regulatory agencies in the 27 countries of the European Union as well as Norway and Iceland will finalise the relevant national licences.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Dr.<wbr> Koenraad de Boulle, dermatologist and key investigator in the registration trials.<wbr> </div><div style="margin-bottom: 10px;">- Based on the results of 2 randomised, multi-centre, placebo-controlled clinical studies involving &gt;1,350 patients (Allergan Data on file - Draft SMPC for VISTABEL® 50 Units).<wbr> </div><div><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- These studies met their primary endpoint, demonstrating that patients who received treatment with VISTABEL® achieved none or mild lines according to investigator assessment at day 30, compared to those patients who did not receive botulinum toxin type A treatment and this significant reduction in the appearance of crow's feet lines lasting an average of 4 months post-treatment.<wbr> </P>
<P>- Patients treated with VISTABEL® reported that they looked younger and more attractive.<wbr></P></BLOCKQUOTE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7224">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-23T11:52:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-23T11:52:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen's Revenue for Q3:13 Rose Ten Percent</title>
	<pubDate>2013-10-23T11:20:58+02:00</pubDate>
	<wp:post_id>4756</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The quarter’s top-line beat was largely attributable to a $155M government purchase of Neupogen.<wbr> Total revenues increased 10% (to $4,748M).<wbr> Key growth contributors across the portfolio were Neulasta<SUP>®</SUP> (pegfilgrastim), Enbrel<SUP>®</SUP> (etanercept), Prolia<SUP>®</SUP> (denosumab) and XGEVA<SUP>®</SUP> (denosumab).<wbr> Management highlighted the repurchase of rights to Neulasta and Neupogen from Roche, and the completion of the acquisition of Onyx and its multiple myeloma drug, Kyprolis.<wbr> Among the six biosimilars in development, one currently is in Ph3 study (Humira for psoriasis).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Enbrel</STRONG> - Tony Hooper reported that: </div><div style="margin-bottom: 10px;">- .<wbr>.<wbr>.<wbr> " two thirds of the business is in rheumatology, and about one third in dermatology".<wbr> </div><div style="margin-bottom: 10px;">- "Rheumatologists and dermatologists continue to recognize Enbrel with track record of efficacy, safety, and long-term experience.<wbr> We are committed to investing in Enbrel over the long term, given our prolonged exclusivity at the end of our profit share agreement with Pfizer at the end of this month.<wbr> Enbrel sales grew 7% year over year, primarily due to price".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Prolia</STRONG> - "we continue to grow share in both the US and the rest of the world.<wbr> We also continue to improve repeat injection rates in the US and our latest data shows over 60% of patients returning for their second injection.<wbr> Earlier this month we launched Prolia in France, which is the largest PMO market in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>XGEVA</STRONG> - " .<wbr>.<wbr>.<wbr> after extensive discussions with EU regulators we've decided not to pursue further our requests for a bone metastasis free survival indication in castrate resistant prostate cancer in Europe".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management are raising the company's guidance for revenues and adjusted earnings per share (EPS) for the FY.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_6_ScreenCapture6.jpg"> </div><!-- Comment details --><a name="oncology9258attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(97,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(99,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(88 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9258_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(36 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9258">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-23T11:20:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-23T11:20:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Orion's Q1-Q3/2013 Results</title>
	<pubDate>2013-10-22T15:48:09+02:00</pubDate>
	<wp:post_id>4757</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P class="hugin">Comment: Orion's net sales in January-September 2013 totalled €734 million (vs €726 million in January- September 2012).<wbr> The review period stood out in promising results from Ph2 trial of ODM-201 (for prostate cancer), the termination of the agreement with Endo, and the collaboration extension with Hospira concerning Precedex (sedative agent).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_5_ScreenCapture5.jpg"></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_1_ScreenCapture1.jpg"></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_2_ScreenCapture2.jpg"></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_3_ScreenCapture3.jpg"></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P class="hugin">&gt;&gt; See recent data @ <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9201" class="defaultlink">Oncology9201: ESMO Intelligence Part 1- New Hormonal Prostate Cancer Therapy Data</a>.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_4_ScreenCapture4.jpg"></P> </div><div><EM>Source: Orion</EM> </div><!-- Comment details --><a name="oncology9255attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(42 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(45,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9255_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(64,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9255">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-22T15:48:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-22T15:48:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation/Astellas Report Interim Results of the Ph3 PREVAIL Trial</title>
	<pubDate>2013-10-22T15:13:04+02:00</pubDate>
	<wp:post_id>4758</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The highly anticipated results show good hazard ratio of survival but disappointing OS benefit (which comes below Zytiga's 5 months).<wbr> Independent panel recommends patients on placebo shift to the drug.<wbr> The upcoming data from STRIVE and TERRAIN studies in earlier prostate cancer patients will be critical for the penetration among urologists.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Companies reported they will initiate regulatory meetings in early 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="color: #585858; font-size: 9pt;"></SPAN> </div><div style="margin-bottom: 10px;">Xtandi showed a 30% reduction in risk of death vs placebo (hazard ratio=0.<wbr>70).<wbr> This is slightly better than the 0.<wbr>75 seen in Zytiga&rsquo;s interim analysis.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="color: #585858; font-size: 9pt;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="color: #585858; font-size: 9pt;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="color: #585858; font-size: 9pt;"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
<LI>
</LI>
<LI>
</LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div>Source and original article: <A href="http://investors.medivation.com/releasedetail.cfm?ReleaseID=798880">http:/<wbr>/<wbr>investors.<wbr>medivation.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=798880</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9252">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-22T15:13:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-22T15:13:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Additional Details on Daewoong / Evolus Toxin Agreement</title>
	<pubDate>2013-10-22T11:01:07+02:00</pubDate>
	<wp:post_id>4759</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Just published in the news section of Daewoong's website, the press release brings additional details on the deal value and launch timelines, the date being different from the original article we published on October 7th in Traction CI.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The deal was announced on Sept 30 at the Shilla Hotel in Seoul.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7223_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Approx.<wbr> KRW 300 billion based on the five-year export value including the technical fees.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Slated for release the <U>second-half of 2017</U> (vs early 2016) in the US and EU.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7191" class="defaultlink">Neurology7191: Evolus to Sell Daewoong's Botulinum Toxin (Nabota) in the US and EU Markets</a>.<wbr> </div><!-- Comment details --><a name="neurology7223attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7223_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7223_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(25,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7223">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-22T11:01:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-22T11:01:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Q3 Figures - Key Takeaways</title>
	<pubDate>2013-10-22T09:12:32+02:00</pubDate>
	<wp:post_id>4760</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis has reported a strong top-line performance with group net sales up 4% to $14.<wbr>3bn but core operating profits down 5% to (+1% c.<wbr>c.<wbr>), a negative currency impact of -6% the main cause of this decline.<wbr> Underlying business ex patent expiries grew by 10%.<wbr> A first filing for Signifor LAR (pasireotide) in acromegaly is still slated for 2013.<wbr> </div><div style="margin-bottom: 10px;">Strong productivity continues to be a feature of the group, with two product approvals in the quarter (COPD in Japan and juvenile arthritis in EU), three sets of phIII results (psoriasis, acute heart failure &amp; COPD) and one product designation as a breakthrough therapy for a degenerative muscle disease.<wbr> </div><div style="margin-bottom: 10px;">In terms of outlook, the group has increased its sales forecast to low to mid-single digit for the full year and operating profit is expected to be in line or better than the prevous year in constant currency terms.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pharmaceutical Performance</STRONG> </div><div style="margin-bottom: 10px;">Sales reached $7.<wbr>9bn (+1%, 4% c.<wbr>c.<wbr>), with strong volume growth of 10% and pricing +1% offset by the impact of generic competition ($0.<wbr>5bn -7%).<wbr> Key growth products highlighted are, Gilenya, Afinitor, Tasigna, Galvus, Xolaire, the Q products (respiratory) &amp; Jakavi.<wbr> Together these generated $3.<wbr>1bn or 39% of divisional sales +28% over the prior year period.<wbr> </div><div style="margin-bottom: 10px;">Operating income declined by 10% (5% cc) due to the impact of generics, R&amp;D investment in three promising products addressing areas in oncology, respiratory medicine and heart failure, as well as higher COGS.<wbr> Operating margin decreased by 2.<wbr>8 percentage points.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sandostatin Performance</STRONG> </div><div style="margin-bottom: 10px;">Sales grew by 5% in the quarter to $401m (7% c.<wbr>c.<wbr>) resulting in 9 months sales of $1,173 +4% (7% c.<wbr>c.<wbr>).<wbr> In the US sales grew by 9% c.<wbr>c.<wbr> whilst in the ROW they grew by 5% c.<wbr>c.<wbr> It was noted that the new injection device is now available in 37 countries with additional filings underway and that the drug is approved in 42 countries for delaying disease progression in neuroendocrine tumours of mid-gut or unknown origin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Afinitor Performance</STRONG> </div><div style="margin-bottom: 10px;">Continues to be one of the group's star performers with sales up 65% to $337m.<wbr> New approvals for breast cancer are to a large extent underpinning this growth performance.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Gilenya Performance</STRONG> </div><div style="margin-bottom: 10px;">Novartis's other star performer is the multiple sclerosis drug Gilenya, sales of which grew by 64% to reach $518m.<wbr> Gilenya has been shown to address all four measures of efficacy in MS &ndash; annualized relapse rate, physical disability, MRI activity and brain volume loss &ndash; and is the only oral disease modifying therapy, Novartis claims with proven superior relapse reduction versus an active comparator and proven high, early, consistent and sustained reductions of brain volume loss to impact long-term disability.<wbr> It is now approved in over 75 countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>R&amp;D Developments</STRONG> </div><div style="margin-bottom: 10px;">Signifor did not feature prominently in the group's innovation review but tabular data still notes that a submission for acromegaly is expected in 2013 and for the LAR formulation in Cushing's in 2015.<wbr> </div><div style="margin-bottom: 10px;">Equally not much was mentioned about Afinitor in non-functioning GI/<wbr>Lung NET other than the unmet need that exists.<wbr> 2015 was specified as the first planned submission.<wbr> </div><div style="margin-bottom: 10px;">One of the priority products in the group's pipeline is serelaxin, Novartis's new drug for the treatment of acute heart failure.<wbr> PhIII data has demonstrated that the drugs improves symptoms and mortality across multiple sub-groups of patients.<wbr> If approved the drug will represent the first significant treatment advance in this area in 20 years.<wbr> </div><div>Source: <a href="http://www.novartis.com" class="defaultlink" title="http://www.novartis.com">novartis.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7494">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-22T09:12:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-22T09:12:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Amgen Astellas BioPharma Officially Began Operations in Japan</title>
	<pubDate>2013-10-22T08:34:10+02:00</pubDate>
	<wp:post_id>4761</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The new venture company will be led by Eiichi Takahashi, and focus on the co-development and co-commercialization in Japan of 5 Amgen pipeline drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9251_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9251_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=8981" class="defaultlink">Oncology8981: Amgen and Astellas Form JV for Japan</a> </div><!-- Comment details --><a name="oncology9251attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9251_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(80,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9251_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(73,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9251_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(14,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9251_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(22,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9251">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-22T08:34:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-22T08:34:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Organisation at Takeda</title>
	<pubDate>2013-10-21T14:37:53+02:00</pubDate>
	<wp:post_id>4762</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has announced new senior leadership at its Pharma Research Division (PRD), as well as at Takeda Development Center America Inc.<wbr>.<wbr> The organizational changes will include the establishment of Talent &amp; Organization Development Office and Integrated Technology Research Laboratories.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">(effective November1 2013) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9250_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">(effective November 1 2013) </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9250_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology9250attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9250_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9250_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(83,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9250">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-21T14:37:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-21T14:37:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>XTANDI Obtains Marketing Autorization in Italy</title>
	<pubDate>2013-10-21T10:46:39+02:00</pubDate>
	<wp:post_id>4763</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to A Corio and M Maraschi we have learnt that the Italian Drug Agency just issued the MA decree for XTANDI.<wbr> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></DIV> </div><div><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9248">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-21T10:46:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-21T10:46:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Recordati to Acquire Laboratorios Casen Fleet for €93M</title>
	<pubDate>2013-10-21T10:03:16+02:00</pubDate>
	<wp:post_id>4764</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Recordati to Acquire Laboratorios Casen Fleet for €93M</span>&nbsp;<br><span style="font-size: 12px;">Comment: Casen Fleet primarily markets internally developed drugs principally in the gastroenterological therapeutic area in Spain and Portugal through its own organisation and in other countries through partners.<wbr> Approx.<wbr> 55% of revenue is generated by a line of products used in the preparation for colonoscopy.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1911">...</a><br></div><div style="margin-bottom: 10px;">Recordati has announced successful completion of the acquisition.<wbr> Approx.<wbr> 55% of  of 100% of Casen Fleet revenue is generated by a line of product used for colonoscopy.<wbr> </div><div style="margin-bottom: 10px;">The company's product portfolio also comorises oral rehydratation products, probiotics and OTC brands for gynea use.<wbr> </div><div>Approx.<wbr> 80% of revenue is generated by private payers and is therefore outside public healthcare reimbursement schemes.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1925">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1911">View thread  GastroEnterology1911: Recordati to Acquire Laboratorios Casen Fleet for €93M</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-21T10:03:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-21T10:03:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Tekmira Presents PhI NET Data At NANETS Meeting</title>
	<pubDate>2013-10-21T09:35:07+02:00</pubDate>
	<wp:post_id>4765</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Tekmira Presents PhI NET Data At NANETS Meeting</span>&nbsp;<br><span style="font-size: 12px;">Comment: Late last week, Tekmira presented data from a phI study with 
its polo-like kinase inhibitor TKM-PLK-1 at NANETS.<wbr> The study was 
undertaken in 36 advanced cancer patients including two patients with 
GI-NET.<wbr> The reduction in Chromagainin levels seen with the drug and 
the patient's response to treatment has supported the initiation of a phI/<wbr>II 
study in NET &amp; ACC patients, a trial that is now ongoing and 
expected to read-out in mid 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7474">...</a><br></div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Last Thursday Tekmira raised </SPAN><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">$30 million through the sale of 3.<wbr>8 million shares at $8 in a follow-on underwritten by Stifel and Maxim Group.<wbr> Tekmira proposed the offering late Wednesday, when its share price on NASDAQ was $8.<wbr>82.<wbr> Tekmira's lead internal candidate is </SPAN>TKM-PLK1<SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">, which is in Phase I/<wbr>II testing to treat advanced gastrointestinal neuroendocrine tumors and adrenocortical carcinoma, with data expected in mid-2014.<wbr> TKM-PLK1 comprises short interfering RNA (siRNA) targeting </SPAN>polo-like kinase 1 <SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> formulated with the company's lipid nanoparticle (LNP) technology.<wbr></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7492">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7474">View thread  Endocrinology7474: Tekmira Presents PhI NET Data At NANETS Meeting</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-21T09:35:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-21T09:35:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GW Gains Approval For Savitex In France</title>
	<pubDate>2013-10-21T09:17:54+02:00</pubDate>
	<wp:post_id>4766</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GW has today announced that Savitex has been approved in France for the treatment of spasticity associated with multiple sclerosis.<wbr> </div><div style="margin-bottom: 10px;">Savitex will be sold in France by its European partner Almirall following completion of national pricing and reimbursement.<wbr> The drug is now available in 10 European markets including the UK, Spain, Germany, Denmark, Norway, Austria, Poland, Sweden, Italy &amp; Finland and available in 20 markets worldwide.<wbr> </div><div>source:www.<wbr>gwpharma.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7220">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-21T09:17:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-21T09:17:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Has Started New Registration Trial of Degarelix vs Goserelin for Prostate Cancer</title>
	<pubDate>2013-10-18T17:44:38+02:00</pubDate>
	<wp:post_id>4767</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The open-label, active-controlled, parallel-arm study, comparing ASP3550 (degarelix 3M) vs goserelin acetate in patients with prostate cancer will recruit approx.<wbr> 230 patients in Japan.<wbr> PE will assess cumulative castration rate of treatment in terms of serum testosterone level.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01964170?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=09%2F18%2F2013&amp;rank=195"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><U>Timeline</U> </div><div style="margin-bottom: 10px;">Completion date: Nov 2015 /<wbr> Nov 2016 </div><div style="margin-bottom: 10px;"><U>Design</U> </div><div style="margin-bottom: 10px;">This study consists of two parts: </div><div style="margin-bottom: 10px;">The purpose of PART 1 is to test non-inferiority of ASP3550 to goserelin acetate with respect to the cumulative castration rate in terms of serum testosterone when ASP3550 or goserelin acetate is administered for one-year in patients with prostate cancer.<wbr> </div><div><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">The patients assigned to receive ASP3550 and completed the treatment in PART 1 are eligible for the treatment in PART 2, and will receive ASP3550 maintenance dose subcutaneously for additional term.<wbr> The long-term safety, efficacy and PK of the continued ASP3550 treatment will be assessed in PART 2.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9242">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-18T17:44:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-18T17:44:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' INC280 to Enter POC for 2nd-Line HCC</title>
	<pubDate>2013-10-18T17:22:31+02:00</pubDate>
	<wp:post_id>4768</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: INC280<SUP> </SUP>is a highly selective small molecule c-Met inhibitor developed for the treatment of solid tumors with activation of the c-Met pathway.<wbr><SUP> </SUP>FIM study in various tumor types started in January 2010.<wbr> PE of this trial will evaluate time to progression using RECIST.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Timeline</STRONG> </div><div style="margin-bottom: 10px;">Start date: Feb 2014 /<wbr> Completion date: March 2016 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=69 </div><div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Patients will be randomized in a 2:1 ratio to receive INC280 at 600mg BID plus best supportive care (BSC) or placebo plus BSC, until disease progression or intolerable to study treatment.<wbr> Patients treated with placebo plus BSC will have the opportunity to receive INC280 treatment upon documented further disease progression (RECIST 1.<wbr>1) per investigator's discretion after unblinding.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Patient will be stratified to geographical region (Asia vs Rest of World) and tumor burden (present macroscopic vascular invasion and/<wbr>or extra-hepatic spread vs not present).<wbr></P></DIV></DIV></DIV></DIV> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9241_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9241attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9241_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(145,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9241">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-18T17:22:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-18T17:22:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Combination therapy for OAB Could Address Some Of The Markets's Unmet Needs</title>
	<pubDate>2013-10-18T12:40:46+02:00</pubDate>
	<wp:post_id>4769</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AltheRx a privately held clinical development company has announced 
that the USPTO has issued a Notice of Allowance for the company's US patent 
apllication claiming the method of use for solabegron a beta-3 adrenergic 
receptor agonist in combination with all commercially available anitmuscarinics 
for the treatment of overactive bladder.<wbr> </div><div style="margin-bottom: 10px;">The company claims that data indicates that the combination of solabegron and 
anti-muscarinic has a synergistic effect on the bladder and can potentially 
improve treatment outcomes and safety for millions of patients suffering from 
OAB </div><div style="margin-bottom: 10px;"><STRONG>Current Status </STRONG> </div><div style="margin-bottom: 10px;">Solabegron is poised to enter phIII developmment in the US &amp; EU having 
generated statistically significant phII data demonstrating favourable 
tolerability.<wbr> </div><div style="margin-bottom: 10px;">AltheRx is currently in active partering discussions to try and progress the 
drug through late stage clinical development.<wbr> </div><div style="margin-bottom: 10px;">Quite how this patent positions AltheRx compared to Astellas remains to be 
deterrmined as Astellas has also noted the potential of combination therapy and 
has a phIII ongoing with its commercialised beta-3 adrenergic agonist miragebron 
and an antimuscarinic.<wbr> </div><div>Source: <A href="http://www.altheRx.com">www.<wbr>altheRx.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7219">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-18T12:40:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-18T12:40:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Traction CI – Email Alert Notifications</title>
	<pubDate>2013-10-18T11:35:46+02:00</pubDate>
	<wp:post_id>4770</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div>Comment: In Traction CI it is possible to be alerted of new articles immediately after they have been published, ahead of the daily CI Digest.<wbr> Strategic articles for each therapeutic area will be flagged by the CI team as &ldquo;Alerts&rdquo; and the following document describes how you can setup your account to receive them.<wbr> <a href="/db/share/pharmaworld/Traction%20CI%20-%20Alerts%20notifications.docx" class="defaultlink">Click here to find out more</a><SPAN style="line-height: 1.5em;">.<wbr></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10655">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-18T11:35:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-18T11:35:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NICE Draft Guidance Recommends Xtandi for Post-Chemo Treatment</title>
	<pubDate>2013-10-18T10:57:32+02:00</pubDate>
	<wp:post_id>4771</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See @ <A href="http://guidance.nice.org.uk/TAG/354">http:/<wbr>/<wbr>guidance.<wbr>nice.<wbr>org.<wbr>uk/<wbr>TAG/<wbr>354</A> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9236_4_ScreenCapture4.jpg"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9236_5_ScreenCapture5.jpg"></SPAN></SPAN> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><a name="oncology9236attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9236_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9236">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-18T10:57:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-18T10:57:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AAA Reaches Halfway Recruitment Milestone in Lutathera® Ph3 Trial</title>
	<pubDate>2013-10-18T10:46:41+02:00</pubDate>
	<wp:post_id>4772</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 100-patient milestone has been reached for the NETTER-1 study.<wbr> The rate of recruitment has accelerated in both EU and US, with 68 additional patients consenting to take part in the study (26 in EU and 42 in the US) in the past 6 months.<wbr> As of today, 43 sites have been initiated (31 in Europe, 12 in US), and 23 of them are actively recruiting.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management expects results from the study to be published in 2015, and hopes to obtain MA in H1:17.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01578239?term=netter-1&amp;rank=1"><STRONG></STRONG></A><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><EM>Design</EM>: to evaluate the efficacy and safety of Lutathera® compared to Novartis’ Sandostatin® LAR, in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumors.<wbr> </div><div style="margin-bottom: 10px;"><U>PE</U>: assessment of Progression- Free Survival.<wbr> </div><div style="margin-bottom: 10px;"><U>Secondary endpoints</U> include Safety, Objective Response Rate, Time to Tumor Progression, Overall Survival and QoL.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Lutathera® is currently used on a named patient basis or compassionate use in : Austria, Estonia, Finland, Greece, Portugal, Spain, Switzerland and the UK, when no alternative therapeutic option is available and under specific authorization.<wbr> </div><div><EM>Source: AAA</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7490">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-18T10:46:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-18T10:46:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 5 - The Role of Immunotherapy in Prostate Cancer and Other Development</title>
	<pubDate>2013-10-17T22:45:45+02:00</pubDate>
	<wp:post_id>4773</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The immune system has a natural response to cancer, recongising and eliminating tumour cells from the body throughout the life.<wbr> Cancer is now recognised as a disease of microenvironment in that tumour cells becoming progressively resistant to immune destruction and also secret the cytokines or growth factors which render immune system to become immuno-suppressed.<wbr> Immuno-Oncology is an innovative treatment approach that harnesses the immune system to fight cancer, countering tumour immune escape mechanisms.<wbr>There is now renewed enthusiasm for immuno-oncology thearapy and belief that it could become an innovative, new treatment modality.<wbr> Here we will discuss the key data presented in ESMO Amsterdam in prostate cancer and PD-1 developments.<wbr> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;">We know already for a long time that there is a natural response for cancer.<wbr> In fact what we don't know is how to manipulate with it.<wbr> More than 50 years ago, grafting and transplantation have opened up a new era for advancing our understanding in immunotherapy.<wbr> It wasn't until 1980s' when IL-2 demonstrated the prolonged survival in a small propotion of patients sparkled a few hints towards the potential of harness the immunoe system.<wbr> By leveraging understanding of the immune system in the cell, the development in new immunotherapy has evolved rapidly.<wbr> Two recent immunotherapies, ipilimumab for melanoma and sipuleucel-T for prostate cancer, have been approved.<wbr> Experimental data with immuno-oncology therapies suggests the potential of durable response.<wbr> Dr Winald Gerritsen in the BMS sponsored symposium stated " The beauty of immunotherapy is that you get long lasting response!"</DIV> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_6_img4.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_7_img5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_17_immunotherapy%20%2d%20good%20and%20bad.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_1_img27.jpg"> </div><div style="margin-bottom: 10px;">There are two approahes for designing immunotherapies: </div><div style="margin-bottom: 10px;"><UL><LI>Passive immunotherapy: patients received immune cells to transiently boost antitumour response, or antibodies that modulate tumour function and mediate antibody dependent cell mediated cytotoxicity.<wbr>
</LI>
<LI>Active immunotherapy: modulate the patient's own immune system with the goal of achieving an effective and long lasting antitumour response.<wbr> Currently agents or targets being evaluated include:
<UL><LI>checkpoint inhibitors:
<UL><LI>anti-CTLA-4 : ipilimumab
</LI>
<LI>anti-PD1 : nivolumab and lambrolizumab
</LI>
<LI>anti-PDL1 :MPDL3280A
</LI>
<LI>anti-LAG3 molecules
</LI>
</UL>

</LI>
<LI>co-stimulatory pathway activators: CD137, CD40, and OX40 agonist antibodies
</LI>
<LI>NK cell killer Immunoglobin (Ig) like receptor inhibitors: anti-KIR (currently Phase 1 in combination with PD-1)
</LI>
<LI>cytokines: IL2, IL21, IFN-&alpha;
</LI>
<LI>vaccines: dendritic cell based (Sipuleucel-T, and CVAC), peptide-based (IM901, HPV16, and NY-ESO-1), or protein-based (MAGE-A3 and biovaxID)
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_8_img23.jpg"> </div><div style="margin-bottom: 10px;">Ipilimumab was first approved in metastatic melanoma and Ipilimumab has also demonstrated activity against prostate cancer in early phase 2 stud.<wbr> Therefore, a phase 3 was designed to investigate the efficacy of ipilimuab versus placebo in patients with post-docetaxel mCRPC (<SPAN style="text-align: left; text-transform: none; text-indent: 0px; display: inline !important; font: 13px Arial, Helvetica, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #3a3a3b; word-spacing: 0px; -webkit-text-stroke-width: 0px;">CA184-043).<wbr></SPAN> Unfortunately, there was no evident overall survival benefit in intenion-to-treat (ITT) population as It did not meet its primary end point.<wbr> During proferred poster session held on 28th Sept, Dr.<wbr> Olmas discussed the published abstract by <SPAN style="background-color: #ffffff;">Gerritsen <EM>et al</EM>.<wbr> and stated that despite of the disappointing result, there are a few crtiical points that we can learn from the study:</SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="background-color: #ffffff;">Subgroup analysis demonstrated that there is clearly a survival benefit for patients without visceral metastses compared to those with visceral metastases.<wbr> suggesting tumours could be heterogenic</SPAN>
</LI>
<LI><SPAN style="background-color: #ffffff;">Subgroup analysis in a subgroup of paitents with a better prognostic profile (based on alkaline phosphate, haemoglobin level, and no visceral metastases) demonstrated significant benefit in the ipi treated gourp and suggesting potential therapeutic value in patients who have low disease/<wbr>tumour burden.<wbr> </SPAN>
</LI>
<LI><SPAN style="background-color: #ffffff;">Secondary endpoints have indicated that ipilimumab's benefit is significant.<wbr> After 6 months, there was still a 1/<wbr>4 of pts in ipi arm continuing on the treatment.<wbr> </SPAN>
</LI>
<LI><SPAN style="background-color: #ffffff;">Most patients discountiuned with ipilimumab is due to disease progression and some (~20%) due to adverse events (AEs).<wbr> Those AEs reported unrelated to durg are very similar to those reported in othere studies for 2L treatment.<wbr> AEs reported related to drug are very similar to those being reported in other studies e.<wbr>g.<wbr> melanoma.<wbr></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Currently there is still an ongoing phase 3 trial to investigae the effect of ipilimumab versus placebo in chemotherapy naive CRPC population (NCT01057810).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_9_ESMO%20420.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_11_ESMO%20422.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_15_ESMO%20427.JPG"> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_12_ESMO%20423.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_13_ESMO%20424.JPG"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_14_ESMO%20425.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_10_ESMO%20421.JPG"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Among immuno-regulatory antibodies, ipilimumab was the first to be approved in melanoma.<wbr> BMS conitnues to fcous their effort on education around MOA and immune related AE management with strong emphasis on therapeutic benefit of durable responses (i,e durable tumour control).<wbr> As more data becomes mature in melanoma, it becomes evident that immune modulation has the potential to provide long term survival.<wbr> Dr.<wbr> Felip suugested that it may be more appropriate to capture survival rate at key timepoints or mean overall survivial for measuring 'the durability of response' for immunotherapy.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_18_img43.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_19_img44.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;">There is ongoing effort for developing other immuno-onco (I-O) therapies as I-O agent such as ipilimumab has demonstrated to deliver prmomising long term benefit in metastatic melanoma patients.<wbr> It has an impressive of 3-year survival rate of 22%.<wbr> There are two other check-point inhibitors of PD1/<wbr>PDL-1 are currently in clinical development.<wbr> Phase 1 investigation indicated clinical activity of PD-1 therapy (nivolumab) in various cancers including melanoma, NSCLC, and RCC (ASCO, 2013).<wbr> More importantly, there was no significant differeces in terms of objective response rate in melanoma patients regardless of prior ipilimumab treatment.<wbr> During poster session on 30th Sept, there was one abstract (P484) published the results for a phase 2 study of nivolumab in Japanese advanced melanoma patients.<wbr> Durable clinical benefit was oberserved and similar efficay and safety profile was observed to those in preceeding clinical studies with Caucasian patients - suggesting phase 3 trial is likely to be warranted in Japan.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_20_img36.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_21_img37.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_31_ESMO%20397.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_32_ESMO%20401.JPG"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_33_ESMO%20404.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_34_ESMO%20406.JPG"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_22_img38.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_24_Poster%20P484%20PD1%20Jp%20Phase%202.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_4_img32.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_5_img33.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;">There are preclinical evidences suggesting concurrent treatment of ianti-CTLA-4 and PD-1 resulted in synergistic antitumour activities.<wbr>Phase 1b (CA209-004) study was designed to explore the combination of nivolumab and ipilimumab in patients with advanced melnaoma and data were presented by Sznol <EM>et al</EM>.<wbr> (Ab#480) who concluded the concurrent combination produced clinical activities that appears to be distinct with previous monotherapy data;
<UL><LI>Responses were rapid, deep, and durable
</LI>
<LI>all responding patients achieved deep or complete responses (1mg/<wbr>kg nivolumab +3 mg/<wbr>kg ipilimumab)
</LI>
<LI>managable AEs profile with higher incidence of rAEs for concurrent therapy compared to<SPAN style="text-decoration: underline;"> previous</SPAN> monotherapy
</LI>
</UL>
<DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Currently there is an ongoing phase 3 trial looking at the effect of combination nivolumab + ipilumumab in melanoma (NCT01844505).<wbr> Based on theses results, a phase 1 trial is also being investigated the efficacy of combination treatment in NSCLC or RCC.<wbr></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_30_ESMO%20395.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_23_img39.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_29_cover%202.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_27_ipi%2bPD1%20result%202.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_26_ipi%2bPD1%20result%201.jpg"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;">From the results that we have seen presented during ESMO, PD-1 and immunotherapy targeting tumour microenviorments are the keys for the future cancer therapy, however, future understanding of potential biomarkers for this type of therapy are indespensible o improve patient selection process.<wbr> Furthermore, identification of resistance pathways and developement of synergistic combinatorial therapies are essential.<wbr></DIV> </div><div><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px Helvetica, Trebuchet, Arial; white-space: normal; margin-bottom: 3px; letter-spacing: normal; color: #222222; margin-left: 0px; word-spacing: 0px; -webkit-text-stroke-width: 0px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_35_ESMO%20410.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_36_ESMO%20411.JPG"></DIV> </div><!-- Comment details --><a name="oncology9232attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_1_img27.jpg">img27.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_2_img29.jpg">img29.jpg</a>&nbsp;&nbsp;(41,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_3_img30.jpg">img30.jpg</a>&nbsp;&nbsp;(48,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_4_img32.jpg">img32.jpg</a>&nbsp;&nbsp;(41,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_5_img33.jpg">img33.jpg</a>&nbsp;&nbsp;(45,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_6_img4.jpg">img4.jpg</a>&nbsp;&nbsp;(47,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_7_img5.jpg">img5.jpg</a>&nbsp;&nbsp;(36,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_8_img23.jpg">img23.jpg</a>&nbsp;&nbsp;(46,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_9_ESMO%20420.JPG">ESMO 420.JPG</a>&nbsp;&nbsp;(2,5 MB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_10_ESMO%20421.JPG">ESMO 421.JPG</a>&nbsp;&nbsp;(3 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_11_ESMO%20422.JPG">ESMO 422.JPG</a>&nbsp;&nbsp;(3 MB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_12_ESMO%20423.JPG">ESMO 423.JPG</a>&nbsp;&nbsp;(2,9 MB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_13_ESMO%20424.JPG">ESMO 424.JPG</a>&nbsp;&nbsp;(3 MB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_14_ESMO%20425.JPG">ESMO 425.JPG</a>&nbsp;&nbsp;(2,9 MB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_15_ESMO%20427.JPG">ESMO 427.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_16_ESMO%20428.JPG">ESMO 428.JPG</a>&nbsp;&nbsp;(3 MB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_17_immunotherapy%20%2d%20good%20and%20bad.jpg">immunotherapy - good and bad.jpg</a>&nbsp;&nbsp;(23,4 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_18_img43.jpg">img43.jpg</a>&nbsp;&nbsp;(47,6 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_19_img44.jpg">img44.jpg</a>&nbsp;&nbsp;(49,8 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_20_img36.jpg">img36.jpg</a>&nbsp;&nbsp;(44,6 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_21_img37.jpg">img37.jpg</a>&nbsp;&nbsp;(39,6 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_22_img38.jpg">img38.jpg</a>&nbsp;&nbsp;(45,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_23_img39.jpg">img39.jpg</a>&nbsp;&nbsp;(45,9 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_24_Poster%20P484%20PD1%20Jp%20Phase%202.jpg">Poster P484 PD1 Jp Phase 2.jpg</a>&nbsp;&nbsp;(2,2 MB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_25_ipi%20PD1%20como%20MOA%201.jpg">ipi PD1 como MOA 1.jpg</a>&nbsp;&nbsp;(1,7 MB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_26_ipi%2bPD1%20result%201.jpg">ipi+PD1 result 1.jpg</a>&nbsp;&nbsp;(2,3 MB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_27_ipi%2bPD1%20result%202.jpg">ipi+PD1 result 2.jpg</a>&nbsp;&nbsp;(2 MB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_28_Poster%20P484%20PD1%20Jp%20Phase%202.jpg">Poster P484 PD1 Jp Phase 2.jpg</a>&nbsp;&nbsp;(2,2 MB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_29_cover%202.jpg">cover 2.jpg</a>&nbsp;&nbsp;(2,3 MB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_30_ESMO%20395.JPG">ESMO 395.JPG</a>&nbsp;&nbsp;(3,2 MB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_31_ESMO%20397.JPG">ESMO 397.JPG</a>&nbsp;&nbsp;(3,7 MB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_32_ESMO%20401.JPG">ESMO 401.JPG</a>&nbsp;&nbsp;(3,2 MB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_33_ESMO%20404.JPG">ESMO 404.JPG</a>&nbsp;&nbsp;(3,3 MB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_34_ESMO%20406.JPG">ESMO 406.JPG</a>&nbsp;&nbsp;(3,2 MB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_35_ESMO%20410.JPG">ESMO 410.JPG</a>&nbsp;&nbsp;(3,2 MB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9232_36_ESMO%20411.JPG">ESMO 411.JPG</a>&nbsp;&nbsp;(3,3 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9232">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-17T22:45:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-17T22:45:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Roche's Jan-Sept 2013 Sales</title>
	<pubDate>2013-10-17T11:37:24+02:00</pubDate>
	<wp:post_id>4774</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pharma sales increased by 7% at 27.<wbr>2 billion Swiss francs due to HER2 breast-cancer franchise, Avastin and Actemra/<wbr>RoActemra.<wbr> The main regional growth drivers are the US (+12%), key emerging markets (+10%), and in particular China where Roche seems to have escaped the problems faced by other drugmakers.<wbr> The R&amp;D update did not provide new information given the recent investor event.<wbr> Of note, the oral octreotide submission is indicated as being in 2014 (no change from previous quarter).<wbr> The company has reconfirmed its FY outlook.<wbr> Severin Schwan slapped down recent speculation that the company could merge with Novartis, and said the Hoffmann-Oeri families, which hold a majority stake in Roche, were committed to the firm's independence.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Strong demand for Roche's <CLASSIFIER class="RIC" value="ROG.VX">speciality cancer medicines, many of which are bought privately in emerging markets, has helped it defy an expected slowdown in sales in China following a crackdown on sales practices there.<wbr></CLASSIFIER> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Split by Country</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><U>Split by Quarter</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG>- Etrolizumab for UC and CD</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><EM></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>- Anti-STEAP1 ADC RG7450</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>- PI3K signaling RG7422</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>- AKT Inhibitor Ipatasertib RG7440</STRONG> (collaborator: Array BioPharma) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_8_ScreenCapture8.jpg"> </div><div> </div><!-- Comment details --><a name="oncology9230attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(26,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(50,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(34,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(19,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(26,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(45 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(29,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(22,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(73,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9230_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(26,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9230">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-17T11:37:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-17T11:37:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Partners a New Paradigm for Bladder Diseases</title>
	<pubDate>2013-10-17T11:33:03+02:00</pubDate>
	<wp:post_id>4775</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Within the framework of revamping its oncology pipeline, AZ has signed the third cancer deal of the week.<wbr> TARIS Biomedical's  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to evaluate its proprietary delivery platform in an oncology setting, to validate the potential of the technology, and leverage its know-how in bladder delivery and bladder cancer.<wbr><STRONG> </STRONG>TARIS Pipeline </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Financial: not disclosed </div><div style="margin-bottom: 10px;">- Terms: The companies will work together to assess multiple novel cancer therapeutics by using TARIS proprietary bladder cancer platform in combination with targeted drugs from AZ.<wbr> AZ has an exclusive option to take a license to the products resulting from the collaboration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.tarisbiomedical.com/our_tech.php">http:/<wbr>/<wbr>www.<wbr>tarisbiomedical.<wbr>com/<wbr>our_tech.<wbr>php</A> </div><div style="margin-bottom: 10px;">- Soft, flexible system developed into and retrieved from the bladder usinf standard urological office procedures.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">- Designed to provide continuous local delivery to the bladder for days to weeks.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_4_ScreenCapture4.jpg"> </div><div><EM>Source:  website</EM> </div><!-- Comment details --><a name="oncology9229attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(44,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(26,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9229_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(44,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9229">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-17T11:33:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-17T11:33:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Xenoport Investor Calls For The Resignation of CEO & New Strategy Focused On MS Drug</title>
	<pubDate>2013-10-16T16:13:53+02:00</pubDate>
	<wp:post_id>4776</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A shareholder in Xenoport has called for the resignation of its CEO and called for a shift in focus to the company's PhI RRMS drug XP23829 a pro-drug of monomethyl fumarate, a drug known as BG12 (TECFIDERA) launched by Biogen-Idecs for the treatment of RRMS.<wbr> Interestingly, Xenoport recently highlighted some phI data with two different formulations of  XP23829 (see below) which points to possible differentiation with one of the formulations in terms of dosing tolerability and patent claims or a potential me-too 505(b) (2) route to registration for the other.<wbr> </div><div style="margin-bottom: 10px;">The investor is claiming that Xenoport's Horizant gabapentin enacarbil, which is approved in the US to treat restless legs and to manage post herpetic neuralgia "will never be the commercial success we all wish it were" It suggest that the company <STRONG>should use its remaining cash to push forward with the development of XP23829 which could potentially address a massive commercial opportunity</STRONG> and would help the company to garner a significant partnering deal or the sale of the company.<wbr> </div><div style="margin-bottom: 10px;">Xenoport currrently has $93.<wbr>4m in cash a recorded a six-month operating loss of $47.<wbr>8m.<wbr> In addition to poor sales of Horizant it has faced recent disappointment with its racemic baclofen which was in PhIII development for the treatment of spasticity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>XP23829 Trial Status</STRONG> </div><div style="margin-bottom: 10px;">Ronald Barrett CEO in early September presented some limited phI data on XP23829.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>First phI study</STRONG> </div><div style="margin-bottom: 10px;">A repeat dose Phase 1 study of 829 tested Formulation 1 and Formulation 2 of 829 and had a TECFIDERA arm to allow for pharmacokinetic comparisons.<wbr> Formulation 1 was designed to mimic the PK profile of TECFIDERA when dosed BID.<wbr> And Formulation 2 was designed as a potential once a day dosage form.<wbr> </div><div style="margin-bottom: 10px;">Barrett stated "We believe that we can now put to rest any questions about the ability of 829 to effectively deliver MMF into the systemic circulation.<wbr> At approximately equimolar doses of 829 Formulation 1 and TECFIDERA, we observed essentially identical PK profiles of MMF in plasma.<wbr> In both cases, there was a lag before MMF appeared in the plasma and then there was a sharp peak of MMF.<wbr> Remarkably, the mean Cmax and the mean AUC of MMF for Formulation 1 and TECFIDERA were within 2% of each other.<wbr> </div><div style="margin-bottom: 10px;">"What are the potential implications of these results? We believe these data provide evidence that Formulation 1 could be bioequivalent to TECFIDERA when it comes to MMF in plasma.<wbr> This may be an important element if we decide to pursue and get agreement from the FDA on a potential 505(b)(2) route for the approval in relapsing-remitting MS.<wbr>" "Assuming we would need to do a formal bioequivalent study, we believe that the probability for success will be high based on these results.<wbr> Therefore, we believe that Formulation 1 could be a candidate for streamline development as a twice a day product for MS.<wbr> Also, given the successful studies of TECFIDERA in psoriasis, we believe that the PK similarity of Formulation 1 makes the likelihood of success in psoriasis high.<wbr>" </div><div style="margin-bottom: 10px;">"So, what about Formulation 2? We're equally excited by these results since we think this formulation holds promise for a differentiated product profile.<wbr> At an 800 mg dose of 829, dosed once a day, which is approximately equimolar to the approved TECFIDERA daily dose, we get a mean daily AUC within about 25% of the twice a day TECFIDERA while maintaining a lower Cmax despite giving the full daily dose at a single time.<wbr>" "I want you to keep in mind that these are mean values that were determined in separate cohorts of patients.<wbr> There is significant overlap in the AUCs in individual subjects between these two groups.<wbr> So, it is not clear that these AUCs are really different and particularly whether they are different enough to be clinically meaningful.<wbr>" </div><div style="margin-bottom: 10px;">"The more sustained exposure to MMF observed for Formulation 2 was distinct from Formulation 1 and TECFIDERA, both of which had a shorter duration of MMF exposure.<wbr> As a result, we believe that Formulation 2 could potentially support once a day dosing in MS and/<wbr>or psoriasis.<wbr>" "So, in summary, we're quite pleased with the MMF PK profiles produced by Formulation 1 and Formulation 2 after repeated dosing.<wbr> These results will allow us to select doses for future studies" </div><div style="margin-bottom: 10px;"><STRONG>Second phI study &amp; Toxicity Data</STRONG> Commenting on the 2nd phI study Barrett continued "Our second Phase 1 study examined metabolism and disposition of two versions of radiolabel 829, one version with the radiolabel in the fumarate portion of the molecule and a second version with the radiolabel in the promoiety portion of the molecule.<wbr> As expected, the metabolism and disposition for the fumarate-labeled version of 829 was similar to what has been publicly reported for dosing of DMF labeled in the same location as the fumarate.<wbr>" </div><div style="margin-bottom: 10px;">"For the promoiety-labeled version of 829, virtually all the recovered radioactivity was found in urine as expected from our animal studies.<wbr>" </div><div style="margin-bottom: 10px;">"Finally, we have now completed 13-week tox studies of 829 in mouse, rat and primate.<wbr> Each study included a DMF group.<wbr> The adverse effects in the 13-week toxicology studies with 829 were similar to the effects in the DMF control group except for fewer and less severe adverse effects in the stomach after dosing of 829.<wbr> These results support a conclusion that the observed adverse effects of 829 were attributable to exposure to MMF, the common active metabolite of DMF and 829.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Competition &amp; Patents</STRONG> </div><div style="margin-bottom: 10px;">Continuing Barrett stated, "let me remind you that with the success of TECFIDERA, there is &ndash; already is and will likely be more formidable competition to develop a best-in-class second-generation fumarate product.<wbr> We believe our new studies have generated important new intellectual property.<wbr> And we're in the process of assessing what aspects of the new information might be patentable.<wbr>" </div><div style="margin-bottom: 10px;">"As mentioned in this press release, we have been working on our novel fumarate program for more than five years.<wbr> We filed 15 patent applications to protect 829 and broader aspects of MMF prodrugs.<wbr> We believe we're in a leadership position.<wbr> We don't believe it's good business practice to provide a lot of details that might be useful to competitors.<wbr>" </div><div style="margin-bottom: 10px;">"So, in summary, we believe we completed a very successful series of studies.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Interesting points to arise from the Q/<wbr>A regarding regulatory pathway and patents</STRONG> Xenoport hopes to have meetings with both the Neurology Products Division and with the Derm Division in the fourth quarter to discuss the pathway forward.<wbr> </div><div style="margin-bottom: 10px;">Barrett noted that one important question is to the relationship between PK and adverse events with the first in human study demonstating a difference between the two formulations with regard to flushing.<wbr> Xenoport has apparently decided to put this out in the public domain exactly what the results are as it is in the process of analyzing whether there's any intellectual property here that could be subject to patent filings.<wbr> </div><div style="margin-bottom: 10px;">Questioned as to whether management are hopeful that either Formulation 1 or 2 could be superior to TECFIDERA in terms of flushing and GI? Barrett responded "Absolutely" Questioned about an overalll pathway forward he stated "Understand that there really are two potential high level things that we're considering.<wbr> There's the go-it-alone strategy, what would we do next if we're not with a partner and then what would we do if we're with a partner.<wbr> And what we've been trying to do, and maybe I haven't been articulating this as well as we should, is to create optionality for the possible progression forward.<wbr>" </div><div style="margin-bottom: 10px;">"So, we have been, as you know, pursuing both the Formulation 1 and Formulation 2.<wbr> Formulation 1 presents the opportunity to do the 505(b)(2) pathway potentially and would be a much more streamlined development path.<wbr> Formulation 2 has the potential for, in our view at this point, differentiation on both dosing frequency as well as potentially on side effects.<wbr> So, that's a different development path.<wbr> So, we want to continue our dialogue with potential partners, get feedback from the FDA and make the decision.<wbr> And, as I said earlier, by the end of the year, I think we'll be able to articulate a &ndash; what we're doing next on our own strategy if we're not partnered by them.<wbr>" One last question focused on whether if he 505(b)(2) sort of me-too to TECFIDERA route was chosen, would Xenoport run into Biogen's dosing patent? Barrett replied, "So, we do not dose 480 mgs of DMF.<wbr> So, on a strict literal infringement, the answer is no.<wbr> You are correct in suggesting that we would have to do a patent certification under 505(b)(2).<wbr> And we don't believe that we would infringe.<wbr> Obviously, that would be subject to potential litigation with the Orange Book listed &ndash; against the Orange Book listed patents.<wbr> We don't believe that we would infringe those patents.<wbr>" </div><div>Source: <A href="http://www.xenoport.com">www.<wbr>xenoport.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7214">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-16T16:13:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-16T16:13:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Funding for Zytiga and Xgeva Moved from Government to Hospital Budget in Norway</title>
	<pubDate>2013-10-16T13:58:10+02:00</pubDate>
	<wp:post_id>4777</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Reimbursement for J&amp;J' Zytiga (abiraterone acetate), and Amgen's bone cancer drug Xgeva (denosumab) will be provided through hospital funding in 2014, under Norway's 2014 budget proposal.<wbr> </div><div style="margin-bottom: 10px;">According to the Norwegian medical newspaper <I>Dagens Medisin</I>, the proposal also foresees that funding responsibility for new cancer drugs that are alternatives to those already reimbursed from hospital budgets are moved from the government to the hospitals' funding responsibility.<wbr> The Health Directorate proposed that competent authorities should be enabled to make a decision about which drugs the provision applies to.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">Earlier this year, the Norwegian Health Directorate decided to exclude Zytiga from the guidelines for cancer treatment.<wbr> The decision was that Zytiga was not recommended as standard treatment in Norwegian hospitals, further to an evaluation of the cost effectiveness.<wbr> </div><div style="margin-bottom: 10px;">According to a study by the University of Oslo, it appears that patients' access to these drugs was not jeopardised by the transfer of the funding to hospital budgets.<wbr> This represents positive news for the patients, as well as manufacturers.<wbr> Financing of treatment through the hospital funding may ensure that companies secure sales for the products in the Norwegian market.<wbr> </div><div><EM>Source: GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9228">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-16T13:58:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-16T13:58:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Q3 Results - Key Takeaways Regarding Zytiga</title>
	<pubDate>2013-10-15T16:53:30+02:00</pubDate>
	<wp:post_id>4778</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Zytiga (abiraterone) sales in the 3rd quarter grew by 75% up 50% in 
the US and 97% internationally as the benefit of the wider approval for 
chemonaive CRPC patients started to impact.<wbr> Sales for the nine months W/<wbr>W 
reached $1.<wbr>2bn +73%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pharmaceutical Division Growth</STRONG> </div><div style="margin-bottom: 10px;">Worldwide pharmaceutical net sales for the third quarter were $7 
billion representing an increase of 9.<wbr>9% versus the same period last year.<wbr> 
On an operational basis, sales increased 10.<wbr>9% with a negative currency impact 
of 1 point.<wbr> Sales in the <BR>U.<wbr>S.<wbr> increased 7.<wbr>9% while sales outside the U.<wbr>S.<wbr> 
increased on an <BR>operational basis by 14% </div><div style="margin-bottom: 10px;"><STRONG>Zytiga </STRONG> </div><div style="margin-bottom: 10px;">U.<wbr>S.<wbr> sales growth of 50% was underpinned byvery strong market growth of 
nearly 25% and increased market share in the combined metastatic castrate 
resistant prostate market.<wbr> Zytiga has captured 33% of that market and is up 
approximately 2.<wbr>5 points sequentially y-o-y.<wbr> </div><div style="margin-bottom: 10px;">Zytiga sales outside the US nearly doubled on an operational basis versus 
third quarter of 2012 and on a sequential basis sales were up over 15%.<wbr> 
Additional country rollouts and the expansion of the label to chemo nave 
patients drove the strong results.<wbr> Zytiga is now approved in more than 80 
countries.<wbr> </div><div style="margin-bottom: 10px;">Within the US market, it was noted that the split of sales is roughly 55% 
chemonaive market and 45%  in the refractory setting in the quarter.<wbr> 
Looking at market growth, refractory grew about 26.<wbr>5% and nave about 23.<wbr>5%.<wbr> 
Refractory market registered a slight dip from 55% to 55.<wbr>4% 
because of new competition, but in the naive segment was 24.<wbr>6% up from 
21%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other developments of note in the oncology </STRONG> </div><div style="margin-bottom: 10px;">Reference was made to the successful completion of the acquisition 
of Aragon pharmaceuticals, initially announced in June.<wbr> J&amp;J sees this 
acquisition as increasing its leadership position in the field of 
prostate cancer, strengthening its pipeline with a "potentially best in 
class" compound.<wbr> It was noted that it has advanced into Phase III 
development and if approved in the MO treatement setting this would 
complement Zytiga and broaden the range of patients that <BR>could potentially 
be treated.<wbr> </div><div>source: <A href="http://www.jnj.com">www.<wbr>jnj.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9226">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-15T16:53:30+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-15T16:53:30+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Long-term Gattex Data Supports Label Revision & EU Commercial Launch Is In Sight</title>
	<pubDate>2013-10-15T10:50:59+02:00</pubDate>
	<wp:post_id>4779</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Based on long-term data from the STEPS-2 
study released yesterday, at the American College of Gastroenterology, NPS 
intends to submit a sNDA to the FDA to revise Gattex's 
(teduglutide) product label.<wbr>  Meanwhile, the company noted  that 
it is preparing to engage in pricing &amp; reimbursement processes in key 
European countries with the goal of commercially launching Revestive 
(teduglutide) in Europe 1H14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>STEPS 2 Study Findings</STRONG> </div><div style="margin-bottom: 10px;">Was a two-year open-label extension study of 88 adult patients with 
short-bowel syndrome.<wbr> Investigators noted that long-termuse resulted in 
additional, clinically meaningful reductions in the volume and days per week of 
parenteral support requirements.<wbr> Moreover, 10 of 13 patients who achieved 
complete independence from parenteral support were those who received 30 months 
of Gattex in the 6-month pivotal STEPS study and 24 months in STEP2.<wbr> No new 
safety concerns have been observed with long-term treatment.<wbr> </div><div style="margin-bottom: 10px;">The poster, entitiled " Long-term safety and efficacy of teduglutide for the 
treatment of intestinal failure associated with short bowel syndrome: Final 
results of the STEPS2 study, 1 2 -year multicentre, open-label clinical trial" 
was recogenised as an ACG Presidential Poster Award recipient.<wbr> </div><div>Source: <A href="http://www.nps.com">www.<wbr>nps.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1922">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-15T10:50:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-15T10:50:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca to Bolster its Portfolio with a New Type of Cancer Therapy</title>
	<pubDate>2013-10-15T08:57:39+02:00</pubDate>
	<wp:post_id>4780</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medimmune unit would buy biotech company Spirogen for up to $440M.<wbr> Spirogen is a clinical stage biotechnology company specialising in novel, sequence-selective, DNA minor groove-binding molecules with potent therapeutic properties.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Found in 2000</LI>
<LI>Private</LI>
<LI>18FTEs</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Technology</U>: Spirogen’s Antibody-Drug Conjugate (ADC) technology delivers extremely potent anticancer agents to cancer cells by attaching them to antibodies.<wbr> Spirogen has developed highly potent warheads based on its proprietory Pyrrolobenzodiazepines (PBDs).<wbr> These PBD warheads are joined to antibodies by linkers which are stable in the blood stream but release the PBD warhead once it is safely inside the targeted cancer cells.<wbr> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;">Spirogen’s lead oncology drug candidate, SG2000, has completed solid tumour Phase I studies in the USA (through the NCI) and Europe (through Cancer Research UK).<wbr> A Phase II study in cisplatin refractory ovarian cancer is underway in the USA, and a haematological Phase II study is planned in Europe for early 2012.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9224_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Partnerships</U> </div><div style="margin-bottom: 10px;"><P class="staff">Q1 2012<STRONG> -</STRONG> Spirogen enters into licensing agreement with ADC Therapeutics sarl for the provision of PBD warhead and linker technology and associated services for antibody drug conjugate (ADC) development.<wbr> </P> </div><div><EM>Source: Spirogen; ThomsonOne</EM> </div><!-- Comment details --><a name="oncology9224attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9224_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9224">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-15T08:57:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-15T08:57:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>France May Be Sanofi's "Biggest Handicap"</title>
	<pubDate>2013-10-14T19:17:37+02:00</pubDate>
	<wp:post_id>4781</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A recent article published by Reuters reports that Sanofi plans 186 net job cuts in French R&amp;D, and wants to regroup scattered R&amp;D sites into hubs.<wbr> France is "a difficult place to cut costs because of complex labour laws, union opposition and a government eager to protect jobs".<wbr> The country represents about a third of the company's R&amp;D resources WW.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sanofi's global workforce is 28,000 people - including around 5,000 in R&amp;D </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In addition to the job cuts in R&amp;D, Sanofi plans 453 transfers to other sites.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the internal memo seen by Reuters, Sanofi said that while it spent more than its peers on research, it took the company on average 20% longer to develop a new drug.<wbr> </div><div style="margin-bottom: 10px;">Between 2008 and 2011, Sanofi spent around 105 million euros for each new molecule entering clinical trials, compared to an industry average of about 35 million euros, the memo said.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10649">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-14T19:17:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-14T19:17:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 4 - Ultimate Treatment Sequence for mCRPC</title>
	<pubDate>2013-10-14T14:15:37+02:00</pubDate>
	<wp:post_id>4782</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Given that the therapeutic options have widened for mCRPC patients including taxanes, new hormonal therapies, bone targeted treatments, and vaccine, the next critical question is to determine the optimal sequence.<wbr> Transition from one treatment to the next is usually based on a combination of clinical, biochemical, and radiologic measures as well as authority guidance.<wbr> Dr.<wbr> Loriot disucssed 2 published posters and reviewed currently available evidences and issues for optimal CRPC managment.<wbr> </div><div style="margin-bottom: 10px;">Below is what Dr.<wbr> Loriot presented to illustrate graphically where we are today with the management of CRPC.<wbr> It is obvious that we have much more options today with the recent approval of abiraterone, enzalutamide, cabazitaxel, radium-223, and sipuleucel-T, as a result, there is more focus on 'when is the right time' and 'what is the right agent of choice'.<wbr> Mezynski <EM>et al</EM>.<wbr> (2012) evaluated activity of docetaxel in 54 mCRPC patients who have been treated previously with abiraterone, and the activity of docetaxel following prior abiraterone appears lower than anticipated and no responses to docetaxel were evident in these patients.<wbr> Interestingly, Albiges presented cabazitaxel's waterfall plot in 2012 ESMO and demonstrated cabazitaxel's activity in post-abiraterone setting.<wbr> These findings implicate potential therapeutic benefit to treat patients with cabaxitaxel for patients who have developed resistance to abiraterone therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_1_ESMO%20551.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_2_ESMO%20553.JPG"> </div><div style="margin-bottom: 10px;">During poster session on 30th Sept, there were one abstract explored preclinical evidence for cross-resistance between taxanes and abiraterone in mCRPC (Soest <EM>et al</EM>.<wbr>, Ab#P436) and two abstracts evaluated oucomes with cabazitaxel and abiraterone sequential treatment following docetaxel in mCRPC (Wissing <EM>et al</EM>.<wbr>, and Sonpavde <EM>et al</EM>.<wbr> ab#P412).<wbr> </div><div style="margin-bottom: 10px;">Soest <EM>et al</EM>.<wbr> : Preclinical evidence for cross-resistance between taxanes and abiraterone in mCRPC </div><div style="margin-bottom: 10px;">&bull;Given treatment options for mCRPC patients have expanded following availability of new systemic therapies including abiraterone, enzalutamide, and cabazitaxel, the optimal treatment sequence is the hottest topic.<wbr> Recent clinical studies suggested: 1) impaired efficacy of docetaxel when given after progression on abiraterone in patients with mCRPC; 2) modest efficacy of abiraterone in patients previously treated with enzalutamide and docetaxel; 3) modest efficacy of enzalutamide in patients previously treated with abiraterone and docetaxel </div><div style="margin-bottom: 10px;">&bull;Preclinical data suggested docetaxel, cabazitaxel and abiraterone all implicate their role in inhibition of AR nuclear transport, thus suggesting a potential mechanism for cross-resistance in mCRPC </div><div style="margin-bottom: 10px;">&bull;This abstract is to identify cross resistance between docetaxel and cabazitaxel, and hormonal agents abiraterone and enzalutamide, the effects of docetaxel and cabazitaxel on cell viability in PC346Abi101 (abiraterone resistant cell line) and PC346Enza (enzalutamide resistant cell line).<wbr> </div><div style="margin-bottom: 10px;">&bull;Docetaxel and cabazitaxel efficacy was significant impaired in both abiraterone and enzalutamide resistant cell line).<wbr> However, this effect was not observed in mitoxantrone (not targeting microtubules, control) efficacy.<wbr> </div><div style="margin-bottom: 10px;">&bull;Interestingly, the extent of efficacy impairment differ for docetaxel and cabazitaxel.<wbr> The efficacy of docetaxel is impaired more in enzalutamide resistant cell line while cabazitaxel&rsquo;s efficacy is impaired at a smaller extent.<wbr> - This may suggest the importance to use different chemotherapeutic agents following progression of either abiraterone or enzalutamide </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_23_Soest%20Preclinical%20cross%20resistance.jpg"> </div><div style="margin-bottom: 10px;">Wissing <EM>et al</EM> : A retrospective study on cabazitaxel and abiraterone acetate sequential treatment (CAST) in docetaxel treated metastatic castrate-resistant prostate cancer patients </div><div style="margin-bottom: 10px;"><UL><LI>The aim is to determine the optimal second line therapy strategy for mCRPC patients, for whom both cabzitaxel and abiraterone are appropriate treatment following docetaxel therapy.<wbr>
</LI>
<LI>There is no signiciant difference in OS, however, improvement of biochemical PFS was observed for patients treatment with cabazitaxel &rarr; abireaterone
</LI>
<LI>Clinical benefit does not depend on duration of prior docetaxel treatment
</LI>
</UL> </div><div style="margin-bottom: 10px;">Similar results were presented by Sonpavde <EM>et al.<wbr> </EM>who concluded that cabaxitaxel &rarr; abiraterone following docetaxel may be a more optimal sequence.<wbr> However, these two studies have limitations include small sample size, and data were analysed retrospectively.<wbr> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_22_Ab%255fWissing%20et%20al%20OS%20and%20PFS%20result%202%20comparing%20with%20cab.png"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_21_Ab%255fWissing%20et%20al%20OS%20and%20PFS%20result%202%20comparing%20docetaxel%20subanalysis.png"> </div><div style="margin-bottom: 10px;">In addition to above results, Johann de Bono<EM> et al</EM>.<wbr>also published a subanalysis from phase 3 AFFIRM trial to assess benefit from enzalutamide and the impact of duration of prior treatments.<wbr> Three patient groups were analysed to evaluate the impact on clinical outcome (i.<wbr>e.<wbr> OS, rPFS and PSA response based on duration of exposure to prior therapy.<wbr> These reuslts were highlighted and discussed by Dr.<wbr> Loriot during poster discussion session and he stated that there were significant improvements in OS, rPFS, and PSA response were observed regardless of duration of prior docetaxel or hormonal therapy.<wbr> Simlar results were reported from COU-AA-301 trial - there was survivval benefit of abiraterone regardless of duration of docetaxel treatment.<wbr> However, it is important to also bear in mind that the longer the duration of prior therapy does not equate to longer time for the disease start progressing.<wbr> The patients can certainly be maintained on previous endocrine therapy while on docetaxel for asymptomatic, slow growing diesease or for patient preference.<wbr> It would certainly be interesting to analyse the number of patients who have stopped docetaxel due to toxicitiy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_4_ESMO%20556.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_5_ESMO%20558.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_6_ESMO%20559.JPG"> </div><div style="margin-bottom: 10px;">"Should Abiraterone and enzalutamide be given before chemotherapy (given that PREVAIL result is pending)?" </div><div style="margin-bottom: 10px;">Dr.<wbr> Loriot commented there are certainly benefits shown in COU-AA-301/<wbr>302 and AFFIRM trial with less toxicity for both agents.<wbr> However, the proportion of pateints receiving docetaxel from COU-AA-302 is slightly lower in AA arm than in the control arm (57% vs 63%).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_7_ESMO%20563.JPG"> </div><div style="margin-bottom: 10px;">The second abstract that Dr.<wbr> Loriot discussed was the data published by Small <EM>et al</EM>.<wbr> (Abstract #2860) from phase 2 randomised study of sipuleucel-T with either concurrent or sequential abiraterone plus prednisone.<wbr> Sicne prednisone may impar production of the immunological respsone to sipuleucel-T, this is to evaluate if sipuleucel-T can be administered with concurrent abiraterone+prednisone without deleterious effects on product potency, safety and immunological benefit.<wbr> The analyses demonstrated there was no evidence suggesting impaired immunological effects of sipuleucel-T in the concurrent treatment arm.<wbr> These data suggested combination treatment with sipuleucel-T and abiraterone is well tolerated and no major safety concern.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_14_ESMO%20572.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_16_ESMO%20574.JPG"> </div><div style="margin-bottom: 10px;">There is certainly strong rationale with no major safety concern to warrent future pivotol combination trials to access clinical outcome benefit.<wbr> We certainly need to think carefully to select appropriate endpoints that are able to define or measure agent specific clinical benefit.<wbr> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_18_ESMO%20576.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_12_ESMO%20570.JPG"> </div><div style="margin-bottom: 10px;">Despite of few studies investigating cross resistance between taxanes and hormonal treatments (abiraterone and enzalutamide), no strong clinical data up to date could provide guidance for the order in which cemo and AR-dreicted agents are given.<wbr> Large scale studies are warrented to invesitigate seuqnecing and biomarkers to identify sensitivity and resistance.<wbr> Appropriate trial design with strong clinical rationale is needed to ensure patients' benefit.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_8_ESMO%20566.JPG"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_9_ESMO%20567.JPG"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_10_ESMO%20568.JPG"> </div><div><DIV>
<DIV class="ii" id="oncology9201.052ii">This report was compiled by Jenny Wu (Scientific Intelligence) in collaboration with Jacquie Cantle (Competitive Intelligence).<wbr></DIV>
</DIV> </div><!-- Comment details --><a name="oncology9222attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_1_ESMO%20551.JPG">ESMO 551.JPG</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_2_ESMO%20553.JPG">ESMO 553.JPG</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_3_ESMO%20554.JPG">ESMO 554.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_4_ESMO%20556.JPG">ESMO 556.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_5_ESMO%20558.JPG">ESMO 558.JPG</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_6_ESMO%20559.JPG">ESMO 559.JPG</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_7_ESMO%20563.JPG">ESMO 563.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_8_ESMO%20566.JPG">ESMO 566.JPG</a>&nbsp;&nbsp;(2,6 MB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_9_ESMO%20567.JPG">ESMO 567.JPG</a>&nbsp;&nbsp;(2,6 MB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_10_ESMO%20568.JPG">ESMO 568.JPG</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_11_ESMO%20569.JPG">ESMO 569.JPG</a>&nbsp;&nbsp;(2,5 MB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_12_ESMO%20570.JPG">ESMO 570.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_13_ESMO%20571.JPG">ESMO 571.JPG</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_14_ESMO%20572.JPG">ESMO 572.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_15_ESMO%20573.JPG">ESMO 573.JPG</a>&nbsp;&nbsp;(2,9 MB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_16_ESMO%20574.JPG">ESMO 574.JPG</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_17_ESMO%20575.JPG">ESMO 575.JPG</a>&nbsp;&nbsp;(2,9 MB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_18_ESMO%20576.JPG">ESMO 576.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_19_ESMO%20577.JPG">ESMO 577.JPG</a>&nbsp;&nbsp;(2,8 MB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_20_Ab%255fWissing%20et%20al%20OS%20and%20PFS%20result%201.png">Ab_Wissing et al OS and PFS result 1.png</a>&nbsp;&nbsp;(61,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_21_Ab%255fWissing%20et%20al%20OS%20and%20PFS%20result%202%20comparing%20docetaxel%20subanalysis.png">Ab_Wissing et al OS and PFS result 2 comparing docetaxel subanalysis.png</a>&nbsp;&nbsp;(142,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_22_Ab%255fWissing%20et%20al%20OS%20and%20PFS%20result%202%20comparing%20with%20cab.png">Ab_Wissing et al OS and PFS result 2 comparing with cab.png</a>&nbsp;&nbsp;(191,3 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9222_23_Soest%20Preclinical%20cross%20resistance.jpg">Soest Preclinical cross resistance.jpg</a>&nbsp;&nbsp;(26,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9222">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-14T14:15:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-14T14:15:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche to Increase Biologic Manufacturing Capacity Over the Next Five Years</title>
	<pubDate>2013-10-14T09:43:32+02:00</pubDate>
	<wp:post_id>4783</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 800 million Swiss francs ($877M) investment will support increasing demand for licensed biologic medicines, such as RoACTEMRA (tocilizumab), Kadcyla (trastuzumab emtansine) and Perjeta (pertuzumab), alongside providing a strong foundation for the delivery of 39 investigational biologic medicines in the Roche pipeline.<wbr> Details of the expansion are provided below.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Biologic manufacturing capacity will be increased at sites in Vacaville and Oceanside in California, U.<wbr>S with a planned investment of approximately 260 million Swiss francs creating around 250 new jobs.<wbr> </div><div style="margin-bottom: 10px;">In Penzberg, Germany, Roche will invest approximately 350 million Swiss francs toward increased manufacturing capacity and equipment refurbishment, creating around 200 positions.<wbr> </div><div style="margin-bottom: 10px;">In addition, construction of an antibody-drug conjugate (ADC) production facility will begin in Basel, Switzerland through an investment of over 190 million Swiss francs, which is expected to create 50 jobs.<wbr> This investment will provide additional capacity and flexibility to support Roche’s first approved ADC, Kadcyla, and a further eight ADCs in clinical development.<wbr> </div><div><EM>Source: Roche</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10646">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-14T09:43:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-14T09:43:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 3 - Novatis's NET Focus & ESMO Guideline Session</title>
	<pubDate>2013-10-11T17:05:08+02:00</pubDate>
	<wp:post_id>4784</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Novartis&rsquo;s NET presence at ESMO centred on its symposia and an oral presentation of updated RADIANT-2 data.<wbr> Its symposia focused on combination NET therapy, new molecular targets but also highlighted some relatively recent pasireotide NET data.<wbr> Soft intelligence leads us to understand that discussions with some KOLs have taken place regarding a new phIII NET study and that the RADIANT-4 interim data is most likely to be presented at ASCO 2014.<wbr> The ESMO Guideline Session certainly highlighted the interest in SSAs generated by the CLARINET data.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><STRONG>Symposia Highlights &ndash; "The GI Tumour Challenge"</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">The symposia provided an overview of the latest scientific data for advanced NET, GIST and HCC, highlighting the need in each area to develop and more personalised approach to patient treatment.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Christos Toumpanakis (Royal Free London) presented the NET section of the symposia.<wbr> He highlighted the range of different antiproliferative treatments available and the expanding knowledge of NET tumour biology resulting in a number of new agents being trialed.<wbr> He emphasised the need for further rational combination therapy to be evaluated to try to improve treatment outcomes.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_1_ScreenCapture1.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_2_ScreenCapture2.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_3_ScreenCapture3.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_4_ScreenCapture4.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Turning his attention to biomarkers, he focused on the established predictive nature of Chromagainin and NSE and the range of novel biomarkers that can potentially be explored.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_5_ScreenCapture6.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_6_ScreenCapture7.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Focus then turned to the antiproliferative effect of SSAs in GEP-NET, the long-term OS results of the PROMID study and then the new NET data on the phIII pasireotide study first presented in poster only form at ASCO 2013.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_7_ScreenCapture8.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_8_ScreenCapture9.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_9_ScreenCapture10.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">To recap, the primary endpoint of this phIII study was symptomatic control.<wbr> A negative futility analysis resulted in the study being terminated early in February 2012 with no difference being demonstrated in symptom control.<wbr> Data for one of the secondary endpoints however, is more positive with the PFS data demonstrating a 5 month improvement in the pasireotide group vs.<wbr> octreotide (11.<wbr>8 vs.<wbr> 6.<wbr>8 HR 0.<wbr>46 p=0.<wbr>045), </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_10_ScreenCapture12.jpg"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Toumpanakis concluded by stating that potentially pasireotide could be another promising agent in NET.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Interestingly, we understand some discussions with investigators took place at ESMO with regard to the future of pasireotide in NET and a possible new phIII study design.<wbr> The question remains as to whether if this occurs it would be conducted with the current formulation or now that a deal with Camurus has been confirmed, a new fluid crystal formulation.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><STRONG>Data Highlighted on Novartis&rsquo;s Booth</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">The medical affairs section of the Novartis Booth was highlighting a number of new agents that are being evaluated for NET including the PI3 K inhibitor BEZ235 and the fibroblast growth factor inhibitor dovitinib.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_11_ScreenCapture13.jpg"> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Turning to the promotional side of the booth, key messaging for Sandostatin LAR is as shown below with the focus on the PROMID data and the new device.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_12_ScreenCapture14.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_13_ScreenCapture15.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Interestingly, two people manning the booth, when questioned about the RADIANT-4 study noted that accrual was completed in August 2013 and that there is an expectation that interim data will be presented at ASCO next year.<wbr> Whether Novartis will be in a position to file based on this interim data remains to be seen but in all recent investor presentations it has highlighted 2015 as the year that it will file for approval in GEP-NETS (non-functioning mid-gut and pulmonary) based on the RADIANT-4 data.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><STRONG>ESMO Guideline Session</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">This is a session repeated every year but it was of particular interest this year to see how clinicians reacted in the context of the newly released CLARINET data.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">The session was introduced with some general comments on the guidelines themselves, noting that the main updates are every 2-5 years.<wbr> The number of new guidelines produced per year is declining but the usage of the guidelines is substantially increasing having more than doubled since 2009.<wbr> There are now 6 pocket guidelines available on mobiles including one on NET.<wbr> ESMO is currently working on a number of guidelines for patients covering 16 different topics including bladder and prostate.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">The NET session that followed examined a patient case history and asked people to vote on their next choice of therapy at the point of progression.<wbr> The patient was diagnosed with a metastatic G2 pNET Ki67 8%.<wbr> Interestingly, when the audience was asked which treatment they would recommend time and time again their first choice was a SSA, although this was not how the patient was treated.<wbr> As you will note he was treated according to the ESMO guidelines and progressively treated with different MTTs</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_14_ScreenCapture16.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_15_ScreenCapture17.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_16_ScreenCapture18.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_17_ScreenCapture19.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_18_ScreenCapture20.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_19_ScreenCapture21.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_20_ScreenCapture22.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_21_ScreenCapture23.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_22_ScreenCapture24.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_23_ScreenCapture25.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_24_ScreenCapture26.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Interesting to note the continued interest in prescribing SSAs and that a higher % of the audience recommended liver directed therapy over PRRT (20% vs 15%).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_25_ScreenCapture27.jpg">.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_26_ScreenCapture28.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">In the discussion that followed K Oberg stated <STRONG>&ldquo;I am happy to see everybody voting time and time again for SSAs after the CLARINET data yesterday&rdquo;.<wbr></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">He proceeded to highlight the range of treatment options that could be considered including chemotherapy and in particular presented two slides one showing the antiproliferative effects of SSAs prior to the CLARINET data and the other recent data from chemotherapy trials.<wbr> He highlighted the temozolamide phII 2010 data where a PR was observed in 70% of patient and PGS was 18 months but emphasised the need for a controlled trial to validate these findings.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">He questioned why targeted agents were used to treat the patient when at that time they were still being trialed and asked what was the reason for not giving chemotherapy or for that matter PRRT.<wbr> The problem he acknowledged is that we have no randomised trials comparing chemotherapy vs.<wbr> targeted agents.<wbr> He concluded that chemotherapy is still a valid alternative for this type of patient.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_27_ScreenCapture29.jpg"> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_28_ScreenCapture30.jpg"></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Key Posters</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">The following key posters were presented with a handful presented in an oral review session.<wbr> All are attached for your reference.<wbr> The number of GSK supported pazopanib posters was notable.<wbr></SPAN> </div><div><OL><LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Updated OS data from the RADIANT-2 study which has demonstrated no difference in OS a study that was compromised by the crossover of patients from the placebo &ndash;OCT LAR arm to the everolimus arm.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt; mso-fareast-font-family: Arial;"><SPAN style="mso-list: Ignore;"><SPAN style="font: 7pt 'Times New Roman';">A s</SPAN></SPAN></SPAN><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">tudy from British Columbia evaluating Ytrium 90 radioembolisation for hepatic metastases which included 20 ~NET patients amongst the 41 patients evaluated in total, which concludes that the NET patients appeared to derive the most benefit from the procedure.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Phase II first line study of combination everolimus and octreotide LAR in 50 patients with well differentiated NETS of gastroenteropancreatic and lung origin.<wbr>conducted by the ITMO group.<wbr> The ORR data of 20% was considered a promising finding and data that complements that obtained in RADIANT-2</SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Real world everolimus data demonstrating that efficacy is found to be similar to that reported in ph3 trials with equal results in both pNETs and non-PNETs.<wbr> However, a 2-fold increase in severe toxicity incidence is observed in patients who have previously benn treated with PRRT or chemotherapy raising the question of influence of previous teratments on the severity of adverse events that can be expected during everolimus treatment.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">PhII Single-arm trial of pazopanib (GSK) in patients with progressive GEP-NETs.<wbr> 44 patients who had failed chemotherapy, SSAs or MTTs received pazopanib 800mg q.<wbr>d.<wbr> Patients showed remarkable activity regardless of previous MTT treatment raising the hypothesis of non-cross resistance between MTTs in this population and possibly justifying the use of sequential targeted therapies.<wbr> A phIII study of pazopanib in progressive GEPNETs is now planned.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">QOL Assessments from an expanded access part of the RADIANT-3 study concluding that throughout the treatment period as reported by patients and assessed by QLQ-C30 and QLQ-GINET21, everolimus maintained QOL in patients with pNET.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Results of long-term radiological follow-up of patients in the PROMID trial.<wbr> Data shows that patients with well differentiated mid-gut tumours low hepatic tumour load (HL) is predictive for better response to early octreotide LAR therapy.<wbr> High HL is associated with a shorter overall survival.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Real word efficacy data regarding sunitinib and everolimus from UKINETS demonstating lower but approaching published efficacy data in heavily pre-treated patients.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">A single-centre study demonstrating similar effiacy with both octreotide LAR and lanreotide LAR in terms of PFS in both pNET and GI-NET.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: 'Arial','sans-serif'; font-size: 10pt;">Pazopanib treatment is associated with a decrease in plasma sVEGFR2.<wbr> A stonger decrease is associated with improved PFS especially in patients without prior anti-angiogenic therapy.<wbr></SPAN>
</LI>
</OL> </div><!-- Comment details --><a name="endocrinology7486attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(329,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(128,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(113,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(125,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(150,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(129,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(120,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(115,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(141,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_10_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(137,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_11_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(228,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_12_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(187,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_13_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(119,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_14_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(140,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_15_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(138,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_16_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(164,8 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_17_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(173,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_18_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(145 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_19_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(124,5 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_20_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(130,7 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_21_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(174,9 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_22_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(130,3 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_23_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(150,2 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_24_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(141,5 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_25_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(183,4 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_26_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(146,6 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_27_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(169 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_28_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(191,4 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_29_Updated%20OS%20Data%20Radiant%2d2.jpg.pdf">Updated OS Data Radiant-2.jpg.pdf</a>&nbsp;&nbsp;(248,2 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_30_Y90%20Radioembolisation%20For%20Primary%20%26%20Metastatic%20Liver%20Cancer.pdf">Y90 Radioembolisation For Primary & Metastatic Liver Cancer.pdf</a>&nbsp;&nbsp;(715,9 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_31_PhII%20Everolimus%20octreotide%20combination%20data%20from%20ITMO.pdf">PhII Everolimus octreotide combination data from ITMO.pdf</a>&nbsp;&nbsp;(917,2 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_32_Compassionate%20Use%20Of%20Everolimus%20in%20advanced%20neuroendocrine%20tumours.pdf">Compassionate Use Of Everolimus in advanced neuroendocrine tumours.pdf</a>&nbsp;&nbsp;(504,4 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_33_PROMID%20long%20term%20radiological%20follow%2dup.pdf">PROMID long term radiological follow-up.pdf</a>&nbsp;&nbsp;(841,7 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_34_Single%20Centre%20Experience%20with%20SSAs.pdf">Single Centre Experience with SSAs.pdf</a>&nbsp;&nbsp;(155 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_35_UKINETS%20study%20with%20sunitinib%20and%20eveolimus.pdf">UKINETS study with sunitinib and eveolimus.pdf</a>&nbsp;&nbsp;(115,4 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_36_Pazonet%20Single%20Arm%20PhII%20Trial%20In%20Progressive%20GEP%2dNETs.pdf">Pazonet Single Arm PhII Trial In Progressive GEP-NETs.pdf</a>&nbsp;&nbsp;(138,4 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_37_Plasma%20sVEGFR2%20as%20a%20predictor%20of%20efficacy%20of%20pazopanib.pdf">Plasma sVEGFR2 as a predictor of efficacy of pazopanib.pdf</a>&nbsp;&nbsp;(212 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7486_38_QOL%20Assessment%20in%20PhIIIb%20Eveolimus%20Study.pdf">QOL Assessment in PhIIIb Eveolimus Study.pdf</a>&nbsp;&nbsp;(343,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7486">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-11T17:05:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-11T17:05:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Canadian Real Life Evaluation of Lupron® for Prostate Cancer</title>
	<pubDate>2013-10-11T16:59:37+02:00</pubDate>
	<wp:post_id>4785</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of the CRONOS II is to assess the effect of diet and exercise in patients managed with Lupron®.<wbr> PE will evaluate the changes in patient QoL using the Medical Outcomes Study Short Form.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Start date: September 2013 (currently recruiting participants) </div><div style="margin-bottom: 10px;">Completion date: November 2020 </div><div style="margin-bottom: 10px;"><STRONG>About the Questionnaire</STRONG> </div><div style="margin-bottom: 10px;">The SF-36 Health is a 36-item general health self-administered questionnaire consisting of 8 scales measuring Physical Function, Physical Role limitations, Vitality, General Health, Pain, Social Function, Emotional Role limitations, and Mental Health.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Approx.<wbr> 860 </div><div style="margin-bottom: 10px;">Will be enrolled from the offices of University or community uro/<wbr>radio-onco across Canada treating patients with prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="header3" style="MARGIN-TOP: 2ex"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><UL><LI>
AbbVie</LI>
<LI>
CMX Research Inc</LI>
<LI>
JSS Medical Research Inc</LI>
</UL> </div><div><P class="indent2" style="MARGIN-TOP: 1ex">Reference in <EM>clinicaltrials.<wbr>gov</EM> <A href="http://clinicaltrials.gov/ct2/show/NCT01960881?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=09%2F11%2F2013&amp;rank=21">NCT01960881</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9220">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-11T16:59:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-11T16:59:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Registration of GP Pharm's Lutrate® 1M in Greece</title>
	<pubDate>2013-10-11T14:36:29+02:00</pubDate>
	<wp:post_id>4786</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Eleni Bozika we have learnt that the drug has been registered this month for prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9060" class="defaultlink">Oncology9060: Registration of GP Pharm's Lutrate® 1M in Poland</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9219">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-11T14:36:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-11T14:36:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ to Co-Promote Abiraterone in Japan</title>
	<pubDate>2013-10-11T10:43:46+02:00</pubDate>
	<wp:post_id>4787</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J&amp;J's abiraterone was submitted for regulatory approval in Japan in July 2013.<wbr> The deal is a strong strategic fit for AZ, reinforcing 'Japan' and 'oncology', both reported as key growth drivers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial terms of the agreement were not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9215_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9215attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9215_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(92,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9215">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-11T10:43:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-11T10:43:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cosmo's Methylene Blue MMX® to Enter Registration Trials for Colon Cancer Diagnosis</title>
	<pubDate>2013-10-10T17:02:20+02:00</pubDate>
	<wp:post_id>4788</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Poster presentation on phase II at EUGW in Berlin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to deliver Methylene Blue along the length of the entire colon via the MMX® technology thus enabling endoscopists to better detect pre-cancerous and cancerous lesions and polyps throughout the entire colon.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- allows the delivery of active pharmaceutical ingredients into the lumen of the colon through tablets in a delayed and controlled extent with the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.<wbr> </div><div style="margin-bottom: 10px;">The tablets manufactured according to the MMX<SUP>®</SUP> technology are coated with pH-resistant acrylic copolymers which delay the release until the tablet reaches the indicated intestinal location where the programmed dissolution begins.<wbr> That allows for protection of the active substances from adverse pH conditions and enzymatic presence in the upper digestive tracts.<wbr> The controlled release over the length of the colon not only simplifies the application for the patients but allows for the topical application of the active pharmaceutical ingredients to the whole bowel surface that is affected by inflammations.<wbr> </div><div style="margin-bottom: 10px;">This technology may also be used for other diseases affecting the colon and can be used as a platform for applications outside the colon where a controlled release is of importance.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1921_1_ScreenCapture1.jpg"> </div><div><EM>Source: Cosmo</EM> </div><!-- Comment details --><a name="gastroenterology1921attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1921_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1921_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(11 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1921">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-10T17:02:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-10T17:02:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</title>
	<pubDate>2013-10-10T15:07:34+02:00</pubDate>
	<wp:post_id>4789</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Bayer hosted an investor meeting in London 
today and confirmed its intention to accelerate the clinical develompent of 
five new promisining NMEs including, an oral progesterone receptor 
modulator for patients with symptomatic uterine fibroids.<wbr> Additionally, it 
highlighted its intentions to develop Radium 223 Xofigo for earlier stages 
of the CRPC treatment paradigm in combination with abiraterone.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9207">...</a><br></div><div style="margin-bottom: 10px;">Thanks to Stefan Pfeifer (Uro BU Director in Germany) we have learnt that Bayer has established a Xofigo sales force of 5 reps for the German market.<wbr> </div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">One source reported that the targets are </SPAN><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">nuclear medicine centers plus referring retail urologists but this </SPAN><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">needs to be confirmed by a 2nd source.<wbr></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9214">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9207">View thread  Oncology9207: Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-10T15:07:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-10T15:07:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</title>
	<pubDate>2013-10-10T14:00:53+02:00</pubDate>
	<wp:post_id>4790</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Bayer hosted an investor meeting in London 
today and confirmed its intention to accelerate the clinical develompent of 
five new promisining NMEs including, an oral progesterone receptor 
modulator for patients with symptomatic uterine fibroids.<wbr> Additionally, it 
highlighted its intentions to develop Radium 223 Xofigo for earlier stages 
of the CRPC treatment paradigm in combination with abiraterone.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9207">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Thanks to Emannuelle Nuris France Uro-Oncology BU Head we have learnt that Bayer is re-organising its one oncology sales force which was promoting Nexavar towards Gastro-enterologists &amp; GI onco &amp; Uro-onco prescribers into 2 sales forces.<wbr> One will focus on Uro-Onco prescribers and in terms of product on Nexavar in renal cancer &amp; Alpharadin in CRPC, whilst the 2nd one will focus on Gastroenterologists and GI  Onco and will promote Nexavar in GI indications + a new product (t.<wbr>b.<wbr>d.<wbr>).<wbr> </SPAN> </div><div><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Effective as of now.<wbr> </DIV> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9213">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9207">View thread  Oncology9207: Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-10T14:00:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-10T14:00:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mallinckrodt Consolidates Leadership in Nuclear Imaging</title>
	<pubDate>2013-10-10T10:29:41+02:00</pubDate>
	<wp:post_id>4791</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has licensed a third US patent for Octreoscan™ imaging agent.<wbr> The patent, <LOCATION>U.<wbr>S.<wbr> 6</LOCATION>,123,916, effective through <CHRON>September 26, 2017</CHRON>, covers the use of Octreoscan™ imaging agent to detect Merkel cell carcinoma (a type of neuroendocrine tumor, which is a rare, aggressive form of skin cancer).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Octreoscan imaging agent is a diagnostic radiopharmaceutical, used to detect certain neuroendocrine tumors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">U.<wbr>S.<wbr> patents 5,753,627 and 5,776,894 granted in 1998.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Business </U> </div><div style="margin-bottom: 10px;">- API, generics, and branded pharmaceuticals business, and then we - global imaging (contrast media and devices, as well as a imaging business).<wbr><BR> </div><div style="margin-bottom: 10px;"><UL><LI>
Staff: approx.<wbr> 5,500 employees worldwide</LI>
<LI>
Geo coverage: sales in roughly 90 countries.<wbr> </LI>
<LI>
2012 revenue: $2.<wbr>1 billion.<wbr></LI>
</UL> </div><div><EM>Source: Mallinckrodt</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7483">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-10T10:29:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-10T10:29:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon's Telotristat Etiprate Did Not Work in UC Ph2</title>
	<pubDate>2013-10-09T18:35:38+02:00</pubDate>
	<wp:post_id>4792</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Although LX1032 (Telotristat etiprate) did lower 5-HIAA and was safe and well-tolerated, reducing 5-HIAA did not have enough of an impact on UC to move forward with this indication.<wbr> Lexicon plans to maintain the focus of its resources on the ongoing Ph 3 program in carcinoid syndrome as the primary indication for the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Design: multicenter study.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: 59 patients with mild-moderate ulcerative colitis.<wbr> </div><div style="margin-bottom: 10px;">Intervention: 500 mg dose of investigational drug telotristat etiprate taken orally once daily, or a 500 mg dose of telotristat etiprate three times daily.<wbr> </div><div style="margin-bottom: 10px;">Duration: Treatment was given for 8 weeks.<wbr> </div><div style="margin-bottom: 10px;">Next steps &gt; In the context of a pilot study, additional analyses will be conducted to best understand the clinical significance of the results, which are planned for presentation at a scientific congress in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Wedbush estimate LX1032 for carcinoid syndrome may be launched in 2015, LX1033 for IBS-d in 2016 and LX4211 for diabetes in 2017.<wbr> </div><div><EM>Source: </EM><A href="http://www.lexgen.com/news/press-releases/2299-lexicon-completes-pilot-study-of-telotristat-etiprate-in-ulcerative-colitis.html"><EM>http:/<wbr>/<wbr>www.<wbr>lexgen.<wbr>com/<wbr>news/<wbr>press-releases/<wbr>2299-lexicon-completes-pilot-study-of-telotristat-etiprate-in-ulcerative-colitis.<wbr>html</EM></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7481">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-09T18:35:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-09T18:35:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>May Botox(R) Be an Alternative to Fight Fat ?</title>
	<pubDate>2013-10-09T14:03:55+02:00</pubDate>
	<wp:post_id>4793</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Within the frame of an EU project called 'Full4Health Program', researchers from the Norwegian U.<wbr> of Science and Technology have had promising experimental results in rats, and hope to start human clinical studies soon.<wbr> Prior to publishing this article, I got written confirmation that the toxin drug tested is Botox (the brand).<wbr> Although Allergan is looking to divest its 'obesity intervention unit', we may bear in mind that the company is still committed to fight 'obesity', and be interested in a new approach of the disease with Botox should this project succeed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Findings show that injection into the vagus nerve in the stomach can lead to weight loss (animals ate less and lost 20-30% of their body weight over 5 weeks).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Paralyzing the nerve paralyzes muscles in the stomach, which appears to slow the passage of food through the stomach.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Use of Botox(R) in this condition can be developed into an alternative to gastric bypass surgery.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">The company is actively pursuing the development of next-generation products and technologies capable of providing high-quality, healthier, and less traumatic long-term weight-loss treatment solutions (<EM>Allergan's website</EM>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the US alone, obesity affects &gt;60 million individuals (<EM>NIH, 2005; Merrill Lynch, May 2006; Monitor Group</EM>), and is considered the second leading cause of preventable death (<EM>American Obesity Association.<wbr> AOA Fact Sheets</EM>).<wbr> </div><div style="margin-bottom: 10px;">Worldwide, approx.<wbr> 1.<wbr>6 billion adults are overweight, and it is estimated that obesity affects at least 400 million adults (<EM>World Health Organization, 2005</EM>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A €9 million EU Framework 7 project which brings together 19 multidisciplinary academic and industry collaborators from across Europe.<wbr> </div><div style="margin-bottom: 10px;">The project will investigate mechanisms of hunger, satiety and feeding behaviour, and how these change across the life course, effects of dietary components and food structure on these processes, and their possible exploitation in addressing obesity, chronic disease and under-nutrition (<A href="http://www.full4health.eu/project/">http:/<wbr>/<wbr>www.<wbr>full4health.<wbr>eu/<wbr>project/<wbr></A>).<wbr> </div><div><EM>Source: <A href="http://www.sciencedaily.com/releases/2013/10/131004104958.htm">Science Daily</A>; Allergan; ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7206">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-09T14:03:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-09T14:03:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 2 - Treatment Approach in CRPC with Bone Metastases</title>
	<pubDate>2013-10-09T12:27:42+02:00</pubDate>
	<wp:post_id>4794</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: ESMO 2013 continues with tremendous focus on prostate cancer management.<wbr> Unlike the decade, the landscape of prostate cancer has changed dramatically with the new generation of AR targeting agents that have widen treatment options for patients.<wbr> However, Bone mets remain the major cause of morbidities and mortalities in prostate cancer.<wbr> Bone mets in prostate cancer have distinctive pattern of complications including pain, fracture, and spinal cord compression.<wbr> Bayer and Amgen held a industry sponsored satellite symposium to discuss the role of bone targeted treatments for mCRPC patients with bone metastases.<wbr> </div><div style="margin-bottom: 10px;">Historically strontium-89 and samarium-153 are the two &beta;-emitters approved for pain palliation.<wbr> Due the nature of &beta;-emitting radiation, the risk of increase bone marrow exposure may result in bone marrow associated toxicities.<wbr> There are several studies evaluating the role of zoledronic acid in non-metastatic CRPC , however, ZEUS trial did not meet its primary endpoint where zoledronic acid vs placebo was not able to demonstrate 1) superiority to delay development of bone metastases (13.<wbr>7% vs 13%, p=0.<wbr>717); 2) OS benefit (p=0.<wbr>717).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_2_IMG%255f1579.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_1_IMG%255f2468.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_2_IMG%255f1579.JPG"> </div><div style="margin-bottom: 10px;">Amgen then conducted a Phase III bone metastases prevention trial in patients with high risk of CRPC.<wbr> Denosumab demonstrated significant prolonged bone metastasis free survival (BMFS) vs placebo by 4.<wbr>3 months with hazard ratio of 0.<wbr>85 (95% CI, 0.<wbr>73-0.<wbr>98; p=0.<wbr>028).<wbr> A subgroup analysis demonstrated denosumab markedly prolonged BMFS by greater than 7 months in patients with PSA doubling time less than 6 months.<wbr> Denosumab significantly prolonged BMFS vs placebo in men with high risk non metastatic CRPC and this validates a potential therapeutic role in non metastatic CRPC patients.<wbr> In 2010, Amgen's denosumab was approved based on its superiority for delay of time to first skeletal related event (SRE) compared to zoledronic acid despite of similar OS.<wbr> This results implicate the potential role of bone targeted agents in delaying disease progression, unfotunately it has not translated into overall survival! </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_3_IMG%255f1585.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_4_IMG%255f1588.JPG"> </div><div style="margin-bottom: 10px;">A new bone targeted agent, Radium 223, has been approved by FDA based on increased OS as well as improvement of first symptomatic SRE .<wbr> In the Bayer sponsored satellite symposium, Professor Fred Saad pointed out that radium 223 is the first bone targeted therapy has demonstrated survival benefit as well as pain palliation.<wbr> Radium 223 is a water soluble radium salt that emits four alpha particles during decay of each isotope.<wbr> Radium 223 is FDA approved for the treatment of symptomatic CRPC and bone metastases with no evidence of visceral disease.<wbr> Dr.<wbr> Stephane Oudard presented Phase 3 ALSYMPCA demonstrated OS benefit in both pre- and post- docetaxel setting.<wbr> This indicates radium 223 may have a role in pre-chemo setting.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_5_IMG%255f1655.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_6_IMG%255f1657.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_7_IMG%255f1658.JPG"> </div><div style="margin-bottom: 10px;">Dr.<wbr> Oliver Sartor also discussed why SRE is an important end point as management of SREs is associated with substantial health resource utilisation.<wbr> The importance of early identification of bone mets could be important in delaying patient morbidity and mortality.<wbr> There are evidences demonstrating patients who had more than 4.<wbr>6 positive area on bone scan (PABI) associate with lower probabllity of survival.<wbr> Radium 223 can be beneficial in this setting.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_5_IMG%255f1655.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_6_IMG%255f1657.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_8_IMG%255f1624.JPG">  <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_9_IMG%255f1625.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_11_IMG%255f1627.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_10_IMG%255f1626.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_13_IMG%255f2474.JPG"> </div><div style="margin-bottom: 10px;">Four poster abstracts (Ab# 2876, 2877, 2878, and 2883) discussed Phase 3 ALSYMPCA findings in terms of time to first symptomatic skeletal event (SSE), haematologic safety, impact on quality of life (QoL) .<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>In all age groups, radium 223 prolonged OS, time to first SSE, time to an increase in total ALP, time to an increase in PSA
</LI>
<LI>Radium 223 prolongs time to first SSE regardless of baseline stratification factors (current bisphosphonate use, prior docetaxel use, and baseline ALP levels).<wbr> Although results suggested a greater effect in the subgroup who received bisphosphonate, this interpretation needs to be taken with caution as this was a non-randomised comparison.<wbr>
</LI>
<LI>Haematologic AEs and bone marrow failure are frequent complications of metastatic CRPC disease progression and treatment - radium 223 treatment arm had a low incidence of haematologic AEs and no major difference in grade 3 or 4 haaematologic toxicity compared to placebo groups.<wbr>
</LI>
<LI>Radium 223 better preserved QoL in terms of physical, emotional and functional subscales and specifically pain related QoL (i.<wbr>e decreased pain)
</LI>
</UL> </div><div style="margin-bottom: 10px;">The question remains when to use radium 223 despite of its promising safety and efficacy data - below are the quoations from expert: </div><div style="margin-bottom: 10px;"><STRONG><EM>"The more symptomatic they are the more I will be thinking of radium"</EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><EM>'It&rsquo;s kind of depending on burden of bone and symptoms"</EM></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_15_IMG%255f1739.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_16_IMG%255f1743.JPG"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_17_IMG%255f1744.JPG"> </div><div style="margin-bottom: 10px;">Dr Smith stated <STRONG><EM>"This is clearly, I believe, an important therapeutic option for patients with advanced disease"</EM></STRONG> and he presented a case, who received combination therapy with abiraterone + radium 223, demonstrated PSA nadir &lt;2 ng/<wbr>ml within 8 weeks and a remarkable resolution of bone disease at month 8.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_12_IMG%255f2477.JPG"> </div><div style="margin-bottom: 10px;">Dr Sartor also presented a case: 67-year-old mCRPC patients with bone metastases and seeking NON-CHEMOTHERAPY treatment options to maintain his active lifesstyle.<wbr> The patient received abiraterone + prednisone and then radium 223 inhections every 4 weeks were added to the secondary hormonal regime.<wbr> Two months after injections, the patient experienced pain relief and test result demonstrated reduction of ~70% in PSA nad 60% in alkaline phosphatase.<wbr> The patient continues to have a actrive life style.<wbr> For many years, docetaxel was the only agent shown to prolong survival in mCRPC, given more options are available now, patients may now have an important voice in treatment decision process.<wbr> </div><div style="margin-bottom: 10px;">Sartor pointed out "<STRONG><EM> we now have many options in US and the post-docetaxel space is losing meaning except to insureres and regulators.<wbr> The post-abiraterone space is much more important today, however, we know little about it</EM></STRONG>.<wbr>" Radium 223 may have a role in this setting, but the ALYSYMPCA Phase III trial has a number of critical unanswered question: 1) what is the MOA to improve clinical outcome? 2) Pain was not systematically evaluated in the trial and requires further investigation 3) efficacy and safety of combination therapy.<wbr> However, we remain sceptical in terms of EMA approval of radium 223 in pre-chemo setting based on ALSYMPCA trial as the comparison arm only received placebo.<wbr> Further trials are warranted to compare efficacy in pre-chemo setting.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_19_IMG%255f2067.JPG"> </div><!-- Comment details --><a name="pharmaworld10643attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_1_IMG%255f2468.JPG">IMG_2468.JPG</a>&nbsp;&nbsp;(988,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_2_IMG%255f1579.JPG">IMG_1579.JPG</a>&nbsp;&nbsp;(756,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_3_IMG%255f1585.JPG">IMG_1585.JPG</a>&nbsp;&nbsp;(728,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_4_IMG%255f1588.JPG">IMG_1588.JPG</a>&nbsp;&nbsp;(705,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_5_IMG%255f1655.JPG">IMG_1655.JPG</a>&nbsp;&nbsp;(755 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_6_IMG%255f1657.JPG">IMG_1657.JPG</a>&nbsp;&nbsp;(750,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_7_IMG%255f1658.JPG">IMG_1658.JPG</a>&nbsp;&nbsp;(713,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_8_IMG%255f1624.JPG">IMG_1624.JPG</a>&nbsp;&nbsp;(670,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_9_IMG%255f1625.JPG">IMG_1625.JPG</a>&nbsp;&nbsp;(853,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_10_IMG%255f1626.JPG">IMG_1626.JPG</a>&nbsp;&nbsp;(795 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_11_IMG%255f1627.JPG">IMG_1627.JPG</a>&nbsp;&nbsp;(793,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_12_IMG%255f2477.JPG">IMG_2477.JPG</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_13_IMG%255f2474.JPG">IMG_2474.JPG</a>&nbsp;&nbsp;(1 MB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_14_IMG%255f1597.JPG">IMG_1597.JPG</a>&nbsp;&nbsp;(690,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_15_IMG%255f1739.JPG">IMG_1739.JPG</a>&nbsp;&nbsp;(839,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_16_IMG%255f1743.JPG">IMG_1743.JPG</a>&nbsp;&nbsp;(823,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_17_IMG%255f1744.JPG">IMG_1744.JPG</a>&nbsp;&nbsp;(824,4 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_18_IMG%255f2073.JPG">IMG_2073.JPG</a>&nbsp;&nbsp;(845,2 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10643_19_IMG%255f2067.JPG">IMG_2067.JPG</a>&nbsp;&nbsp;(996,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10643">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-09T12:27:42+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-09T12:27:42+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Versartis Raises $20M Series D Venture Financing</title>
	<pubDate>2013-10-09T11:26:03+02:00</pubDate>
	<wp:post_id>4795</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This new financing round brings the company's total venture capital raised in 2013 to $45M.<wbr> Management reported the new capital will support the preparation for an international Ph3 trial of LA hGH in Ped.<wbr> patients planned to start in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><A href="http://clinicaltrials.gov/ct2/show/NCT01718041?term=versartis&amp;rank=2">NCT01718041</A> - The company’s VERTICAL study of VRS-317 in pre-pubertal children with GHD is currently being conducted in approx 30 sites in the US and was initiated following the successful results of a Ph1 study in adults with GHD.<wbr></DIV> </div><div style="margin-bottom: 10px;">The VERTICAL study is designed in two stages: </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- the <STRONG>Phase 1b</STRONG> utilized a single ascending-dose design to evaluate the safety and tolerability of six dosing levels of a subcutaneous (SC) dose of VRS-317.<wbr>  </P>
<P>- the <STRONG>Phase 2a</STRONG> was initiated last month and will further study these patients to determine the efficacy of VRS-317 as defined by an increase in height velocity over 3 and 6 months of treatment.<wbr> </P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7238" class="defaultlink">Endocrinology7238: Versartis Closed $25M Series C Financing</a>.<wbr> </div><div><EM>Source: Versartis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7480">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-09T11:26:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-09T11:26:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SMC Issued Positive Recommendation for Botox(R)</title>
	<pubDate>2013-10-09T10:29:49+02:00</pubDate>
	<wp:post_id>4796</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/18px Arial; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(68,68,68); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/18px Arial; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(68,68,68); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/18px Arial; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(68,68,68); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/18px Arial; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(68,68,68); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7204">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-09T10:29:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-09T10:29:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ADT +/- Local RT +/- Abiraterone in Metastatic Hormone-naïve Prostate Cancer (PEACE1)</title>
	<pubDate>2013-10-08T19:58:39+02:00</pubDate>
	<wp:post_id>4797</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph3, sponsored by UNICANCER, will compare the clinical benefit of ADT with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.<wbr> The randomisation will result in the allocation of arm A (ADT), arm B (ADT + Abiraterone), arm C (ADT + radiotherapy) or arm D (ADT + Abiraterone + radiotherapy) in a 1:1:1:1 ratio.<wbr> PE will assess survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><a href="http://www.clinicaltrials.gov/ct2/show/NCT01957436?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=09%2F08%2F2013&amp;rank=262" class="defaultlink">NCT01957436</a> </div><div style="margin-bottom: 10px;">n= 916 </div><div style="margin-bottom: 10px;">Start date: Oct 2013 </div><div style="margin-bottom: 10px;">Completion date: Oct 2016 /<wbr> October 2023 </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline">Principal Investigators</SPAN> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table indent2"><TBODY><TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Karim FIZAZI, Professor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Gustave Roussy, Cancer Campus Grand Paris - Paris</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Guilhem ROUBAUD, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Institut Bergonié - Bordeaux</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Igor LATORZEFF, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Clinique Pasteur - Toulouse</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Jean-François BERDAH, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Clinique Ste Marguerite - Hyères</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Marlon SILVA, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Centre François Baclesse - Caen</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Stéphane SUPIOT, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">ICO-Centre René Gauducheau - St Herblain</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Loïc MOUREY, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Institut Claudius Régaud - Toulouse</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Xavier ARTIGNAN, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHP Saint Grégoire - St Grégoire</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Aude FLECHON, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Centre Léon Bérard - Lyon</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Patricia BURBAN-PROVOST, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Clinique Armoricaine de radiologie - St Brieuc</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Stéphane DROUPY, Professor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHU Carémeau - Nîmes</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Jean-Christophe EYMARD, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Institut Jean Godinot - Reims</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Xavier MURACCIOLE, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHU Timone - Marseille</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Gwenaëlle GRAVIS, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Institut Paoli Calmettes - Marseille</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Philippe RONCHIN, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Centre Azuréen de Cancérologie - Mougins</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Philippe BEUZEBOC, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Institut Curie - Paris</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Christophe HENNEQUIN, Professor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Hôpital St Louis - Paris</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Frank PRIOU, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHD Vendée - La Roche sur Yon</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Jean-Marc FERRERO, Professor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Centre Antoine Lacassagne - Nice</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Ali HASBINI, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Clinique Pasteur - Brest</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Brigitte LAGUERRE, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Centre Eugène Marquis - Rennes</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Sophie ABADIE-LACOURTOISIE, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">ICO-Paul Papin - Angers</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Carol ALLIOT, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Centre Hospitalier Alpes Leman - Contamine sur Arve</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Abdennacer GHOUL, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">SERA - Contamine sur Arve</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Thierry WACHTER, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHR La source - Orléans</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Jean-Luc LANDRY, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Hopitaux du Leman - Thonon les Bains</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Guy De LAROCHE, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Institut de Cancérologie Lucien Neuwirth - St Priest en Jarez</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Etienne MARTIN, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Centre Georges-François LECLERC - Dijon</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Antoine THIERY-VUILLEMIN, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHU JEAN MINJOZ - Besançon</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Pierre CLAVERE, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHU Limoges - Limoges</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Alexandre De La TAILLE, Doctor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHU Henri Mondor - Créteil</TD>
</TR>
<TR><TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">Christian PFISTTER, Professor</TD>
<TD style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 1em; PADDING-TOP: 1ex">CHU Rouen - Rouen</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9211">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-08T19:58:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-08T19:58:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Octreolin Intelligence From Two Recent Surveys</title>
	<pubDate>2013-10-08T17:03:09+02:00</pubDate>
	<wp:post_id>4798</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Over the course of the last six-months, two sources of intelligence on Octreolin have identified a number of points regarding the efficacy, safety and positioning of the drug and Roche's involvement with the programme.<wbr> The first set of data came from a primary intelligence survey conducted by the CI Dept.<wbr> in Europe involving 8 KOLs &amp; undertaken between April and June 2013, and the second is feedback from a recent US ad-board held on the 16th September.<wbr> Thanks to Dan Commerford  (Senior Director US Marketing) for sharing this with us.<wbr> </div><div style="margin-bottom: 10px;">A summary of some of the key conclusions from both studies is shown below but we would welcome any further information you have on the points raised: </div><div style="margin-bottom: 10px;">From a regulatory standpoint, primary intelligence highlighted Roche's ambition to file a.<wbr>s.<wbr>a.<wbr>p for the treatment of acromegaly and if possible in the 1H2014.<wbr> However, with datalock as highighted below not occuring until the end of the quarter these timelines could be stretched.<wbr> Sources from Genentech interviewed at ENDO stated that a decision on FDA filing will be taken at the time of data release as to whether or not a separate US based trial will be required/<wbr>undertaken.<wbr> </div><div style="margin-bottom: 10px;">Chiasma itself has for some time been pointing to a filing in both the US &amp; EU in Q114.<wbr> </div><div style="margin-bottom: 10px;">There is no evidence at the current time of a planned NET study and as far as we understand none of the clinicians involved with octreolin have been approached regarding such a study.<wbr> Some specialists have questioned the feasibility of adminstering an oral agent to patients with functional tumours, albeit for non-functioning tumours this could be less of an issue.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7477_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>US Ad Board Key Findings</STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: Wingdings; mso-fareast-font-family: Wingdings; mso-bidi-font-family: Wingdings;"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> <SPAN lang="EN-US" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN><SPAN lang="EN-US" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><div><SPAN lang="EN-US" style="font-family: 'Courier New'; mso-fareast-font-family: 'Courier New';"><SPAN style="mso-list: Ignore;"> </SPAN></SPAN> </div><!-- Comment details --><a name="endocrinology7477attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7477_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(135,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7477">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-08T17:03:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-08T17:03:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First FFA2 Inhibitor to be Evaluated Clinically</title>
	<pubDate>2013-10-08T15:11:01+02:00</pubDate>
	<wp:post_id>4799</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First FFA2 Inhibitor to be Evaluated Clinically</span>&nbsp;<br><span style="font-size: 12px;">Comment: Galapagos reported that the positive outcome of the phase 1 study with GLPG0974 supports progression to a POC trial next month for ulcerative colitis (UC).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1881">...</a><br></div><div style="margin-bottom: 10px;">The drug has entered into the first Ph2 trial for testing safety and efficacy, with top-line results expected Q1:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: Four-week study with approx.<wbr> 45 patients with mild to moderate UC </LI>
<LI>Objective: to assess efficacy, effects on selected biomarkers, afety and tolerability and PK.<wbr> </LI>
<LI>Regimen: patients will receive either 200 mg of the drug twice-daily or placebo for a period of 4 weeks.<wbr> </LI>
<LI>Location: Belgium; Latvia; Czech Rep.<wbr> and Slovakia.<wbr></LI>
</UL> </div><div><EM>Source: Galapagos</EM> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1918">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1881">View thread  GastroEnterology1881: First FFA2 Inhibitor to be Evaluated Clinically</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-08T15:11:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-08T15:11:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</title>
	<pubDate>2013-10-08T13:48:59+02:00</pubDate>
	<wp:post_id>4800</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer hosted an investor meeting in London 
today and confirmed its intention to accelerate the clinical develompent of 
five new promisining NMEs including, an oral progesterone receptor 
modulator for patients with symptomatic uterine fibroids.<wbr> Additionally, it 
highlighted its intentions to develop Radium 223 Xofigo for earlier stages 
of the CRPC treatment paradigm in combination with abiraterone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Potential New NMEs</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Amongst the 5 NMEs highlighted were 3 
cardiovascular agents, one oncology compound and a new treatment for uterine 
fibroids</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>BAY 1002670 </STRONG> </div><div style="margin-bottom: 10px;">Is a novel oral progesterone receptor modulator that 
holds the promises of long-term treatment of patients with symptomatic uterine 
fibroids.<wbr> Based on promising early clinical data the initiation of a Phase III 
study is planned for mid-2014.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Meanwhile, in oncology, Copanlisib (BAY 80-6946), a 
novel, oral phosphatidylinositol-3 kinases (PI3K) inhibitor, has been selected 
for accelerated development in patients with follicular lymphoma.<wbr> A Phase II 
study in patients with Non-Hodgkin's lymphoma is currently ongoing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Xofigo - Radium 223</STRONG> </div><div style="margin-bottom: 10px;">Alongside its discussion of potential NMEs, Bayer was 
also keen to emphasise the life-cycle opportunities for some of its newer 
products including the CRPC agent Xofigo which is now commercially available in 
both the US and Europe.<wbr> The most interesting aspect of its development programme 
is its decision to move into earlier treatment settings within the CPRC 
treatment pardigm with plans to conduct a combination study with abiraterone 
(see deisgn below).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_4_ScreenCapture4.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_5_ScreenCapture5.jpg"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9213c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Thanks to Emannuelle Nuris France Uro-Oncology BU Head we have learnt that Bayer is re-organising its one oncology sales force which was promoting Nexavar towards Gastro-enterologists &amp; GI onco &amp; Uro-onco prescribers into 2 sales forces.<wbr> One will focus on Uro-Onco prescribers and in terms of product on Nexavar in renal cancer &amp; Alpharadin in CRPC, whilst the 2nd one will focus on Gastroenterologists and GI  Onco and will promote Nexavar in GI indications + a new product (t.<wbr>b.<wbr>d.<wbr>).<wbr> </SPAN> </div><div><DIV style="text-transform: none; background-color: #ffffff; text-indent: 0px; font: 12px arial, sans-serif; white-space: normal; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Effective as of now.<wbr> </DIV> </div></div><a name="Oncology9214c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Thanks to Stefan Pfeifer (Uro BU Director in Germany) we have learnt that Bayer has established a Xofigo sales force of 5 reps for the German market.<wbr> </div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">One source reported that the targets are </SPAN><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">nuclear medicine centers plus referring retail urologists but this </SPAN><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">needs to be confirmed by a 2nd source.<wbr></SPAN> </div></div><a name="oncology9207attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(196,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(199,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(177,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(188,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9207_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(168,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9207">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-08T13:48:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-08T13:48:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan/MedyTox Licensing Agreement - Further Assumptions</title>
	<pubDate>2013-10-08T11:55:59+02:00</pubDate>
	<wp:post_id>4801</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Further to the announcement of a potential licensing agreement on September 26th, a number of Asian investment houses have clearly had further discussions with Medytox and highlighted some assumptions about the future development plan for MT101019 and are forecasting a potential market share of 20%.<wbr> </div><div style="margin-bottom: 10px;">Nomura (see below) has highlighted the development schedule of the next generation Meditoxin MT10109 (the freeze-dried, HSA free (utilises plant protein instead), room temperature product) quoting the company as the source of development timelines.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7199_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The chart notes that phIII in Korea is complete.<wbr> Although there is no reference to any phIII study in any of the clinical trial databases, including the Korean database CRIS, we believe the lead indication studied was glabellar lines.<wbr> Intelligence gained earlier in the year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=6888" class="defaultlink">Neurology6888: Nomura Highlights Medy-Tox As One Of Its Top Buys Due To Export Growth & Emerging Potential Of Next Generation Toxin</a>) did suggest that Medytox had filed for approval in March 2013.<wbr> Seemingly, the contract with Allergan is contingent on this approval in Korea.<wbr> The timelines as you will note suggest a global phIII trial will start in the fourth quarter and complete within 1 year, followed by regulatory submissions in the US thereafter and launch in 2H16.<wbr> </div><div style="margin-bottom: 10px;">Two phII studies with MT10109, that are highlighted in the public domain have been undertaken in Australia, We are aware that Medytox is hoping to use these as part of any global submission, one has been conducted in glabellar lines and the other in cervical dsytonia.<wbr> The former completed in August 2012 and the latter was scheduled to complete last month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Liquid Toxin Status</STRONG> </div><div style="margin-bottom: 10px;">Meanwhile, the Korean clinical trial database CRIS is currently listing a phI trial with another Medy-Tox product MT101017.<wbr> The trial is a 25 patient phI study which started recruitement in September last year.<wbr> Our current assumption (to be validated) is that this is a trial with the new next generation liquid toxin, something that was also referred to in the Allergan/<wbr>Medy-Tox press release as being part of the agreement.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; text-indent: 0px; display: inline !important; font: 11px dotum; white-space: normal; float: none; letter-spacing: normal; color: #666666; word-spacing: 0px; -webkit-text-stroke-width: 0px;">This is a randomised, double-blind, intra-individual controlled, dose escalation study to assess the safety, tolerability and preliminary effectiveness of a single dose of MT10107 in comparison to Botox&reg;50U (BOTOX&reg; is a registered trademark owned by Allergan).<wbr> This is the first-in-human study for MT10107, and will be performed in healthy volunteers.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">Given both Nomura and Woori appear to be both talking about a peak market share in the US &amp; EU of 20%, we suspect some guidance has been given by Medy-Tox to this effect.<wbr> </div><div style="margin-bottom: 10px;">We hope that we will have more concrete data to back up some of these assumptions before the end of the year.<wbr> </div><div style="margin-bottom: 10px;">Sources.<wbr> </div><div style="margin-bottom: 10px;">CRIS <A href="http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=2729">http:/<wbr>/<wbr>cris.<wbr>nih.<wbr>go.<wbr>kr/<wbr>cris/<wbr>en/<wbr>search/<wbr>search_result_st01.<wbr>jsp?seq=2729</A> </div><div style="margin-bottom: 10px;">Nomura report September 27th </div><div style="margin-bottom: 10px;">Woori report September 27th </div><div>Shinhan Investment Corp report September 27th </div><!-- Comment details --><a name="neurology7199attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7199_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(55,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7199">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-08T11:55:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-08T11:55:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J's SIMPONI® (golimumab) Approved in the EU</title>
	<pubDate>2013-10-08T10:53:40+02:00</pubDate>
	<wp:post_id>4802</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: European Commission has approved SIMPONI® (golimumab) for the treatment of moderately to severely active UC in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.<wbr> The drug is the first and only subcutaneous anti–tumor necrosis factor (TNF)-alpha treatment administered as an every-4-week maintenance therapy for UCF.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Prior to Simponi's approval, the only other TNF blocking options were J&amp;J's Remicade (infliximab), and AbbVie's Humira (adalimumab).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">GlobalData’s primary research has uncovered concerns among KOLs who believe that TNF blocker usage carries a significant financial burden of aftercare, and adverse-event management expenses.<wbr> </div><div style="margin-bottom: 10px;">The aftercare and adverse-event expenses associated with biologics treatment are estimated at around $28,000 annually per TNF blocker patient in the US as infectious diseases such as tuberculosis, hepatitis virus flares, and opportunistic lung infections can raid UC patients treated with TNF blockers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Colectomy still comprises a significant part of UC management because: one, not all severe patients will respond to the anti-TNF treatments, and two, the total response to these therapies has seen a gradual decline in the last decade.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Hospira’s Inflectra, a biosimilar to J&amp;J Remicade (infliximab) was approved by the European Commission for marketing in the EU for multiple autoimmune diseases including rheumatoid arthritis (RA), Crohn’s disease (CD), ulcerative colitis (UC), ankylosing spondylitis (AS), and psoriatic arthritis (PsA).<wbr> </div><div style="margin-bottom: 10px;">Although approved for marketed use in the EU, Inflectra’s launch will be pending based on potential intellectual property protections.<wbr> </div><div><EM>Source: Company PR, GlobalData</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1916">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-08T10:53:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-08T10:53:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sirtex - Sir-Sphere Application in NET Therapy & Reimbursement Coverage By NHS England for mCRC</title>
	<pubDate>2013-10-07T17:55:51+02:00</pubDate>
	<wp:post_id>4803</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the upcoming EANM meeting in Lyon, a significant amount of data will be presented in oral sessions on the usage of PRRT to treat neuroendocrine tumours.<wbr> Sirtex will also be present, featuring its SIR-Spheres during a lunch time symposium, talking about future directions with SIRT amongst them its use for the treatment of liver metastases in NET.<wbr> The speaker Dr Hojjat Ahmadzadehfar has published a number of papers on the use of PRRT for NET therapy.<wbr> Interestingly SIRT has recently become the first treatment under the new UK CtE initiative to be funded for the treatment of mCRC and ICC.<wbr> </div><div style="margin-bottom: 10px;">For those interested in a full listing of PRRT events that will take place in Lyon please contact Jacquie Cantle </div><div style="margin-bottom: 10px;"><STRONG>Sirtex's Presence At ESMO</STRONG> </div><div style="margin-bottom: 10px;">Interestingly, Sirtex were recently present at ESMO distributing a supplement on its booth from the 4th European symposium on Liver-Directed Cancer Therapy using Sir-Spheres included in which was a chapter on SIRT for neuroendocrine tumours.<wbr> An overview of NET liver mets by P Ruszniewski (France) and a paper on SIRT therapy by L Bester (Syndey Australia) were included.<wbr> Dr Bester concludes that "SIRT with 90Y microspheres is a promising treatment option for unresectable NETLM and that patients with low hepatic tumour burden, well differentiated tumour and no extrahepatic disease are the best candidates for SIRT.<wbr>" </div><div style="margin-bottom: 10px;">It should be pointed out that at this juncture, SIRT is not a licensed therapy for the treatment of neuroendocrine tumours but there appears to be a growing interest in its application (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7198" class="defaultlink">Endocrinology7198: The Consensus Conference On NET-Liver-Metastases - London Dec 13th 2012</a>).<wbr> Emory University is currently conducting a study evaluating pasireotide everolimus and SIRT in a phI/<wbr>II study that is examining the safety of the combination.<wbr> The study is scheduled to complete by the end of this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Reimbursement Development For Sirtex</STRONG> </div><div>Regarding the recent development for Sirtex in the UK, Sir-Spheres represent the first treatement under the new Commissioning through Evaluation (CtE) initiative to be funded within defined parameters in a small number of participating centres and within an explicit evaluation programm for a period of 1-2 years.<wbr> The CtE allows treatments or services that are not routinely funded by the NHS.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7475">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-07T17:55:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-07T17:55:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights of Allergan's Activities at WCN 2013 (Sept. 21-26 Vienna, Austria)</title>
	<pubDate>2013-10-07T15:26:56+02:00</pubDate>
	<wp:post_id>4804</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan's symposium focused on the effect of BOTOX(R) on sensory and motor pathways, and the evidence for its role across cervical dystonia (CD), chronic migraine (CM), and neurogenic detrusor overactivity (NDO).<wbr> The possible direct or indirect benefit of BoNT-A on the non-motor symptoms of CD was discussed, among other key topics highlighted below.<wbr> The presented posters covered baseline data from CD-PROBE, as well as results of three studies and safety results from a pooled analysis in lower limb spasticity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Professor O.<wbr> Dolly</STRONG> (Mayo Clinic College of Medicine, Scottsdale, Arizona) concluded a very scientific session outlining that BoNT-A is a versatile inhibitor of the exocytosis of cell mediators from motor, autonomic and sensory neurons that displays specificity, potency, prolonged clinical benefit, and a well proven safety profile.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_3_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">For <STRONG>Doctor Marion Simonetta-Moreau</STRONG> (Toulouse U.<wbr> Hospital, Toulouse, France) cervical dystonia is more than a motor condition.<wbr> Patients with CD frequently meet criteria for anxiety disorders, especially social phobia (71%) and major depressive disorder (present in about 15-55% of patients).<wbr> </div><div style="margin-bottom: 10px;">She highlighted that pain is present in 67-75% of CD patients and can be the most disabling feature of the disease.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_5_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Non-motor symptoms contribute significantly to the functional disability induced by CD, and have negative impact on health-related QoL, and could represent therapeutic targets to relieve dystonia.<wbr> </div><div style="margin-bottom: 10px;">She concluded that : </div><div style="margin-bottom: 10px;">- there is a need for a scale that considers both motor AND non-motor symptoms in CD, </div><div style="margin-bottom: 10px;">- multidisciplinary burden care is imperative (neurologists, physiotherapists, psychiatrics and pain specialists), </div><div style="margin-bottom: 10px;">- BoNT injections are helpful to alleviate sensorimotor symptoms but often not enough.<wbr> </div><div style="margin-bottom: 10px;"><U>During a 45-minute "Meet the Expert" session</U> hosted on Allergan exhibition booth, she was questionned on dysphagia, pain in CD, and doses.<wbr> </div><div style="margin-bottom: 10px;">She answered that : </div><div style="margin-bottom: 10px;">- incidence of dysphagia after injection depends on 1-/<wbr>dose injected 2-/<wbr>the product and 3-/<wbr>the volume of the muscles.<wbr> </div><div style="margin-bottom: 10px;">- pain in CD is not completely explained by the contractions and the musculoskeletal forces.<wbr> There is a strong evidence that BoNT also has effect on other neuromediators involved in pain.<wbr> </div><div style="margin-bottom: 10px;">- doses depend on the volume of the muscles.<wbr> For example, women at first injection not up to 40 U, and for 2nd injection up to 60U.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Professor Clare Fowler</STRONG> (UK) presented the results of two Ph3 trials (DIGNITY), which demonstrate that the targeted sensorimotor action of BOTIX(R) significantly reduced the number of UI episodes experienced by patients with either MS or SCI allowing 37% of patients to achieve complete continence at wk6 vs only 9% with placebo (Kennelly M, et al.<wbr> <EM>J Urol</EM> 2013;81:491-7).<wbr> </div><div style="margin-bottom: 10px;">She concluded that: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_6_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Professor David Dodick</STRONG> (USA) started his presentation by highlighting the global prevalence of chronic migraine (CM), that affects 1-3% of the population WW.<wbr> The condition is associated with sensitisation of central sensory neural pathways and functional/<wbr>structural brain changes.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_7_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">CM is responsive to BoNT-A (BOTOX) due to its effect on the sensory afferent pathways.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Pain at Baseline</STRONG> </div><div style="margin-bottom: 10px;">CD is the most common focal movement disorder, and pain is one of its most common and disabling features (Albanese A, et al.<wbr> <EM>Mov Disord</EM>.<wbr> 2013;28:863-873).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>OnabotulinumtoxinA Efficacy in Lower Limb Spasticity: Results of Three Studies (full poster attached )</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>300U significantly decreases ankle flexor tone in adults with post strole lower lib spasticity.<wbr></LI>
<LI>Treated patients experienced greater improvements per the investigator's overall assessment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Neurorehabilitation OnabotulinumtoxinA in lower limb spasticity: Safety results from a pooled analysis</STRONG> </div><div><UL><LI>OnabotulinumtoxinA treatment in LLS was well tolerated.<wbr> The majority of AEswere considered not related to onabotulinumtoxinA, and treatment-related AEs were consistent with the known mechanism of action of onabotulinumtoxinA.<wbr></LI>
</UL> </div><!-- Comment details --><a name="neurology7196attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_2_OnabotulinumtoxinA%20efficacy%20in%20LLS%255fresults%20of%20three%20studies.pdf">OnabotulinumtoxinA efficacy in LLS_results of three studies.pdf</a>&nbsp;&nbsp;(164,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_3_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(129 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_4_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(25,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_5_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(24,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_6_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(46,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7196_7_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(85,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7196">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-07T15:26:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-07T15:26:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tekmira Presents PhI NET Data At NANETS Meeting</title>
	<pubDate>2013-10-07T15:26:13+02:00</pubDate>
	<wp:post_id>4805</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Late last week, Tekmira presented data from a phI study with 
its polo-like kinase inhibitor TKM-PLK-1 at NANETS.<wbr> The study was 
undertaken in 36 advanced cancer patients including two patients with 
GI-NET.<wbr> The reduction in Chromagainin levels seen with the drug and 
the patient's response to treatment has supported the initiation of a phI/<wbr>II 
study in NET &amp; ACC patients, a trial that is now ongoing and 
expected to read-out in mid 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhI Study Results</STRONG> </div><div style="margin-bottom: 10px;">40%(6 out of 15) of patients in the phI study evaluable for response, treated 
at a dose equal to or greater than 0.<wbr>6 mg/<wbr>kg, showed clinical benefit.<wbr> </div><div style="margin-bottom: 10px;">Of the 36 patients enrolled, three out of the four ACC patients (75%) treated 
with TKM-PLK1 achieved stable disease, including one patient who saw a 19.<wbr>3% 
reduction in tumor size and is still on study receiving TKM-PLK1.<wbr> </div><div style="margin-bottom: 10px;">Of the two GI-NET patients enrolled, both experienced clinical benefit: one 
patient had a partial response based on RECIST criteria, and the other GI-NET 
patient achieved stable disease and showed a greater than 50% reduction in 
Chromogranin-A (CgA) levels, a key biomarker used to predict clinical outcome 
and tumor response.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps<BR></STRONG>The company has stated that it is are 
encouraged that a GI-NET patient who achieved stable disease showed a greater 
than 50% decline in CgA levels  and that it intends to CgA data 
in its ongoing TKM-PLK1 Phase I/<wbr>II clinical trial.<wbr> </div><div style="margin-bottom: 10px;">It expects to have results from this completed trial by mid-2014 and 
if the data is postiive commence a pivotal trial in GI-NET in 
2014.<wbr> </div><div>The company is hosting an R&amp;D investor presentation tomorrow at 4pm EST 
to review this data and company pipeline information in more detail.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7492c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Last Thursday Tekmira raised </SPAN><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">$30 million through the sale of 3.<wbr>8 million shares at $8 in a follow-on underwritten by Stifel and Maxim Group.<wbr> Tekmira proposed the offering late Wednesday, when its share price on NASDAQ was $8.<wbr>82.<wbr> Tekmira's lead internal candidate is </SPAN>TKM-PLK1<SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">, which is in Phase I/<wbr>II testing to treat advanced gastrointestinal neuroendocrine tumors and adrenocortical carcinoma, with data expected in mid-2014.<wbr> TKM-PLK1 comprises short interfering RNA (siRNA) targeting </SPAN>polo-like kinase 1 <SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;"> formulated with the company's lipid nanoparticle (LNP) technology.<wbr></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7474">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-07T15:26:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-07T15:26:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Reports Results of Ph1/2 Trial with its Norovirus Vaccine</title>
	<pubDate>2013-10-07T11:13:19+02:00</pubDate>
	<wp:post_id>4806</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda highlighted the data from the study at an IDWeek 2013-sponsored press conference.<wbr> <SPAN style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/21px Arial, 'Hiragino Kaku Gothic Pro', sans-serif, Helvetica, Geneva; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/21px Arial, 'Hiragino Kaku Gothic Pro', sans-serif, Helvetica, Geneva; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/21px Arial, 'Hiragino Kaku Gothic Pro', sans-serif, Helvetica, Geneva; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.takeda.com/news/2013/20131007_6021.html">http:/<wbr>/<wbr>www.<wbr>takeda.<wbr>com/<wbr>news/<wbr>2013/<wbr>20131007_6021.<wbr>html</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><A href="http://www.cdc.gov/norovirus/hcp/clinical-overview.html">http:/<wbr>/<wbr>www.<wbr>cdc.<wbr>gov/<wbr>norovirus/<wbr>hcp/<wbr>clinical-overview.<wbr>html</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1914">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-07T11:13:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-07T11:13:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Evolus to Sell Daewoong's Botulinum Toxin (Nabota) in the US and EU Markets</title>
	<pubDate>2013-10-07T10:27:54+02:00</pubDate>
	<wp:post_id>4807</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to an article published in the Korea Herald newspaper, the deal was signed end of September between Daewoong and Evolus, a US biotech company founded by Allergan veterans, in a bid to sell the products as early as 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Designed to start regulatory process for approval of BoNT-A in the EU and US.<wbr> </div><div style="margin-bottom: 10px;">Daewoong to export the toxin, which will be marketed as Nabota, while Evolus will be in charge of clinical tests.<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.koreaherald.com/view.php?ud=20130930001079">http:/<wbr>/<wbr>www.<wbr>koreaherald.<wbr>com/<wbr>view.<wbr>php?ud=20130930001079</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7191_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7151" class="defaultlink">Neurology7151: Comparison Study of Daewoong's DWP450 Vs.<wbr> Botox®  for Post Stroke Upper Limb Spasticity</a>.<wbr></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=6487" class="defaultlink">Neurology6487: New Trial of Daewoong's Botulinum Toxin for Glabellar Line</a>.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>- Acquired by private equity investor Strathspey Crown (Financial details of the acquisition were not disclosed).<wbr> </div><!-- Comment details --><a name="neurology7191attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7191_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7191_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(87,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7191">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-07T10:27:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-07T10:27:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>WCN 2013 (Sept. 21-26 Vienna, Austria) - How to Maximize BoNT-A Effects for Post-Stroke Spasticity ?</title>
	<pubDate>2013-10-04T17:22:44+02:00</pubDate>
	<wp:post_id>4808</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ryuji Kaji MD, PhD (Department of Neurology, Tokushima U.<wbr> Hospital) started his presentation with key figures of stroke in Japan, where Botox was approved in October 2010 for use in upper and lower limb spasticity (including arm and thigh) caused by any diseases other than ALS.<wbr> Outlining that spasticity is a syndrome of motor dysfunction caused by loss of upper motor neuron and its maladaptive plasticity, he discussed his 'clinical pearls' to face the challenge of botulinum treatment in PSS and the crucial role of rehabilitation after injection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Facts &amp; Figures of Stroke in Japan</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>2,830,000 patients (estimated 2012)
</LI>
<LI>Less patients die of stroke (5 year survival 60.<wbr>9%)
</LI>
<LI>Increase in number of patients suffering from its residual symptoms, and care for those costs more than 2,000 billion Yen (20 billion US $) per year.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>BoNT-A Mechanism of Action</STRONG> </div><div style="margin-bottom: 10px;">Ryuji Kaji selected 3 slides showing : </div><div style="margin-bottom: 10px;">- Intrafusal fibers are also affected by botulinum toxin (Rosales et al.<wbr> Muscles Nerves 1996).<wbr> </div><div style="margin-bottom: 10px;"><P align="left" style="padding-left: 30px;">- Rosales et al.<wbr> din both extrafusal and intrafusal muscle fibres in the biceps femoris of Wistar rats after injection of botulinum toxin type A.<wbr> After BT injection muscle action potentials elicited by stimulation were abolished in both, extrafusal and intrafusal fibres, and spindle afferent discharges were progressively reduced.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">- Central actions of BOTOX (Caleo et al.<wbr> 2009)</P> </div><div style="margin-bottom: 10px;"><P align="left" style="padding-left: 30px;">Nowadays there is evidence that after i.<wbr>m.<wbr> injection BTX-A might exert CNS effects, partially ascribed to plastic rearrangements subsequent to the peripheral blockade and partially due to retrograde axonal transport and direct BTX-A central effects.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">- BoNT-A modifies the activity of the spinal recurrent inhibitory pathways, when injected at muscular level, in humans (Marchand-Pauvert V, Aymard C, Giboin LS, Dominici F, Rossi A, Mazzocchio R.<wbr> - J Physiol.<wbr> 2013 Feb 15;591(Pt 4):1017-29. doi: 10.<wbr>1113/<wbr>jphysiol.<wbr>2012.<wbr>239178.<wbr> Epub 2012 Oct 8).<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">He also presented a recent slide showing the immunohistochemistry of SNAP25 degradation product after injection of 10U type A BoNT into L5 muscle L5 segment of the spinal cord (Koizumi, Goto, Kohda, Kozaki, Torii, Kaji - submitted).<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Clinical Pearl 1 - </STRONG>make wanted muscves contract immediately after injection or electriclly stimulated</P> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Pearl 2 - </STRONG>Treat key muscles </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;">- Upper limb: pect maojr, subscapularis; biceps; brachioradialis; PT; FCR FDS; FDP; Add Pol; lumbricales, FPL</P> </div><div style="margin-bottom: 10px;"><P style="padding-left: 30px;">- Lower limb: TP; med gastroc; adductors, med hamstrings, FDL; EHL; QF (excl.<wbr> rectus femoris)</P> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Pearl 3 - </STRONG>Intensive Rehabilitation after BoNT-A Injection </div><div style="margin-bottom: 10px;">- goal setting of tasks (use chopsticks, hold spoon .<wbr>.<wbr>.<wbr>) </div><div style="margin-bottom: 10px;">- approx 3 hours (intensive activation (active + passive) of injected muscles </div><div style="margin-bottom: 10px;">- approx 3 days (continued use of injected muscles (2 hrs + 2 hrs) </div><div style="margin-bottom: 10px;">- approx 7 days (task training) </div><div style="margin-bottom: 10px;"><STRONG>Key Messages</STRONG> </div><div style="margin-bottom: 10px;">He concluded that active motor function can be regained using BoNT-A </div><div><UL><LI>- if immediately followed by intensive rehabilitation
</LI>
<LI>- with repeated injection at min intervals
</LI>
<LI>- with good-directed approach
</LI>
<LI>- observing injections into certain key muscles
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7182">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-04T17:22:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-04T17:22:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESMO Intelligence Part 1- New Hormonal Prostate Cancer Therapy Data</title>
	<pubDate>2013-10-03T17:57:07+02:00</pubDate>
	<wp:post_id>4809</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: One of the more fascinating congress sessions was the preferred paper oral abstract session on prostate cancer held last Saturday.<wbr> It highlighted both "stunning new waterfall plot" data with enzalutamide in hormone naive patients, combination therapy data with enzalutamide and abiraterone in CRPC patients demonstrating that it can be safely combined, phII data on Orion's new androgen antagonists ODM-201 and new cardiovascular risk data with degarelix.<wbr> One consequence of the new combination data is that a PhIII study evaluating ABI/<wbr>ENZ will now commence.<wbr> It was recently listed in ClinicalTrials.<wbr>gov and is poised to commence by the end of the year.<wbr> Overall suvival over a 5 year timeframe will be the primary endpoint.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Enzalutamide Hormone Naive Prostate Cancer Data</STRONG> </div><div style="margin-bottom: 10px;">Matthew Smith (Massachusetts General Hospital Cancer Center) presented the highly anticipated phII data from an open-label singe arm study of enzalutamide in patients with hormone naive prostate cancer (see study design below).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">40% of patients entered into the study had detectable metastases.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">As noted there were no cases of seizure observed.<wbr> When Smith was asked if the gyaecomastia could be treated with tamoxifen as is often done when patients experience painful gynaecomastia with bicalutamide, he stated that a choice was made not to do this in this phII study but it would be a reasonable strategy if the drug is to move forward.<wbr> Someone else asked about the impact of enzalutamide on sexual function and it was noted that this was not evaluated comprehensively in this study.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Smith concluded that:- </div><div style="margin-bottom: 10px;"><UL><LI>Enzalutamide monotherapy achieved a high PSA resopnse rate and a marked PSA decine
</LI>
<LI>The PSA decline was maintained beyond 25 weeks and up to 1 year in patients who continued treatment
</LI>
<LI>In contrast to castration, enzalutamide monotherapy was associated with stable bone mineral density and small changes in serum cholesterol and tryglicerides
</LI>
<LI>The assessed endocrine changes and AEs were consitent with potent androgen receptor inhibition
</LI>
</UL> </div><div style="margin-bottom: 10px;">He stated that in his peronal opinion the data does support the phIII development of enzalutamide for this indication but he acknowledged that the regulatory pathway is challenging, "very challenging" but the prospect of such a study is under consideration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ODM-201 (Orion/<wbr>Endo) Data</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_19_ScreenCapture24.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_20_ScreenCapture26.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_21_ScreenCapture27.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_22_ScreenCapture28.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_23_ScreenCapture29.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_24_ScreenCapture30.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_25_ScreenCapture31.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_26_ScreenCapture32.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Enzalutamide/<wbr>Abiraterone Combination Data</STRONG> </div><div style="margin-bottom: 10px;">Eleni Efstathiou (MD Anderson Cancer Centre) presented preliminary data on enzalutamide/<wbr>abiraterone combination therapy, a study funded by Astellas, which appears to demonstrate how co-targeting avoids the adaptive response with either agent alone.<wbr> Monotherapy with enzalutamide increases testosterone and decreases concentrations of the androgen receptor whereas abiraterone does the reverse.<wbr> The combination seemingly decreases both.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_9_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_13_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_14_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_27_ScreenCapture33.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Degarelix Data</STRONG> </div><div style="margin-bottom: 10px;">Bertrand Tombal (Belgium) presented the next paper on Degarelix and the pooled analysis from 2328 patients, 1491 treated with degarelix and 837 with LHRH-agonists highlighting in his slides the benefit of degarelix compared to LHRH-agonist in terms of PSA PFS.<wbr> Data such as this has been presented before showing that the more beneficial effects is seen in those patients with a higher burden of disease i.<wbr>e.<wbr> those patients with a PSA&gt;20-ng/<wbr>ml (HR0.<wbr>74 p=0.<wbr>057).<wbr> He highlighted data showing a lower probability of muscular skeletal events but the main focus of his presentation was on the lower risk of CV events (see slide below) especially in patients with baseline CV disease.<wbr> These patients experience a risk reduction of 64% at 1 year.<wbr> He acknowledged that the data shown in total probably doesn't completely prove overall that antagonists are overall better than agonists and he also noted that at this juncture there is no standard regulatory path to validate this with the regulators.<wbr> He conluded by saying that both agonists and antagonists are fit for purpose but it is very difficult to see how antagonists will replace agonist.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_10_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">Gerard Attard (UK Royal Marsden) reviewed all four of these key hormonal therapy abstracts in reverse order.<wbr> He questioned:- "Are we done with hormonal therapy?" and stated "Clearly not there are different drugs/<wbr>different regimens/<wbr>combination that definitely require further evaluation.<wbr> </div><div style="margin-bottom: 10px;">Reviewing the Degarelix data, he noted that practice has assumed that orchiectomy, LHRH-agonists and antagonists have equal efficacy but he acknowledged that this may not be the case with the degarelix data demonstrating a significant benefit in terms of PSA PFS for patients treated with degarelix significant benefit for patients with a higher baseline PSA.<wbr> You can only speculate about the reason for this and suggested one possible explanation suggested by a recent paper is that resistance associated with LHRH-agonists may be overcome with the antagonists.<wbr> We could design a relatively easy experiment to test this utilising an antagonist in those progressin on an agonist I think there is a study already aiming to do this.<wbr> </div><div style="margin-bottom: 10px;">He also speculated that lower risk of CV events could be due to that action of antagonists on extra pituitary LHRH receptors but in terms of the question as to whether standard practice should change accept the limitations of this unplanned analysis he advocated it should not at this stage, as some of the results have yet to be properly explained mechanistically enough to support such action.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_11_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">With the recent approval of several new agents for CRPC, he acknowledged that it is tempting to consider moving these drugs into an earlier and earlier treatment setting.<wbr> The Stampede study he noted has been designed to rapidly assess the effects of these new drugs in patients about to start ADT.<wbr> </div><div style="margin-bottom: 10px;">Attard postulated that Mathew Smith's data raises the possibility of replacing or delaying the use of agonists and antagonists with an agent that has a reduced risk of causing metabolic effects and less propensity to cause changes in bone mineral density.<wbr> However, the risk of doing this is that you see a lower level of activity and a shorter duration of benefit due to the higher levels of testosterone that occur with this drug.<wbr> So whilst the "stunning waterfall plot" observed confirms activity and activity higher than that seen with bicalutamide a couple of decades ago, althought the populations are not the same, he suggested that the limitations of the study are that there is:- </div><div style="margin-bottom: 10px;"><UL><LI>no data on long-term follow-up, side-effects and future response
</LI>
<LI>no comparison with bicalutamide to know whether enzalutamide is more effective in HNPC we cannot assume superiority: and,
</LI>
<LI>no comparitive data with an LHRH-agonist
</LI>
</UL> </div><div style="margin-bottom: 10px;">Moving on to the ODM-201 data, Attard suggested that we are in a situation where we might say we have seen this data before but emphasised that it shouldn't take anything away from the ver significant activity shown with this agent.<wbr> There is clearly a suggestion of very high activity at the 1400mg dose, enough to speculate whether this drug may be able to reverse enzalutamide resistance.<wbr> However, in terms of activity after abiraterone, he noted that clearly from the waterfall plots shown by Karim, the response rate is quite modest indicating some level of cross resistance between AR antagonists and Cyp17 inhibitors.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_12_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;">Attard continued by acknowledging the temptation to look at combination therapy, accepting the low level of activity seen with sequential Cyp 17/<wbr>AR antagonsit use.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_17_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;">Attard noted that combination study data presented by E confirms tolerability, provides important results for translational research but that the single arm nature of the study with two highly active drugs needs validation in a larger treatment setting.<wbr> The newly listed ALLIANCE Oncology Group study (NCT01949337) should help to address this question.<wbr> Mike Morris at Memorial Sloane Kettering is the Principal Investigator and the maximun number of patients to be recruited to this study is 1428.<wbr> The study is scheduled to start by the end of this year and to conclude in terms of primary endpoint (OS) in December 2019.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_18_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_15_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_16_ScreenCapture19.jpg"> </div><div>This report was compiled by Jacquie Cantle (Competitive Intelligence) in collaboration with Jenny Wu (Scientific Intelligence) </div><!-- Comment details --><a name="oncology9201attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(186,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(207,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(206 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(190,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(185,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(190,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(180,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(179,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_9_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(113 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_10_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(123,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_11_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(122,9 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_12_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(143,9 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_13_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(124,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_14_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(112,8 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_15_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(120,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_16_ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(112,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_17_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(115,1 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_18_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(107,6 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_19_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(146,5 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_20_ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(158,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_21_ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(155,2 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_22_ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(150,3 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_23_ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(136,6 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_24_ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(152,9 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_25_ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(144,1 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_26_ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(137 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9201_27_ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(116,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9201">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-03T17:57:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-03T17:57:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sandoz' Nick Haggar Named New EGA President</title>
	<pubDate>2013-10-02T18:13:59+02:00</pubDate>
	<wp:post_id>4810</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P class="intro">Comment: The European Generic medicines Association (EGA) has named Sandoz’s N.<wbr> Haggar as the new incoming president of the European generic medicines industry body.<wbr> He will take over the role on October 8, 2013 alongside his responsibilities at Sandoz as Head of Western Europe, Middle East and Africa.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">On October 8, 2013, Nick will speak about the value of generic and biosimilar medicines at the "Industrial Policy Conference" in Brussels, hosted by the EGA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The EGA is the official representative body of the European generic and biosimilar pharmaceutical industry.<wbr> Founded in 1993, the EGA represent generic pharmaceutical companies and their subsidiaries throughout Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Purpose and Objectives</STRONG> (<A href="http://www.egagenerics.com/index.php/about-us/purpose-and-objectives">http:/<wbr>/<wbr>www.<wbr>egagenerics.<wbr>com/<wbr>index.<wbr>php/<wbr>about-us/<wbr>purpose-and-objectives</A>) </div><div style="margin-bottom: 10px;"><STRONG>Structure</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10637_1_ScreenCapture1.jpg"> </div><div><EM>Source: Sandoz</EM> </div><!-- Comment details --><a name="pharmaworld10637attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10637_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10637">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-02T18:13:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-02T18:13:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Teva Forms Global Research Collaboration in Huntington Disease (HD)</title>
	<pubDate>2013-10-02T16:18:56+02:00</pubDate>
	<wp:post_id>4811</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of this colaboration is to create a comprehensive understanding of HD and to drive insights into neuroprotective therapeutic approaches in the disease.<wbr> The collaboration brings together the field's leading scientific researchers from Singapore, the UK, Canada, Germany, USA and Israel in a coordinated and intense research program developed in Israel by Dr.<wbr> Michael Hayden, one of the foremost experts on Huntington disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The focus of the program is the interaction between laquinimod, a neuroprotective agent currently being investigated in multiple sclerosis, and various molecular pathways operative in Huntington disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Of note</STRONG> analysts at Morgan Stanley expect Teva to move Laquinimod for Huntington's disease into late-stage development in 2014 (<EM>Teva Mgmt.<wbr> bullish on Copax 3TW - report from Sept 9 2013</EM>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb"><U>Prof.<wbr> Sarah Tabrizi</U>, Professor of Clinical Neurology, University College London (UCL), Institute of Neurology </LI>
<LI class="bwlistitemmargb"><U>Dr.<wbr> Mahmoud A.<wbr> Pouladi</U>, Translational Laboratory in Genetic Medicine (TLGM) at the National University of Singapore (NUS) and Biomedical Science Institutes (BMSI) </LI>
<LI class="bwlistitemmargb"><U>Prof.<wbr> Ralf Gold</U>, Department of Neurology, St.<wbr> Josef Hospital/<wbr>Ruhr University Bochum, Germany, </LI>
<LI class="bwlistitemmargb"><U>Dr.<wbr> Blair Leavitt</U>, Department of Medical Genetics, The University of British Colombia </LI>
<LI class="bwlistitemmargb"><U>Prof.<wbr> Gareth John</U>, Associate Professor Neurology, Mount Sinai School of Medicine </LI>
<LI class="bwlistitemmargb"><U>Prof.<wbr> Daniel Offen</U>, Director, the Neuroscience Laboratory at Felsenstein Medical Research Center, Sackler School of Medicine, Tel Aviv university.<wbr></LI>
</UL> </div><div><P class="bwlistitemmargb"><EM>Source: Teva Pharm</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7178">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-02T16:18:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-02T16:18:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acino to be Acquired for $439M</title>
	<pubDate>2013-10-02T09:20:23+02:00</pubDate>
	<wp:post_id>4812</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Avista Capital Partners and Nordic Capital are jointly launching a public tender offer to acquire all outstanding shares of Acino for a cash price of CHF 115.<wbr>00 per share (approx.<wbr> CHF 398M).<wbr> This represents a 33% premium over Acino’s closing share price on October 1, 2013, the last trading day prior to the pre-announcement of the offer, and a 53% premium to the volume weighted average price during the last 60 trading days prior to preannouncement of the offer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>- to gain access to financial funds to pursue its business expansion </LI>
<LI>- to further exploit the potential of the company’s in-house innovation</LI>
<LI>- to drive sales growth</LI>
<LI>- to support profit improvements</LI>
<LI>- to strengthen its competitive position</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Timelines: The acceptance period for the offer is expected to commence on October 21, 2013 and to end on November 15, 2013 </div><div style="margin-bottom: 10px;">Financial: Under the terms of the tender offer, Pharma Strategy Partners GmbH, a wholly-owned subsidiary of Avista and Nordic Capital, offers to purchase all outstanding shares of Acino for an offer price of CHF 115.<wbr>00 in cash per share, corresponding to an offer value for all shares of Acino of approximately CHF 398 million.<wbr> </div><div><EM>Source: Acino</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20131231&edate=20130901&rec=234">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-02T09:20:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-02T09:20:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>WCN 2013 (Sept. 21-26 Vienna, Austria) - Comparative Studies of Botulinum Toxins for CD</title>
	<pubDate>2013-10-01T16:56:28+02:00</pubDate>
	<wp:post_id>4813</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During one of the first session dedicated to "therapeutic neurotoxins", Cynthia Comella (USA) presented results from comparative clinical studies with different botulinum toxins.<wbr> She ended the Q&amp;A session by indicationg that " .<wbr>.<wbr>.<wbr> each of the toxin works with very similar outcomes".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- onabotulinumtoxinA vs rimabotulinumtoxinB </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">- Two controlled studies have compared abobotulinumtoxinA vs onabotulinumtoxinA: </div><div style="margin-bottom: 10px;"><UL><LI>
1 study parallel arm design:</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>
1 study 3 period crossover design:</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">- One trial has directly compared incobotulinumtoxinA vs onatotulinumtoxinA in a non-inferiority study: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">She reported that: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">In conclusion she highlighted that: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="neurology7176attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(43,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(38,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(39,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(32,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(37,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(34,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(30,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(40 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(36,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7176_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(33,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7176">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-01T16:56:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-01T16:56:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Impact of Xeomin (incobotulinumtoxinA) on the QoL of Patients Following Treatment of Facial Lines</title>
	<pubDate>2013-10-01T15:08:21+02:00</pubDate>
	<wp:post_id>4814</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: While the present study was limited by small patient numbers recruited from a single center and the lack of a control group, the results support the contention that QoL is significantly improved following BoNT-A treatment.<wbr> These results, in combination with those of Dayan et al*, suggest that serious consideration should be given to incorporating the measurement of QoL as an outcome measure following BoNT-A treatment.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="sec" id="__abstractid946993">
<DIV>
<P id="__p1"><STRONG>Methods</STRONG></P>
<P>Quality of life was assessed using the Schedule for the Evaluation of Individual Quality of Life Direct-Weighting tool.<wbr> Patients identified the five areas of their life of the greatest importance to them, weighted the areas as to their relative importance, and rated their status in each area on a visual scale before treatment (old cues) and 28 days later (using both old cues and newly defined and weighted cues).<wbr> At both visits, patients also rated their overall quality of life using a visual analogue scale.<wbr> Patient satisfaction with their appearance was measured using a 10-point scale in conjunction with standardized photographs taken at each visit.<wbr> </P>
<P><STRONG>Results</STRONG></P>
<P>Fifty-three patients (median age 39.<wbr>5 years; 87% women) with moderate-to-severe wrinkles of the glabella, forehead, or crow’s feet were enrolled.<wbr> Treatment with incobotulinumtoxinA consistently resulted in a significant improvement in quality of life according to Schedule for the Evaluation of Individual Quality of Life Direct-Weighting tool index scores (old cues, <EM>P</EM>=0.<wbr>0006; new cues <EM>P</EM>=0.<wbr>0235) and patient assessment of their overall quality of life (<EM>P</EM>&lt;0.<wbr>0001 for both old and new cues).<wbr> Family, work, finance, relationships, and health were the five most frequently identified cues at each assessment.<wbr> No correlation between quality of life and satisfaction scores was found, although both were significantly increased after treatment.<wbr> </P>
<P><STRONG>Conclusion</STRONG></P>
<P>These results support the contention that quality of life is significantly improved following botulinum toxin A treatment and that consideration should be given to incorporating the measurement of quality of life as an outcome measure following botulinum toxin A treatment, especially as satisfaction does not correlate to quality of life.<wbr></P></DIV></DIV> </div><div style="margin-bottom: 10px;"> </div><div>Source: J Clin Aesthet Dermatol.<wbr> 2013 September; 6(9): 41–45.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7175">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-01T15:08:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-01T15:08:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Internal Promotions Within Merz North America</title>
	<pubDate>2013-10-01T13:56:24+02:00</pubDate>
	<wp:post_id>4815</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bhushan Hardas has been appointed Chief Scientific Officer, and Glenn Block to the position of VP &amp; U.<wbr>S Head of Neurosciences.<wbr> Bob Bennett will take the lead of Merz Pharma Canada.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7174">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-01T13:56:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-01T13:56:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Highlights its Most Promising Treatments In and Above Oncology</title>
	<pubDate>2013-10-01T10:09:21+02:00</pubDate>
	<wp:post_id>4816</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The London Investor event was an opportunity to discuss clinical data and development plans for key late-stage compounds, including lampalizumab (anti-factor D) in dry AMD, etrolizumab in ulcerative colitis, selected oncology compounds, and "follow on" drugs that Roche hopes will replace or breathe new life into old cancer products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9195_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9195_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Etrolizumab - Phase 3 Outlook</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9195_3_ScreenCapture3.jpg"> </div><div>Roche reported it expects to start a late-stage trial for etrolizumab in ulcerative colitis and in Crohn's disease in the first half of 2014.<wbr> </div><!-- Comment details --><a name="oncology9195attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9195_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9195_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(63,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9195_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(73,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9195">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-01T10:09:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-01T10:09:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Details of Astellas Innovation Management (AIM)</title>
	<pubDate>2013-10-01T09:59:05+02:00</pubDate>
	<wp:post_id>4817</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: President and CEO has established AIM to explore external opportunities, and to realize innovation during the preclinical development stage.<wbr> The initiative is part of the company's plan announced last May, which aims at reshaping its research framework.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In May, Astellas announced plans to reshape its research framework by introducing new initiatives to further enhance the ability to generate innovative drugs (see <A href="http://www.astellas.com/en/corporate/news/detail/reshaping-research-framework-t.html">http:/<wbr>/<wbr>www.<wbr>astellas.<wbr>com/<wbr>en/<wbr>corporate/<wbr>news/<wbr>detail/<wbr>reshaping-research-framework-t.<wbr>html</A>) </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 28.3pt"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-LEFT: 28.3pt"></P> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10635">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-10-01T09:59:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-10-01T09:59:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Strengthening the Pharmaceutical Industry's Supply Chain - New McKinsey Report</title>
	<pubDate>2013-09-30T17:55:09+02:00</pubDate>
	<wp:post_id>4818</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: McKinsey has just published a report covering a 5-step plan to strengthen the industry's supply chain.<wbr> Operational comparisons with other industries suggests there is scope for improvement and 5 specific capabilities are identified in the report that it suggests could have a dramatic impact on performance and bottom line.<wbr> </div><div style="margin-bottom: 10px;">A copy of the full report is available to download and attached for review.<wbr> </div><div style="margin-bottom: 10px;">Supply chains now account for nearly 25% of pharmaceutical costs and more than 40% of medical device costs.<wbr> The annual spending is about $240bn on pharmaceuticals and $122m on devices.<wbr> Even minor efficiency gains, it is claimed, could free up billions of dollars for investment elsewhere.<wbr> In fact , it is suggested.<wbr> that if the sector adopted straightforward advances well established in other industries costs could fall by $130bn.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10632_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Mckinsey's 5-step plan focuses on:- </div><div style="margin-bottom: 10px;"><UL><LI>better segmentation of products, markets and customers;
</LI>
<LI>greater agility to reduce costs and increase flexibility
</LI>
<LI>measurement and benchmarking
</LI>
<LI>alignment with global standards
</LI>
<LI>greater collaboration across the health-care value chain.<wbr>
</LI>
</UL> </div><div><BR>Source:<A href="http://www.mckinsey.com/Insights/Health_systems_and_services/Strengthening_health_cares_supply_chain_A_five_step_plan?cid=other-eml-alt-mip-mck-oth-1309">http:/<wbr>/<wbr>www.<wbr>mckinsey.<wbr>com/<wbr>Insights/<wbr>Health_systems_and_services/<wbr>Strengthening_health_cares_supply_chain_A_five_step_plan?cid=other-eml-alt-mip-mck-oth-1309</A> </div><!-- Comment details --><a name="pharmaworld10632attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10632_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10632_2_Building%20new%20strengths%20in%20the%20health%2dcare%20supply%20chain.pdf">Building new strengths in the health-care supply chain.pdf</a>&nbsp;&nbsp;(870,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10632">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-30T17:55:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-30T17:55:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PDE10 Inhibitor Poised To Enter Ph2 For Huntington's Disease</title>
	<pubDate>2013-09-30T17:24:49+02:00</pubDate>
	<wp:post_id>4819</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Omeros Corporation has announced that OMS824, its phosphodiesterase 10 (PDE10) inhibitor, has received orphan drug designation from the U.<wbr>S.<wbr> FDA for the treatment of Huntington's disease.<wbr> Omeros plans to begin a Phase 2 clinical trial evaluating OMS824 in patients with Huntington's disease later this year.<wbr> </div><div style="margin-bottom: 10px;">OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including Huntington's disease and schizophrenia.<wbr> </div><div style="margin-bottom: 10px;">As previously reported, Phase 1 clinical results in healthy subjects demonstrated that OMS824 is well tolerated and suggest that it has a better clinical therapeutic index or "safety factor" than other PDE10 inhibitors in development.<wbr> </div><div style="margin-bottom: 10px;">A Phase 2 clinical trial of the drug is already underway in patients with schizophrenia.<wbr> </div><div style="margin-bottom: 10px;">Other PDE10 inhibitors in development for Huntington's Disease include Pfizer's PF-2545920.<wbr> A phII study in early PD is listed in ClinicalTrials.<wbr>gov but as of this month it is listed as not yet open for recruitment.<wbr> The other company with a PDE-10 inhibitor in discovery is Zenobia.<wbr> </div><div>Source: <A href="http://www.omeros.com/">www.<wbr>omeros.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7170">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-30T17:24:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-30T17:24:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence on Merz Ph3 Timelines for AUL and ALL Spasticity</title>
	<pubDate>2013-09-30T15:00:08+02:00</pubDate>
	<wp:post_id>4820</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Discussing with a Polish KOL at the WCN congress last week in Vienna, Jovita Balcaitiene and Sandrine Guillebaud have learnt that the PURE study (for AUL) is now complete, and the PLUS study (for ALL) delayed.<wbr> Details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><a href="http://clinicaltrials.gov/ct2/show/NCT01464307?term=%28PURE+OR+PLUS%29+AND+MERZ&amp;no_unk=Y&amp;rank=1" class="defaultlink">PLUS</a> - Reasons for the Delay</STRONG> </div><div style="margin-bottom: 10px;">According to the KOL, the study only has recruited half of participants.<wbr> The difficulty to recruiting comes from competitive trials from Ipsen and Allergan, and hemiplegic patients who prefer to be treated first for AUL.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinicaltrials.<wbr>gov source</STRONG> </div><div>The completion date for the PE of the PLUS study has changed to Q1:14 (from Q1:13) however the one for the PURE study remains unchanged (Q1:13).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7168">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-30T15:00:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-30T15:00:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New CEO to be Appointed at Bayer Healthcare</title>
	<pubDate>2013-09-30T12:36:52+02:00</pubDate>
	<wp:post_id>4821</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Olivier Brandicourt has been appointed Chairman of the Board of Management of Bayer HealthCare and member of the Bayer AG Executive Council effective November 1, 2013.<wbr> He will oversee the market launch of a range of potential blockbusters such as stroke prevention pill Xarelto, eye drug Eylea and cancer treatment Stivarga, and be responsible to translate successful drug trials into revenue growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic Rationale</STRONG> </div><div style="margin-bottom: 10px;">- Company's aspiration is to accelerate Healthcare sales growth to &euro;22bn in 2015 (to &euro;18.<wbr>6bn in 2012).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Brandicourt Short Bio</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Professional Activity</SPAN> </div><div style="margin-bottom: 10px;">Has 25 years of international experience in the pharmaceutical industry, including executive responsibilities in France, the United States, Canada and the United Kingdom.<wbr> </div><div style="margin-bottom: 10px;">Has been a member of the Executive Leadership Team of Pfizer Inc.<wbr>, New York, USA, for the last three years.<wbr> </div><div style="margin-bottom: 10px;">Until recently he was President and General Manager of the Emerging Markets and Established Products Business Units.<wbr> Before that he held senior operational positions as President of the Global Specialty Business Unit, and until 2012 he was head of the Global Primary Care Business Unit.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Education</SPAN> </div><div style="margin-bottom: 10px;">- Holds a medical degree with a subspecialty in infectious diseases and tropical medicine, as well as a master&rsquo;s degree in biology from Paris 12 University, France.<wbr> </div><div style="margin-bottom: 10px;">After completing his studies, Brandicourt spent two years in the Republic of Congo as a doctor and eight years with the Institute for Infectious and Tropical Diseases at Piti&eacute;-Salp&ecirc;tri&egrave;re Hospital in Paris, spending half this time in West and Central Africa working on malaria research.<wbr> </div><div><EM>Source: Bayer</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10631">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-30T12:36:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-30T12:36:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's Vision of Botulinum Toxin of the Future</title>
	<pubDate>2013-09-27T22:21:54+02:00</pubDate>
	<wp:post_id>4822</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Myriam Korn (Ipsen Germany) has forwarded an interesting flyer coming from Allergan booth at the congress of the German Association of Neurology (Dresden).<wbr> Please see details below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Botulinum toxin of the future (translation)</U></STRONG> </div><div style="margin-bottom: 10px;">Mutual inspiration of clinical practice and research pushed the enhancement of BOTOX&reg;.<wbr> In the domain of biochemistry and recombinant toxin development there are a lot of approaches in research, too, to achieve new targets as well as other active profiles.<wbr> </div><div style="margin-bottom: 10px;">Thus, for example, experiments have shown that botulinum toxin type A used for BOTOX&reg; could also be produced by E.<wbr> coli.<wbr> This minimizes not only the risks, as E.<wbr> coli does not produces dangerous spores - like Clostridium botulinum does, but also enables the production of further recombinant molecules, which are combining properties of different botulinum toxin types.<wbr> </div><div style="margin-bottom: 10px;">For example a chimera of the serotypes A and B has been developed, which showed a sustained duration of action in experimental.<wbr> For this effect, diverse distinctive properties of the different toxin serotypes were used: botulinum toxin type B has about four times more of receptor binding sites as type A.<wbr> The part of the type B protein, which is responsible for the binding protein, has been combined with protein fractions of the type A.<wbr> Thus, in the animal model there could be observed a significantly longer duration of action compared to a "normal" form of type A.<wbr> </div><div style="margin-bottom: 10px;">Countless combinations for transmitting properties of different serotypes are currently under research.<wbr> Let's wait and see what will be enforced and used clinically in the future.<wbr> It remains of strong interest.<wbr> </div><div>Attached the original version in Geman </div><!-- Comment details --><a name="neurology7166attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7166_1_Botulinumtoxin%20of%20the%20future.doc">Botulinumtoxin of the future.doc</a>&nbsp;&nbsp;(570,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7166">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-27T22:21:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-27T22:21:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New POC Trial with Anterios' ANT-1401 for Crow's Feet</title>
	<pubDate>2013-09-27T21:59:50+02:00</pubDate>
	<wp:post_id>4823</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The PE of the dose finding study will assess investigators Global Assessment Scale at 4 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details <a href="http://clinicaltrials.gov/ct2/show/NCT01951742?recr=Open&no_unk=Y&fund=2&rcv_s=08%2F27%2F2013&rank=123" class="defaultlink">NCT01951742</a></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx 133 men/<wbr>women </div><div style="margin-bottom: 10px;"><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">30 - 60 years of age
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">mild to moderate Crow's Feet wrinkles at rest
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">moderate to severe Crow's Feet wrinkles on contraction
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">willingness to refrain from any product affecting skin remodeling
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">female subjects must be not pregnant and non-lactating
</LI>
</UL> </div><div style="margin-bottom: 10px;">Start Date: Sept 2013 - Completion date: Dec 2013 /<wbr> January 2014 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7165">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-27T21:59:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-27T21:59:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merck Serono Current COO Appointed as CEO</title>
	<pubDate>2013-09-27T10:42:44+02:00</pubDate>
	<wp:post_id>4824</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Belén Garijo, who joined Merck in 2011, will succeed Stefan Oschmann as of Oct.<wbr> 1st.<wbr> Additional organizational changes are reported below.<wbr> </div><div style="margin-bottom: 10px;">- Annalisa Jenkins, the current head of global development and medical, has been appointed head of global R&amp;D for Merck Serono.<wbr> </div><div style="margin-bottom: 10px;">- Thierry Hulot, who currently leads Merck's biosimilars unit, was selected as head of global manufacturing and supply, replacing Jim Stewart, who was recently named chief information officer of Merck.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Merck aims to further tap into the global allergy market with a very competitive product range.<wbr> </div><div style="margin-bottom: 10px;">With its investments in the evolving biosimilars market, the company expects to benefit from rising demand for biotechnology solutions to address unmet medical and access needs in many parts of the world.<wbr><BR> </div><div style="margin-bottom: 10px;"><STRONG>Merck Serono Organic Growth by Product</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10629_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">- sales decline of Saizen in the U.<wbr>S.<wbr> and Europe.<wbr> </div><div><EM>Source: Company PR</EM> </div><!-- Comment details --><a name="pharmaworld10629attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10629_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(74,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10629">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-27T10:42:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-27T10:42:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results from a National Survey of Men with Advanced Prostate Cancer</title>
	<pubDate>2013-09-26T18:59:35+02:00</pubDate>
	<wp:post_id>4825</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas and <ORG value="NASDAQ-NMS:MDVN">Medivation announced results of a national survey of men with advanced prostate cancer and caregivers of men with advanced prostate cancer.<wbr> The survey was conducted online among 91 men with advanced prostate cancer and 100 caregivers of such men, and was designed to evaluate the physical and emotional impact of advanced prostate cancer on both patients and caregivers.<wbr></ORG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9194_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Key findings from patients who participated in the survey reveal: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Forty-one percent do not feel like people understand what they are going through in terms of managing and treating their prostate cancer.<wbr> Of these, 78 percent* wish people better understood the stress of coping with prostate cancer, and more than half wish others understood the inconvenience caused by prostate cancer (59 percent) or the side effects of treatment (also 59 percent).<wbr> 
</LI>
<LI>While many patient respondents reported feeling hopeful about their disease (58 percent), the greatest percentage said their disease makes them feel uncertain (62 percent).<wbr> Among other responses, 33 percent said they feel fearful, 32 percent feel sad, and 20 percent feel lonely or alone.<wbr> 
</LI>
<LI>There are disconnects in terms of patients' treatment priorities and what they perceive to be the priorities of their physicians.<wbr> While 66 percent of patients said that the level of discomfort they will experience is important or very important to them when choosing therapies, only 45 percent believe that this factor is important or very important to their physicians.<wbr> 
</LI>
<LI>Despite the older age of patients who participated in the survey (median age: 70 years), the Internet is an important source of information for them.<wbr> After their physicians, it is the most highly used source of information for patients and caregivers who participated in this survey.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Caregiver participants expressed considerable stress and anxiety, as well as a desire for more direct support networks.<wbr> Key findings include: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Seventy-three percent said they are concerned or very concerned about their ability to continue providing care over a long period of time.<wbr> 
</LI>
<LI>Caregivers' top areas of concern are their ability to help their patient cope with the physical and emotional effects of the disease (83 percent said they are concerned/<wbr>very concerned about each).<wbr> 
</LI>
<LI>Among the 93 percent of caregivers who reported experiencing troublesome feelings as a result of caregiving (e.<wbr>g.<wbr>, stress, sadness, fear, etc.<wbr>), 58 percent said they rely most on family members to help relieve these feelings.<wbr> 
</LI>
<LI>Among caregivers who expressed a desire for additional support, the most common request was for a support network or group.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Survey findings also suggest that many patient and caregiver respondents are overwhelmed by the volume of information available to them.<wbr> About one-third (35 percent) of patients said there is too much information available about prostate cancer to understand it all, and 47 percent of caregivers agreed with this statement.<wbr> These findings suggest the need for navigation tools that will help guide patients and caregivers to the information that is most relevant to them over the course of the disease.<wbr> </div><div><EM>Source: </EM><A href="http://investors.medivation.com/releasedetail.cfm?ReleaseID=793404"><EM>http:/<wbr>/<wbr>investors.<wbr>medivation.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=793404</EM></A> </div><!-- Comment details --><a name="oncology9194attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9194_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9194_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9194">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-26T18:59:35+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-26T18:59:35+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on COMET-1 Ph3 Trial of Exelixis' Cabozantinib for mCRPC</title>
	<pubDate>2013-09-26T18:46:12+02:00</pubDate>
	<wp:post_id>4826</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The enrollment target of 960 patients has been reached for COMET-1.<wbr> Exelixis continues to expect top-line data from COMET-1 and a second pivotal trial in mCRPC, COMET-2, in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9193_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">COMET-2 design <A href="http://www.clinicaltrials.gov/ct2/show/NCT01522443">http:/<wbr>/<wbr>www.<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01522443</A> </div><div style="margin-bottom: 10px;">COMET-1 design <A href="http://www.clinicaltrials.gov/ct2/show/NCT01605227?term=comet-1&amp;rank=1">http:/<wbr>/<wbr>www.<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01605227?term=comet-1&amp;rank=1</A> </div><div><EM>Source: Exelixis</EM> </div><!-- Comment details --><a name="oncology9193attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9193_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9193">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-26T18:46:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-26T18:46:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Another BTXA Developed in Korea</title>
	<pubDate>2013-09-26T16:04:29+02:00</pubDate>
	<wp:post_id>4827</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Ipsen Korea (Young-Eun Lee and Jung-Seung Lim)  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Highlights of the original article, published in DailyPharm indicates the following (translation done by the Team): </div><div style="margin-bottom: 10px;">- "Huons announced through the disclosure on 26th Sep, they start to invest KRW 8 bn for the new facilities to joint research and develop botulinum toxin with local bio venture company in Korea.<wbr> </div><div style="margin-bottom: 10px;">This bio venture company has completed the report to the government about the strain of botulinum toxin which they separated and identified and Huons made a contract with this company to do joint research.<wbr> </div><div style="margin-bottom: 10px;">Huons is also planning to complete the production facility by April 2014, start phase III study  by July 2014 and launch the product  1st half of 2016.<wbr> </div><div style="margin-bottom: 10px;">The company personnel says “Botulinum toxin treatment is the most popular cosmetic treatment but the competitors are very  few due to difficulties of development” and “Oversea market is our target as well as Korean market, leveraging the knowhow to get CE certification of Elravie in Europe.<wbr>” </div><div style="margin-bottom: 10px;"><EM>Source </EM> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Activity</U>: Korea-based company engaged in the manufacture of pharmaceuticals.<wbr> </div><div style="margin-bottom: 10px;"><U>Products</U>: remedies for the circulatory systems, digestive systems, endocrine systems, genitourinary systems, central nervous systems, autonomic nervous systems and respiratory systems, as well as other drugs, such as antibiotics, chemotherapeutics, anticancer drugs and obesity treatments, among others.<wbr> </div><div style="margin-bottom: 10px;">It also provides medical devices.<wbr> </div><div style="margin-bottom: 10px;"><U>Geo scope</U>: The Company distributes its pharmaceuticals within domestic market and to overseas markets.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7161">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-26T16:04:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-26T16:04:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SurePal™ Device Launched for Patients Using hGH</title>
	<pubDate>2013-09-26T13:44:06+02:00</pubDate>
	<wp:post_id>4828</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: SurePal™ is now available for patients in the UK, and will be launched globally.<wbr> The new device is a Sandoz innovation to be exclusively used with Omnitrope(R).<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7470_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Characteristics</U> </div><div style="margin-bottom: 10px;">SurePal™ is a medical device for Omnitrope with cartridges that require no reconstitution, or priming, and a sliding injection button that requires minimum force to operate.<wbr> </div><div style="margin-bottom: 10px;">Its safety features include non-interchangeable dose-specific cartridges, a dose memory function that remembers the patient’s daily dose and needle hider to reduce anxiety for patients afraid of needles.<wbr> </div><div style="margin-bottom: 10px;"><U>Regulary Status</U> </div><div style="margin-bottom: 10px;">Sandoz filed for approval of the SurePal™ injection pen for use with Omnitrope® with EU and US medicine authorities in 2013.<wbr> </div><div style="margin-bottom: 10px;">SurePal™ has been CE marked in accordance with EU laws on medical devices and is awaiting US FDA action.<wbr> </div><div><EM>Source: Sandoz</EM> </div><!-- Comment details --><a name="endocrinology7470attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7470_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(12,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7470">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-26T13:44:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-26T13:44:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aspireo's Somatoprim Gets Orphan Drug Designation in the US for Acromegaly</title>
	<pubDate>2013-09-26T12:02:18+02:00</pubDate>
	<wp:post_id>4829</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The decision is based on a comprehensive package of pre-clinical and clinical data showing that Somatoprim has the potential to be a safe and effective treatment for acromegaly and may provide a valuable treatment alternative to the many patients suffering from the disease or being faced with the significant side effects that come with current treatment options.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">FDA’s grant of orphan drug designation follows a similar decision by the European Commission in December.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7469_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Somatoprim (DG3173) is a novel and proprietary somatostatin analog (SSA) that is based on a novel amino acid composition and a unique backbone cyclization technology used for stabilization of the peptide.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
<DIV class="hfeed" id="content">
<DIV class="post-68 page type-page status-publish hentry entry">
<DIV class="entry-content">
<P><EM>Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.<wbr> Afargan M, Janson ET, Gelerman G, Rosenfeld R, Ziv O, Karpov O, Wolf A, Bracha M, Shohat D, Liapakis G, Gilon C, Hoffman A, Stephensky D, Oberg K.<wbr> Endocrinology.<wbr> 2001 Jan;142(1):477-86.</EM></P></DIV></DIV></DIV></LI>
<LI>
<DIV class="hfeed">
<DIV class="post-68 page type-page status-publish hentry entry">
<DIV class="entry-content">
<P><EM>PTR-3173 (somatoprim), a novel somatostatin analog with affinity for somatostatin receptors 2, 4 and 5 is a potent inhibitor of human GH secretion.<wbr> Shimon I, Rubinek T, Hadani M, Alhadef N.<wbr> J Endocrinol Invest.<wbr> 2004 Sep;27(8):721-7.</EM></P></DIV></DIV></DIV></LI>
<LI>
<DIV class="hfeed">
<DIV class="post-68 page type-page status-publish hentry entry">
<DIV class="entry-content">
<P><EM>Colao A, Auriemma RS, Lombardi G, Pivonello R.<wbr> Resistance to somatostatin analogs in acromegaly.<wbr> Endocr Rev.<wbr> 2011 Apr;32(2):247-71. Epub 2010 Dec 1.<wbr></EM></P></DIV></DIV></DIV></LI>
<LI>
<DIV class="hfeed">
<DIV class="post-68 page type-page status-publish hentry entry">
<DIV class="entry-content">
<P><EM>Plöckinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajkoczy P, Jakob W, Saeger W, Schulz S, Dohrmann C.<wbr>.<wbr> DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.<wbr> Eur J Endocrinol.<wbr> 2012 Feb;166(2):223-34. Epub 2011 Nov 7</EM></P></DIV></DIV></DIV></LI>
</UL> </div><div>From <A href="http://www.aspireopharma.com/">http:/<wbr>/<wbr>www.<wbr>aspireopharma.<wbr>com</A>, see <A href="http://www.aspireopharma.com/somatoprim/">original source</A>.<wbr> </div><!-- Comment details --><a name="endocrinology7469attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7469_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7469">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-26T12:02:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-26T12:02:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan and MedyTox Announce Licensing Agreement</title>
	<pubDate>2013-09-26T10:54:17+02:00</pubDate>
	<wp:post_id>4830</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><LOCATION value="LU/us.ca.irvine">Comment: Allergan and Medytox announced that they have entered into a license agreement pursuant to which, upon closing, <ORG value="NYSE:AGN">Allergan</ORG> will pay Medytox an upfront payment of U.<wbr>S.<wbr> <MONEY>$65 million</MONEY> and Medytox will grant <ORG value="NYSE:AGN">Allergan</ORG> exclusive rights, worldwide outside of </LOCATION><LOCATION value="LC/kr">Korea</LOCATION>, to develop and, if approved, commercialize certain neurotoxin product candidates currently in development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Part of the agreement is the potential liquid-injectable product.<wbr> </div><div style="margin-bottom: 10px;">Pursuant to the agreement, <ORG value="NYSE:AGN">Allergan</ORG> has also agreed to make additional contingent payments, including up to an aggregate of U.<wbr>S.<wbr> <MONEY>$116.<wbr>5 million</MONEY> upon achieving certain development milestones, up to an aggregate of U.<wbr>S.<wbr> <MONEY>$180.<wbr>5 million</MONEY> upon achieving certain commercialization milestones, and royalties on product sales.<wbr><I> </I> </div><div>The closing of the transaction is contingent on obtaining certain government approvals.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7160">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-26T10:54:17+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-26T10:54:17+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Magnesium Formulation Enters PhII Development For SCI</title>
	<pubDate>2013-09-25T18:07:50+02:00</pubDate>
	<wp:post_id>4831</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  Acorda Therapeutics has announced that the first patient 
has been enrolled in a trial of AC105, its proprietary magnesium formulation for 
the treatment of spinal cord injury (SCI).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Phase 2 Study Design</STRONG> </div><div style="margin-bottom: 10px;">The primary objective of this double-blind, randomized and placebo controlled 
study is to evaluate the safety and tolerability of AC105 in people who have 
suffered an SCI.<wbr> The study also includes several exploratory efficacy measures, 
including standard scales used to assess motor function.<wbr> Participants in the 
trial will receive six intravenous doses of AC105 or placebo over 30 hours; the 
first dose to be administered within 12 hours of the injury.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Preclinical Data &amp; Treatment Rational</STRONG> </div><div style="margin-bottom: 10px;">In preclinical studies, AC105 improved motor function in SCI when therapy was 
initiated within a few hours after injury.<wbr> Magnesium’s neuroprotective 
properties are well established in the laboratory; however, the tolerable dosage 
range in the clinic is relatively narrow, which has made it a challenge to 
develop a practical therapy.<wbr> Preclinical research shows that AC105’s formulation 
helps deliver magnesium to the injury site within the CNS, thereby providing a 
protective effect, but without requiring higher levels in the blood, which might 
result in significant side effects.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Development Status</STRONG> </div><div style="margin-bottom: 10px;">The U.<wbr>S.<wbr> <ORG>FDA has</ORG> granted Fast Track designation for 
AC105 to improve functional recovery following acute SCI.<wbr> The Company received a 
<MONEY>$2.<wbr>67 million</MONEY> research contract from the <ORG>U.<wbr>S.<wbr> Army Medical 
Research</ORG> and Material Command to support the study.<wbr> Acorda may potentially 
expand its AC105 program into other neurological injury indications.<wbr> </div><div>Source: <A href="http://www.acorda.com">www.<wbr>acorda.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7159">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-25T18:07:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-25T18:07:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: J&J / Aragon's AR Antagonist to Enter Registration Trial for Non-Metastatic CRPC</title>
	<pubDate>2013-09-25T12:11:24+02:00</pubDate>
	<wp:post_id>4832</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">J&J /<wbr> Aragon's AR Antagonist to Enter Registration Trial for Non-Metastatic CRPC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Approx.<wbr> 1200 patients will be recruited, and final data collection planned for December 2016.<wbr> The PE of the SPARTAN study will assess metastasis-free survival.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9181">...</a><br></div><div style="margin-bottom: 10px;">Some interesting observations are made in FirstWord today about J&amp;J's development strategy with ARN-509 which as seen as both "bullish and cautious".<wbr> </div><div style="margin-bottom: 10px;">The choice of the non-metastatic setting means that J&amp;J does not have to conduct a head-to-head trial versus Zytiga or Medivation's XTANDI, although commercially in the long-term such studies vs.<wbr> XTANDI may increase the drug's commercial potential </div><div style="margin-bottom: 10px;">However, the choice of primary endpoint of PFS with OS as a secondary endpoint  is viewed by some commentators as potentially risky as the ODAC has previously not accepted PFS as a surrogate for OS data in the pre-chemo setting.<wbr> </div><div>J&amp;J's involvement certainly seems to have the potential to speed up the development time of ARN-509 and by choosing the non-metastatic setting it could potentially leapfrog Xtandi in this indication.<wbr> If successful, this will position the drug in direct competition with hormonal therapies prior to pre-chemotherapy treatment with Zytiga.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9192">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9181">View thread  Oncology9181: J&J /<wbr> Aragon's AR Antagonist to Enter Registration Trial for Non-Metastatic CRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-25T12:11:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-25T12:11:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Board Member Floats Idea Of A Merger With Roche</title>
	<pubDate>2013-09-25T11:54:14+02:00</pubDate>
	<wp:post_id>4833</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A story in yesterday's Independent cites Pierre Landolt, a 
Novartis board member since 1996 as saying that combining Roche and Novartis 
would create a European "pharmaceutical champion".<wbr> 
He highlighted forthcoming changes in leadership that may pave the way 
for such a union.<wbr> </div><div style="margin-bottom: 10px;">Usually, such a mega-merger is stifled by senior leadership, however, Landolt 
pointed out that: “Soon both companies will have new chairmen.<wbr> That might make 
the dialogue easier.<wbr>” </div><div>Novartis indicated last month that it was actively looking for a major 
purchase, up to €7.<wbr>5bn in value, in its drive to expand.<wbr> "Novartis would be 
willing to invest significant money for a very good opportunity.<wbr> I don't think a 
$10bn (€7.<wbr>5bn) acquisition is out of reach" said chairman Joerg 
Reinhardt.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10626">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-25T11:54:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-25T11:54:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New US Acromegaly H/C Drug & Utilisation Cost Data</title>
	<pubDate>2013-09-25T11:38:34+02:00</pubDate>
	<wp:post_id>4834</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New US Acromegaly H/<wbr>C Drug & Utilisation Cost Data</span>&nbsp;<br><span style="font-size: 12px;">Comment A new paper published in Pituitary evaluates the economic burden of 
acromegaly in the US.<wbr> The article indicates that to date this impact has been 
largely unknown.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7467">...</a><br></div><div style="margin-bottom: 10px;">The market share of lanreotide is explained by the fact that data were collected between 2002 and 2009 whereas Somatuline Depot was launched beginnng of 2008.<wbr> </div><div>Today the market shares of Somatuline Depot and octreotide LAR in Acromegaly are equivalent, with an advantage to Somatuline Depot.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7468">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7467">View thread  Endocrinology7467: New US Acromegaly H/<wbr>C Drug & Utilisation Cost Data</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-25T11:38:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-25T11:38:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CRPC Market and Medivation's PREVAIL Trial View From Two US Physicians</title>
	<pubDate>2013-09-24T19:00:37+02:00</pubDate>
	<wp:post_id>4835</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Investors with Barclay have hosted a Tcall with Dr.<wbr> Evan Yu of University of Washington and Dr.<wbr> Neal Shore of Carolina Urologic Research Center.<wbr> Details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Physicians's Positions</STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Evan Yu provided his view as an oncologist while Dr.<wbr> Neal Shore is an urologist by training and has extensive experience in clinical trials in prostate and bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PREVAIL Survival Benefit</STRONG> </div><div style="margin-bottom: 10px;">Both estimated PREVAIL survival benefit in the 6-8 month range </div><div style="margin-bottom: 10px;"><STRONG>Xtandi Could Surpass Zytiga</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">Both believe that if Xtandi is approved for pre-chemo use, 90% of the patients will get both Xtandi and Zytiga with Xtandi used first in about 70% of the patients (usually longer treatment period).<wbr> If this is the case, Xtandi should see meaningful sales in the pre-chemo market though it will need to aggressively market the next few years before generic Zytiga enters the market.<wbr> If generics are launched, both physicians believe the payors will require the use of generic Zytiga before Xtandi</P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Expansion of the CRPC Market</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">One differing view between Dr.<wbr> Yu and Dr.<wbr> Shore was on whether the pre-chemo CRPC market will expand as new therapies are launched into the market.<wbr> Dr.<wbr> Yu doesn&rsquo;t expect the market to grow as the vast majority of pre-chemo CRPC patients (with a few exceptions) are already on Zytiga and Xtandi will only cut into existing market.<wbr> On the other hand, Dr.<wbr> Shore sees interest but hesitancy amongst urologists to use Zytiga in pre-chemo patients leaving a group of eligible patients who are not currently being treated.<wbr> Dr.<wbr> Shore believes new products and education will result in increased use of these therapies.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Comment on PROVENGE</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Both feel that Provenge should be used early in the treatment cycle while the immune system is strong enough to benefit and there is enough time for Provenge to take effect.<wbr> Dr.<wbr> Yu commented that he believes that the patients with more aggressive diseases in the IMPACT trial did not have enough time to benefit from Provenge and may have washed out the progression-free survival benefit in the trial.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Both physicians expect to increase their use of Provenge and plan to use more Provenge two years from now.<wbr></P> </div><div><P align="left"><EM>Source: Barclay Report September 23 2013</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9189">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-24T19:00:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-24T19:00:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nanobiotix Strengthens Its Management Team</title>
	<pubDate>2013-09-24T17:33:08+02:00</pubDate>
	<wp:post_id>4836</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nanobiotix a clinical-stage nanomedicine company pioneering novel 
approaches for the local treatment of cancer, announced today the strengthening 
of its management team </div><div style="margin-bottom: 10px;"><STRONG style="TEXT-ALIGN: left">1.<wbr>   Appointment of 
Philippe MAUBERNA, CFO of Nanobiotix since the end of May 2013 to the Executive 
Board by the Supervisory Board effective from August 28, 2013.<wbr></STRONG><SPAN style="TEXT-ALIGN: justify"> Philippe MAUBERNA (ISG-INSEAD), has been 
involved in several international projects (UK, Saudi Arabia, South Africa and 
Indonesia).<wbr> Dedicated to the Life Sciences industry for more than 10 years, he 
has held senior Financial and Operations positions at Astellas Pharma Europe 
participating in the reinforcement of EMEA commercial effectiveness in Africa 
and in Europe, most notably this was supporting market authorization for several 
healthcare products.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify">He has also been heavily involved in financial 
projects for start-up launches and innovative SME development.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify"> <STRONG>2.<wbr>    
</STRONG><STRONG>Creation of a Communication and Public Affairs Department 
headed up by Sarah Gaubert</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify">Fomerly advisor to the French Presidency and 
several ministries Sarah Gaubert a consultant in strategic communications, heads 
Nanobiotix’ newly created Communication and Public Affairs Department.<wbr></P> </div><div><P style="TEXT-ALIGN: justify">Source:- <A href="http://www.nanobiotix.com">www.<wbr>nanobiotix.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9188">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-24T17:33:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-24T17:33:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GW Pharma Announces Agreement on Savitex Pricing in Germany</title>
	<pubDate>2013-09-24T17:19:36+02:00</pubDate>
	<wp:post_id>4837</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GW has announced today agreement for a revised 
mutually-acceptable reimbursement price for Sativex® with the German 
National Association of Statutory Health Insurance Funds (GKV-SV), resulting in 
an increase to the previously reduced price imposed by the German authorities in 
March 2013.<wbr> </div><div style="margin-bottom: 10px;">GW Pharma estimates that approximately 4,000 patients are currently 
being treated with Sativex in Germany.<wbr> Sativex® is approved in Germany as an 
add-on therapy for the alleviation of symptoms in patients with moderate to 
severe spasticity due to multiple sclerosis who have not responded adequately to 
other anti-spasticity medications.<wbr> </div><div>Source: <A href="http://www.gwpharm.com">www.<wbr>gwpharm.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7158">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-24T17:19:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-24T17:19:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BIND Therapeutics Announces IPO Price & Highlights Lead Ph II mCRPC drug</title>
	<pubDate>2013-09-24T17:13:10+02:00</pubDate>
	<wp:post_id>4838</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BIND Therapeutics is a clinical-stage nanomedicine platform company 
developing targeted and programmable therapeutics called Accurins™.<wbr> Post the 
initiation of its first phII study in mCRPC it announced the pricing of 
its IPO of 4,700,000 shares of its common stock at a public offering price 
of $15.<wbr>00 per share </div><div style="margin-bottom: 10px;">The shares were expected to begin trading on The NASDAQ Global Select 
Market under the ticker symbol "BIND" on September 20, 2013.<wbr> </div><div style="margin-bottom: 10px;"><B>About BIND Therapeutics</B> </div><div style="margin-bottom: 10px;">BIND Therapeutics intends to leverage its medicinal nanoengineering platform 
to develop a pipeline of Accurins, initially in oncology, as well as Accurins in 
collaboration with biopharmaceutical companies.<wbr> </div><div style="margin-bottom: 10px;">BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and 
contains docetaxel, a clinically-validated and widely used cancer chemotherapy 
drug.<wbr> BIND-014 is currently in Phase 2 clinical trials for non-small cell lung 
cancer and chemotherapy naive castrate resistant prostate cancer who 
fail hormonal therapy.<wbr> The trial in prostate cancer patients was initiated in 
August.<wbr> </div><div style="margin-bottom: 10px;">Accurins are polymeric nanoparticles that incorporate a therapeutic payload 
and are designed to have prolonged circulation within the bloodstream, enable 
targeting of the diseased tissue or cells, and provide for the controlled and 
timely release of the therapeutic payload.<wbr> BIND has demonstrated in preclinical 
studies that Accurins can improve tumor growth suppression, achieve higher 
concentrations of the payload in tumors compared to the payload administered in 
conventional form, and have pharmacokinetics and tolerability differentiated 
from their therapeutic payloads.<wbr> </div><div>Source: <A href="http://www.bindtherapeutics.com">www.<wbr>bindtherapeutics.<wbr>com</A><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9187">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-24T17:13:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-24T17:13:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New US Acromegaly H/C Drug & Utilisation Cost Data</title>
	<pubDate>2013-09-24T15:38:50+02:00</pubDate>
	<wp:post_id>4839</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment A new paper published in Pituitary evaluates the economic burden of 
acromegaly in the US.<wbr> The article indicates that to date this impact has been 
largely unknown.<wbr> </div><div style="margin-bottom: 10px;">The article features prevalence data complication rates and associated 
healthcare utilization costs of acromegaly in the US amongst patients identified 
between January 2002 and December 2009 in claims databases.<wbr> The data 
extracted has examined care during a patient's first year as a 
claimant.<wbr> </div><div style="margin-bottom: 10px;">2,171 patients were evaluated (mean age 45.<wbr>3yrsm 49.<wbr>7% female); 77.<wbr>8% of whom 
received the majority of their care from non-endocrinologists.<wbr> </div><div style="margin-bottom: 10px;">Interestingly, pharmacologic treatment was used by 30.<wbr>8% of patients: </div><div style="margin-bottom: 10px;"><UL><LI>octreotide LAR in 18.<wbr>6%, </LI>
<LI>dopamine agonists in 9.<wbr>8%, </LI>
<LI>short-acting octreotide in 4.<wbr>7%.<wbr> </LI>
<LI>pegvisoment in 4.<wbr>1%, and</LI>
<LI>lanreotide in 1.<wbr>2%.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">56% had biochemical monitoring.<wbr> </div><div style="margin-bottom: 10px;">Co-morbidities were common, randing from 6.<wbr>6% (colon neoplasma) to 25.<wbr>6% 
(musculoskeletal abnormalities).<wbr> Mean annual healthcare costs were $24,900.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Adjusted analyses indicated comorbidities increased the odds of 
  hospitalisation by 76% for musculoskeletal abnormalities, 193% for 
  cardiovascular abnormalities and 56% for sleep apnea (p&lt;0.<wbr>05).<wbr></LI>
<LI>Odds of emergency department visits increased by 87% (musculorskeletal) 
  and 132% (cardiovascular abnormalities (p&lt;0.<wbr>01).<wbr></LI>
<LI>After adjustments, colon neoplasms were associated with $8,401 mean 
  increase in costs, musculoskeletal abnormalities with $7,50, cardiovascular 
  abnormalities with $13,331, sleep apnea with $10,453, and hypopituitarism with 
  $6,742 (p&lt;0.<wbr>01).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">The conclusion is that complications are common and that adequate management 
of the disease may be able to reduce health care utilisation costs associated 
with these complications and with acromegaly in general.<wbr> </div><div style="margin-bottom: 10px;">Pituitary 2013 Sept 14 epub </div><div style="margin-bottom: 10px;"><DIV class="auths" style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; FONT-FAMILY: arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); FONT-SIZE: 0.92em; FONT-WEIGHT: normal; WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Broder%20MS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24037646" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102); TEXT-DECORATION: underline">Broder 
MS</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Neary%20MP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24037646" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102); TEXT-DECORATION: underline">Neary 
MP</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Chang%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24037646" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102); TEXT-DECORATION: underline">Chang 
E</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Cherepanov%20D%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24037646" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102); TEXT-DECORATION: underline">Cherepanov 
D</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Katznelson%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=24037646" style="BORDER-BOTTOM-WIDTH: 0px; COLOR: rgb(102,0,102); TEXT-DECORATION: underline">Katznelson 
L</A>.<wbr></DIV> </div><div><DIV class="aff" style="TEXT-ALIGN: left; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 0.84em/1.09em arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<H3 class="label" style="POSITION: absolute; LINE-HEIGHT: 1.2857; MARGIN: 1.28em 0px 0.64em; WIDTH: 1px; HEIGHT: 1px; COLOR: rgb(114,65,40); FONT-SIZE: 1.07em; OVERFLOW: hidden; TOP: auto; LEFT: -10000px">Source</H3>
<P style="MARGIN: 0.5em 0px">Partnership for Health Analytic Research, LLC, 280 
S.<wbr> Beverly Dr.<wbr>, Suite 404, Beverly Hills, CA, 90212-3904, 
USA</P></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7468c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The market share of lanreotide is explained by the fact that data were collected between 2002 and 2009 whereas Somatuline Depot was launched beginnng of 2008.<wbr> </div><div>Today the market shares of Somatuline Depot and octreotide LAR in Acromegaly are equivalent, with an advantage to Somatuline Depot.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7467">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-24T15:38:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-24T15:38:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BOTOX® to be Assessed for UI in Patients with OAB</title>
	<pubDate>2013-09-23T18:20:36+02:00</pubDate>
	<wp:post_id>4840</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The COMFORT trial will evaluate the efficacy and safety of BOTOX&reg; compared with placebo, in achieving a 100% reduction in urinary incontinence (primary endpoint) in patients with overactive bladder (OAB) not properly managed with an anticholinergic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details - <a href="http://clinicaltrials.gov/ct2/show/NCT01945489?recr=Open&no_unk=Y&fund=2&rcv_s=08%2F23%2F2013&rank=234" class="defaultlink">NCT01945489</a></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx 258 patients with symptoms of Overactive Bladder (OAB) (frequency and urgency) with urinary incontinence for at least 6 months prior to screening </div><div style="margin-bottom: 10px;">Start date: Sept 2013 - Completion date: July 2015 /<wbr> May 2016 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7157">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-23T18:20:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-23T18:20:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hikma Expands License and Supply Agreement for GP Pharm's Lutrate® in Germany and Portugal</title>
	<pubDate>2013-09-23T17:13:33+02:00</pubDate>
	<wp:post_id>4841</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This agremeent covers Lutrate<SUP>&reg;</SUP> (leuprolide acetate) 1M (already market in several EU countries), the 3M (still under development), and includes an option for the 6M depot formulation.<wbr> Financial terms are not disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Historical Background</STRONG> </div><div style="margin-bottom: 10px;">This new agreement complements Hikma's existing agreement to license and Supply GP Pharm Lutrate<SUP>&reg;</SUP> 1M in 23 countries across the MENA region.<wbr> Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=8542" class="defaultlink">Oncology8542: Hikma Signs License and Supply Agreement with GP Pharm for Lutrate 1M</a>.<wbr> </div><div><EM>Source: Hikma</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9185">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-23T17:13:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-23T17:13:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>China Implements New Online System For Hospital Tenders</title>
	<pubDate>2013-09-23T15:47:09+02:00</pubDate>
	<wp:post_id>4842</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Commment : Guangdong province has introduced a new system for online hospital drug procurement that will see hospitals procure medicines through an online exchange based on molecule and price, effectivement removing direct negotiations with companies from the equation.<wbr> </div><div style="margin-bottom: 10px;">The new rules establish a third-party stock exchange system whereby hospitals stipulate drug and dosage but have no say in which company supplies any particular molecule/<wbr>product.<wbr> Bids will use the "Anhui" model, ie a double-blind tender model, with a 90% weighting on price versus 10% on quality in order to determine winning bids.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 1.5em;">The GVT wants to </SPAN><SPAN lang="EN-US" style="line-height: 1.5em;">move from a market where price has been entirely Gvt-guided (through NDRC retail price ceilings)  to a market where it only offers guidance, but price changes are effected by market pressure.<wbr> As part of this trend, the NDRC has indicated it is in the process of moving away from the setting of retail price ceilings towards caps on prices of drugs at the reimbursement level.<wbr>  </SPAN> </div><div style="margin-bottom: 10px;">Where the system has been used, ie in Fujian, &ndash; prices fell by up to one-third, and many companies withdrew from the market.<wbr> However, Guangdong's hospital drug market is the largest provincial market in China, and it will not be easy for companies to ignore.<wbr> </div><div>Source : Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10623">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-23T15:47:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-23T15:47:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Drisapersen Fails in GSK Study</title>
	<pubDate>2013-09-20T17:09:00+02:00</pubDate>
	<wp:post_id>4843</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Drisapersen fails to help patients walk better in Phase III study.<wbr> GSK and Prosensa now plan to study the clinical trial results in detail to see if the drug has a future.<wbr> The setback may be good news for Sarepta , which is developing a rival treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Findings</STRONG> </div><div style="margin-bottom: 10px;">Drisapersen, did not show a statistically significant improvement in the distance that patients could walk in six minutes compared with placebo in the Phase III test run by GSK.<wbr> </div><div style="margin-bottom: 10px;">Data released on GSK's website last month had already indicated a substantial number of patients treated with drisapersen might not be getting a meaningful drug effect.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7156">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-20T17:09:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-20T17:09:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Algeta Reports 1Q:13 Results and US Approval of Radium-233 for CRPC</title>
	<pubDate>2013-09-20T14:29:13+02:00</pubDate>
	<wp:post_id>4844</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;"><STRONG></STRONG></span>&nbsp;<br></div><div style="margin-bottom: 10px;">Bayer has received a positive opinion from the EMA CHMP recommending radium Ra 223 dichloride (radium-223) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.<wbr> </div><div style="margin-bottom: 10px;">According to Algeta CEO: " .<wbr>.<wbr>.<wbr>  </div><div style="margin-bottom: 10px;">Algeta is eligible for royalties and milestones based on Bayer&rsquo;s sales of Xofigo outside the US, and Algeta US, LLC is co-promoting Xofigo with Bayer in the US.<wbr> </div><div> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9184">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8943">View thread  Oncology8943: Algeta Reports 1Q:13 Results and US Approval of Radium-233 for CRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-20T14:29:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-20T14:29:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: J&J / Aragon's AR Antagonist to Enter Registration Trial for Non-Metastatic CRPC</title>
	<pubDate>2013-09-20T12:54:52+02:00</pubDate>
	<wp:post_id>4845</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">J&J /<wbr> Aragon's AR Antagonist to Enter Registration Trial for Non-Metastatic CRPC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Approx.<wbr> 1200 patients will be recruited, and final data collection planned for December 2016.<wbr> The PE of the SPARTAN study will assess metastasis-free survival.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9181">...</a><br></div><div style="margin-bottom: 10px;">Thanks to Monica de Abadal we have learnt that a meeting took place in Sydney with investigators who will be partciipating in the study.<wbr> </div><div>Several Australian sites have been selected.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9183">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9181">View thread  Oncology9181: J&J /<wbr> Aragon's AR Antagonist to Enter Registration Trial for Non-Metastatic CRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-20T12:54:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-20T12:54:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trial to Assess Abiraterone Acetate + Prednisone + LHRHa +/- Enzalutamide</title>
	<pubDate>2013-09-19T18:21:35+02:00</pubDate>
	<wp:post_id>4846</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The goal of this Ph2 study is to learn if adding the combination of abiraterone acetate and prednisone with or without enzalutamide to hormonal therapy can help to control prostate cancer when given before surgery.<wbr> The safety of the drug combination will also be studied.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01946165?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F19%2F2013&amp;rank=289"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Sponsor: M.<wbr>D Anderson Cancer Center </div><div style="margin-bottom: 10px;">PE will evaluate difference in Pathologic Stage &lt;pT2 at prostatectomy </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 66 </div><div>Start date: Dec.<wbr> 2013 - Completion: Dec.<wbr> 2021 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9182">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-19T18:21:35+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-19T18:21:35+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J / Aragon's AR Antagonist to Enter Registration Trial for Non-Metastatic CRPC</title>
	<pubDate>2013-09-19T18:04:14+02:00</pubDate>
	<wp:post_id>4847</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Approx.<wbr> 1200 patients will be recruited, and final data collection planned for December 2016.<wbr> The PE of the SPARTAN study will assess metastasis-free survival.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01946204?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F19%2F2013&amp;rank=31"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><U>Start date</U>: Sept 2013 </div><div><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><U>Description</U> - Serial pharmacokinetic blood samples will be collected.<wbr> Participants will be followed for safety and efficacy and will remain on study treatment until documented radiographic disease progression, development of unacceptable toxicity, or withdrawal of consent.<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Participants discontinuing study treatment will enter the survival follow-up period where they will be followed for the development of symptomatic progression and initiation of subsequent anti-cancer therapies, until death, loss of follow-up, or withdrawal of consent, whichever comes first.<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">The total study duration will be approximately up to Month 59.<wbr></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Location: 2 countries listed USA and Germany.<wbr></P>
</DIV></DIV></DIV></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9183c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Thanks to Monica de Abadal we have learnt that a meeting took place in Sydney with investigators who will be partciipating in the study.<wbr> </div><div>Several Australian sites have been selected.<wbr> </div></div><a name="Oncology9192c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Some interesting observations are made in FirstWord today about J&amp;J's development strategy with ARN-509 which as seen as both "bullish and cautious".<wbr> </div><div style="margin-bottom: 10px;">The choice of the non-metastatic setting means that J&amp;J does not have to conduct a head-to-head trial versus Zytiga or Medivation's XTANDI, although commercially in the long-term such studies vs.<wbr> XTANDI may increase the drug's commercial potential </div><div style="margin-bottom: 10px;">However, the choice of primary endpoint of PFS with OS as a secondary endpoint  is viewed by some commentators as potentially risky as the ODAC has previously not accepted PFS as a surrogate for OS data in the pre-chemo setting.<wbr> </div><div>J&amp;J's involvement certainly seems to have the potential to speed up the development time of ARN-509 and by choosing the non-metastatic setting it could potentially leapfrog Xtandi in this indication.<wbr> If successful, this will position the drug in direct competition with hormonal therapies prior to pre-chemotherapy treatment with Zytiga.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9181">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-19T18:04:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-19T18:04:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Has Exercised Option to Acquire Camurus' FluidCrystal® Product CAM2029</title>
	<pubDate>2013-09-19T17:49:21+02:00</pubDate>
	<wp:post_id>4848</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The license also covers additional future products based on Camurus' FluidCrystal&reg; Injection depot technology.<wbr> The option exercise is the next stage in the collaboration, option and license agreement between Novartis and Camurus executed in December 2011.<wbr> More details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Historical Background (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=6794" class="defaultlink">Endocrinology6794: Novartis In-licenses Camurus's Long-acting Octreotide</a>).<wbr> </div><div style="margin-bottom: 10px;">The agreement triggers an undisclosed milestone payment to Camurus from eligible potential payments of up to US$ 700 million, subject to achievement of predefined development, regulatory and commercial milestones for the products included in the agreement.<wbr> </div><div style="margin-bottom: 10px;">In addition, Camurus is entitled to royalties on global product sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px; -webkit-text-size-adjust: auto;"></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px; -webkit-text-size-adjust: auto;"></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px; -webkit-text-size-adjust: auto;"></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px; -webkit-text-size-adjust: auto;"></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px; -webkit-text-size-adjust: auto;"></P> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="background-color: #ffffff; color: #ffffff;"></SPAN> </div><div><EM>Source: Camurus</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7463">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-19T17:49:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-19T17:49:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Medy-Tox and Allergan to be in Very Late Stage of Finalising Agreement</title>
	<pubDate>2013-09-19T09:28:57+02:00</pubDate>
	<wp:post_id>4849</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Medy-Tox and Allergan to be in Very Late Stage of Finalising Agreement</span>&nbsp;<br><span style="font-size: 12px;">Comment: An article in Hankyung newspaper, cited today by a Nomura Quick Note, indicates that Medy-Tox would secure a technology transfer fee of KRW100bn, along with a running guarantee.<wbr> From 2H13, the company has progressed to technology export of its 'next-generation' product of Meditoxin to Allergan, and Allergan has already completed its due diligence, according to the news.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7144">...</a><br></div><div style="margin-bottom: 10px;">Medytox has been communicating on two clinical development projects MT10109 and MT10107 as development of "new generation".<wbr> </div><div style="margin-bottom: 10px;">- According to CI, <STRONG>MT 10109 is a HSA free dry form</STRONG>, Ph III in GL is expected to be completed in 1Q:14 and PhIII CD will be started in 4Q:13, both developments being conducted in Australia.<wbr> </div><div style="margin-bottom: 10px;">- According to CRIS (Clinical Research Information Service), <STRONG>MT 10107 : Ph I study</STRONG> to determine the pharmacodynamic and safety in comparison with Botox, This study is conducted in South Korea.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>There is not information about indication and formulation.<wbr> </STRONG> </div><div><STRONG>CI is working on getting more information about MT 10107.<wbr></STRONG> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7153">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7144">View thread  Neurology7144: Medy-Tox and Allergan to be in Very Late Stage of Finalising Agreement</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-19T09:28:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-19T09:28:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Comparison Study of Daewoong's DWP450 Vs. Botox® for Post Stroke Upper Limb Spasticity</title>
	<pubDate>2013-09-18T17:39:58+02:00</pubDate>
	<wp:post_id>4850</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: clinicaltrials.<wbr>gov is listing a new Ph3 which is currently recruiting participants at the SMG-SNU Boramae Medical Center in Seoul.<wbr> PE will assess the change in MAS grade for Wrist flexor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01945684?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=08%2F18%2F2013&amp;rank=223"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: Sept 2013 - Completion date: Nov 2013/<wbr> July 2014 </div><div>Recruitment: N/<wbr>A.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7151">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-18T17:39:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-18T17:39:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The Toxin Aesthetic Landscape (2)</title>
	<pubDate>2013-09-18T16:05:32+02:00</pubDate>
	<wp:post_id>4851</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached an updated version of the toxin aesthetic landscape.<wbr> This slide kit has been created in close collaboration with the Neurology Franchise.<wbr> Next update is due in Q1:14.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7150_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="neurology7150attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7150_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7150_2_AESTHETIC%20%e2%80%93%20Final%20TAL%255ffor%20Traction%20CI%255fSept18.pptx">AESTHETIC – Final TAL_for Traction CI_Sept18.pptx</a>&nbsp;&nbsp;(596,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7150">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-18T16:05:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-18T16:05:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Polish Agency for HTA Rejects Zoladex as an Option for Assisted Reproduction</title>
	<pubDate>2013-09-18T14:21:07+02:00</pubDate>
	<wp:post_id>4852</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The regulator has stated that there are therapies already available in Poland that are cheaper and have at least the same efficacy as the drug, pointing out that these other treatments are associated with fewer complications concerning ovarian stimulation.<wbr> </div><div><EM>Source: GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9180">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-18T14:21:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-18T14:21:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Personalised Immunotherapy Approved in EU for mCRPC</title>
	<pubDate>2013-09-18T09:22:53+02:00</pubDate>
	<wp:post_id>4853</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The EU Commission has authorised Dendreon to market PROVENGE® for asymptomatic or minimally symptomatic mCRPC in adult males for whom chemotherapy is not yet clinically indicated.<wbr> It is not clear whether the company could find a marketing partner or would decide to launch the drug alone in Europe.<wbr> Of note, there has still been no manufacturing partnership established for the drug in EU.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">With no manufacturing partners, likely stemming from the drug’s high cost of production, launch cannot be forecasted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">At US prices ($93,000), it is priced higher than a full year’s course of either Zytiga or Xtandi in the US or EU.<wbr> </div><div style="margin-bottom: 10px;">Consequently and given the price sensitivities of the region it is unlikely the company would garner a meaningful level of sales in the EU countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Status - In 2010 Provenge garnered FDA approval for men with advanced metastatic prostate cancer who were not responding to hormone therapy.<wbr> </div><div style="margin-bottom: 10px;">2012 Sales - $321.<wbr>5M </div><div style="margin-bottom: 10px;"><STRONG></STRONG> <STRONG></STRONG> </div><div style="margin-bottom: 10px;">P10-1 - An Open-Label, Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11 </div><div style="margin-bottom: 10px;">P10-2 - A Randomized, Open-Label, Phase 2 Trial Examining the <STRONG>Sequencing</STRONG> of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and a Rising Prostate Specific Antigen After Primary Therapy </div><div style="margin-bottom: 10px;">P10-3 (called PROCEED) - A Registry of Sipuleucel-T in Men with Advanced Prostate Cancer (called PROCEED) to Further Evaluate Safety and Survival Associated with Sipuleucel-T </div><div style="margin-bottom: 10px;">P11-1 - An Open-Label Study of Sipuleucel-T in European Men with Metastatic, Castrate Resistant Prostate Cancer </div><div style="margin-bottom: 10px;">P11-3 - A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent Versus Sequential Administration of <STRONG>Abiraterone</STRONG> Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer </div><div><EM>Source: Dendreon</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9177">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-18T09:22:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-18T09:22:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: World’s First Toxin-free Treatment for Dynamic Wrinkles Approved in Canada</title>
	<pubDate>2013-09-17T18:20:11+02:00</pubDate>
	<wp:post_id>4854</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">World’s First Toxin-free Treatment for Dynamic Wrinkles Approved in Canada</span>&nbsp;<br><span style="font-size: 12px;">Comment: Myoscience's iovera˚ has received regulatory approval in Canada.<wbr> The company presented the EU launch of the treatment at the IMCAS in Paris (Jan-Feb 2013), and AMWC in Monaco (April 2013).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7073">...</a><br></div><div style="margin-bottom: 10px;">Myoscience has reported that the iovera<STRONG>*</STRONG> treatment is now available from the Vancouver Cosmetic Medicine and Dermatology Clinic, Doctors Alastair and Jean Carruthers and Doctor Shannon Humphrey.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Testimonies</STRONG> </div><div style="margin-bottom: 10px;">Doctor Jean Carruthers feels iovera˚ will be an important new tool for doctors that want to offer patients options, "We are all familiar with the safety and efficacy of cosmetic neuromodulation using neurotoxins.<wbr> The iovera˚ technology is a totally new approach to reducing wrinkles by treating nerves with cold.<wbr> After some months, the nerves recover and retreatment may be desired.<wbr>" </div><div>Doctor Shannon Humphrey is enthusiastic to be one of the first to offer the iovera˚ treatment, "iovera provides us with a new alternative to treat forehead wrinkles in a natural way that provides immediate results, something we feel many patients will find appealing.<wbr>" </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7148">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7073">View thread  Neurology7073: World’s First Toxin-free Treatment for Dynamic Wrinkles Approved in Canada</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-17T18:20:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-17T18:20:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trial to Assess Response to Treatment with Enzalutamide for CRPC</title>
	<pubDate>2013-09-17T18:11:36+02:00</pubDate>
	<wp:post_id>4855</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this Ph2 study is to analyze features of tumor specimens sampled prior to therapy and at disease progression to determine why patients respond or stop responding to treatment with enzalutamide.<wbr> PE will analyze possible Androgen Receptor (AR) related mechanisms of resistance to the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01942837?phase=01234&amp;fund=2&amp;rcv_s=08%2F17%2F2013&amp;rank=244"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;"><DIV class="info-text">Sponsor: Dana-Farber Cancer Institute</DIV> </div><div style="margin-bottom: 10px;"><DIV class="info-text">Collaborator: Medivation</DIV> </div><div style="margin-bottom: 10px;">Start date: Sept 2013 - Completion: Feb 2017 /<wbr> Aug 2020 </div><div style="margin-bottom: 10px;">Recruitment: approx 66 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9173">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-17T18:11:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-17T18:11:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medy-Tox and Allergan to be in Very Late Stage of Finalising Agreement</title>
	<pubDate>2013-09-17T16:27:57+02:00</pubDate>
	<wp:post_id>4856</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: An article in Hankyung newspaper, cited today by a Nomura Quick Note, indicates that Medy-Tox would secure a technology transfer fee of KRW100bn, along with a running guarantee.<wbr> From 2H13, the company has progressed to technology export of its 'next-generation' product of Meditoxin to Allergan, and Allergan has already completed its due diligence, according to the news.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">"Given the fact that the newspaper mentioned detailed progress (e.<wbr>g.<wbr> it is at the final stage), the amount of technology transfer fee, and the running guarantee structure, we now think that the expected contract signing could be announced in the near future".<wbr> </div><div style="margin-bottom: 10px;"><EM>Source: Nomura</EM> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7153c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Medytox has been communicating on two clinical development projects MT10109 and MT10107 as development of "new generation".<wbr> </div><div style="margin-bottom: 10px;">- According to CI, <STRONG>MT 10109 is a HSA free dry form</STRONG>, Ph III in GL is expected to be completed in 1Q:14 and PhIII CD will be started in 4Q:13, both developments being conducted in Australia.<wbr> </div><div style="margin-bottom: 10px;">- According to CRIS (Clinical Research Information Service), <STRONG>MT 10107 : Ph I study</STRONG> to determine the pharmacodynamic and safety in comparison with Botox, This study is conducted in South Korea.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>There is not information about indication and formulation.<wbr> </STRONG> </div><div><STRONG>CI is working on getting more information about MT 10107.<wbr></STRONG> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7144">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-17T16:27:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-17T16:27:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence on Commercialization of Xeomin in Spain</title>
	<pubDate>2013-09-17T15:00:54+02:00</pubDate>
	<wp:post_id>4857</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ricardo Castrillo has reported strong rumours from the field (different regions in Spain) indicating that UCB is promoting Merz' Xeomin (for medical indication).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Terms of the agreement between UCB and Merz are unknown.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Has Merz difficulties to penetrate the Spanish market ? </div><div style="margin-bottom: 10px;">Is UCB looking at levaraging its sales in Spain ? </div><div style="margin-bottom: 10px;">It is needed to better understand the geographical scope of the agreement, and whether it is a national move limited to Spain or a wider approach (in EU or WW) ? </div><div>If you hear anything similar in your country please advise the CI department.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7143">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-17T15:00:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-17T15:00:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Real-World Treatment Patterns Following the Launch of Xeomin for GL in Latin America</title>
	<pubDate>2013-09-16T11:41:33+02:00</pubDate>
	<wp:post_id>4858</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Xeomin (IncobotulinumtoxinA) was approved in Argentina in 2007 for the treatment of moderate to severe glabellar lines.<wbr> Medical records from a multicenter, retrospective chart review conducted in Argentina reviewed for demographics, dosing, reason for switching between products, treatment satisfaction, and interval between injection cycles.<wbr> </div><div style="margin-bottom: 10px;"><H1></H1> </div><div style="margin-bottom: 10px;"><DIV class="auths">Banegas RA, Farache F, Rancati A, Chain M, Gallagher CJ, Chapman MA, Caulkins CA.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="aff">
<P>(Dr Banegas, Dr Farache, and Dr Rancati are plastic surgeons in private practice in Buenos Aires, Argentina).<wbr></P></DIV> </div><div><DIV class="abstr">
<H3></H3>
<DIV>
<P><U>Background</U>: IncobotulinumtoxinA was approved in Argentina in 2007 for the treatment of moderate to severe glabellar lines.<wbr>ObjectiveThe authors evaluate real-world changes in facial aesthetic treatment patterns and patient satisfaction following the introduction of incobotulinumtoxinA in Argentina.<wbr></P>
<P><U>Methods</U>: This multicenter, retrospective chart review conducted in Argentina included women who had received at least 2 treatment cycles of onabotulinumtoxinA (Allergan, Irvine, California) for glabellar lines (period 1) prior to switching to incobotulinumtoxinA (Merz Pharma, GmbH, Frankfurt, Germany (period 2).<wbr> Subjects were given the option to continue with incobotulinumtoxinA treatments (captured in period 2) or switch back to onabotulinumtoxinA (documented as period 3).<wbr> Medical records were reviewed for demographics, dosing, reason for switching between products, treatment satisfaction, and interval between injection cycles.<wbr></P>
<P><U>Results</U>: One hundred ten women were enrolled and collectively received 662 treatment cycles with botulinum toxin.<wbr> Subjects were switched to incobotulinumtoxinA at unit doses that were numerically and statistically similar to the onabotulinumtoxinA doses they received in period 1.<wbr> Most subjects (92%) initially switched to incobotulinumtoxinA because of <STRONG>lower cost</STRONG>.<wbr> Ninety-two subjects (84%) switched back to onabotulinumtoxinA in period 3, most commonly due to <STRONG>insufficient duration of effect</STRONG> with incobotulinumtoxinA (61/<wbr>92; 66%).<wbr> Subjects reported satisfaction with treatment in &gt;90% of their onabotulinumtoxinA visits and in 34% of their incobotulinumtoxinA visits.<wbr> Median <STRONG>interinjection intervals</STRONG> with onabotulinumtoxinA were 180.<wbr>3 days (period 1) and 176.<wbr>9 days (period 3) and 144.<wbr>3 days with incobotulinumtoxinA in period 2.<wbr></P>
<P><U>Conclusions</U>: In this real-world setting, subjects did not appear to perceive the same facial aesthetic benefits from incobotulinumtoxinA as onabotulinumtoxinA when the products were administered at comparable doses.<wbr></P>
<DIV class="cit"><EM>Aesthet Surg J.<wbr> 2013 Aug 29.<wbr> [Epub ahead of print].<wbr></EM></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7142">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-16T11:41:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-16T11:41:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Names New CEO</title>
	<pubDate>2013-09-16T10:16:49+02:00</pubDate>
	<wp:post_id>4859</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Next year Lufthansa CEO Christoph Franz will be replacing Franz Humer.<wbr> Novartis has also just got a new chairman and the changing of the guard at Switzerland’s two biggest drugmakers has fuelled talk that Novartis may finally sell its multi-billion-dollar stake in Roche.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Roche's top-selling medicines are expected to face competition from cheaper copies from 2016.<wbr> </LI>
<LI>Negotiating with Novartis over the possible repurchase of Novartis's stake in the company.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Franz, 53, has been Lufthansa CEO since 2011.<wbr> </LI>
<LI>He previously served as CEO of Swiss International Air Lines.<wbr> </LI>
<LI>Education: Doctorate from Darmstadt Technical U.<wbr> Germany.<wbr> </LI>
</UL> </div><div><EM>Source: Roche</EM> </div><!-- Comment details --><a name="pharmaworld10616attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10616_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(10,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10616_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(31,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10616">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-16T10:16:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-16T10:16:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Targeted in Chinese Pharma Probe</title>
	<pubDate>2013-09-13T13:45:01+02:00</pubDate>
	<wp:post_id>4860</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chinese authorities visited a China office of Bayer AG in late August to investigate a potential case of unfair competition.<wbr> The company employs around 11,000 people in Greater China, and gets a quarter of its global revenue from the Asia-Pacific region ($3.<wbr>1billion in 2012; up to 17.<wbr>7% vs 2011).<wbr> Of note Sino Biopharmaceutical, Gan &amp; Lee Pharmaceuticals drawn into China's corruption probe.<wbr> Sino Pharm.<wbr>'s shares fell nearly as much as 25% on the news.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Endometriosis - Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=8879" class="defaultlink">Oncology8879: Registration Trial of Bayer's Visanne(R) Has Started in China</a></LI>
<LI>HCC - <A href="http://clinicaltrials.gov/ct2/show/NCT01839630?term=bayer+AND+china&amp;recr=Open&amp;rank=2">NCT01839630</A>; <A href="http://clinicaltrials.gov/ct2/show/NCT01774344?term=bayer+AND+china&amp;recr=Open&amp;rank=6">NCT01774344</A></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>approx 1500 sales reps added since 2011</LI>
<LI>improved presence in lower-tier cities in 2012</LI>
<LI>€100M over 5 years to set-up a global R&amp;D center</LI>
<LI>Beijing manufacturing site expansion (approx €45M through 2015)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9170_1_ScreenCapture1.jpg"> </div><div><EM>Source: Bayer; clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><a name="oncology9170attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9170_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(17,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9170">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-13T13:45:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-13T13:45:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Updates on Versartis' Once Monthly hGH</title>
	<pubDate>2013-09-13T11:22:29+02:00</pubDate>
	<wp:post_id>4861</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has reported that EU granted Orphan Medicinal Product Designation for VRS-317.<wbr> In parallel management has announced it will provide clinical updates at ESPE in Milan, where it will be meeting with an international group of leading investigators from EU, US and Japan to plan and design its Ph3 program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The latest results from the company's ongoing <SPAN style="TEXT-DECORATION: underline">Ver</SPAN>sartis <SPAN style="TEXT-DECORATION: underline">T</SPAN>rial <SPAN style="TEXT-DECORATION: underline">I</SPAN>n <SPAN style="TEXT-DECORATION: underline">C</SPAN>hildren to <SPAN style="TEXT-DECORATION: underline">A</SPAN>ssess <SPAN style="TEXT-DECORATION: underline">L</SPAN>ong-Acting Growth Hormone (VERTICAL) study will be presented at the 9<SUP>th</SUP> Joint Meeting of Paediatric Endocrinology in Milan on Sunday, September 22, by Versartis Vice President of Medical Affairs George M.<wbr> Bright, MD.<wbr> </div><div style="margin-bottom: 10px;">The VERTICAL trial of VRS-317 consists of two stages: a single ascending dose stage (Phase 1b) to determine the safety, PK and PD of VRS-317 doses and to enable selection of dose regimens used in the repeat dose stage (Phase 2a) to obtain 6-month height velocity results.<wbr> </div><div style="margin-bottom: 10px;">The oral presentation will include data from the Phase Ib dose-escalating stage of the study, which was conducted in approximately 30 pediatric endocrinology centers in the United States.<wbr> The results from this stage support initiation of the repeat dose stage (Phase 2a) of the trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Abstract Title</U>: "A Phase Ib/<wbr>2a study of a new long-acting growth hormone (VRS-317) in pre-pubertal children with growth hormone deficiency (GHD)" </div><div style="margin-bottom: 10px;">Presentation number: FC16-214<BR>Session: Novel Growth-promoting Treatment <BR>Date: Sunday, September 22<BR>Time: 7:30 - 8:30 am </div><div><EM>Source: Versartis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7462">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-13T11:22:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-13T11:22:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Novartis Management @ Morgan H/C Conference</title>
	<pubDate>2013-09-12T16:09:48+02:00</pubDate>
	<wp:post_id>4862</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Joseph Jimenez (CEO) reported he is focusing the company on 3 priorities (innovation, growth and productivity), and 3 "big engines" (pharmaceuticals, eye care and generics), taking a hard look to the other 3 businesses (vaccines and diagnostics, OTC and animal health) in terms of either creating scale or thinking about other options.<wbr> Additional information is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management mainly discussed the dynamic of the ophtalmology/<wbr>eye care market and products such as Elya and Lucentis, and the Alcon business.<wbr> </div><div style="margin-bottom: 10px;">Only one question was asked on the oncology pipeline, and the development of CART-19 (T cell immunotherapy), partnered with the U.<wbr> of Pennsylvania.<wbr> CART-19 targets a protein called CD19 that is associated with a number of B-cell malignancies such as chronic lymphocytic leukemia (CLL), B-cell acute lymphocytic leukemia and diffuse large B-cell lymphoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> We have a 33% voting stake in Roche.<wbr> That has earned a decent return, but at the same time, we call that a financial investment with a strategic component.<wbr> </div><div style="margin-bottom: 10px;">.<wbr>.<wbr>.<wbr> I inherited that stake and I look at that as worth more than the current market price.<wbr> Because I think about the current market price, and I think, could you create a 33% voting stake today in Roche on the open market, and the answer is no.<wbr> </div><div style="margin-bottom: 10px;">So the question is, how do we get value for that stake? And that is really what we are thinking about now.<wbr> That doesn't mean that we will immediately sell it, but it does mean that I feel like we have got an obligation to Novartis shareholders to ensure that we get what that stake is worth.<wbr> </div><div style="margin-bottom: 10px;">In terms of what has changed, as Dan Vasella has left the chairmanship, he is the one who acquired the stake, so with Joerg Reinhardt coming in and with a number of new Board members, I think there is not the same -- I don't know, what I would call emotion that could have been there before around looking at this and looking at it really as a financial asset".<wbr> </div><div><STRONG></STRONG> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7461">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-12T16:09:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-12T16:09:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS' Immunotherapy Drug Yervoy (ipilimumab) Falls Short for CRPC (Post-Chemo)</title>
	<pubDate>2013-09-12T12:04:49+02:00</pubDate>
	<wp:post_id>4863</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The drug failed to significantly prolong survival among patients with advanced prostate cancer who had previously received chemotherapy, according to limited data from the first late-stage study of the drug for the condition.<wbr> Researchers are slated to present full results of the trial at ESMO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">A second Ph3 trial of Yervoy, expected to be completed by 2015, which has enrolled patients who are asymptomatic or have only mild symptoms of prostate cancer, and whose cancer has not spread to the lungs or liver.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Ph3 trial (<A href="http://clinicaltrials.gov/ct2/show/NCT00861614?term=ipilimumab+AND+prostate&amp;rank=14&amp;submit_fld_opt=">NCT00861614</A>) involved almost 800 patients that had failed to benefit from drugs that lower the amount of testosterone and from treatment with docetaxel.<wbr> </div><div style="margin-bottom: 10px;">Half the patients in the trial received Yervoy after treatment with a dose of radiation, while others received a placebo after radiation.<wbr> </div><div style="margin-bottom: 10px;">- Patients taking Yervoy lived, on average, 11.<wbr>2 months, compared with 10 months for those in the placebo group, a difference that was deemed slightly below statistical significance.<wbr> </div><div>- Drug-related side effects, including gastrointestinal problems, were similar to those seen with Yervoy in melanoma trials.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9164">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-12T12:04:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-12T12:04:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approved BOTOX® Cosmetic for Moderate-to-Severe Lateral Canthal Lines</title>
	<pubDate>2013-09-12T11:42:55+02:00</pubDate>
	<wp:post_id>4864</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: With this approval, BOTOX<SUP>®</SUP> Cosmetic is now the only pharmaceutical approved to treat both lateral canthal lines (crow's feet lines) and frown lines between brows (glabellar lines).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The safety and efficacy of BOTOX<SUP>®</SUP> Cosmetic as a treatment for crow's feet lines was demonstrated in 2 randomized, multi-center, placebo-controlled clinical trials.<wbr> </div><div style="margin-bottom: 10px;">The studies enrolled &gt;1,350 subjects with 833 subjects receiving treatment with BOTOX<SUP>®</SUP> Cosmetic.<wbr> </div><div style="margin-bottom: 10px;">The trial demonstrated that BOTOX<SUP>®</SUP> Cosmetic was an effective treatment compared to the control group, which did not receive BOTOX<SUP>®</SUP> Cosmetic treatment.<wbr> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=5188" class="defaultlink">Neurology5188: Allergan Launches Major New PhIII Programme</a>.<wbr> </div><div><EM>Source: Allergan</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7140">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-12T11:42:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-12T11:42:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Medivation Management @ Morgan Stanley H/C Conference</title>
	<pubDate>2013-09-11T16:49:51+02:00</pubDate>
	<wp:post_id>4865</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: David Hung (CEO) confirmed the PREVAIL (pre-chemo) trial to go unblind "sometime" this year, and outlined that the company will announce the results with "a hazard ratio and a p-value on endpoints".<wbr> Management commented on the differences between the PREVAIL trial and Zytiga 302 trial in terms of size and inclusion of patients with/<wbr>without visceral metastases (the label for PREVAIL will include only metastatic patients).<wbr> The importance of overall survival benefit from a commercial standpoint as well as combining or sequencing XTANDI were discussed at the end of the conference.<wbr> More information is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PREVAIL trial vs.<wbr> Zytiga 302</STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> if you look at J&amp;J's 301 study, which is a post-chemo study, they had 1,195 patients in that study.<wbr> In our AFFIRM trial, we have 1,199 patients.<wbr> But in 302, the J&amp;J pre-chemo study there were only 1,088 people in that study.<wbr> So that 302 study was actually even smaller than the post-chemo study, it's a bit unusual.<wbr> And what we've decided to do is, we decided to increase the power of our pre-chemo study.<wbr><BR><BR>.<wbr>.<wbr>.<wbr> we had 1,199 patients in our AFFIRM trial, PREVAIL enrolled 1,717 patients.<wbr> So that's quite a bit more -- that's quite a few more patients than the 1,088 in the 302 study.<wbr> So the most obvious difference is that it's a much bigger study.<wbr> </div><div style="margin-bottom: 10px;">The second difference, which does not -- probably not as much of a big deal is that whereas visceral metastases is excluded in the 302 study, they were not excluded in the PREVAIL study.<wbr> So patients with visceral metastases tend to be a little sicker.<wbr> We want to make sure that the placebo arm is structured in such a way that we'll be able to get a very reasonable median survival in that arm so that you can be able to detect the drug placebo difference.<wbr> And I think that including a few more patients with visceral metastases they allow us to accomplish that objective".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commercial Importance of Overall Survival</STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> there are very few agents that have shown a survival benefit in pre-chemo patients in prostate cancer .<wbr>.<wbr>.<wbr> So the only drug to-date that has demonstrated a statistically significant survival benefit in pre-chemo patients is Provenge.<wbr> So they had a 4.<wbr>2-month benefit in the IMPACT trial and it's the only drug that's shown a statistically significant advantage in survival in that population.<wbr><BR><BR>.<wbr>.<wbr>.<wbr> if you look at our AFFIRM trial in post-chemo patients, we had a 4.<wbr>8-month benefit .<wbr>.<wbr>.<wbr> we think that XTANDI is mechanistically well positioned for the pre-chemo space.<wbr> So given the fact that there are no other agents that have demonstrated an OS benefit in pre-chemo, if we were to hit OS in PREVAIL, we think that would make XTANDI quite unique, because unlike Provenge we know that XTANDI causes a robust reduction in PSA".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale for trying XTANDI in neoadjuvant</STRONG> </div><div style="margin-bottom: 10px;">The neoadjuvant study started enrolling last April 2012 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=8155" class="defaultlink">Oncology8155: MDV3100 to Enter POC Study as Neoadjuvant Prior to Prostatectomy</a>).<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> So we are doing this study.<wbr> We're doing with a cocktail of other inhibitors, Lupron, dutasteride .<wbr>.<wbr>.<wbr> and the rationale there is that we can now show that we can actually eradicate prostate cancer in even a small fraction of these patients.<wbr> I would imagine that would significantly impact the way physicians and patients think about treating their disease".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Combining or Sequencing</STRONG> </div><div>" .<wbr>.<wbr>.<wbr> medicines generally gravitated towards combination therapies for bad diseases.<wbr> So if you look at what's happened in the HIV and HCV field, certainly combo therapy is now standard of care.<wbr> And I think that, as I said earlier, you have a finite window to eradicate all those bad clones that will eventually become resistant and kill the patient.<wbr><BR><BR>So my guess is that you will eventually gravitate toward combination therapies in prostate cancer.<wbr> The question is which combination.<wbr> And I think that's a much bigger unknown.<wbr> I would say that I feel pretty confident that XTANDI will always be one of those -- one of that combination, because AR signaling is without a doubt one of the major swimming paddles in prostate cancer and we are the most advanced AR antagonist in development.<wbr><BR><BR>So I feel pretty comfortable with that.<wbr> Now what you would add on to XTANDI, I don't really know.<wbr> I think it's -- there are a lot of -- there's lots of data emerging that might suggest one or another agent, but I think that -- you will have to kind of wait and see what happens".<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9160">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-11T16:49:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-11T16:49:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Polish HTA Agency Transparency Board Recommends Afinitor</title>
	<pubDate>2013-09-11T15:16:04+02:00</pubDate>
	<wp:post_id>4866</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In its 24th session of 2013, the transparency board of the Agency for Health Technology Assessment in Poland (AOTM) has recommended the reimbursement of Afinitor (unresectable or metastatic, highly or moderately differentiated pancreatic neuroendocrine tumours in adult patients with a progressive course).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reimbursement of Afinitor</STRONG> </div><div style="margin-bottom: 10px;">Afinitor is likely to be added to the reimbursement list soon, following the acceptance of Novartis' risk-sharing agreement.<wbr> </div><div style="margin-bottom: 10px;">The drug is already reimbursed in Poland for the treatment of kidney cancer.<wbr> </div><div><EM>Source: GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7460">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-11T15:16:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-11T15:16:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Milestone for Naproxcinod (DMD)</title>
	<pubDate>2013-09-11T14:55:48+02:00</pubDate>
	<wp:post_id>4867</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nicox has received a positive opinion from the EU COMP recommending orphan drug designation for naproxcinod.<wbr> Management reported this " .<wbr>.<wbr>.<wbr> will support its strategy of partenring the development of the drug in this condition".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the drug</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">In a long-term preclinical study, naproxcinod was shown to improve skeletal and cardiac muscle function and to reduce skeletal muscle inflammation in <EM></EM>Association (MDA) Scientific Conference in Washington, DC in April 2013.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">A patent covering nitric oxide releasing compounds, including naproxcinod, for the treatment of muscular dystrophies is pending in Europe and has been granted in the United States in July 2013.<wbr></P> </div><div><P align="left"><EM>Source: Nicox</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7139">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-11T14:55:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-11T14:55:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BOTOX® Has Received Green Light in the UK for OAB</title>
	<pubDate>2013-09-11T13:00:58+02:00</pubDate>
	<wp:post_id>4868</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BOTOX&reg; has been licensed by the Medicines and Healthcare Products Regulatory Agency (MHRA), and is the only toxin indicated for this indication in the UK.<wbr>  The use of botulinum toxin A in the management of this condition is recommended by the NICE in its guideline of urinary incontinence.<wbr> Allergan noted that this is the tenth indication for its product in the country.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>OAB in the UK</STRONG> </div><div style="margin-bottom: 10px;">OAB is a common condition in the UK with studies indicating that up to 19% of the population may have the condition </div><div style="margin-bottom: 10px;"><STRONG>About the Registration Study</STRONG> </div><div>The EMBARK programme, with 2 Ph3, RCT, conducted in US and EU involving &gt;1,100 patients (not adequately managed with anticholinergic therapy due to side effects or lack of efficacy).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7138">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-11T13:00:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-11T13:00:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Celltrion and Hospira to Sell First Copies of J&J's Remicade</title>
	<pubDate>2013-09-11T10:45:18+02:00</pubDate>
	<wp:post_id>4869</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Celltrion and Hospira to Sell First Copies of J&J's Remicade</span>&nbsp;<br><span style="font-size: 12px;">Comment: The European Commission should give the two companies approval to market their versions, called Remsima and Inflectra, for the same medical conditions for which Remicade is marketed.<wbr> The EMA’s recommendations are the final stage before the European Commission, the European Union’s executive arm, approves or rejects a drug for sale to patients in the 27-nation region.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1899">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">European Commission approved Inflectra (infliximab), making the product the first biosimilar monoclonal antibody therapy authorised in the EU.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 22px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Savings Coming from Three Countries</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 22px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="background-color: #ffffff;">Hospira suggested that the launch of biosimilar monoclonal antibody products in Europe is expected to deliver savings of up to 20.<wbr>4 billion euros ($27 billion) by 2020, with the greatest savings coming from France, Germany and the UK.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="line-height: 22px; widows: 2; text-transform: none; background-color: #ffffff; font-variant: normal; font-style: normal; text-indent: 0px; display: inline !important; font-family: Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; font-size: 14px; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Approvals in the US &amp; Japan</SPAN></STRONG> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="background-color: #ffffff;">At the time of the CHMP's recommendation, Celltrion said it was planning to seek approval of Inflectra in Japan later this year, while an application in the US is possible in 2015.<wbr></SPAN></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1912">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1899">View thread  GastroEnterology1899: Celltrion and Hospira to Sell First Copies of J&J's Remicade</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-11T10:45:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-11T10:45:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Biopsy-Based Prostate Cancer Prognostic Test to be Available Before Year-End</title>
	<pubDate>2013-09-10T15:15:33+02:00</pubDate>
	<wp:post_id>4870</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Positive results from a lage clinical validation study demonstrate that Metamark Genetics' ProMark™ can differentiate indolent from aggressive disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The study, conducted in collaboration with Fred Saad, M.<wbr>D.<wbr>, F.<wbr>R.<wbr>C.<wbr>S.<wbr>, Professor and Chief, Division of Urology, Director of Urologic Oncology, University of Montreal Hospital Center, met its primary endpoint demonstrating that ProMark™, evaluated in standard formalin-fixed, paraffin-embedded prostate tissue, can differentiate indolent from aggressive disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Metamark plans to make ProMark™ available to pathologists, urologists and their patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Metamark Genetics, Inc.<wbr> is a privately-held biotechnology company founded in 2007 to develop novel, function-based prognostic and diagnostic tests aimed at improving cancer care.<wbr> </div><div style="margin-bottom: 10px;">The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon and breast cancers.<wbr> </div><div><EM>Source: Metamark Genetics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9158">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-10T15:15:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-10T15:15:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Roche and Inovio Strategic Partnership for Immunotherapy Products</title>
	<pubDate>2013-09-10T14:59:46+02:00</pubDate>
	<wp:post_id>4871</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The exclusive WW licensing and collaboration agreement signed with Roche provides validation of Inovio's DNA immunotherapy for prostate cancer (INO5150) and hepatitis B.<wbr> All products in those indications are at a near clinical stage.<wbr> Part of this agreement also is a research funding.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Terms</STRONG> </div><div style="margin-bottom: 10px;">Roche acquired an exclusive license for Inovio's DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of Inovio's CELLECTRA® electroporation technology for delivery of the vaccines.<wbr> </div><div style="margin-bottom: 10px;">Roche also obtained an option to license additional vaccine opportunities in connection with a collaborative research program in oncology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financials</STRONG> </div><div style="margin-bottom: 10px;">Upfront payment:$10M to Inovio </div><div style="margin-bottom: 10px;">Roche to provide clinical R&amp;D support and payments for near term regulatory mile milestones as well as the payment upon reaching certain development and commercial milestones, potentially up to a $412.<wbr>5M.<wbr> </div><div style="margin-bottom: 10px;">Inovio is entitled to receive up to double digits here royalties on product sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Inovio's dual-antigen synthetic DNA vaccine (INO-5150) targets prostate-specific membrane antigen (PSMA) and prostate-specific antigen (PSA).<wbr> </div><div style="margin-bottom: 10px;">- A study in monkeys showed that vaccination with INO-5150 generated strong and robust T-cell immune responses that were the highest generated by a PSA-based immunotherapy in animal studies.<wbr> </div><div style="margin-bottom: 10px;">- close to start Ph1 IND filing (end of 2013).<wbr> </div><div style="margin-bottom: 10px;">-  Inovio are finalizing the specific study protocol and other clinical details with Roche.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please also see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9079" class="defaultlink">Oncology9079: Positive PC Data Generated by Inovio's 'Universal' Cancer Vaccine</a> </div><div><EM>Source: Inovio's conference call and press release</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9157">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-10T14:59:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-10T14:59:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Exelixis to Start Registration Trial with Cabozantinib in 2nd-line HCC</title>
	<pubDate>2013-09-10T14:30:56+02:00</pubDate>
	<wp:post_id>4872</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Exelixis to Start Registration Trial with Cabozantinib in 2nd-line HCC</span>&nbsp;<br><span style="font-size: 12px;">Comment: Advancing the cabozantinib franchise in pivotal trials for HCC is one of the company key priorities.<wbr> The study is to assess the effect of the drug vs placebo on OS (as primary endpoint) in approx 760 patients with advanced HCC who have received prior sorafenib.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9080">...</a><br></div><div style="margin-bottom: 10px;">The company has reported it has initiated CELESTIAL, with Ghassan K.<wbr> Abou-Alfa, M.<wbr>D.<wbr>, (Associate Attending at Memorial Sloan-Kettering Cancer Center, New York) as lead investigator.<wbr> CELESTIAL is the fifth pivotal trial for cabozantinib overall, and the second phase 3 trial to initiate this year.<wbr> It was designed with the input of leading oncologists and HCC experts.<wbr> Additional details are provided below.<wbr> </div><div style="margin-bottom: 10px;">Locations: up to 200 sites globally in up to 30 countries.<wbr> </div><div style="margin-bottom: 10px;">Protocol: Patients will be randomized 2:1 to receive 60 mg of cabozantinib daily or placebo.<wbr> </div><div>Exploratory endpoints include patient-reported outcomes, biomarkers, and safety.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9156">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9080">View thread  Oncology9080: Exelixis to Start Registration Trial with Cabozantinib in 2nd-line HCC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-10T14:30:56+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-10T14:30:56+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Mixed Ph2 Data with Neurocrine's VMAT2 Inhibitor for Tardive Dyskinesia</title>
	<pubDate>2013-09-10T10:56:14+02:00</pubDate>
	<wp:post_id>4873</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 50mg dose of NBI-98854 did not meet the primary endpoint in the Ph2b Kinect study while the 100mg dose showed a statistical and clinically significant improvement.<wbr> Neurocrine has started an additional Ph2 utilizing 100mg and higher doses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01688037?term=kinect&amp;rank=5"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Also See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7041" class="defaultlink">Neurology7041: Enrollment of Neurocrine' NBI-98854 for Tardive Dyskenesia is Complete</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Planning for an additional Phase II study of NBI-98854 at daily doses of 100mg and above has begun and the Company's timeline to an end-of-phase II meeting is delayed by approximately one year.<wbr> </div><div style="margin-bottom: 10px;">- Tourette Indication : Management plans to begin a healthy volunteer PK study early 2014 and shortly after a proof of concept study.<wbr> </div><div><EM>Source: Neurocrine Biosciences</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7136">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-10T10:56:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-10T10:56:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan to Assess Impact of Systemic Bladder Health Screening in Patients with MS</title>
	<pubDate>2013-09-09T17:27:11+02:00</pubDate>
	<wp:post_id>4874</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.<wbr> PE will evaluate change from baseline in the King's Health Questionnaire (KHQ) Score.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01930799?recr=Open&amp;phase=0123&amp;fund=2&amp;rcv_s=08%2F09%2F2013&amp;rank=178"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">N= approx.<wbr> 240 with diagnosis of relapsing-remitting multiple sclerosis and currently being treated by study doctor </div><div style="margin-bottom: 10px;">Start date: Aug 2013 - Completion: July 2014 /<wbr> Aug 2014 </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7134">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-09T17:27:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-09T17:27:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Antibiotics a New Strategic Therapeutic Area for Debiopharm</title>
	<pubDate>2013-09-09T16:54:39+02:00</pubDate>
	<wp:post_id>4875</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Debiopharm has announced the signature of an exclusive collaboration with TCG Lifesciences Limited to develop innovative antibiotics targeting drug-resistant bacteria.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to establish a leadership position in the area of antibiotics.<wbr> </div><div style="margin-bottom: 10px;">- to accelerate development of Debio1348 (in discovery stage), innovative target for infectious diseases.<wbr> </div><div style="margin-bottom: 10px;">- to increase commitment in this area (additional partnerships forseen).<wbr> </div><div style="margin-bottom: 10px;"><P class="c1"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;">TCGLS is a leading contract research services company in the area of early drug discovery and development.<wbr> They started their operations in the year 2001 in India.<wbr> </div><div style="margin-bottom: 10px;">Currently TCGLS is present  in the United States, Europe, Japan and Australia.<wbr> </div><div style="margin-bottom: 10px;">The company has a strong talent pool of 800+ trained scientists, drawn from the best national and international institutes as well as the industry.<wbr> </div><div style="margin-bottom: 10px;">Their services span from specific solutions to integrated discovery projects across multiple therapeutic areas with focus on Central Nervous System (CNS), Inflammation and Pain, Metabolic Disorders and Infectious Diseases.<wbr> </div><div><EM>Source: Debiopharm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10609">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-09T16:54:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-09T16:54:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Recordati to Acquire Laboratorios Casen Fleet for €93M</title>
	<pubDate>2013-09-09T16:26:36+02:00</pubDate>
	<wp:post_id>4876</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Casen Fleet primarily markets internally developed drugs principally in the gastroenterological therapeutic area in Spain and Portugal through its own organisation and in other countries through partners.<wbr> Approx.<wbr> 55% of revenue is generated by a line of products used in the preparation for colonoscopy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to reinforce presence in Spain </div><div style="margin-bottom: 10px;">- to improve profitability </div><div style="margin-bottom: 10px;">- to acquire a portfolio of products, and in particular CitraFleet® (with WW marketing rights).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Casen Fleet develops and manufactures most of its medicines in its own facility in Utebo, Zaragoza, which occupies an area of 23,165 sq.<wbr> m.<wbr> </div><div style="margin-bottom: 10px;">The company employs around 230 people and sales in 2012 are € 45.<wbr>3 million.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><U>Main Products</U></STRONG> </div><div style="margin-bottom: 10px;">- CitraFleet®, already marketed by Recordati in Germany.<wbr> </div><div style="margin-bottom: 10px;">- oral rehydration products, probiotics and OTC brands for gynecological use.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Thanks to Anna Szczepanska we have learnt that CitraFleet® was registered in Poland recently (Approval: June 2013).<wbr> </div><div><EM>Source: Recordati</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology1925c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Recordati has announced successful completion of the acquisition.<wbr> Approx.<wbr> 55% of  of 100% of Casen Fleet revenue is generated by a line of product used for colonoscopy.<wbr> </div><div style="margin-bottom: 10px;">The company's product portfolio also comorises oral rehydratation products, probiotics and OTC brands for gynea use.<wbr> </div><div>Approx.<wbr> 80% of revenue is generated by private payers and is therefore outside public healthcare reimbursement schemes.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1911">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-09T16:26:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-09T16:26:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approved ABRAXANE®/Gemcitabine for 1st-Line Metastatic Pancreatic Cancer</title>
	<pubDate>2013-09-09T10:30:11+02:00</pubDate>
	<wp:post_id>4877</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The approval represents a significant advancement in a therapeutic area where historically many agents have failed to improve overall survival.<wbr> Celgene noted that the combination is the 1st treatment approved for metastatic pancreatic cancer in almost 8 years.<wbr> The expanded indication strengthens the ABRAXANE® franchise beyond the existing indications of breast and non-small cell lung cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: verdana, arial, sans-serif">Investors with Barclays believe Abraxane/<wbr>gemcitabine will become the new standard of care in front-line setting.<wbr></SPAN> Abraxane offers a different class of agent and appears to have a more tolerable side effect profile compared to FOLFIRINOX, which is the current standard of care for patients with good performance status.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">EU - In April 2013, the European Medicines Agency (EMA) also accepted for review a Type II Variation to the current Marketing Authorization Application (MAA) for ABRAXANE®, in combination with gemcitabine, for the first–line treatment of patients with metastatic adenocarcinoma of the pancreas.<wbr> </div><div style="margin-bottom: 10px;">Elsewhere - Celgene has submitted dossiers for registration in other countries/<wbr>regions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> </div><div><DIV class="i" id="oncology8592.03i">

<UL><LI>
</LI>
<LI>
</LI>
<LI>
</LI>
</UL>

<DIV class="ii"><STRONG></STRONG></DIV>

<DIV class="ii"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN></DIV>

<DIV class="ii"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN></DIV>

<DIV class="ii"><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(49,102,50); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 14px/22px Helvetica, Arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(26,26,26); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN>.<wbr></DIV>

<DIV class="ii"><STRONG></STRONG></DIV>

<DIV class="ii"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9155_1_ScreenCapture1.jpg"></DIV>

<DIV class="ii"></DIV>
</DIV> </div><!-- Comment details --><a name="oncology9155attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9155_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9155">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-09T10:30:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-09T10:30:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Adult Spasticity Registry of BOTOX Treatment</title>
	<pubDate>2013-09-06T17:30:01+02:00</pubDate>
	<wp:post_id>4878</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The aim of the ASPIRE registry study in adults with spasticity is to determine the use of BOTOX in clinical practice (real life).<wbr> PE will evaluate percentage of patients/<wbr>health care providers reporting satisfaction with treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01930786?term=botulinum&amp;recr=Open&amp;no_unk=Y&amp;rank=84"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">n= 1000 participants (both genders - &gt;18 years old) </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Inclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Treatment with onabotulinumtoxinA according to the decision of the physician for spasticity</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Willingness to complete study questionnaires and answer study questions by phone or internet</LI>
</UL> </div><div style="margin-bottom: 10px;">Start date: Sept 2013 - Completion date: Sept 2017 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7131">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-06T17:30:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-06T17:30:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Pen Device for Omnitrope®</title>
	<pubDate>2013-09-06T13:57:11+02:00</pubDate>
	<wp:post_id>4879</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The validation and ease of use of SurePal™ for self-administration of rGH has been recently published in <EM>Medical Devices: Evidence and Research</EM>.<wbr> The article outlines the results from a two-center (US and Germany) usability study, as well as the characteristics of the device.<wbr> Preliminary feedback from the field has indicated that this new device has not yet been launched in Spain and the UK.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7452_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>semi-reusable needle-based injection system (the pen itself is reusable, while the drug-containing cartridges are replaced when empty)</LI>
<LI>safety features, including a system to ensure that only cartridges of the correct dose can be used with each device, and an optional needle guard</LI>
<LI>dose memory function that enables the correct dose to be preset by a doctor or nurse and locked into the device, thereby reducing the risk of incorrect dosing </LI>
<LI>designed to minimize drug wastage</LI>
<LI>more convenient to administer a second injection compared with most other rhGH injection devices, for which the user must calculate the amount of additional dose required and reset their device accordingly</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the US, 100% of the children liked the look of the device, and 90% of adults had a good impression of it.<wbr> </div><div style="margin-bottom: 10px;">Among the German participants, 90% of children and 74% of adults had a good first impression of the device.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Spencer Schipper</U> indicates that " .<wbr>.<wbr>.<wbr> Sandoz seems to have listened to their costumers, as the current device has been perceived to be poor in terms of quality".<wbr> </div><div style="margin-bottom: 10px;">For <U>Bruno Fiorentino</U>, " .<wbr>.<wbr>.<wbr> the characteristics of  SurePal™are very similar to the new developing Nutropin Pen but its design not very attractive".<wbr> </div><div><STRONG></STRONG> </div><!-- Comment details --><a name="endocrinology7452attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7452_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7452">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-06T13:57:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-06T13:57:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Current Status of XTANDI in the Netherlands</title>
	<pubDate>2013-09-06T12:01:19+02:00</pubDate>
	<wp:post_id>4880</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Saskia Groos we have got more details on the price of the product (and versus Zytiga) in the Netherlands.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Registration in June 2013 </div><div style="margin-bottom: 10px;">- Current price per capsule: €27.<wbr>50 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9152_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<UL><LI><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN></LI>
<LI><SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN></LI>
</UL></BLOCKQUOTE> </div><div><DIV style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></DIV> </div><!-- Comment details --><a name="oncology9152attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9152_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(20,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9152">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-06T12:01:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-06T12:01:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis to Boost Internal Cell Therapy Assets and Gain Access to Stem Cell Technology</title>
	<pubDate>2013-09-06T11:48:16+02:00</pubDate>
	<wp:post_id>4881</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis has signed an exclusive global licensing and research collaboration with Regenerex, which will enlarge its scope of novel cell therapy portfolio and stem cell technology for conditions where little treatment is currently available.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- access to Regenerex' novel Facilitating Cell Therapy (FCRx) Platform (curative potential for multiple underserved diseases such as inherited metabolic storage disorders and hemoglobinopathies).<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<UL><LI>HSC835 is currently in a Phase II trial in patients with high-risk hematological malignancies.<wbr> </LI>
<LI>CTL019, a chimeric antigen receptor T cell therapy currently in Phase II development in acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).<wbr></LI>
</UL></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- startup biology company, based in Louisville, Kentucky.<wbr> </div><div><EM>Sources: ThomsonOne; Regenerex; Novartis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10600">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-06T11:48:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-06T11:48:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NET Therapy Area Landscape</title>
	<pubDate>2013-09-06T11:24:53+02:00</pubDate>
	<wp:post_id>4882</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached an updated version of the competitive landscape in NET.<wbr> This slide kit has been created in close collaboration with Scientific Intelligence and the Endocrinology Franchise.<wbr> Next update is due in Q4:13.<wbr> </div><div style="margin-bottom: 10px;">We encourage you to contribute to our internal knowledge by evaluating some of the "Key Intelligence Questions" included in the document.<wbr> <SPAN style="line-height: 1.5em;">However, no matter what competitive information /<wbr> soft intelligence you have, please do keep us informed on any key developments in your countries.<wbr></SPAN> </div><div>We hope that you will find it a useful tool.<wbr> </div><!-- Comment details --><a name="endocrinology7450attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7450_1_NET%20Therapeutic%20Landscape%20%2d%20%20September%202013.ppt">NET Therapeutic Landscape - September 2013.ppt</a>&nbsp;&nbsp;(3,4 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7450">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-06T11:24:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-06T11:24:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer Aims for Strong Growth in Russia by 2017</title>
	<pubDate>2013-09-06T10:49:45+02:00</pubDate>
	<wp:post_id>4883</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company aims to increase sales (prescription and non-prescription products) by 80% in 2017 (compared to last year's level).<wbr> CEO reported that ".<wbr>.<wbr>.<wbr> the middle class, which is an incremental driver of overall consumption, is rapidly expanding, and that " .<wbr>.<wbr>.<wbr> this trend is expected to be relevant for Bayer".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company's plans is: </div><div style="margin-bottom: 10px;">- to generate sales of €1.<wbr>3 billion ($1.<wbr>7 billion) by 2017 </div><div style="margin-bottom: 10px;">- to increase its number of staff by 800 (bringing the total of approx.<wbr> 2,400 employees).<wbr> </div><div><EM>Source: DowJones</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10599">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-06T10:49:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-06T10:49:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OncoMed Granted Patent with Vantictumab</title>
	<pubDate>2013-09-06T10:25:00+02:00</pubDate>
	<wp:post_id>4884</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN style="LINE-HEIGHT: 1.5em">Vantictumab is currently being evaluated in a Ph1 clinical trial, where it has provided early signs of single-agent activity in patients with neuroendocrine tumors.<wbr> The antibody is part of OncoMed's collaboration with Bayer Pharma AG.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.5em"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.5em">OncoMed Pharm.<wbr> has been granted Patent for Methods of Treating Cancer with Vantictumab (OMP-18R5).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.5em">United States Patent and Trademark Office has issued U.<wbr>S.<wbr> Patent No.<wbr> 8,507,442.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Vantictumab is a first-in-class antibody that has shown broad anti-CSC and anti-tumor activity in patient-derived xenograft tumor models.<wbr> </div><div style="margin-bottom: 10px;">Vantictumab inhibits a key signaling pathway in cancer, the Wnt pathway.<wbr> Specifically, vantictumab selectively targets Frizzled receptors, which are activators of Wnt signaling.<wbr> Although vantictumab was originally identified by binding to Frizzled 7, the antibody selectively targets five different Frizzled receptors.<wbr> </div><div><EM>Source: OncoMed</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10598">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-06T10:25:00+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-06T10:25:00+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PET Imaging to Detect Prostate Cancer Has Entered Ph1/Ph2a</title>
	<pubDate>2013-09-05T17:22:25+02:00</pubDate>
	<wp:post_id>4885</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The trial started last month with the aim to evaluate the safety and feasibility of ImaginAb's radiopharmaceutical in detecting metastatic prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01923727?phase=0123&amp;rcv_s=08%2F05%2F2013&amp;rank=12&amp;submit_fld_opt="><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 38 </div><div style="margin-bottom: 10px;">Completion date: Feb 2014 /<wbr> March 2014 </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- privately held U.<wbr>S.<wbr> biotechnology company based in Los Angeles, CA, </div><div style="margin-bottom: 10px;">- focus: re-engineering antibodies into smaller protein formats with kinetics optimized for diagnostic imaging.<wbr> </div><div style="margin-bottom: 10px;">- founded in October 2007 by Anna Wu, Rob Reiter, Chris Behrenbruch and Tove Olafsen.<wbr> </div><div><DIV class="column" id="content">
<DIV class="field field-name-body field-type-text-with-summary field-label-hidden">
<DIV class="field-items">
<DIV class="field-item even">
<P>- March 2012, ImaginAb announced that the company closed $12.<wbr>5m in financing led by Novartis Venture Fund (NVF).<wbr></P>
<P><EM>Source: ImaginAb; clinicaltrials.<wbr>gov</EM></P></DIV></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9149">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-05T17:22:25+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-05T17:22:25+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Civitas Therapeutics Initiates PhII Study For Parkinson Disease</title>
	<pubDate>2013-09-05T16:57:33+02:00</pubDate>
	<wp:post_id>4886</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Civitas Therapeutics Initiates PhII Study For Parkinson Disease</span>&nbsp;<br><span style="font-size: 12px;">Comment: Civitas has announced the initiation of a phase 2 a clinical trial 
evaluating its pulmonary inhaled formulation of L-Dopa CVT-301 as an adjunctive 
treatment to oral L-Dopa.<wbr> Funding for the study is being  provided by the 
Michael J Fox Foundation.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=6481">...</a><br></div><div style="margin-bottom: 10px;">Civitas has initiated a Ph2b for CVT-301 in the USA and EU to test the efficacy, safety and tolerability of the drug in the treatment of intermittent OFF episodes.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 80 patients </div><div style="margin-bottom: 10px;">Preliminary data: H1 14 </div><div>Drug Characteristics: ease of use; simple ARCUS(R) inhaler; allows whenever and whereever use.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7130">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6481">View thread  Neurology6481: Civitas Therapeutics Initiates PhII Study For Parkinson Disease</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-05T16:57:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-05T16:57:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Norwegian Medicines Agency (NMA) Urges Doctors to consider Cost Implications When Prescribing Growth Hormone</title>
	<pubDate>2013-09-05T15:19:41+02:00</pubDate>
	<wp:post_id>4887</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7445_1_ScreenCapture1.jpg"></P> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><div><P style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></P> </div><!-- Comment details --><a name="endocrinology7445attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7445_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(60,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7445">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-05T15:19:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-05T15:19:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Otsuka to Buy Astex for Up to $886M</title>
	<pubDate>2013-09-05T14:54:43+02:00</pubDate>
	<wp:post_id>4888</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The acquisition of Astex adds an important MDS franchise with DACOGEN (WW sales: $280M), and lead development candidates such as AT13387, a second generation HSP90 inhibitor.<wbr> Data from Ph1/<wbr>Ph2 trial of the drug in combination with abiraterone for CRPC are expected 1H14.<wbr> Astex also has 5 partner-funded programs that are being developed by Novartis, AstraZeneca and Janssen.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=8461" class="defaultlink">Oncology8461: Astex' HSP90 Inhibitor Enters Ph1/<wbr>Ph2 Trial for CRPC</a>.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><H1 class="solo_record"><STRONG></STRONG></H1> </div><div style="margin-bottom: 10px;">Otsuka will acquire all of the outstanding shares of Astex for $8.<wbr>50 per share in cash representing a 48% premium to the average closing stock price for the prior 30 day period.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- To increase revenue streams as patents for its mainstay ABILIFY schizophrenia treatment will begin to expire.<wbr> The drug is sold in &gt;60 countries and regions WW including Japan with global sales of 438.<wbr>5 billion yen in fiscal 2012 accounting for 36% of Otsuka Holdings‟ consolidated results.<wbr> </div><div style="margin-bottom: 10px;">- To strengthen anti-cancer drug R&amp;D position and expand portfolio in the cancer area.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9145_1_ScreenCapture1.jpg"> </div><div><EM>Source: Astex; Otsuka; ThomsonOne</EM> </div><!-- Comment details --><a name="oncology9145attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9145_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(114,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9145">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-05T14:54:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-05T14:54:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Takeda Seeks Regulatory Approval For New Ulcerative Colitis Therapy</title>
	<pubDate>2013-09-05T09:35:39+02:00</pubDate>
	<wp:post_id>4889</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Takeda Seeks Regulatory Approval For New Ulcerative Colitis Therapy</span>&nbsp;<br><span style="font-size: 12px;">Comment: Takeda has submitted an MAA to the EMA for vedolizumab to treat 
moderately to severely active ulcerative colitis and Crohn's disease.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1879">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">FDA has accepted and granted Priority Review to a BLA from </SPAN>Takeda <SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">for vedolizumab to treat moderately to severely active ulcerative colitis (UC).<wbr> The pharma expects a decision in 1Q14.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-stroke-width: 0px;">The agency also is reviewing vedolizumab to treat Crohn's disease under a standard review time frame.<wbr> Takeda, which submitted a single BLA to FDA in June, said the agency chose to review the indications under different timelines.<wbr></SPAN> </div><div><EM><SPAN style="line-height: normal; text-transform: none; background-color: #ffffff; font-variant: normal; text-indent: 0px; display: inline !important; font-family: arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #222222; font-size: 13px; font-weight: normal; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Source: Biocentury</SPAN></EM> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20131231&edate=20130901&rec=1910">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1879">View thread  GastroEnterology1879: Takeda Seeks Regulatory Approval For New Ulcerative Colitis Therapy</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-05T09:35:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-05T09:35:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Trial to Assess Eligard 6M on Cancer Markers of Prostate Cancer</title>
	<pubDate>2013-09-04T18:28:54+02:00</pubDate>
	<wp:post_id>4890</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas is to start this month a Ph4 trial in approx.<wbr> 50 participants with confirmed metastatic prostate cancer for whom ADT is indicated.<wbr> PE will assess changes from baseline on prostate cancer biomarkers.<wbr> A blood sample for RNA analysis will also be collected and stored for future investigation in patients giving specific informed consent.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Testosterone in serum, Prostate Specific Antigen (PSA) in serum, Prostate Cancer Antigen (PCA3 score) in urine, PSA mRNA in blood/<wbr>Peripheral Blood Mononuclear Cell (PBMC), PCA3 mRNA in blood/<wbr>PBMC, Transmembrane protease, serine 2-Ets Related Gene (TMPRSS2-ERG) mRNA in blood/<wbr>PBMC.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01933022?recr=Open&amp;phase=0123&amp;fund=2&amp;rcv_s=08%2F04%2F2013&amp;rank=60"><STRONG></STRONG></A></P> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;">Start date: Sept 2013 - Completion: Aug 2014 /<wbr> Feb 2015</P> </div><div><P style="margin-top: 0ex; margin-bottom: 1ex;">Location: the Netherlands (5 sites)</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9144">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-04T18:28:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-04T18:28:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study - Results of 3 years of Octreotide LAR Treatment in Autosomal Dominant Polycystic Kidney Disease: ALADIN trial</title>
	<pubDate>2013-09-04T17:52:08+02:00</pubDate>
	<wp:post_id>4891</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : .<wbr> The primary endpoint ,<STRONG><SPAN style="color: #888888;"> mean increase in total kidney volume TKV,</SPAN> </STRONG>showed a numerical but non significant difference between the octreotide LAR group compared with the placebo group, at 3-year follow-up.<wbr> The protective effect of octreotide LAR against TKV growth was larger in the first year of treatment  than at subsequent follow-up.<wbr>  However the results show that octreotide LAR slowed the increase in TKV by blunting the growth of cyst volume.<wbr> </div><div style="margin-bottom: 10px;">Design: Randomized single-blind placebo-controlled study </div><div style="margin-bottom: 10px;">Patients: Adult patients with autosomal dominant polycystic kidney disease and large kidney volumes with preserved or moderately impaired renal function.<wbr> They received 2 monthly injections of octreotide LAR 20mg or placebo during 3 years.<wbr> </div><div style="margin-bottom: 10px;">Endpoints: Change in total kidney volume (TKV) ,  in total cyst volume (TCV) and in non-cyst kidney-volume (NCV) measured by MRI at 1 year and 3-year follow-up; glomerular filtration rate (GFR) </div><div style="margin-bottom: 10px;">Results: 3 year treatment with octreotide LAR slowed kidney volume growth.<wbr> The slower growth in TKV in the octreotide LAR group was associated with slower growth in TCV.<wbr> GFR stabilised in the octreotide LAR group  whereas it progressively declined in the placebo group: the difference in rate of renal function loss was significant between groups.<wbr> </div><div style="margin-bottom: 10px;">Authors conclusion: The protective effect of somatostatin analogues against renal function loss and progression to end-stage kidney disease  should be tested in larger trials adequately powered.<wbr>.<wbr> </div><div><EM><STRONG>Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.<wbr> </STRONG><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Caroli%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=23972263" target="_blank">Caroli A</A>, Lancet.<wbr> 2013 Aug 20 [Epub ahead of print] <a href="http://ac.els-cdn.com/S0140673613614075/1-s2.0-S0140673613614075-main.pdf?_tid=ead492be-1577-11e3-9b19-00000aacb360&acdnat=1378309233_579f39d250055325d6da6832f1d400df" class="defaultlink">Scie</a><a href="http://ac.els-cdn.com/S0140673613614075/1-s2.0-S0140673613614075-main.pdf?_tid=ead492be-1577-11e3-9b19-00000aacb360&acdnat=1378309233_579f39d250055325d6da6832f1d400df" class="defaultlink">ncedirectAccesstoPDF</a></EM> </div><!-- Comment details --><a name="endocrinology7444attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7444_1_CaroliLancet2013%255foct%20PCKD%20Aladin%20trial.pdf">CaroliLancet2013_oct PCKD Aladin trial.pdf</a>&nbsp;&nbsp;(659,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7444_2_QianLancet2013%255foct%20PCKD%20Aladin%20trial%20comments.pdf">QianLancet2013_oct PCKD Aladin trial comments.pdf</a>&nbsp;&nbsp;(504,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20131231&edate=20130901&rec=7444">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-04T17:52:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-04T17:52:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: First Time Evaluation of BOTOX® for New Daily Persistent Headache (NDPH)</title>
	<pubDate>2013-09-04T15:59:28+02:00</pubDate>
	<wp:post_id>4892</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First Time Evaluation of BOTOX®  for New Daily Persistent Headache (NDPH)</span>&nbsp;<br><span style="font-size: 12px;">Comment: The aim of the Ph2 open label trial, sponsored by St.<wbr> Luke's-Roosevelt Hospital Center, is to assess the effect of the drug on the number of headache days in patients with NDPH.<wbr> PE will measure change from baseline in frequency of headache days.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7124">...</a><br></div><div>The head/<wbr>neck muscles injected are very similar to those injected for aesthetic indications, could it be other primary or secondary end point linked to aesthetic indications in this study ? </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7128">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7124">View thread  Neurology7124: First Time Evaluation of BOTOX®  for New Daily Persistent Headache (NDPH)</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-04T15:59:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-04T15:59:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Data On nOAB Drug At The International Continence Society Meeting</title>
	<pubDate>2013-09-04T14:40:47+02:00</pubDate>
	<wp:post_id>4893</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the recent 43rd International Continence Society Meeting, Astellas reported on the positive results of a phII trial with solifenacin pediatric suspension in children with nOAB.<wbr> Additionally, TRPM8 blockade was highlighted as a potential new treatment strategy for urinary bladder disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Solifenacin</STRONG> </div><div style="margin-bottom: 10px;">Brigitte Bosman (<A href="http://ci.beaufour-ipsen.com/" style="color: #505050; cursor: text; text-decoration: none;">Astellas Pharma Europe</A>) presented the results of the Elefant trial (NCT01539707), in which children (n = 7) and adolescents (n = 7) with neurogenic detrusor overactivity were treated with the product at a weight-based dose extrapolated from the approved adult dose.<wbr> </div><div style="margin-bottom: 10px;">The actual doses delivered were 3-fold the corresponding adult dose to explore the safety at high exposure levels; 4, 6, 9, 13.<wbr>4 and 15 mg for children weighting 14 to 20 kg, 21 to 31 kg, 32 to 50 kg, 51 to 70 kg and &gt; 70 kg, respectively.<wbr> At these levels of exposure, pharmacokinetic values were comparable between children and adolescents, although total drug exposure tended to be lower in children (AUC(0 to infinity) = 831.<wbr>9 ng.<wbr>h/<wbr>ml compared with 1614.<wbr>8 ng.<wbr>h/<wbr>ml in adolescents).<wbr> The half-life was also shorter in children (30.<wbr>7 h) than adolescents (52.<wbr>9 h), with the younger patients also exhibiting lower distribution volumes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New TRPM8 Blockers - Potential In Bladder Disorders</STRONG> </div><div style="margin-bottom: 10px;">TRPM8 receptors, which are activated by cold temperatures, may have a role in the control of bladder contractility; blockers able to inhibit exaggerated stimulation in pathologic conditions have been investigated.<wbr> </div><div style="margin-bottom: 10px;">Stefano Palea (<A href="http://ci.beaufour-ipsen.com/" style="color: #505050; cursor: text; text-decoration: none;">UROsphere</A>) reported preclinical investigations comparing the potent TRPM8 blocker <A href="http://ci.beaufour-ipsen.com/" style="color: #505050; cursor: text; text-decoration: none;">DFL-14817</A> (Dompe) with <A href="http://ci.beaufour-ipsen.com/" style="color: #505050; cursor: text; text-decoration: none;">Johnson &amp; Johnson</A>'s <A href="http://ci.beaufour-ipsen.com/" style="color: #505050; cursor: text; text-decoration: none;">TRPM8 inhibitor</A> and <A href="http://ci.beaufour-ipsen.com/" style="color: #505050; cursor: text; text-decoration: none;">Purdue Pharma</A>&amp;apos;s <A href="http://ci.beaufour-ipsen.com/" style="color: #505050; cursor: text; text-decoration: none;">BCTC</A>.<wbr> Using calcium mobilization assays with icilin, a cooling agent that stimulates TRPM8 receptors, in HEK293 cells expressing human TRPM8 receptors, DFL-14817 was the most potent compound, with an IC50 value of 4 nM, compared with 10 and 5 nM for the comparator compounds.<wbr> </div><div style="margin-bottom: 10px;">Furthermore, DFL-14817 was inactive against muscarinic M2, M3, TRPA1, TRPV1 and TRPV4 receptors, whereas BCTC blocked TRPV1 receptors with an IC50 value of 19 nM.<wbr> </div><div style="margin-bottom: 10px;">DFL-14817 dose-dependently inhibited rat bladder contractions after iv administration, attaining periods of inhibition of approximately 526 s after a single dose of 10 mg/<wbr>kg, which was statistically significant compared with approximately 204 s for the vehicle.<wbr> BCTC also inhibited rat bladder contractions, attaining an inhibition period of approximately 1762 s that was also significantly different from the 198 s observed in the corresponding control animals.<wbr> </div><div style="margin-bottom: 10px;">These results confirm the role of TRPM8 activation in the control of bladder contraction and underline the therapeutic potential of DFL-14817, which had no effect on amplitude of micturition, suggesting low likelihood for urinary retention after treatment.<wbr> Intravesical administration of DFL-14817 also inhibited rat bladder contractions reaching a threshold volume of 1.<wbr>94 and 3 ml after doses of 0.<wbr>3 and 2.<wbr>3 mg, respectively; these were significantly greater than the 0.<wbr>70 ml calculated in control, vehicle-treated animals, again without an effect on micturition amplitude.<wbr> Administered by intravesical instillation, Johnson &amp; Johnson's TRPM8 blocker also increased threshold volume from 0.<wbr>8 ml in control animals to 1.<wbr>56 ml in treated animals.<wbr> </div><div style="margin-bottom: 10px;">This pharmacokinetic profile was similar to that previously demonstrated in a pediatric population of patients with overactive bladder and translated into a favorable safety profile, with only two adolescents experiencing a total of five treatment-emerging adverse events not considered related to the study medication.<wbr> </div><div>Source; Cortellis </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7127">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-04T14:40:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-04T14:40:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Avanir Continues To Make Solid Progress With Generic Litigation Suits</title>
	<pubDate>2013-09-04T14:02:52+02:00</pubDate>
	<wp:post_id>4894</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As part of its ongoing litigation against a number of ANDA filers 
for approval of a generic form of NEUDEXTA, Avanir's product for the 
treatment of pseudobulbar affect, it has announced a settlement with 
Actavis.<wbr> This is the second agreement to be reached, the one prior being with 
Sandoz.<wbr> </div><div style="margin-bottom: 10px;">Both settlement agreement grant Actavis &amp; Sandoz the 
right to begin selling a generic version of NUEDEXTA on July 30, 2026, or 
earlier under certain circumstances.<wbr> </div><div style="margin-bottom: 10px;">The parties have also agreed to file a stipulation and order of dismissal 
with the United States District Court for the District of Delaware which will 
conclude their litigation.<wbr> </div><div>Source: <A href="http://www.avanir.com">www.<wbr>avanir.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7126">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-04T14:02:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-04T14:02:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Addex To Initiate New PhII Dystonia Trial</title>
	<pubDate>2013-09-04T13:55:23+02:00</pubDate>
	<wp:post_id>4895</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">In the study that is part of an ongoing collaboration with Professor Antonio 
Pisani, University of Rome Tor Vergata and Fondazione Santa Lucia, chronic 
treatment with dipraglurant (50 mg/<wbr>kg i.<wbr>p.<wbr> for 8 days) partially restored 
long-term depression and synaptic de-potentiation which are impaired in the DYT1 
mutant mice over expressing the human mutant TOR1A gene.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Is Primary Generalised Torsion Dystonia</STRONG> </div><div style="margin-bottom: 10px;">Early-onset primary dystonia (DYT1) is the most common form of hereditary 
primary dystonia.<wbr> Usually first symptoms occur in the limbs and dystonia 
generalizes within a few years of onset.<wbr> Onset can be during adolescence and 
early adulthood.<wbr> DYT1 is caused by mutations in the TOR1A gene, a gene that 
encodes the protein torsin A.<wbr> Torsin A is widely expressed in human tissues, 
particularly in neurons where mutations in TOR1A selectively alter normal 
functioning.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Basis For New Trial</STRONG> </div><div style="margin-bottom: 10px;">These data together with previously reported results obtained with 
dipraglurant in <EM>in vitro</EM> and in <EM>in vivo</EM> preclinical behavioral 
models, as well as observations made in the Phase 2a study of dipraglurant in 
Parkinson's disease patients, further support the hypothesis that inhibition of 
mGlu5 could be beneficial in counteracting the abnormal electrophysiological 
function observed in dystonia.<wbr> </div><div><DIV>

<P class="hs2 align-justify" style="MARGIN: 0cm 0cm 0pt; FONT-FAMILY: arial"><SPAN lang="EN" style="FONT-FAMILY: 'arial'">"These 
findings in the DYT1 mutant mice over expressing the human mutant TOR1A gene are 
very promising," stated Professor Antonio Pisani, University of Rome Tor Vergata 
and Fondazione Santa Lucia, and principal investigator on the study.<wbr> "These 
results are consistent with previous observations obtained with mGlu5 tool 
compounds and provide additional support for further exploration of dipraglurant 
in preclinical and clinical studies of dystonia.<wbr>"</SPAN></P>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7125">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-04T13:55:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-04T13:55:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ Re-initiates The Development Of Olaparnib in Ovarian Cancer</title>
	<pubDate>2013-09-04T13:42:35+02:00</pubDate>
	<wp:post_id>4896</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AstraZeneca has reversed a $285m impairment charge as it re-starts 
the development of its experimental ovarian cancer drug olaparnib with a phIII 
trial in a sub-group of patients with a particular mutation of the BRCA 
gene.<wbr> </div><div style="margin-bottom: 10px;">New analysis has shown that the drug could help this certain group of 
patients.<wbr> It would seem that AZ's Pascal Soriot, who left Roche last year 
to become AZ's new CEO has taken a particularly keen interest in 
olaparnib as he tries to accelerate AZ's oncology development programme.<wbr> Myriad 
Genetics will provide a companion diagnostic to test for the specific type of 
BRCA mutation.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9143">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-04T13:42:35+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-04T13:42:35+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Time Evaluation of BOTOX® for New Daily Persistent Headache (NDPH)</title>
	<pubDate>2013-09-03T18:33:58+02:00</pubDate>
	<wp:post_id>4897</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The aim of the Ph2 open label trial, sponsored by St.<wbr> Luke's-Roosevelt Hospital Center, is to assess the effect of the drug on the number of headache days in patients with NDPH.<wbr> PE will measure change from baseline in frequency of headache days.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01920945?term=prostate+OR+botulinum+OR+acromegaly+OR+neuroendocrine&amp;recr=Open&amp;phase=012&amp;rcv_s=08%2F03%2F2013&amp;rank=17"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Other study number: Allergan-13-002 </div><div style="margin-bottom: 10px;">Start date: Sept 2013 - Completion: Sept 2014 </div><div style="margin-bottom: 10px;"><U>Protocol</U> </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="MARGIN-TOP: 0.5ex">155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.<wbr>5 inch needle as 0.<wbr>1 mL (5 Units) injections per each site.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="MARGIN-TOP: 0.5ex">Injections will be divided across 7 specific head/<wbr>neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/<wbr>lateral occipital, and trapezius).<wbr></DIV> </div><div><EM>Source: clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7128c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The head/<wbr>neck muscles injected are very similar to those injected for aesthetic indications, could it be other primary or secondary end point linked to aesthetic indications in this study ? </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7124">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-03T18:33:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-03T18:33:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Santhera Explores New Strategic Options for Catena®</title>
	<pubDate>2013-09-03T10:14:08+02:00</pubDate>
	<wp:post_id>4898</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Santhera has reached an agreement with Takeda to license back previously granted EU rights to Catena<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top">®</SUP> (idebenone) in Duchenne Muscular Dystrophy (DMD).<wbr> Potential licensees interested in Catena<SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top"><STRONG class="hugin">®</STRONG></SUP> can now be offered global rights to this program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The ongoing <A href="http://clinicaltrials.gov/ct2/show/NCT01027884?term=delos&amp;rank=1">DELOS</A>* Ph3 study has recently passed a futility analysis.<wbr> </div><div style="margin-bottom: 10px;">Top-line data from the first cohort of patients in this study expected to be reported in Q2:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><SUP class="hugin" style="FONT-SIZE: 0.8em; VERTICAL-ALIGN: text-top"></SUP></STRONG> <STRONG></STRONG> <STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the first six months of 2013, net sales of Catena® reached CHF 1.<wbr>1 million (2012: CHF 1.<wbr>7 million).<wbr> </div><div style="margin-bottom: 10px;">The majority of sales (CHF 0.<wbr>9 million) were generated in Canada by the end of April 2013, when the product was voluntarily withdrawn from the market.<wbr> </div><div style="margin-bottom: 10px;">Sales under named patient and special access programs in EU and the rest of the world increased to CHF 0.<wbr>3 million (2012: CHF 0.<wbr>2 million).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=4538" class="defaultlink">Neurology4538: Santhera Initiates Pivotal Muscular Dystrophy Trial</a>.<wbr> </div><div style="margin-bottom: 10px;"><EM>*</EM>The <U>DELOS</U> (<U>D</U>uch<U>E</U>nne Muscular Dystrophy <U>L</U>ong-term Ideben<U>O</U>ne <U>S</U>tudy) study is a double-blind, randomized, placebo-controlled clinical trial evaluating the safety, tolerability and efficacy of one dose of Catena® (idebenone, 900 mg/<wbr>day) compared to placebo.<wbr> </div><div><EM>Source: Santhera</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20131231&edate=20130901&rec=7123">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-03T10:14:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-03T10:14:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer to Evaluate Xofigo in Japanese Patients with mCRPC</title>
	<pubDate>2013-09-02T17:37:23+02:00</pubDate>
	<wp:post_id>4899</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The POC study of Radium-223 dichloride (Xofigo, BAY88-8223) will start this month in approx.<wbr> 43 men confirmed with adenocarcinoma of the prostate and multiple bone metastases.<wbr> PE will assess percentage of change in total alkaline phosphatase from baseline at 12 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01929655?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=08%2F02%2F2013&amp;rank=102"><STRONG></STRONG></A> </div><div style="margin-bottom: 10px;">Completion dates: Nov 2014 /<wbr> May 2017.<wbr> </div><div style="margin-bottom: 10px;">Location: Japan (13 sites listed).<wbr> </div><div style="margin-bottom: 10px;">Protocol </div><div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV align="center">
<TABLE border="1" cellpadding="5" cellspacing="0" class="data_table" width="100%"><TBODY><TR align="left" valign="top"><TD class="body3">
<DIV class="indent2" style="MARGIN-TOP: 0.5ex">50 kBq/<wbr>kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration</DIV></TD>
</TR>
</TBODY>
</TABLE></DIV><BR><A id="desc" name="desc"></A></DIV></DIV></DIV> </div><div>Source: clinicaltrials.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9140">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-02T17:37:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-02T17:37:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>XTANDI Available in Germany</title>
	<pubDate>2013-09-02T16:46:59+02:00</pubDate>
	<wp:post_id>4900</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Claudia Schymczyk's feedback we have learnt that on Sept 1st XTANDI reached the German market for the treatment of patient with mCRPC whose disease progresses during or after chemotherapy with docetaxel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9139_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Claudia's comment outlines that "<SPAN style="TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><a name="oncology9139attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9139_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20131231&edate=20130901&rec=9139">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-02T16:46:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-02T16:46:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Menarini Sets Up New Entity in China</title>
	<pubDate>2013-09-02T10:06:59+02:00</pubDate>
	<wp:post_id>4901</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has reported that it will invest $30M to establish Menarini (China) Investment Co.<wbr>, Ltd at its Chinese HQ at Wuhan Biolake.<wbr> The strategic rationale for the company is to expand its local R&amp;D, manufacturing and marketing capabilities.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><div><SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 12px Arial, Helvetica, sans-serif; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20131231&edate=20130901&rec=10594">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2013-09-02T10:06:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2013-09-02T10:06:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
